

Requester

Name: BIANCHI, KRISTIN A
Organization: TC 1600
Art Unit: 1622
Employee Number:
Office Location: REM-5A05
Phone Number: (571)270-5232
Email: Kristin.Bianchi@uspto.gov

Request Detail

Attachment: 569873, Claims, Page Range4 pages.pdf

Case/Application number: 10/569873 PALM
Priority App. Filing Date: 08/29/2003
Format for Search Results: EMAIL

Meaning of unusual acronyms or initialisms:

Identify the novelty:

Additional Comments:

Please search the compounds of claim 1. Please note the proviso on page 3 of the claims (line 9) which states that "there exists at least one of R3 that is halogen or trihalomethyl."
Thank you!

Request Date: **Tuesday, September 13, 2011 11:12 AM**

RECEIVED
SEP 13 AM 01
USPTO
RECEIVED
K. BIANCHI

INVENTOR SEARCH

=> fil capl; d que nos l82

FILE 'CAPLUS' ENTERED AT 14:17:02 ON 14 SEP 2011

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2011 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 14 Sep 2011 VOL 155 ISS 12

FILE LAST UPDATED: 13 Sep 2011 (20110913/ED)

REVISED CLASS FIELDS (/NCL) LAST RELOADED: Jun 2011

USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Jun 2011

CAPLUS now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2011.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

'OBI' IS DEFAULT SEARCH FIELD FOR 'CAPLUS' FILE

L10	STR	
L11	STR	
L13	5217	SEA FILE=REGISTRY SSS FUL L10 AND L11
L18	165	SEA FILE=CAPLUS SPE=ON ABB=ON L13
L47	4779	SEA FILE=CAPLUS SPE=ON ABB=ON CHENG W?/AU,AUTH
L48	25	SEA FILE=CAPLUS SPE=ON ABB=ON CO E?/AU,AUTH
L49	28337	SEA FILE=CAPLUS SPE=ON ABB=ON KIM M?/AU,AUTH
L50	2799	SEA FILE=CAPLUS SPE=ON ABB=ON KLEIN R?/AU,AUTH
L51	282	SEA FILE=CAPLUS SPE=ON ABB=ON LEW A?/AU OR LEW TSUHAKO A?/AU OR TSUHAKO A?/AU,AUTH
L52	204	SEA FILE=CAPLUS SPE=ON ABB=ON NUSS J?/AU,AUTH
L53	16047	SEA FILE=CAPLUS SPE=ON ABB=ON XU W?/AU,AUTH
L54	5	SEA FILE=CAPLUS SPE=ON ABB=ON BAJJALIEH W?/AU,AUTH
L56	11	SEA FILE=CAPLUS SPE=ON ABB=ON L47 AND (L48 OR L49 OR L50 OR L50 OR L51 OR L52 OR L53 OR L54)
L57	8	SEA FILE=CAPLUS SPE=ON ABB=ON L48 AND (L49 OR L50 OR L50 OR L51 OR L52 OR L53 OR L54)
L58	21	SEA FILE=CAPLUS SPE=ON ABB=ON L49 AND (L50 OR L50 OR L51 OR L52 OR L53 OR L54)

L59 2799 SEA FILE=CAPLUS SPE=ON ABB=ON L50 AND (L50 OR L51 OR L52 OR L53 OR L54)
 L60 5 SEA FILE=CAPLUS SPE=ON ABB=ON L50 AND (L51 OR L52 OR L53 OR L54)
 L61 10 SEA FILE=CAPLUS SPE=ON ABB=ON L51 AND (L52 OR L53 OR L54)
 L62 14 SEA FILE=CAPLUS SPE=ON ABB=ON L52 AND (L53 OR L54)
 L63 2 SEA FILE=CAPLUS SPE=ON ABB=ON L53 AND L54
 L65 4 SEA FILE=CAPLUS SPE=ON ABB=ON L56 AND (L57 OR L58 OR L59 OR L60 OR L61 OR L62 OR L63)
 L66 7 SEA FILE=CAPLUS SPE=ON ABB=ON L57 AND (L58 OR L59 OR L60 OR L61 OR L62 OR L63)
 L67 13 SEA FILE=CAPLUS SPE=ON ABB=ON L58 AND (L59 OR L60 OR L61 OR L62 OR L63)
 L68 5 SEA FILE=CAPLUS SPE=ON ABB=ON L59 AND (L60 OR L61 OR L62 OR L63)
 L69 5 SEA FILE=CAPLUS SPE=ON ABB=ON L60 AND (L61 OR L62 OR L63)
 L70 7 SEA FILE=CAPLUS SPE=ON ABB=ON L61 AND (L62 OR L63)
 L71 2 SEA FILE=CAPLUS SPE=ON ABB=ON L62 AND L63
 L73 3 SEA FILE=CAPLUS SPE=ON ABB=ON L65 AND (L66 OR L67 OR L68 OR L69 OR L70 OR L71)
 L74 7 SEA FILE=CAPLUS SPE=ON ABB=ON L66 AND (L67 OR L68 OR L69 OR L70 OR L71)
 L75 7 SEA FILE=CAPLUS SPE=ON ABB=ON L67 AND (L68 OR L69 OR L70 OR L71)
 L76 5 SEA FILE=CAPLUS SPE=ON ABB=ON L68 AND (L69 OR L70 OR L71)
 L77 5 SEA FILE=CAPLUS SPE=ON ABB=ON L69 AND (L70 OR L71)
 L78 1 SEA FILE=CAPLUS SPE=ON ABB=ON L70 AND L71
 L79 7 SEA FILE=CAPLUS SPE=ON ABB=ON (L73 OR L74 OR L75 OR L76 OR L77 OR L78)
 L81 1 SEA FILE=CAPLUS SPE=ON ABB=ON (L47 OR L48 OR L49 OR L50 OR L51 OR L52 OR L53 OR L54) AND L18
 L82 7 SEA FILE=CAPLUS SPE=ON ABB=ON (L79 OR L81)

=> d ibib abs hitstr l82 1-7

L82 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 2006:655708 CAPLUS Full-text

DOCUMENT NUMBER: 145:124611

TITLE: Preparation of
 [1H-pyrazolo[3,4-d]pyrimidin-4-yl]piperidine or
 -piperazine compounds as serine-threonine kinase
 modulators (p70S6K, Akt-1 and Akt-2) for the treatment
 of immunological, inflammatory and proliferative
 diseases

INVENTOR(S): Rice, Ken; Co, Erick Wang; Kim, Moon Hwan; Bannen,
 Lynn Canne; Bussenius, Joerg; Le, Donna; Tsubako, Amy
 Lew; Nuss, John; Wang, Yong; Xu, Wei; Klein,
 Rhett Ronald

PATENT ASSIGNEE(S): Exelixis, Inc., USA

SOURCE: PCT Int. Appl., 126 pp.

CODEN: PIXXD2



DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006071819	A1	20060706	WO 2005-US46938	20051227
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
AU 2005322085	A1	20060706	AU 2005-322085	20051227
CA 2590961	A1	20060706	CA 2005-2590961	20051227
EP 1848719	A1	20071031	EP 2005-855490	20051227
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				
JP 2008525526	T	20080717	JP 2007-549530	20051227
US 20080188482	A1	20080807	US 2007-722291	20071010
US 7994172	B2	20110809		
PRIORITY APPLN. INFO.:			US 2004-640200P	P 20041228
			WO 2005-US46938	W 20051227
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT				
OTHER SOURCE(S): CASREACT 145:124611; MARPAT 145:124611				
GI				



AB The title compds. I [R¹ = H, halo, CN, aryl, etc.; R² = H, NH₂, SH, OH or alkyl; R³-R⁶ = H, oxo, alkyl, alkoxy, etc.; L = alkylene, alkenylene, C(O), etc.; Q¹ = N, CR¹³ (wherein R¹³ = H or C(O)NR¹²(CH₂)_nNR¹⁰R¹¹); Q² = a bond, CR¹⁴, O or N (R¹⁴ = H, OH, alkyl, etc.); n = 1-4; W = alkyl, NR¹⁰R¹¹, aryl, cycloalkyl, etc.; or V, Q², L and W together form aryl ring, heteroaryl ring, cycloalkyl ring, etc.; R¹⁰, R¹¹, R¹² = H or alkyl which is optionally substituted with aryl or heteroaryl; with provisos], useful for inhibition of kinases, more specifically p70S6 kinases, and more preferably p70S6, Akt-1

and Akt-2 kinases, were prepared E.g., a multi-step synthesis of II, starting from N-Boc-4-(4-chlorobenzoyl)piperidine and 2-(diethylamino)ethylamine, was given. Compds. I were tested against p70S6K, Akt-1 and Akt-2 (IC50 values were given for representative compds. I). The invention provides compds. for modulating protein kinase enzymic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration, chemoinvasion and metabolism Compds. I inhibit, regulate and/or modulate kinase receptor signal transduction pathways related to the changes in cellular activities as mentioned above, and the invention includes compns. which contain these compds., and methods of using them to treat kinase-dependent diseases and conditions.

OS.CITING REF COUNT: 7 THERE ARE 7 CAPLUS RECORDS THAT CITE THIS RECORD (10 CITINGS)
 REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L82 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 2005:1314205 CAPLUS Full-text

DOCUMENT NUMBER: 144:51610

TITLE: Preparation and structure activity of pyrazolo-pyrimidine derivatives as antitumor agents and kinase modulators

INVENTOR(S): Anand, Neel K.; Blazey, Charles M.; Bowles, Owen Joseph; Bussenius, Joerg; Canne Bannen, Lynne; Chan, Diva Sze-Ming; Chen, Baili; Co, Erick Wang; Costanzo, Simona; Defina, Steven Charles; Dubenko, Larisa; Franzini, Maurizio; Huang, Ping; Jammalamadaka, Vasu; Khoury, Richard George; Kim, Moon Hwan; Klein, Rhett Ronald; Le, Donna Tra; Mac, Morrison B.; Nuss, John M.; Parks, Jason Jevious; Rice, Kenneth D.; Tsang, Tsze H.; Tsuhako, Amy Lew; Wang, Yong; Xu, Wei

PATENT ASSIGNEE(S): Exelixis, Inc., USA

SOURCE: PCT Int. Appl., 211 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005117909	A2	20051215	WO 2005-US13860	20050422
WO 2005117909	A3	20060427		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,			


RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
MR, NE, SN, TD, TG

AU 2005249380	A1	20051215	AU 2005-249380	20050422
CA 2563699	A1	20051215	CA 2005-2563699	20050422
EP 1750727	A2	20070214	EP 2005-804792	20050422
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU				
JP 2007534687	T	20071129	JP 2007-509678	20050422
US 20080076774	A1	20080327	US 2007-568173	20070726
PRIORITY APPLN. INFO.:			US 2004-564908P	P 20040423
			WO 2005-US13860	W 20050422

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): CASREACT 144:51610; MARPAT 144:51610

GI



AB Pyrazolo-pyrimidine derivs. I, wherein X1 is N, CR2. X2 is N, CR3; X3 is N, CR4, but when X2 is N then X3 is CR4; R is H, halogen, tri-halomethyl, substituted nitrogen, substituted sulfur, sulfonyl, sulfonamide, carboxylate, amide, substituted oxygen, acyl, alkyl, aryl, heterocycle, heterocycloalkyl, arylalkyl R1-R13 are independently H, halogen, tri-halomethyl, CN, NO2, substituted nitrogen, substituted sulfur, sulfonyl, sulfonamide, carboxylate, amide, substituted oxygen, acyl, alkyl, aryl, heterocycle, heterocycloalkyl, arylalkyl; Q is (C)nR11R12; n is 0-1 are prepared as kinase modulators. Combination chemotherapy and structure activity of title compds. are reported. The compds. modulate protein kinase enzymic activity to modulate cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. Compds. of the invention inhibit, regulate and/or modulate kinases, particularly p70S6 and/or AKT kinases. Methods of using and preparing the compds., and pharmaceutical compns. thereof, to treat kinase-dependent diseases and conditions are also an aspect of the invention. Thus, 3-(azetidin-3-ylidene-methyl)-4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidine was prepared and tested in vitro as kinase modulator (IC50 > 1000 nM).

OS.CITING REF COUNT: 16 THERE ARE 16 CAPLUS RECORDS THAT CITE THIS RECORD (19 CITINGS)

L82 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 2005:395042 CAPLUS Full-text

DOCUMENT NUMBER: 142:447414

TITLE: P70S6 kinase modulators and method of use

INVENTOR(S): Cheng, Wei; Co, Erick Wang; Kim, Moon Hwan;
Klein, Rhett Ronald; Le Donna, T.; Lew, Amy;
Nuss, John M.; Xu, Wei

PATENT ASSIGNEE(S): Exelixis, Inc., USA

SOURCE: PCT Int. Appl., 165 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1



PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005039506	A2	20050506	WO 2004-US35470	20041022
WO 2005039506	A3	20060119		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2004283751	A1	20050506	AU 2004-283751	20041022
AU 2004283751	B2	20110519		
CA 2541989	A1	20050506	CA 2004-2541989	20041022
EP 1678168	A2	20060712	EP 2004-796443	20041022
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR			
JP 2007527413	T	20070927	JP 2006-536929	20041022
US 20070208020	A1	20070906	US 2006-576653	20061116
US 7816353	B2	20101019		
US 20110021525	A1	20110127	US 2010-839925	20100720
PRIORITY APPLN. INFO.:			US 2003-514432P	P 20031024
			US 2004-551429P	P 20040308
			WO 2004-US35470	W 20041022
			US 2006-576653	A3 20061116

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): CASREACT 142:447414; MARPAT 142:447414

GI



AB Peptide derivs. I [E = C(R2)-substituted pyridine, pyridazine, pyrimidine, or 1,3,5-triazine; B = (R1)_n; R1, R2 = H, halo, trihalomethyl, CN, NO₂, aminoalkyl, carboxyalkyl, (un)substituted alkyl, alkenyl, alkynyl, aryl, heterocyclyl, heterocyclyl, heterocyclylalkyl, arylalkyl, etc.; X, Y = CO, O, (un)substituted amine, (un)substituted imine, SO; X and Y can combine to form either C(R3):C(R3), or C.tplbond.C; when X = O, (un)substituted amine, or (un)substituted imine, Y cannot be CH(R3); R3 = (un)substituted Ph, naphthyl, cyclohexyl, dihydronaphthyl, five- to six-membered heteroaryl; Z = O, S, double bond to an atom of B; A = single bond, NH, (un)substituted aminoalkyl, aminoaryl, aminoarylalkyl, aminoheterocyclyl, aminoheterocyclylalkyl; J = (un)substituted five- to ten-membered aryl or heteroaryl, etc.; n = 0-5] or pharmaceutically acceptable salts, hydrates, or prodrugs were prepared as p70S6 kinase signal transduction inhibitors and cellular activities modulators for treating kinase-dependent diseases and conditions. Thus, compound II was prepared by coupling of 2-amino-4,6-di-chloro-5-formylpyrimidine with 2-amino-N-(3-trifluoromethylphenyl)acetamide in 43%yield and showed IC₅₀ < 50 nM in p70S6 kinase activity assey.

OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L82 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 2005:216619 CAPLUS Full-text

DOCUMENT NUMBER: 142:297864

TITLE: Preparation of aniline derivatives and related compounds as c-kit modulators

INVENTOR(S): Cheng, Wei; Co, Erick Wang; Kim, Moon Hwan; Klein, Rhett Ronald; Le Donna, T.; Lew, Amy; Nuss, John M.; Xu, Wei; Bajjalieh, William

PATENT ASSIGNEE(S): Exelixis, Inc., USA

SOURCE: PCT Int. Appl., 169 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1



PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005020921	A2	20050310	WO 2004-US28001	20040827
WO 2005020921	A3	20051006		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2004268621	A1	20050310	AU 2004-268621	20040827
AU 2004268621	B2	20101216		
CA 2536954	A1	20050310	CA 2004-2536954	20040827
EP 1663204	A2	20060607	EP 2004-782473	20040827
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR			
JP 2007504160	T	20070301	JP 2006-524905	20040827
US 20080096892	A1	20080424	US 2007-569873	20070904
PRIORITY APPLN. INFO.:			US 2003-499224P	P 20030829
			WO 2004-US28001	W 20040827

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): CASREACT 142:297864; MARPAT 142:297864

GI



AB Compds. I [wherein ring A is a five- to fourteen-membered heteroaryl; R1, R2 and R3 are H, halo, trihalomethyl, cyano, nitro, etc.; L1 is a single bond, (un)substituted alkylene, O, CH2O, etc.; ring B is five- to ten-membered aryl or heterocyclyl; ring C is five- to ten-membered (hetero)aryl; L2 is alkylene, alkylidene, alkylidyne, etc.; with some limitations and exclusions, and pharmaceutically acceptable salts, hydrates or prodrugs thereof], as exemplified by carbonyl compds. of anilines, were prepared as c-Kit kinase modulators. For example, 3-aminophenoxyacetic acid, which was obtained from the corresponding nitro compound in 76% yield via catalytic hydrogenation, was treated with HC(OEt)₃ and NaN₃ in AcOH followed by NaNO₂/HCl to give a tetrazole in 61% yield. This acid was coupled with 5-amino-2-chlorobenzotrifluoride in the presence of HATU to afford acetamide

II in 46% yield, which showed inhibition against c-Kit kinase with a IC₅₀ of < 50 nM. Therefore, I and pharmaceutical compns. thereof are useful for modulating c-Kit kinase activity and for treating diseases or disorders associated with uncontrolled, abnormal, and/or unwanted cellular activities.

IT	332176-74-6P	483337-32-2P	483337-34-4P
	483337-36-6P	483337-37-7P	483337-38-8P
	483337-39-9P	483337-40-2P	483337-41-3P
	483978-03-6P	505052-18-6P	506433-09-6P
	552825-29-3P	847606-67-1P	847606-71-7P
	847606-73-9P	847606-74-0P	847606-76-2P
	847606-77-3P	847606-81-9P	847606-84-2P
	847606-87-5P	847606-90-0P	847606-93-3P
	847606-95-5P	847607-13-0P	847607-14-1P
	847607-15-2P	847607-17-4P	847607-18-5P
	847607-19-6P	847607-20-9P	847607-22-1P
	847607-25-4P	847607-26-5P	847607-27-6P
	847607-28-7P	847607-29-8P	847607-37-8P
	847607-38-9P	847607-47-0P	847607-48-1P
	847607-51-6P	847607-58-3P	847607-61-8P
	847607-68-5P	847607-69-6P	847607-71-0P
	847607-74-3P	847607-76-5P	847607-77-6P
	847607-78-7P	847607-79-8P	847607-80-1P
	847607-81-2P	847607-82-3P	847607-83-4P
	847607-84-5P	847607-86-7P	847607-87-8P
	847607-88-9P	847607-89-0P	847607-92-5P
	847607-93-6P	847607-94-7P	847607-95-8P
	847607-96-9P	847607-97-0P	847607-98-1P
	847607-99-2P	847608-00-8P	847608-01-9P
	847608-02-0P	847608-03-1P	847608-04-2P
	847608-05-3P	847608-06-4P	847608-07-5P
	847608-08-6P	847608-09-7P	847608-10-0P
	847608-12-2P	847608-13-3P	847608-14-4P
	847608-15-5P	847608-16-6P	847608-17-7P
	847608-18-8P	847608-19-9P	847608-20-2P
	847608-21-3P	847608-23-5P	847608-24-6P
	847608-25-7P	847608-26-8P	847608-27-9P
	847608-29-1P	847608-30-4P	847608-31-5P
	847608-32-6P	847608-33-7P	847608-35-9P
	847608-37-1P	847608-39-3P	847608-42-8P
	847608-44-0P	847608-46-2P	847608-48-4P
	847608-50-8P	847608-51-9P	847608-53-1P
	847608-55-3P	847608-58-6P	847608-59-7P
	847608-60-0P	847608-62-2P	847608-63-3P
	847608-65-5P	847608-66-6P	847608-67-7P
	847608-68-8P	847608-69-9P	847608-70-2P
	847608-71-3P	847608-74-6P	847608-75-7P
	847608-77-9P	847608-79-1P	847608-80-4P
	847608-81-5P	847608-82-6P	847608-83-7P
	847608-84-8P	847608-85-9P	847608-86-0P
	847608-87-1P	847608-89-3P	847608-90-6P
	847608-91-7P	847608-98-4P	847609-00-1P
	847609-04-5P	847609-06-7P	847609-08-9P
	847609-10-3P	847609-12-5P	847609-14-7P
	847609-18-1P	847609-20-5P	847609-28-3P


847609-30-7P 847609-32-9P 847609-50-1P
 847609-52-3P 847609-54-5P 847609-56-7P
 847609-57-8P 847609-58-9P 847609-59-0P
 847609-60-3P 847609-63-6P 847609-65-8P
 847609-67-0P 847609-73-8P 847609-75-0P
 847609-79-4P 847609-81-8P 847609-86-3P
 847609-93-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(modulator; preparation of anilines and related compds. as C-kit modulators)


RN 332176-74-6 CAPLUS

CN Acetamide, N-(5-chloro-2-methoxyphenyl)-2-[3-(1H-tetrazol-1-yl)phenoxy]- (CA INDEX NAME)




RN 483337-32-2 CAPLUS

CN Acetamide, N-(2-chlorophenyl)-2-[3-(1H-tetrazol-1-yl)phenoxy]- (CA INDEX NAME)




RN 483337-34-4 CAPLUS

CN Acetamide, N-(2,3-dichlorophenyl)-2-[3-(1H-tetrazol-1-yl)phenoxy]- (CA INDEX NAME)




RN 483337-36-6 CAPLUS

CN Acetamide, N-(3-chloro-2-methylphenyl)-2-[3-(1H-tetrazol-1-yl)phenoxy]- (CA INDEX NAME)




RN 483337-37-7 CAPLUS

CN Acetamide, N-(4-bromophenyl)-2-[3-(1H-tetrazol-1-yl)phenoxy]- (CA INDEX NAME)




RN 483337-38-8 CAPLUS

CN Acetamide, N-(2-fluorophenyl)-2-[3-(1H-tetrazol-1-yl)phenoxy]- (CA INDEX NAME)




RN 483337-39-9 CAPLUS

CN Acetamide, N-(4-fluorophenyl)-2-[3-(1H-tetrazol-1-yl)phenoxy]- (CA INDEX NAME)




RN 483337-40-2 CAPLUS

CN Acetamide, 2-[3-(1H-tetrazol-1-yl)phenoxy]-N-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 483337-41-3 CAPLUS

CN Acetamide, 2-[3-(1H-tetrazol-1-yl)phenoxy]-N-[3-(trifluoromethyl)phenyl]-
(CA INDEX NAME)




RN 483978-03-6 CAPLUS

CN Acetamide, N-(3-fluorophenyl)-2-[3-(1H-tetrazol-1-yl)phenoxy]- (CA INDEX NAME)




RN 505052-18-6 CAPLUS

CN Acetamide, N-[2-chloro-5-(trifluoromethyl)phenyl]-2-[3-(1H-tetrazol-1-yl)phenoxy]- (CA INDEX NAME)




RN 506433-09-6 CAPLUS

CN Acetamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[3-(1H-tetrazol-1-yl)phenoxy]- (CA INDEX NAME)



RN 552825-29-3 CAPLUS


CN Acetamide, N-(4-chlorophenyl)-2-[3-(1H-tetrazol-1-yl)phenoxy]- (CA INDEX NAME)



RN 847606-67-1 CAPLUS


CN Acetamide,

N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[3-(1H-1,2,3-triazol-1-yl)phenoxy]- (CA INDEX NAME)




RN 847606-71-7 CAPLUS

CN Hydrazinecarboxamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[3-(1H-tetrazol-1-yl)phenoxy]- (CA INDEX NAME)




RN 847606-73-9 CAPLUS

CN Acetamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[[3-(1H-tetrazol-1-yl)phenyl]amino]- (CA INDEX NAME)




RN 847606-74-0 CAPLUS

CN Acetamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[3-(5-methyl-1H-tetrazol-1-yl)phenoxy]- (CA INDEX NAME)




RN 847606-76-2 CAPLUS

CN Acetamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[[3-(1H-tetrazol-1-yl)phenyl]thio]- (CA INDEX NAME)




RN 847606-77-3 CAPLUS

CN Acetamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[4-(5-pyrimidinyl)phenoxy]- (CA INDEX NAME)




RN 847606-81-9 CAPLUS

CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[[3-(1H-tetrazol-1-yl)phenyl]methyl]- (CA INDEX NAME)




RN 847606-84-2 CAPLUS

CN Propanamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[3-(1H-tetrazol-1-yl)phenoxy]- (CA INDEX NAME)




RN 847606-87-5 CAPLUS

CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[[3-(6-quinoxaliny)phenyl]methyl]- (CA INDEX NAME)




RN 847606-90-0 CAPLUS

CN Benzamide, N-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]-3-(1H-tetrazol-1-yl)- (CA INDEX NAME)




RN 847606-93-3 CAPLUS

CN Carbamic acid, [3-(trifluoromethyl)phenyl]-, [3-(1H-tetrazol-1-yl)phenyl]methyl ester (9CI) (CA INDEX NAME)




RN 847606-95-5 CAPLUS

CN Acetamide, N-(4-chloro-3-methylphenyl)-2-[3-(1H-tetrazol-1-yl)phenoxy]- (CA INDEX NAME)




RN 847607-13-0 CAPLUS

CN Acetamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[3-(2H-tetrazol-5-yl)phenoxy]- (CA INDEX NAME)




RN 847607-14-1 CAPLUS

CN Acetamide, N-(4-chloro-2-fluorophenyl)-2-[3-(1H-tetrazol-1-yl)phenoxy]- (CA INDEX NAME)




RN 847607-15-2 CAPLUS

CN Acetamide, N-(4-bromo-3-methylphenyl)-2-[3-(1H-tetrazol-1-yl)phenoxy]- (CA INDEX NAME)




RN 847607-17-4 CAPLUS

CN Acetamide, N-[4-fluoro-3-(trifluoromethyl)phenyl]-2-[3-(1H-tetrazol-1-yl)phenoxy]- (CA INDEX NAME)




RN 847607-18-5 CAPLUS

CN Acetamide, N-[4-bromo-3-(trifluoromethyl)phenyl]-2-[3-(1H-tetrazol-1-yl)phenoxy]- (CA INDEX NAME)




RN 847607-19-6 CAPLUS

CN Acetamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[4-(1H-tetrazol-1-yl)phenoxy]- (CA INDEX NAME)




RN 847607-20-9 CAPLUS

CN Acetamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[2-methyl-5-(1H-tetrazol-1-yl)phenoxy]- (CA INDEX NAME)




RN 847607-22-1 CAPLUS

CN Acetamide, N-[4-chloro-2-(trifluoromethyl)phenyl]-2-[3-(1H-tetrazol-1-yl)phenoxy]- (CA INDEX NAME)




RN 847607-25-4 CAPLUS

CN Acetamide, N-[4-fluoro-3-(trifluoromethyl)phenyl]-2-[4-(1H-tetrazol-1-yl)phenoxy]- (CA INDEX NAME)




RN 847607-26-5 CAPLUS

CN Acetamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[3-(2-methyl-2H-tetrazol-5-yl)phenoxy]- (CA INDEX NAME)




RN 847607-27-6 CAPLUS

CN Acetamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[2,4-dichloro-5-(1H-tetrazol-1-yl)phenoxy]- (CA INDEX NAME)



RN 847607-28-7 CAPLUS


CN Acetamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[2-(1H-tetrazol-1-yl)phenoxy]- (CA INDEX NAME)



RN 847607-29-8 CAPLUS


CN 1H-1,2,3-Triazole-4-carboxylic acid,

1-[3-[2-[[4-chloro-3-(trifluoromethyl)phenyl]amino]-2-oxoethoxy]phenyl]-,
methyl ester (CA INDEX NAME)




RN 847607-37-8 CAPLUS

CN Acetamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[3-(4-pyridinyl)phenoxy]- (CA INDEX NAME)



RN 847607-38-9 CAPLUS


CN Propanamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[[3-(1H-tetrazol-1-yl)phenyl]amino]- (CA INDEX NAME)



RN 847607-47-0 CAPLUS


CN Benzamide, 5-chloro-2-[[2-[3-(1H-tetrazol-1-yl)phenoxy]acetyl]amino]-

(CA
INDEX NAME)




RN 847607-48-1 CAPLUS

CN Acetamide, N-(5-chloro-2,4-dimethoxyphenyl)-2-[3-(1H-tetrazol-1-yl)phenoxy]- (CA INDEX NAME)




RN 847607-51-6 CAPLUS

CN Acetamide, N-[2-methoxy-5-(trifluoromethyl)phenyl]-2-[3-(1H-tetrazol-1-yl)phenoxy]- (CA INDEX NAME)




RN 847607-58-3 CAPLUS

CN Acetamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[3-(5-pyrimidinyl)phenoxy]- (CA INDEX NAME)




RN 847607-61-8 CAPLUS

CN Acetamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[3-(3-pyridinyl)phenoxy]- (CA INDEX NAME)




RN 847607-68-5 CAPLUS

CN Acetamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[3-(3,5-dimethyl-4-isoxazolyl)phenoxy]- (CA INDEX NAME)




RN 847607-69-6 CAPLUS

CN Acetamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[3-(7-quinoliny)phenoxy]- (CA INDEX NAME)




RN 847607-71-0 CAPLUS

CN Acetamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[3-(4-dibenzofuranyl)phenoxy]- (CA INDEX NAME)




RN 847607-74-3 CAPLUS

CN Acetamide, N-[4-fluoro-3-(trifluoromethyl)phenyl]-2-[[3-(1H-tetrazol-1-yl)phenyl]amino]- (CA INDEX NAME)




RN 847607-76-5 CAPLUS

CN Hydrazinecarboxamide, N-[2-fluoro-5-(trifluoromethyl)phenyl]-2-[3-(1H-tetrazol-1-yl)phenyl]- (CA INDEX NAME)




RN 847607-77-6 CAPLUS

CN Acetamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[4-(3-pyridinyl)phenoxy]- (CA INDEX NAME)




RN 847607-78-7 CAPLUS

CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[[3-(5-pyrimidinyl)phenyl]methyl]- (CA INDEX NAME)




RN 847607-79-8 CAPLUS

CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[[4-(5-pyrimidinyl)phenyl]methyl]- (CA INDEX NAME)




RN 847607-80-1 CAPLUS

CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[[4-(3-pyridinyl)phenyl]methyl]- (CA INDEX NAME)




RN 847607-81-2 CAPLUS

CN Carbamic acid, [4-chloro-3-(trifluoromethyl)phenyl]-, [3-(1H-tetrazol-1-yl)phenyl]methyl ester (9CI) (CA INDEX NAME)



RN 847607-82-3 CAPLUS


CN Acetamide, N-[4-fluoro-3-(trifluoromethyl)phenyl]-2-[4-(5-pyrimidinyl)phenoxy]- (CA INDEX NAME)



RN 847607-83-4 CAPLUS


CN Acetamide, 2-[[4-chloro-3-(trifluoromethyl)phenyl]amino]-N-[3-(1H-tetrazol-

1-yl)phenyl]- (CA INDEX NAME)




RN 847607-84-5 CAPLUS

CN Acetamide, 2-[4-chloro-3-(trifluoromethyl)phenoxy]-N-[3-(1H-tetrazol-1-yl)phenyl]- (CA INDEX NAME)




RN 847607-86-7 CAPLUS

CN Acetamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[3-methyl-4-(1H-tetrazol-1-yl)phenoxy]- (CA INDEX NAME)




RN 847607-87-8 CAPLUS

CN Acetamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[4-(1H-1,2,3-triazol-1-yl)phenoxy]- (CA INDEX NAME)




RN 847607-88-9 CAPLUS

CN Acetamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[3-fluoro-4-(1H-tetrazol-1-yl)phenoxy]- (CA INDEX NAME)




RN 847607-89-0 CAPLUS

CN Acetamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[2-fluoro-4-(1H-tetrazol-1-yl)phenoxy]- (CA INDEX NAME)




RN 847607-92-5 CAPLUS

CN Acetamide, N-[4-fluoro-3-(trifluoromethyl)phenyl]-2-[4-(3-pyridinyl)phenoxy]- (CA INDEX NAME)




RN 847607-93-6 CAPLUS

CN Acetamide, 2-[4-(2,4-dimethoxy-5-pyrimidinyl)phenoxy]-N-[4-fluoro-3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 847607-94-7 CAPLUS

CN Acetamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[4-(2,4-dimethoxy-5-pyrimidinyl)phenoxy]- (CA INDEX NAME)




RN 847607-95-8 CAPLUS

CN Acetamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[4-(4-pyridinyl)phenoxy]- (CA INDEX NAME)




RN 847607-96-9 CAPLUS

CN Acetamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[[3-methoxy-4-(1H-tetrazol-1-yl)phenyl]amino]- (CA INDEX NAME)




RN 847607-97-0 CAPLUS

CN Acetamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[[4-methoxy-3-(1H-tetrazol-1-yl)phenyl]amino]- (CA INDEX NAME)




RN 847607-98-1 CAPLUS

CN Acetamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[[4-(1H-tetrazol-1-yl)phenyl]amino]- (CA INDEX NAME)




RN 847607-99-2 CAPLUS

CN Hydrazinecarboxamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[2,3,5,6-tetrafluoro-4-(5-pyrimidinyl)phenyl]- (CA INDEX NAME)




RN 847608-00-8 CAPLUS

CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[[4-(1H-tetrazol-1-yl)phenyl]methyl]- (CA INDEX NAME)




RN 847608-01-9 CAPLUS

CN Hydrazinecarboxamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[4-(5-pyrimidinyl)phenyl]- (CA INDEX NAME)




RN 847608-02-0 CAPLUS

CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[[3-(3-pyridinyl)phenyl]methyl]- (CA INDEX NAME)




RN 847608-03-1 CAPLUS

CN Propanamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-methyl-2-[3-(1H-tetrazol-1-yl)phenoxy]- (CA INDEX NAME)




RN 847608-04-2 CAPLUS

CN Propanamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[4-(1H-tetrazol-1-yl)phenoxy]- (CA INDEX NAME)




RN 847608-05-3 CAPLUS

CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[[4-(2,4-dimethoxy-5-pyrimidinyl)phenyl]methyl]- (CA INDEX NAME)




RN 847608-06-4 CAPLUS

CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[[3-(2-methoxy-5-pyrimidinyl)phenyl]methyl]- (CA INDEX NAME)




RN 847608-07-5 CAPLUS

CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[[3-(6-methoxy-3-pyridinyl)phenyl]methyl]- (CA INDEX NAME)




RN 847608-08-6 CAPLUS

CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[[4-(2-methoxy-5-pyrimidinyl)phenyl]methyl]- (CA INDEX NAME)




RN 847608-09-7 CAPLUS

CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[[4-(6-methoxy-3-pyridinyl)phenyl]methyl]- (CA INDEX NAME)




RN 847608-10-0 CAPLUS

CN 1H-Indole-1-carboxylic acid, 2-[4-[2-[[4-chloro-3-(trifluoromethyl)phenyl]amino]-2-oxoethoxy]phenyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 847608-12-2 CAPLUS

CN Acetamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[[3-(2H-tetrazol-5-yl)phenyl]amino]- (CA INDEX NAME)




RN 847608-13-3 CAPLUS

CN Acetamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[2,6-difluoro-4-(1H-tetrazol-1-yl)phenoxy]- (CA INDEX NAME)




RN 847608-14-4 CAPLUS

CN Carbamic acid, [4-chloro-3-(trifluoromethyl)phenyl]-, [3-(3-pyridinyl)phenyl]methyl ester (9CI) (CA INDEX NAME)




RN 847608-15-5 CAPLUS

CN Carbamic acid, [4-chloro-3-(trifluoromethyl)phenyl]-,
[3-(5-pyrimidinyl)phenyl]methyl ester (9CI) (CA INDEX NAME)




RN 847608-16-6 CAPLUS

CN Carbamic acid, [4-chloro-3-(trifluoromethyl)phenyl]-,
[3-(4-pyridinyl)phenyl]methyl ester (9CI) (CA INDEX NAME)




RN 847608-17-7 CAPLUS

CN Hydrazinecarboxamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[4-(1H-tetrazol-1-yl)phenyl]- (CA INDEX NAME)




RN 847608-18-8 CAPLUS

CN Hydrazinecarboxamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[4-(3-pyridinyl)phenyl]- (CA INDEX NAME)




RN 847608-19-9 CAPLUS

CN Carbamic acid, [4-chloro-3-(trifluoromethyl)phenyl]-,
[4-(3-pyridinyl)phenyl]methyl ester (9CI) (CA INDEX NAME)




RN 847608-20-2 CAPLUS

CN Carbamic acid, [4-chloro-3-(trifluoromethyl)phenyl]-,
[4-(4-pyridinyl)phenyl]methyl ester (9CI) (CA INDEX NAME)




RN 847608-21-3 CAPLUS

CN Carbamic acid, [4-chloro-3-(trifluoromethyl)phenyl]-,
[4-(5-pyrimidinyl)phenyl]methyl ester (9CI) (CA INDEX NAME)




RN 847608-23-5 CAPLUS

CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[[4-(4-pyridinyl)phenyl]methyl]- (CA INDEX NAME)




RN 847608-24-6 CAPLUS

CN Hydrazinecarboxamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[3-(3-pyridinyl)phenyl]- (CA INDEX NAME)




RN 847608-25-7 CAPLUS

CN Hydrazinecarboxamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[3-(5-pyrimidinyl)phenyl]- (CA INDEX NAME)




RN 847608-26-8 CAPLUS

CN Urea, N-(5-chloro-2,4-dimethoxyphenyl)-N'-[[4-(5-pyrimidinyl)phenyl]methyl]- (CA INDEX NAME)




RN 847608-27-9 CAPLUS

CN Urea,
N-(5-chloro-2,4-dimethoxyphenyl)-N'-[[4-(3-pyridinyl)phenyl]methyl]-
(CA INDEX NAME)




RN 847608-29-1 CAPLUS

CN Carbamic acid, (5-chloro-2,4-dimethoxyphenyl)-,
[4-(5-pyrimidinyl)phenyl]methyl ester (9CI) (CA INDEX NAME)




RN 847608-30-4 CAPLUS

CN Carbamic acid, (5-chloro-2,4-dimethoxyphenyl)-,
[4-(3-pyridinyl)phenyl]methyl ester (9CI) (CA INDEX NAME)




RN 847608-31-5 CAPLUS

CN Carbamic acid, [4-chloro-3-(trifluoromethyl)phenyl]-,
1-[4-(3-pyridinyl)phenyl]ethyl ester (9CI) (CA INDEX NAME)




RN 847608-32-6 CAPLUS

CN Carbamic acid, [4-chloro-3-(trifluoromethyl)phenyl]-,
1-[4-(5-pyrimidinyl)phenyl]ethyl ester (9CI) (CA INDEX NAME)




RN 847608-33-7 CAPLUS

CN Urea,
N-(5-chloro-2,4-dimethoxyphenyl)-N'-[[3-(3-pyridinyl)phenyl]methyl]-
(CA INDEX NAME)




RN 847608-35-9 CAPLUS

CN Urea, N-(5-chloro-2,4-dimethoxyphenyl)-N'-[[3-(5-pyrimidinyl)phenyl]methyl]- (CA INDEX NAME)




RN 847608-37-1 CAPLUS

CN Carbamic acid, (5-chloro-2,4-dimethoxyphenyl)-, [3-(3-pyridinyl)phenyl]methyl ester (9CI) (CA INDEX NAME)




RN 847608-39-3 CAPLUS

CN Carbamic acid, (5-chloro-2,4-dimethoxyphenyl)-, [3-(5-pyrimidinyl)phenyl]methyl ester (9CI) (CA INDEX NAME)




RN 847608-42-8 CAPLUS

CN Urea, N-[4-fluoro-3-(trifluoromethyl)phenyl]-N'-[[4-(3-pyridinyl)phenyl]methyl]- (CA INDEX NAME)




RN 847608-44-0 CAPLUS

CN Urea, N-[[3-(6-amino-3-pyridinyl)phenyl]methyl]-N'-[4-chloro-3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 847608-46-2 CAPLUS

CN Urea, N-[[4-(6-amino-3-pyridinyl)phenyl]methyl]-N'-[4-chloro-3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 847608-48-4 CAPLUS

CN Urea, N-[[3-(2-amino-5-pyrimidinyl)phenyl]methyl]-N'-[4-chloro-3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 847608-50-8 CAPLUS

CN Urea, N-[[4-(2-amino-5-pyrimidinyl)phenyl]methyl]-N'-[4-chloro-3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 847608-51-9 CAPLUS

CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[1-[4-(3-pyridinyl)phenyl]ethyl]- (CA INDEX NAME)




RN 847608-53-1 CAPLUS

CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[1-[4-(5-pyrimidinyl)phenyl]ethyl]- (CA INDEX NAME)




RN 847608-55-3 CAPLUS

CN Acetamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[4-(1H-indol-2-yl)phenoxy]- (CA INDEX NAME)




RN 847608-58-6 CAPLUS

CN Hydrazinecarboxamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[4-(4-pyridinyl)phenyl]- (CA INDEX NAME)




RN 847608-59-7 CAPLUS

CN Hydrazinecarboxamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[3-(4-pyridinyl)phenyl]- (CA INDEX NAME)




RN 847608-60-0 CAPLUS

CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[[3-(4-pyridinyl)phenyl]methyl]- (CA INDEX NAME)




RN 847608-62-2 CAPLUS

CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[[4-(6-quinoxaliny)phenyl]methyl]- (CA INDEX NAME)



RN 847608-63-3 CAPLUS


CN Urea, N-[[3-(2-amino-5-methyl-3-pyridinyl)phenyl]methyl]-N'-[4-chloro-3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 847608-65-5 CAPLUS

CN Carbamic acid, (3-chloro-4-methoxyphenyl)-,


[3-(1H-tetrazol-1-yl)phenyl]methyl ester (9CI) (CA INDEX NAME)



RN 847608-66-6 CAPLUS

CN Urea,


N-(3-chloro-4-methoxyphenyl)-N'-[[3-(1H-tetrazol-1-yl)phenyl]methyl]-
(CA INDEX NAME)



RN 847608-67-7 CAPLUS


CN Acetamide,

N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[4-(2,5-dihydro-5-oxo-1H-tetrazol-1-yl)phenoxy]-
(CA INDEX NAME)




RN 847608-68-8 CAPLUS

CN Urea, N-[[3-(2-amino-5-chloro-3-pyridinyl)phenyl]methyl]-N'-[4-chloro-3-(trifluoromethyl)phenyl]-
(CA INDEX NAME)




RN 847608-69-9 CAPLUS

CN Urea, N-[[4-(2-amino-5-chloro-3-pyridinyl)phenyl]methyl]-N'-[4-chloro-3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 847608-70-2 CAPLUS

CN Urea, N-[[3-(6-chloro-3-pyridinyl)phenyl]methyl]-N'-[4-chloro-3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 847608-71-3 CAPLUS

CN Urea, N-[[4-(6-chloro-3-pyridinyl)phenyl]methyl]-N'-[4-chloro-3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 847608-74-6 CAPLUS

CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[[3-(6-fluoro-3-pyridinyl)phenyl]methyl]- (CA INDEX NAME)




RN 847608-75-7 CAPLUS

CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[[3-(2-methoxy-3-pyridinyl)phenyl]methyl]- (CA INDEX NAME)




RN 847608-77-9 CAPLUS

CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[[4-(6-fluoro-3-pyridinyl)phenyl]methyl]- (CA INDEX NAME)




RN 847608-79-1 CAPLUS

CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[[4-(2-methoxy-3-pyridinyl)phenyl]methyl]- (CA INDEX NAME)




RN 847608-80-4 CAPLUS

CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[[4-(6-methyl-3-pyridinyl)phenyl]methyl]- (CA INDEX NAME)




RN 847608-81-5 CAPLUS

CN Urea, N-[[4-(2-amino-5-fluoro-3-pyridinyl)phenyl]methyl]-N'-[4-chloro-3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 847608-82-6 CAPLUS

CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[[3-(6-methyl-3-pyridinyl)phenyl]methyl]- (CA INDEX NAME)




RN 847608-83-7 CAPLUS

CN Urea, N-[[4-(2-amino-3-pyridinyl)phenyl]methyl]-N'-[4-chloro-3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 847608-84-8 CAPLUS

CN Urea, N-[[3-(2-amino-3-pyridinyl)phenyl]methyl]-N'-[4-chloro-3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 847608-85-9 CAPLUS

CN Carbamic acid, [4-chloro-3-(trifluoromethyl)phenyl]-,
[3-(6-methyl-3-pyridinyl)phenyl]methyl ester (9CI) (CA INDEX NAME)




RN 847608-86-0 CAPLUS

CN Carbamic acid, [4-chloro-3-(trifluoromethyl)phenyl]-,
[3-(2-amino-5-fluoro-3-pyridinyl)phenyl]methyl ester (9CI) (CA INDEX NAME)




RN 847608-87-1 CAPLUS

CN Carbamic acid, [4-chloro-3-(trifluoromethyl)phenyl]-,
[3-(2-amino-3-pyridinyl)phenyl]methyl ester (9CI) (CA INDEX NAME)




RN 847608-89-3 CAPLUS

CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[[3-[6-(hydroxymethyl)-3-pyridinyl]phenyl]methyl]- (CA INDEX NAME)




RN 847608-90-6 CAPLUS

CN Urea, N-[[3-(6-acetyl-3-pyridinyl)phenyl]methyl]-N'-[4-chloro-3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 847608-91-7 CAPLUS

CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[[3-(6-cyano-3-pyridinyl)phenyl]methyl]- (CA INDEX NAME)




RN 847608-98-4 CAPLUS

CN Carbamic acid, [4-chloro-3-(trifluoromethyl)phenyl]-, [3-(1H-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl]methyl ester (9CI) (CA INDEX NAME)




RN 847609-00-1 CAPLUS

CN Urea, N-[[3-(2-amino-5-fluoro-3-pyridinyl)phenyl]methyl]-N'-[4-chloro-3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 847609-04-5 CAPLUS

CN Carbamic acid, [4-chloro-3-(trifluoromethyl)phenyl]-,
[3-(1H-benzimidazol-2-yl)phenyl]methyl ester (9CI) (CA INDEX NAME)




RN 847609-06-7 CAPLUS

CN Carbamic acid, [4-chloro-3-(trifluoromethyl)phenyl]-,
[3-(6-amino-2-methyl-3-pyridinyl)phenyl]methyl ester (9CI) (CA INDEX NAME)




RN 847609-08-9 CAPLUS

CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[[3-[5-(methylthio)-3-pyridinyl]phenyl]methyl]- (CA INDEX NAME)




RN 847609-10-3 CAPLUS

CN Carbamic acid, [4-chloro-3-(trifluoromethyl)phenyl]-,
[4-(6-methyl-3-pyridinyl)phenyl]methyl ester (9CI) (CA INDEX NAME)




RN 847609-12-5 CAPLUS

CN Carbamic acid, [4-chloro-3-(trifluoromethyl)phenyl]-,
[4-(2-amino-5-fluoro-3-pyridinyl)phenyl]methyl ester (9CI) (CA INDEX
NAME)



RN 847609-14-7 CAPLUS


CN Carbamic acid, [4-chloro-3-(trifluoromethyl)phenyl]-,
[4-(2-amino-3-pyridinyl)phenyl]methyl ester (9CI) (CA INDEX NAME)




RN 847609-18-1 CAPLUS

CN Carbamic acid, [4-chloro-3-(trifluoromethyl)phenyl]-,
[4-(1H-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl]methyl ester (9CI) (CA INDEX
NAME)


PAGE 1-A




PAGE 2-A



RN 847609-20-5 CAPLUS
 CN Carbamic acid, [4-chloro-3-(trifluoromethyl)phenyl]-,
 [4-(6-amino-2-methyl-3-pyridinyl)phenyl]methyl ester (9CI) (CA INDEX
 NAME)




RN 847609-28-3 CAPLUS
 CN Carbamic acid, (5-chloro-2-methoxyphenyl)-, [3-(3-pyridinyl)phenyl]methyl
 ester (9CI) (CA INDEX NAME)




RN 847609-30-7 CAPLUS

CN Carbamic acid, [4-chloro-3-(trifluoromethyl)phenyl]-,
[4-(1H-tetrazol-1-yl)phenyl]methyl ester (9CI) (CA INDEX NAME)




RN 847609-32-9 CAPLUS

CN Carbamic acid, (5-chloro-2-methoxyphenyl)-,
[3-(5-pyrimidinyl)phenyl]methyl ester (9CI) (CA INDEX NAME)



RN 847609-50-1 CAPLUS

CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[[3-(1H-pyrazol-4-yl)phenyl]methyl]- (CA INDEX NAME)




RN 847609-52-3 CAPLUS

CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[[4-(1H-pyrazol-4-yl)phenyl]methyl]-

yl)phenyl]methyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A

C1


RN 847609-54-5 CAPLUS

CN Carbamic acid, [4-chloro-3-(trifluoromethyl)phenyl]-, [3-[2-(1-piperazinyl)-5-pyrimidinyl]phenyl]methyl ester (9CI) (CA INDEX NAME)




RN 847609-56-7 CAPLUS

CN Carbamic acid, [4-chloro-3-(trifluoromethyl)phenyl]-, [4-[2-(1-piperazinyl)-5-pyrimidinyl]phenyl]methyl ester (9CI) (CA INDEX NAME)




RN 847609-57-8 CAPLUS

CN Urea, N-[[3-(2-chloro-3-pyridinyl)phenyl]methyl]-N'-[4-chloro-3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 847609-58-9 CAPLUS

CN Urea, N-[[4-(2-chloro-3-pyridinyl)phenyl]methyl]-N'-[4-chloro-3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 847609-59-0 CAPLUS

CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[[3-(2-fluoro-3-pyridinyl)phenyl]methyl]- (CA INDEX NAME)




RN 847609-60-3 CAPLUS

CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[[4-(2-fluoro-3-pyridinyl)phenyl]methyl]- (CA INDEX NAME)




RN 847609-63-6 CAPLUS

CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[[3-[5-(methylthio)-2-pyridinyl]phenyl]methyl]- (CA INDEX NAME)




RN 847609-65-8 CAPLUS

CN Carbamic acid, [4-chloro-3-(trifluoromethyl)phenyl]-, [3-(2,6-dimethyl-3-pyridinyl)phenyl]methyl ester (9CI) (CA INDEX NAME)




RN 847609-67-0 CAPLUS

CN Carbamic acid, [4-chloro-3-(trifluoromethyl)phenyl]-, [3-(5-methoxy-3-pyridinyl)phenyl]methyl ester (9CI) (CA INDEX NAME)




RN 847609-73-8 CAPLUS

CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[[3-(4-isoquinolinyl)phenyl]methyl]- (CA INDEX NAME)




RN 847609-75-0 CAPLUS

CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[[4-(4-isoquinolinyl)phenyl]methyl]- (CA INDEX NAME)



RN 847609-79-4 CAPLUS


CN Carbamic acid, [4-chloro-3-(trifluoromethyl)phenyl]-, [3-(1H-pyrazol-4-yl)phenyl]methyl ester (9CI) (CA INDEX NAME)



RN 847609-81-8 CAPLUS

CN Carbamic acid, [4-chloro-3-(trifluoromethyl)phenyl]-,
[4-(1H-pyrazol-4-yl)phenyl]methyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A

C1

RN 847609-86-3 CAPLUS


CN Acetamide,

N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[3-(2,5-dihydro-5-oxo-1H-tetrazol-1-yl)phenoxy]- (CA INDEX NAME)



RN 847609-93-2 CAPLUS

CN Carbamic acid, [4-chloro-3-(trifluoromethyl)phenyl]-,
[4-(4-pyrimidinyl)phenyl]methyl ester (9CI) (CA INDEX NAME)



IT 847606-70-6P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of anilines and related compds. as C-kit modulators)

RN 847606-70-6 CAPLUS

CN Acetamide,

N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[3-[4-(trimethylsilyl)-1H-1,2,3-triazol-1-yl]phenoxy]- (CA INDEX NAME)



OS.CITING REF COUNT: 7 THERE ARE 7 CAPLUS RECORDS THAT CITE THIS RECORD (8 CITINGS)

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L82 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 2004:493723 CAPLUS Full-text

DOCUMENT NUMBER: 141:54195

TITLE: Preparation of oxindole derivatives as kinase modulators

INVENTOR(S): Bannen, Lynne Canne; Brown, S. David; Cheng, Wei; Co, Erick Wang; Nuss, John M.; Kim, Moon Hwan; Klein, Rhett Ronald; Le, Donna T.; Lew, Amy; Mac, Morrison B.; Parks, Jason Jevious; Wen, Zhaoyang; Xu, Wei

PATENT ASSIGNEE(S): Exelixis, Inc., USA

SOURCE: PCT Int. Appl., 120 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English



FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004050681	A2	20040617	WO 2003-US36567	20031114
WO 2004050681	A3	20041104		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE,

GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,
 LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ,
 OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
 TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
 BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,
 ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK,
 TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 CA 2506546 A1 20040617 CA 2003-2506546 20031114
 AU 2003302665 A1 20040623 AU 2003-302665 20031114
 AU 2003302665 B2 20091224
 EP 1581309 A2 20051005 EP 2003-812437 20031114
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
 JP 2006510727 T 20060330 JP 2004-570758 20031114
 US 20060122171 A1 20060608 US 2005-533555 20050502
 US 7626031 B2 20091201
 PRIORITY APPLN. INFO.: US 2002-426680P P 20021115
 US 2003-470674P P 20030514
 WO 2003-US36567 W 20031114
 ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
 OTHER SOURCE(S): MARPAT 141:54195
 GI



AB The title compds. I [W = N or CR₁; R₁ = H, halo, trihaloalkyl, CN, NH₂, NO₂, OR₆, N=CNR₆R₇, N(R₆)C(=NR₈)NR₆R₇, SR₆, S(O)₁₋₂R₆, SO₂NR₆R₇, CO₂R₆, etc.; L = O, S(O)₀₋₂, or NR₃; Q = C or N, when Q = N, then R₄ does not exist; R₂, R₃ = H or R₇; R₄, R₅ = H, OR₆, NR₆R₇, S(O)₀₋₂R₆, SO₂NR₆R₇, CO₂R₆, C(O)NR₆R₇, N(R₆)SO₂R₆, NC(O)₂R₆, C(O)R₇, CN, NO₂, NH₂, halo, trihaloalkyl, R₇; or R₄, R₅ when taken together, form a five or six-membered aromatic ring containing 0-2 N; R₆, R₇ = H, (substituted)(aryl)alkyl, (substituted)heterocyclalkyl, (substituted)aryl,

(substituted)heterocyclyl, with proviso or R6, R7 = when taken together with a common N to which they are attached, form a five to seven-membered heterocyclic ring containing at least one addnl. heteroatom selected from N, O, S, or P; R8 = H, NO2, CN, OR6, or (substituted)alkyl; X = (substituted)(hetero)aromatic ring; K = O, S, (substituted)amino] were prepared as kinase modulators to treat kinase-dependent diseases and conditions. For example compound II was prepared in a multi-step synthesis starting from 4-methylimidazole. The latter inhibited KDR and EGFR with IC50 < 50 nM.

OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
(1 CITINGS)
REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L82 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 2003:1006921 CAPLUS Full-text

DOCUMENT NUMBER: 140:42210

TITLE: Preparation of 1-sulfonyl-2-piperazinehydroxamic acids as selective inhibitors of human ADAM-10 for treating cancer, arthritis and diseases related to angiogenesis
INVENTOR(S): Bannen, Lynne Canne; Co, Erick W.; Jammalamadaka, Vasu; Nuss, John M.; Kim, Moon Hwan; Le Tra, Donna; Lew, Amy; Mac, Morrison B.; Mamo, Shumeye; Wen, Zhaoyang; Xu, Wei

PATENT ASSIGNEE(S): Exelixis, Inc., USA

SOURCE: PCT Int. Appl., 94 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003106381	A2	20031224	WO 2003-US18262	20030611
WO 2003106381	A3	20040415		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2485346	A1	20031224	CA 2003-2485346	20030611
AU 2003237532	A1	20031231	AU 2003-237532	20030611
AU 2003237532	B2	20090730		
EP 1511488	A2	20050309	EP 2003-736979	20030611
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
JP 2005533789	T	20051110	JP 2004-513217	20030611
JP 4718172	B2	20110706		
US 20060199820	A1	20060907	US 2005-518110	20051026

US 7629341	B2	20091208		
US 20100105953	A1	20100429	US 2009-605118	20091023
US 7989661	B2	20110802		
AU 2009230801	A1	20091119	AU 2009-230801	20091028
JP 2010265276	A	20101125	JP 2010-142096	20100622
PRIORITY APPLN. INFO.:			US 2002-388326P	P 20020612
			AU 2003-237532	A3 20030611
			JP 2004-513217	A3 20030611
			WO 2003-US18262	W 20030611
			US 2005-518110	A3 20051026

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 140:42210

GI



AB The present invention provides 1-sulfonyl-2-piperazinehydroxamic acids (shown as I; variables defined below; e.g. II) useful for inhibiting the ADAM-10 protein, with selectivity vs. MMP-1. Inhibition activities of 66 examples of I towards ≤ 8 metalloproteinases are tabulated. Such compds. are useful in the in vitro study of the role of ADAM-10 (and its inhibition) in biol. processes. The present invention also comprises pharmaceutical compns. comprising ≥ 1 ADAM-10 inhibitors according to the invention in combination with a pharmaceutically acceptable carrier. Such compns. are useful for the treatment of cancer, arthritis, and diseases related to angiogenesis. Correspondingly, the invention also comprises methods of treating forms of cancer, arthritis, and diseases related to angiogenesis in which ADAM-10 plays a critical role. A method of preparation of sulfonyl halide intermediates is claimed. For example, [4-(4-fluorophenoxy)-3,5-difluorophenyl]sulfonyl chloride was prepared in 3 steps (105, 98 and 83 % yields) starting from 3,4,5-trifluoronitrobenzene, 4-fluorophenol, and Cs_2CO_3 in DMF and involving intermediates 4-(4-fluorophenoxy)-3,5-difluoronitrobenzene and 4-(4-fluorophenoxy)-3,5-difluoroaniline. The prepared [4-(4-fluorophenoxy)-3,5-difluorophenyl]sulfonyl chloride was used in a 5-step procedure (65, 78, -, 69 and 62 % yields) to give II involving intermediates (R)-1-[[4-(4-fluorophenoxy)-3,5-difluorophenyl]sulfonyl]-4-boc-piperazine-2-carboxylic acid, Me

(R)-1-[[4-(4-fluorophenoxy)-3,5-difluorophenyl]sulfonyl]-4-boc-piperazine-2-carboxylate, Me (R)-1-[[4-(4-fluorophenoxy)-3,5-difluorophenyl]sulfonyl]piperazine-2-carboxylate trifluoroacetate and Me (R)-1-[[4-(4-fluorophenoxy)-3,5-difluorophenyl]sulfonyl]-4-(ethoxycarbonyl)piperazine-2-carboxylate. Although the methods of preparation of I are not claimed, several example preps. and characterization data for 66 examples of I are included. For I: L1 is -C(O)-, -S(O)2-, or -(CH2)n-; R1 is -H, -OR11, -(CH2)nR11, -C(O)R11, or -NR12R13; R2 is -R21-L2-R22 (R21 is saturated or mono- or poly- unsatd. C5-C14-mono- or fused poly- cyclic hydrocarbyl, optionally containing one or two annular heteroatoms per ring and (un)substituted with 1-3 R50 substituents; L2 is -O-, -C(O)-, -CH2-, -NH-, -SO2- or a direct bond; R22 is saturated or mono- or poly- unsatd. C5-C14-mono- or fused polycyclic hydrocarbyl, optionally containing one or two annular heteroatoms per ring and (un)substituted with 1-3 R50 substituents); n = 0-3; provided that an O or S is not singly bonded to another O or S in a chain of atoms; addnl. details are given in the claims.

OS.CITING REF COUNT: 7 THERE ARE 7 CAPLUS RECORDS THAT CITE THIS RECORD (8 CITINGS)

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L82 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 2003:491172 CAPLUS Full-text

DOCUMENT NUMBER: 139:69520

TITLE: Preparation of N-sulfonyl amino acid hydroxamide derivatives as human ADAM-10 inhibitors

INVENTOR(S): Brown, S. David; Canne, Lynne; Co, Erick W.; Jammalamadaka, Vasu; Khoury, Richard G.; Kim, Moon Hwan; Le, Donna T.; Lew, Amy; Mac, Morrison B.; Mamo, Shumeye; Nuss, John M.; Prisbylla, Michael P.; Xu, Wei

PATENT ASSIGNEE(S): Exelixis, Inc., USA

SOURCE: PCT Int. Appl., 144 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003051825	A1	20030626	WO 2002-US39816	20021213
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2473938	A1	20030626	CA 2002-2473938	20021213
AU 2002346724	A1	20030630	AU 2002-346724	20021213
AU 2002346724	B2	20090430		

EP 1461313	A1	20040929	EP 2002-784794	20021213
EP 1461313	B1	20090805		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
JP 2005513065	T	20050512	JP 2003-552713	20021213
JP 4427328	B2	20100303		
AT 438618	T	20090815	AT 2002-784794	20021213
ES 2331177	T3	20091223	ES 2002-784794	20021213
US 20050227973	A1	20051013	US 2005-498338	20050511
US 7498358	B2	20090303		
US 20090143386	A1	20090604	US 2009-322422	20090202
US 7951972	B2	20110531		

PRIORITY APPLN. INFO.:

US 2001-340179P	P	20011214
WO 2002-US39816	W	20021213
US 2005-498338	A3	20050511

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 139:69520

AB The invention provides amino acid derivs. R5SO2NR4CHR3CONR2OR1 [R1 is H, alkyl, alkanoyl, (un)substituted arylalkyl or arylalkanoyl; R2 is any group given for R1 plus alkoxy; R3 is -Z-Q-J, where Z is (un)substituted alk(en)yl, alkoxyalkyl, or alkylthioalkyl; Q is a bond, CO, (un)substituted aryl, heteroaryl, or heterocycloalkyl; J is an amino group, including ureido groups; R4 is H, (un)substituted alkyl or arylalkyl; R5 is -M-G-A, where M and A are (un)substituted aryl or heteroaryl; G is a bond, CH2, -alkyl-O-, -O-alkyl-, O, S, SO, or SO2 (with provisos)] useful for inhibiting the ADAM-10 protein, also known as human Kuzbanian. Such compds. are useful in the in vitro study of the role of ADAM-10 (and its inhibition) in biol. processes. Pharmaceutical compns. comprising one or more ADAM-10 inhibitors are useful for the treatment of cancer, arthritis, and diseases related to angiogenesis. The invention also provides methods for making bis-aryl ether sulfonyl chloride intermediates. Thus, claimed compound

N2-[[6-(3-fluorophenyl)pyridin-3-yl]sulfonyl]-N1-hydroxy-D-argininamide showed IC50 < 50 nM for inhibition of ADAM-10.

OS.CITING REF COUNT: 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD (6 CITINGS)

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

STRUCTURE SEARCH

=> fil reg; d stat que l41

FILE 'REGISTRY' ENTERED AT 14:17:24 ON 14 SEP 2011

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2011 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 13 SEP 2011 HIGHEST RN 1332075-54-3

DICTIONARY FILE UPDATES: 13 SEP 2011 HIGHEST RN 1332075-54-3

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

TSCA INFORMATION NOW CURRENT THROUGH June 24, 2011.


Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stdoc/properties.html>

L10

STR



VAR G1=40/37

VAR G2=16-4 19-12/16-12 19-4/20-4 23-12/20-12 23-4/24-4 27-12/24-12 27-4/28-4 31-12/31-4 28-12

VPA 15-1/2/3/5/6 U

VPA 14-7/8/9/10/11 U

NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM

MLEVEL IS CLASS AT 15 28 36 38 39 40

GGCAT IS UNS AT 15
 DEFAULT ECLEVEL IS LIMITED


GRAPH ATTRIBUTES:

RSPEC 12

NUMBER OF NODES IS 40

STEREO ATTRIBUTES: NONE

L11 STR



VAR G1=O/S/N

VAR G2=N/C

VAR G3=1/6/12/25/33/38/52

NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:


RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 56


STEREO ATTRIBUTES: NONE

L13 5217 SEA FILE=REGISTRY SSS FUL L10 AND L11

L34 STR



Page 1-A



Page 2-A

VAR G1=23/29/32/38/42/44/48

VAR G2=BR/F/CL

NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED


GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 62

STEREO ATTRIBUTES: NONE

L37 STR



NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 24

STEREO ATTRIBUTES: NONE

L40 9 SEA FILE=REGISTRY SUB=L13 CSS FUL (L34 OR L37)

L41 5208 SEA FILE=REGISTRY SPE=ON ABB=ON L13 NOT L40

=> fil capl; d que nos 142; s 142 not 182

FILE 'CAPLUS' ENTERED AT 14:17:33 ON 14 SEP 2011

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2011 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 14 Sep 2011 VOL 155 ISS 12
 FILE LAST UPDATED: 13 Sep 2011 (20110913/ED)
 REVISED CLASS FIELDS (/NCL) LAST RELOADED: Jun 2011
 USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Jun 2011

CAPLUS now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2011.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

'OBI' IS DEFAULT SEARCH FIELD FOR 'CAPLUS' FILE

```
L10          STR
L11          STR
L13          5217 SEA FILE=REGISTRY SSS FUL L10 AND L11
L34          STR
L37          STR
L40          9 SEA FILE=REGISTRY SUB=L13 CSS FUL (L34 OR L37)
L41          5208 SEA FILE=REGISTRY SPE=ON ABB=ON L13 NOT L40
L42          165 SEA FILE=CAPLUS SPE=ON ABB=ON L41
```

```
L83          164 L42 NOT L82
```

```
=> s 183 and patent/dt
```

```
7871275 PATENT/DT
```

```
L84          144 L83 AND PATENT/DT
```

```
=> s (183 not 184) and py<2004
```

```
24055414 PY<2004
```

```
L85          7 (L83 NOT L84) AND PY<2004
```

```
=> s 184 and (PD<20030829 OR AD<20030829 OR PRD<20030829)
```

```
23902702 PD<20030829
```

```
(PD<20030829)
```

```
4748234 AD<20030829
```

```
(AD<20030829)
```

4210879 PRD<20030829
 (PRD<20030829)
 L86 77 L84 AND (PD<20030829 OR AD<20030829 OR PRD<20030829)

=> s 185,186
 L87 84 (L85 OR L86)

=> d ibib abs hitstr 187 1-84;fil hom

L87 ANSWER 1 OF 84 CAPLUS COPYRIGHT 2011 ACS on STN
 ACCESSION NUMBER: 2005:641873 CAPLUS Full-text
 DOCUMENT NUMBER: 143:153299
 TITLE: Preparation of substituted urea derivatives for use in
 treating heart failure
 INVENTOR(S): Morgan, Bradley Paul; Elias, Kathleen A.; Kraynack,
 Erica Anne; Lu, Pu-Ping; Malik, Fady; Muci, Alex;
 Qian, Xiangping; Smith, Whitney Walter; Tochimoto,
 Todd; Tomasi, Adam Lewis; Morgans, David J.
 PATENT ASSIGNEE(S): USA
 SOURCE: U.S. Pat. Appl. Publ., 64 pp., Cont.-in-part of Appl.
 No. PCT/US04/001069.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20050159416	A1	20050721	US 2004-890829	20040714 <--
US 7491826	B2	20090217		
WO 2004064730	A2	20040805	WO 2004-US1069	20040114 <--
WO 2004064730	A3	20050324		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI				
US 20090176307	A1	20090709	US 2009-348786	20090105 <--
PRIORITY APPLN. INFO.:			US 2003-440133P	P 20030114 <--
			US 2003-440183P	P 20030114
<--			US 2003-476086P	P 20030604
<--			US 2003-476517P	P 20030605
<--			US 2003-501376P	P 20030908
			WO 2004-US1069	A2 20040114
			US 2004-890829	A1 20040714

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 143:153299

AB The present invention provides substituted urea derivs., pharmaceutical
 compns. containing the derivs., and methods for the treatment of heart
 failure including congestive heart failure, particularly systolic heart
 failure. The compns. are selective modulators of the cardiac sarcomere, for
 example, potentiating cardiac myosin. The ureas of the invention are

represented by the formula $R_1NHC(O)NHR_2$ wherein: R_1 is optionally substituted aryl or heteroaryl; and R_2 is optionally substituted aryl, aralkyl; cycloalkyl, heteroaryl, heteroaralkyl or heterocyclyl, including single stereoisomers, mixts. of stereoisomers, and the pharmaceutically acceptable salts, solvates, and solvates of pharmaceutically acceptable salts thereof.


IT 1056969-80-2 1056969-81-3

RL: PRPH (Prophetic)

(Preparation of substituted urea derivatives for use in treating heart failure)

RN 1056969-80-2 CAPLUS

CN Urea, N-[3-fluoro-5-(3-pyridinyloxy)phenyl]-N'-[[4-(1H-imidazol-1-yl)phenyl]methyl]- (CA INDEX NAME)




RN 1056969-81-3 CAPLUS


CN Urea,

N-[3-fluoro-5-(3-pyridinyloxy)phenyl]-N'-[[4-(1-methyl-1H-pyrazol-4-yl)phenyl]methyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)

REFERENCE COUNT: 105 THERE ARE 105 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L87 ANSWER 2 OF 84 CAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 2005:122807 CAPLUS Full-text

DOCUMENT NUMBER: 142:219152

TITLE: Preparation of tetrahydro-2H-thiopyran-4-carboxamides as anti-herpesvirus agents

INVENTOR(S): Kontani, Toru; Miyata, Junji; Hamaguchi, Wataru; Kawano, Tomoaki; Kamikawa, Akio; Suzuki, Hiroshi; Sudo, Kenji

PATENT ASSIGNEE(S): Yamanouchi Pharmaceutical Co., Ltd., Japan; Rational Drug Design Laboratories

SOURCE: U.S. Pat. Appl. Publ., 13 pp.
CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

```


-----
US 20050032855      A1      20050210      US 2004-912232      20040806 <--
US 6903125          B2      20050607
AU 2004263448      A1      20050217      AU 2004-263448      20040805 <--
AU 2004263448      B2      20090205
CA 2535199          A1      20050217      CA 2004-2535199      20040805 <--
CA 2535199          C      20101214
WO 2005014559      A1      20050217      WO 2004-JP11573      20040805 <--
W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
    CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
    GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
    LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
    NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
    TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
    AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
    EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
    SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
    SN, TD, TG
JP 3623228          B1      20050223      JP 2004-228812      20040805 <--
JP 2005089452      A      20050407
JP 2005089451      A      20050407      JP 2004-228811      20040805 <--
EP 1652843          A1      20060503      EP 2004-748296      20040805 <--
R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
    IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK
CN 1832930          A      20060913      CN 2004-80022258      20040805 <--
CN 100445271        C      20081224
BR 2004013430      A      20061017      BR 2004-13430      20040805 <--
RU 2336273          C2      20081020      RU 2006-106922      20040805 <--
JP 4549974          B2      20100922      JP 2005-513013      20040805 <--
IN 2006DN00617      A      20070831      IN 2006-DN617      20060206 <--
IN 231879          A1      20090403
KR 2006073928      A      20060629      KR 2006-7002614      20060207 <--
MX 2006001526      A      20060525      MX 2006-1526      20060208 <--
US 20060229295      A1      20061012      US 2006-567565      20060208 <--
US 7465748          B2      20081216
NO 2006001100      A      20060307      NO 2006-1100      20060307 <--
PRIORITY APPLN. INFO.:      JP 2003-290850      A      20030808 <--
                                WO 2004-JP11573      W      20040805

```

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): CASREACT 142:219152; MARPAT 142:219152

GI



AB A pharmaceutical drug, particularly a novel compound useful for the prophylaxis or therapeutic treatment of various diseases involving

infections with viruses of the Herpesviridae family, specifically various herpesvirus infections such as varicella (chicken pox) via varicella zoster virus, varicella zoster via recurrent infection with latent varicella zoster virus, herpes labialis and herpes encephalitis via HSV-1 and genital herpes via HSV-2 infection, is disclosed. The title compds. I [Z = 1,2,4-oxadiazol-3-yl or 4-oxazolyl; A = Ph substituted with one Me group and addnl. with one or two substituents selected from Me, halo; 5-indanyl] have such great anti-virus activity that the oral dosing thereof at a low dose enabled the therapeutic treatment of the diseases. Forty compds. I were prepared. Thus, treating Et {(2,6-dimethylphenyl)[(1,1,-dioxo-tetrahydro-2H-thiopyran-4-yl)carbonyl]amino}acetate (preparation given) with NaOH solution followed by reacting the crude acid with [4-(1,3-oxazol-4-yl)phenyl]amine afforded I [Z = 1,3-oxazol-4-yl; A = 2,6-(Me)₂C₆H₃] which showed inhibitory activity in HSV-1 infected hairless mice model (93%), and EC₅₀ of 0.075 μ M in anti-VZV activity assay.

IT 841301-36-8P 841301-37-9P 841301-39-1P
 841301-40-4P 841301-41-5P 841301-42-6P
 841301-43-7P 841301-44-8P 841301-45-9P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of tetrahydro-2H-thiopyran-4-carboxamides as anti-herpesvirus agents)

RN 841301-36-8 CAPLUS

CN 2H-Thiopyran-4-carboxamide,


N-(4-fluoro-2,6-dimethylphenyl)tetrahydro-N-[2-[[4-(1,2,4-oxadiazol-3-yl)phenyl]amino]-2-oxoethyl]-, 1,1-dioxide (CA INDEX NAME)




RN 841301-37-9 CAPLUS

CN 2H-Thiopyran-4-carboxamide,


N-(4-fluoro-3-methylphenyl)tetrahydro-N-[2-[[4-(1,2,4-oxadiazol-3-yl)phenyl]amino]-2-oxoethyl]-, 1,1-dioxide (CA INDEX NAME)




RN 841301-39-1 CAPLUS
 CN 2H-Thiopyran-4-carboxamide,
 N-(3-bromo-4-methylphenyl)tetrahydro-N-[2-[[4-
 (1,2,4-oxadiazol-3-yl)phenyl]amino]-2-oxoethyl]-, 1,1-dioxide (CA INDEX
 NAME)




RN 841301-40-4 CAPLUS
 CN 2H-Thiopyran-4-carboxamide,
 N-(3-fluoro-4-methylphenyl)tetrahydro-N-[2-[[4-
 (1,2,4-oxadiazol-3-yl)phenyl]amino]-2-oxoethyl]-, 1,1-dioxide (CA INDEX
 NAME)




RN 841301-41-5 CAPLUS
 CN 2H-Thiopyran-4-carboxamide,
 N-(3-chloro-4-methylphenyl)tetrahydro-N-[2-[[4-
 (1,2,4-oxadiazol-3-yl)phenyl]amino]-2-oxoethyl]-, 1,1-dioxide (CA INDEX
 NAME)




RN 841301-42-6 CAPLUS
 CN 2H-Thiopyran-4-carboxamide,
 N-(4-chloro-3-methylphenyl)tetrahydro-N-[2-[[4-
 (1,2,4-oxadiazol-3-yl)phenyl]amino]-2-oxoethyl]-, 1,1-dioxide (CA INDEX
 NAME)




RN 841301-43-7 CAPLUS
 CN 2H-Thiopyran-4-carboxamide,
 N-(4-fluoro-3,5-dimethylphenyl)tetrahydro-N-[2-
 [[4-(1,2,4-oxadiazol-3-yl)phenyl]amino]-2-oxoethyl]-, 1,1-dioxide (CA
 INDEX NAME)



RN 841301-44-8 CAPLUS
 CN 2H-Thiopyran-4-carboxamide,
 N-(3-fluoro-2,4-dimethylphenyl)tetrahydro-N-[2-
 [[4-(1,2,4-oxadiazol-3-yl)phenyl]amino]-2-oxoethyl]-, 1,1-dioxide (CA
 INDEX NAME)



RN 841301-45-9 CAPLUS
 CN 2H-Thiopyran-4-carboxamide,
 N-(2-fluoro-4-methylphenyl)tetrahydro-N-[2-[[4-
 (1,2,4-oxadiazol-3-yl)phenyl]amino]-2-oxoethyl]-, 1,1-dioxide (CA INDEX
 NAME)



OS.CITING REF COUNT: 6 THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD
 (10 CITINGS)
 REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L87 ANSWER 3 OF 84 CAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 2005:120889 CAPLUS Full-text

DOCUMENT NUMBER: 142:198069

TITLE: Preparation of diaryl and arylheteroaryl urea
 derivatives, in particular pyrazolylphenyl ureas, as
 5-HT_{2A} serotonin receptor modulators

INVENTOR(S): Teegarden, Bradley; Jayakumar, Honnappa; Li, Hongmei;
 Strah-Pleyne, Sonja; Dosa, Peter Ian

PATENT ASSIGNEE(S): Arena Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 260 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English



FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005012254	A1	20050210	WO 2004-US23488	20040721 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,				

CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
 GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
 LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
 NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
 TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
 AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
 EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
 SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
 SN, TD, TG

AU 2004261582	A1	20050210	AU 2004-261582	20040721 <--
CA 2533369	A1	20050210	CA 2004-2533369	20040721 <--
CA 2533369	C	20090714		
US 20050080124	A1	20050414	US 2004-895789	20040721 <--
EP 1558582	A1	20050803	EP 2004-758159	20040721 <--
EP 1558582	B1	20051221		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
AT 313532	T	20060115	AT 2004-758159	20040721 <--
PT 1558582	E	20060531	PT 2004-758159	20040721 <--
CN 1826322	A	20060830	CN 2004-80021009	20040721 <--
EP 1695966	A1	20060830	EP 2005-25004	20040721 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
ES 2258760	T3	20060901	ES 2004-758159	20040721 <--
BR 2004012263	A	20060919	BR 2004-12263	20040721 <--
JP 2006528195	T	20061214	JP 2006-521215	20040721 <--
JP 4198733	B2	20081217		
NZ 544331	A	20100326	NZ 2004-544331	20040721 <--
CN 101871931	A	20101027	CN 2010-10200790	20040721 <--
IL 172582	A	20101031	IL 2004-172582	20040721 <--
CN 101875961	A	20101103	CN 2010-10199162	20040721 <--
HK 1072943	A1	20060310	HK 2005-106673	20050803 <--
IN 2005KN02588	A	20061124	IN 2005-KN2588	20051213 <--
IN 220494	A1	20080530		
KR 2006041260	A	20060511	KR 2006-7001437	20060120 <--
MX 2006000795	A	20060823	MX 2006-795	20060120 <--
ZA 2006000596	A	20070131	ZA 2006-596	20060120 <--
NO 2006000877	A	20060222	NO 2006-877	20060222 <--
JP 2007039461	A	20070215	JP 2006-242161	20060906 <--
US 20070072857	A1	20070329	US 2006-603601	20061122 <--
US 20070078134	A1	20070405	US 2006-603626	20061122 <--
JP 2008143908	A	20080626	JP 2008-3748	20080110 <--
IN 2008KN00669	A	20081114	IN 2008-KN669	20080214 <--
PRIORITY APPLN. INFO.:				
			US 2003-489572P	P 20030722 <--
			US 2003-503586P	P 20030916
			CN 2004-80021009	A3 20040721
			EP 2004-758159	A3 20040721
			JP 2006-521215	A3 20040721
			US 2004-895789	A1 20040721
			WO 2004-US23488	W 20040721
			IN 2005-KN2588	A3 20051213
OTHER SOURCE(S): CASREACT 142:198069; MARPAT 142:198069				
GI				



AB Title compds. I [wherein R1 = (un)substituted hetero/aryl; R2 = H, alk(en/yn)yl, cycloalkyl; R3 = H, alk(en/yn)yl, alkylcarboxamido, alkylsulfonamido, carboxy, cyano, halo, etc.; R4 = NH2, CN, OH, SH, NO2, sulfonamido, halo, alk(en/yn)yl, acyl, acyloxy, etc.; R5 = acyl, acyloxy, alk(en/yn)yl, NH2, halo, haloalkylthio, etc.; R6a, R6b, R6c = independently H, acyl, acyloxy, alk(en/yn)yl, CN, OH, SH, NO2, alkylsulfinyl, alkylureyl, etc.; R7, R8 = independently H, alkyl; X = O, S; Q = a bond, (un)substituted alkylene; and their pharmaceutically acceptable salts, hydrates and solvates] were prepared as modulators of the 5-HT2A serotonin receptor. Thus, reacting

[3-(4-Bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxyphenyl]amine (preparation given) with 4-Chloro-2-(trifluoromethyl)phenyl isocyanate gave II in 60% yield. Nine biol. tests are given. The majority of I showed IC50 activities in the 5-HT2A IP3 accumulation assay of at least about 10 μ M. Selected I attenuated DOI-induced hypolocomotion in rats, demonstrating their inverse agonistic activity. Thus, I and their pharmaceutical compns. thereof are directed to methods useful in the prophylaxis or treatment of platelet aggregation, coronary artery disease, myocardial infarction, transient ischemic attack, angina, stroke, atrial fibrillation, reducing the risk of blood clot formation, asthma or symptoms thereof, agitation or a symptom, behavioral disorders, drug induced psychosis, excitative psychosis, Gilles de la Tourette's syndrome, manic disorder, organic or NOS psychosis, psychotic disorder, psychosis, acute schizophrenia, chronic schizophrenia, NOS schizophrenia and related disorders, and sleep disorders, sleep disorders, diabetic-related disorders and the like. The invention also relates to the method of prophylaxis or treatment of 5-HT2A serotonin receptor mediated disorders in combination with a dopamine D2 receptor antagonist such as haloperidol, administered sep. or together.

IT 339715-19-4P, 1-(4-Chlorobenzyl)-3-[4-(3-dimethylaminopropoxy)-3-(2-methyl-2H-pyrazol-3-yl)phenyl]urea


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES

(Uses)

(drug candidate; preparation of pyrazolylphenyl ureas as 5-HT_{2A} serotonin receptor modulators for treatment of heart disease, stroke, psychosis, sleep disorder and other disorders)

RN 839715-19-4 CAPLUS

CN Urea, N-[(4-chlorophenyl)methyl]-N'-[4-[3-(dimethylamino)propoxy]-3-(1-methyl-1H-pyrazol-5-yl)phenyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 7 THERE ARE 7 CAPLUS RECORDS THAT CITE THIS RECORD (7 CITINGS)

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L87 ANSWER 4 OF 84 CAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 2005:34603 CAPLUS Full-text

DOCUMENT NUMBER: 142:134589

TITLE: Preparation of indazole derivatives for treating or preventing diseases associated with protein kinases
INVENTOR(S): Bhagwat, Shripad S.; Satoh, Yoshitaka; Sakata, Steven T.; Buhr, Chris A.; Albers, Ronald; Sapienza, John; Plantevin, Veronique; Chao, Qi; Sahasrabudhe, Kiran; Ferri, Rachel; Narla, Rama K.

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 240 pp., Cont.-in-part of U.S. Ser. No. 414,839.

CODEN: USXXCO

DOCUMENT TYPE: Patent


LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20050009876	A1	20050113	US 2003-718185	20031119 <--
US 20020103229	A1	20020801	US 2001-910950	20010723 <--
US 6897231	B2	20050524		
US 20040127536	A1	20040701	US 2003-414839	20030416 <--
US 7211594	B2	20070501		
US 20070060616	A1	20070315	US 2006-512836	20060830 <--
PRIORITY APPLN. INFO.:			US 2000-221799P	P 20000731 <--
			US 2001-910950	A2 20010723 <--
			US 2003-414839	A2 20030416 <--
			US 2003-718185	A1 20031119

OTHER SOURCE(S): MARPAT 142:134589
GI



AB Methods of treating or preventing diseases associated with protein kinases, including tyrosine kinases, such as proliferative diseases, inflammatory diseases, abnormal angiogenesis and diseases related thereto, atherosclerosis, macular degeneration, diabetes, obesity, pain and others, comprising administering to a patient in need thereof an effective amount of the title indazole I [A = a direct bond, (CH₂)_a, (CH₂)_bCH:CH(CH₂)_c, or (CH₂)_bC.tplbond.C(CH₂)_c; R₁ = (un)substituted aryl, heteroaryl or heterocycle fused to Ph; R₂ = R₃, R₄, (CH₂)_bC(O)R₅, (CH₂)_bC(:O)OR₅, (CH₂)_bC(O)NR₅R₆, (CH₂)_bC(O)NR₅(CH₂)_cC(O)R₆, (CH₂)_bNR₅C(O)R₆, (CH₂)_bNR₅C(O)NR₆R₇, (CH₂)_bNR₅R₆, (CH₂)_bOR₅, (CH₂)_bSO_dR₅ or (CH₂)_bSO₂NR₅R₆; a = 1-6; b, c = 0-4; d = 0-2; R₃ = halo, hydroxy, carboxy, alkyl, alkoxy, haloalkyl, etc.; R₄ = (un)substituted alkyl, aryl, arylalkyl, heterocycle or heterocyclealkyl, or R₄ = halo or OH; R₅-R₇ = H, (un)substituted alkyl, aryl, arylalkyl, heterocycle or heterocyclealkyl], are disclosed. Many of the claimed compds. I have IC₅₀ values ≤0.5 μM in the JNK2 assay, e.g. 5-[3-(4-fluorophenyl)-1H-indazol-5-yl]-2H-1,2,3,4-tetrazole. Although the methods of preparation are not claimed, >400 example preps. are included.


IT 716322-98-4

RL: PRPH (Prophetic)

(Preparation of indazole derivatives for treating or preventing diseases associated with protein kinases)

RN 716322-98-4 CAPLUS

CN 1H-Indazole-5-carboxamide, 3-[3-[[[(4-fluorophenyl)methyl]amino]carbonyl]amino]phenyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD (5 CITINGS)

L87 ANSWER 5 OF 84 CAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 2004:902232 CAPLUS Full-text

DOCUMENT NUMBER: 141:374691

TITLE: Anthranilic acid derivatives useful in treating infection with hepatitis C virus

INVENTOR(S): Bloom, Jonathan D.; Bailey, Thomas R.

PATENT ASSIGNEE(S): Wyeth, John, and Brother Ltd., USA; Viropharma Incorporated
 SOURCE: PCT Int. Appl., 38 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004091724	A1	20041028	WO 2003-US32032	20031008 <--
W:			AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW	
RW:			GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG	
AU 2003304040	A1	20041104	AU 2003-304040	20031008 <--
US 20050004192	A1	20050106	US 2003-682647	20031008 <--
US 7408078	B2	20080805		
US 20080269333	A1	20081030	US 2008-168645	20080707 <--
PRIORITY APPLN. INFO.:			US 2002-416521P	P 20021008 <--
			US 2003-682647	A1 20031008
			WO 2003-US32032	W 20031008

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 141:374691

AB The present invention provides pharmaceutical compns. comprising anthranilic acid derivs. useful in treating hepatitis C infection by virtue of their ability to inhibit hepatitis C polymerase (NS5B). The present invention also provides methods of treating hepatitis C infection by administering to a mammal the pharmaceutical compns. of the present invention.


IT 782481-09-8

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(anthranilic acid derivs. for treatment of hepatitis C virus infection)

RN 782481-09-8 CAPLUS

CN Acetamide, 2-(4-chlorophenoxy)-N-[2-(2H-tetrazol-5-yl)phenyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD
(2 CITINGS)
REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L87 ANSWER 6 OF 84 CAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 2004:780704 CAPLUS Full-text

DOCUMENT NUMBER: 141:296035

TITLE: Preparation of oxopyrazolocinnolines as CD80
inhibitors useful as immunomodulators

INVENTOR(S): Mathews, Ian Richard

PATENT ASSIGNEE(S): Avidex Limited, UK

SOURCE: PCT Int. Appl., 76 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004081011	A1	20040923	WO 2004-GB1008	20040310 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004220310	A1	20040923	AU 2004-220310	20040310 <--
CA 2519063	A1	20040923	CA 2004-2519063	20040310 <--
CA 2519063	C	20110510		
EP 1603917	A1	20051214	EP 2004-719006	20040310 <--
EP 1603917	B1	20101124		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
BR 2004008365	A	20060321	BR 2004-8365	20040310 <--
CN 1761664	A	20060419	CN 2004-80006886	20040310 <--
CN 100363365	C	20080123		
JP 2006520372	T	20060907	JP 2006-505937	20040310 <--
NZ 541973	A	20090626	NZ 2004-541973	20040310 <--
AT 489388	T	20101215	AT 2004-719006	20040310 <--
PT 1603917	E	20110204	PT 2004-719006	20040310 <--
EP 2284172	A1	20110216	EP 2010-14524	20040310 <--
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LI, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
ES 2357110	T3	20110418	ES 2004-719006	20040310 <--
MX 2005009667	A	20060127	MX 2005-9667	20050909 <--
ZA 2005007364	A	20061025	ZA 2005-7364	20050913 <--
NO 2005004710	A	20051213	NO 2005-4710	20051013 <--

IN 2005CN02624	A	20070406	IN 2005-CN2624	20051013 <--
IN 229041	A1	20090320		
US 20070021428	A1	20070125	US 2006-547448	20060620 <--
US 7276505	B2	20071002		
HK 1090921	A1	20080704	HK 2006-111573	20061019 <--
US 20080045527	A1	20080221	US 2007-845837	20070828 <--
US 7598247	B2	20091006		
US 20090312334	A1	20091217	US 2009-545902	20090824 <--
PRIORITY APPLN. INFO.:			GB 2003-5876	A 20030314 <--
			GB 2003-19429	A 20030819
<--			EP 2004-719006	A3 20040310
			WO 2004-GB1008	W 20040310
			US 2006-547448	A3 20060620
			US 2007-845837	A3 20070828

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 141:296035

GI



I

AB Title compds. [I; R1, R3 = H, F, Cl, Br, NO2, cyano, alkyl, fluoroalkyl, chloroalkyl, alkoxy, fluoroalkoxy; R4 = CO2H (ester), CONR6R7, NR7COR6, NR7COOR6, NHCONR6R7, NHCSNR6R7; R6 = H, (Alk)mQ; m = 0, 1; Alk = (substituted) alkylene, alkenylene, alkynylene, carbocyclylene which may contain ≥ 1 O, S, NR8; R8 = H, alkyl, alkenyl, alkynyl, cycloalkyl; Q = H, NR9R10; R9, R10 = H, alkyl, alkenyl, alkynyl, cycloalkyl, ester group, (substituted) carbocyclyl, heterocyclyl; R9R10N = (substituted) heterocyclyl; R7 = H, alkyl; R6R7 = atoms to form (substituted) heterocyclyl; X = bond, (Z)n(Alk), (Alk)(Z)n; Z = O, S, NH; n = 0, 1], were prepared Thus, 4-(3-oxo-1,3-dihydro-2H-pyrazolo[4,3-c]cinnolin-2-yl)benzoic acid (preparation given) was stirred with DMF, diisopropylethylamine, 3-dimethylaminopropylamine, and HTBU at room temperature for 2 h to give 40% N-[(3-dimethylamino)propyl] 4-(3-oxo-1,3-dihydro-2H-pyrazolo[4,3-c]cinnolin-2-yl)benzamide (AV1142005). The latter inhibited interleukin-2 production by human Jurkat T cells by 65% at 30 μ M.


IT 763143-44-8P 763144-94-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of oxopyrazolocinnolines as CD80 inhibitors useful as immunomodulators)


RN 763143-44-8 CAPLUS

CN Urea, N-[4-(1,3-dihydro-3-oxo-2H-pyrazolo[4,3-c]cinnolin-2-yl)phenyl]-N'-[(4-fluorophenyl)methyl]- (CA INDEX NAME)



RN 763144-94-1 CAPLUS

CN Urea, N-[4-(1,3-dihydro-3-oxo-2H-pyrazolo[4,3-c]cinnolin-2-yl)phenyl]-N'-[(3-fluorophenyl)methyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD (7 CITINGS)

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L87 ANSWER 7 OF 84 CAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 2004:566609 CAPLUS Full-text

DOCUMENT NUMBER: 141:123608

TITLE: Preparation of pyrrolopyridinones as mitogen activated protein kinase-activated protein kinase-2 inhibiting compounds

INVENTOR(S): Anderson, David R.; Mahoney, Matthew W.; Phillion, Dennis P.; Rogers, Thomas E.; Meyers, Marvin J.; Poda, Gennadiy; Hegde, Shridhar G.; Singh, Megh; Reitz, David B.; Wu, Kun K.; Buchler, Ingrid P.; Xie, Jin; Vernier, William F.

PATENT ASSIGNEE(S): Pharmacia Corporation, USA

SOURCE: PCT Int. Appl., 573 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
WO 2004058762	A1	20040715	WO 2003-US40811	20031219 <--

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2509565 A1 20040715 CA 2003-2509565 20031219 <--
WO 2004058762 A1 20040715 WO 2003-XA40811 20031219 <--

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG


AU 2003297431 A1 20040722 AU 2003-297431 20031219 <--
US 20040152739 A1 20040805 US 2003-742494 20031219 <--
US 20040209897 A1 20041021 US 2003-742072 20031219 <--
EP 1572693 A1 20050914 EP 2003-814268 20031219 <--

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK


BR 2003017430 A 20051025 BR 2003-17430 20031219 <--
CN 1747949 A 20060315 CN 2003-80109626 20031219 <--
JP 2006514043 T 20060427 JP 2004-563888 20031219 <--
ZA 2005004898 A 20061129 ZA 2005-4898 20031219 <--
MX 2005006569 A 20050922 MX 2005-6569 20050617 <--
US 20080113971 A1 20080515 US 2007-958229 20071217 <--

PRIORITY APPLN. INFO.: US 2002-434962P P 20021220 <--
US 2003-742494 A1 20031219
WO 2003-US40811 W 20031219

OTHER SOURCE(S): MARPAT 141:123608
GI



I



II

AB The title compds. [I; Z1, Z3, Z4 = C, N; Z2, Z5 = C, N, S, O, and join together with Z1, Z3 and Z4 to form a ring that is selected from a pyrrole, furan, thiophene, oxazole, thiazole, triazole, and imidazole; when either Z2, or Z5 = O or S, it has no substituent group; when Z1-Z5 form an imidazole ring,

Z1 = C and if Z2 and Z5 = N, one is unsubstituted and Z3 and Z4 = C, if Z3 and Z5 = N, Z5 is unsubstituted and Z2 and Z4 = C, and if Z2 and Z4 = N, Z2 is unsubstituted and Z3 and Z5 = C; when Z1-Z5 form an oxazole or thiazole ring, Z1, Z3 and Z4 = C and one of Z2 and Z5 = N that is unsubstituted; when Z1-Z5 form a triazole ring, Z2 and Z5 = N that is unsubstituted; T = C, N; p = 0-3; X = C, S; Ra = (un)substituted 5-6 membered hetero(aryl) or partially unsatd. 5-6 membered ring; R2, R5, R50-R53, R56 = absent, H, alkyl, aryl, etc.; R54, R55 = oxo, absent] which inhibit mitogen activated protein kinase-activated protein kinase-2 (MK-2), were prepared Thus, reacting 2-(2-chloropyridin-4-yl)-1,5,6,7-tetrahydro-4H-pyrrolo[3,2-c]pyridin-4-one (preparation given) with 3-thiopheneboronic acid in the presence of Cs2CO3, Pd(PPh3)4 in DMF afforded 57% II.TFA. The compds. I were tested for MK-2 inhibition activity (biol. data given for over 800 compds). Methods of using compds. I for the inhibition of MK-2, and for the prevention or treatment of a disease or disorder that is mediated by TNF α , are described, where the method involves administering to the subject an MK-2 inhibiting compound I. Therapeutic compns., pharmaceutical compns. and kits which contain the present MK-2 inhibiting compds. I are also described. [This abstract record is one of 2 records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.]

IT 724730-57-8P 724730-68-1P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrrolopyridinones as mitogen activated protein kinase-activated protein kinase-2 inhibiting compds. for preventing or treating a TNF α mediated diseases)

RN 724730-57-8 CAPLUS

CN Acetamide, 2-[2-methoxy-4-[4-(4,5,6,7-tetrahydro-4-oxo-1H-pyrrolo[3,2-c]pyridin-2-yl)-2-pyrimidinyl]phenoxy]-N-[3-(trifluoromethyl)phenyl]-


(CA INDEX NAME)



RN 724730-68-1 CAPLUS

CN Acetamide, 2-[2-ethoxy-4-[4-(4,5,6,7-tetrahydro-4-oxo-1H-pyrrolo[3,2-c]pyridin-2-yl)-2-pyrimidinyl]phenoxy]-N-[3-(trifluoromethyl)phenyl]-

(CA INDEX NAME)



OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD
(3 CITINGS)

L87 ANSWER 8 OF 84 CAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 2004:533982 CAPLUS Full-text

DOCUMENT NUMBER: 141:89085

TITLE: Preparation of indazole derivatives as JNK enzyme inhibitors

INVENTOR(S): Bhagwat, Shripad S.; Satoh, Yoshitaka; Sakata, Steven T.; Buhr, Chris A.; Albers, Ronald; Sapienza, John; Plantevin, Veronique; Chao, Qi; Sahasrabudhe, Kiran; Ferri, Rachel

PATENT ASSIGNEE(S): Signal Pharmaceuticals, LLC, USA

SOURCE: U.S. Pat. Appl. Publ., 275 pp., Cont.-in-part of U.S. Ser. No. 910,950.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20040127536	A1	20040701	US 2003-414839	20030416 <--
US 7211594	B2	20070501		
US 20020103229	A1	20020801	US 2001-910950	20010723 <--
US 6897231	B2	20050524		
US 20040077877	A1	20040422	US 2003-673121	20030926 <--
US 7220771	B2	20070522		
US 20050009876	A1	20050113	US 2003-718185	20031119 <--
AU 2004232981	A1	20041104	AU 2004-232981	20040416 <--
CA 2522682	A1	20041104	CA 2004-2522682	20040416 <--
WO 2004094388	A2	20041104	WO 2004-US11958	20040416 <--
WO 2004094388	A3	20041209		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1618093	A2	20060125	EP 2004-750298	20040416 <--

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR

BR 2004009417	A	20060425	BR 2004-9417	20040416 <--
JP 2006523721	T	20061019	JP 2006-513108	20040416 <--
ZA 2005008359	A	20090225	ZA 2005-8359	20040416 <--
US 20050107457	A1	20050519	US 2004-462	20041130 <--
US 7208513	B2	20070424		
MX 2005010958	A	20060130	MX 2005-10958	20051012 <--
US 20070060616	A1	20070315	US 2006-512836	20060830 <--
PRIORITY APPLN. INFO.:			US 2000-221799P	P 20000731 <--
			US 2001-910950	A2 20010723 <--
			US 2003-414839	A2 20030416 <--
			US 2003-718185	A1 20031119
			WO 2004-US11958	W 20040416

OTHER SOURCE(S): MARPAT 141:89085
 GI




AB Indazole derivs. I [A = a bond, (CH₂)_a, (CH₂)_bCH:CH(CH₂)_c, (CH₂)_bC.tplbond.C(CH₂)_c; R₁ = (un)substituted aryl, heteroaryl or heterocycle fused to Ph; R₂ = R₃, R₄, (CH₂)_bC(O)R₅, (CH₂)_bC(:O)OR₅, (CH₂)_bC(O)NR₅R₆, (CH₂)_bC(O)NR₅(CH₂)_cC(O)R₆, (CH₂)_bNR₅C(O)R₆, (CH₂)_bNR₅C(O)NR₆R₇, (CH₂)_bNR₅R₆, (CH₂)_bOR₅, (CH₂)_bSO_dR₅ or (CH₂)_bSO₂NR₅R₆; a = 1-6; b, c = 0-4; d = 0-2; R₃ = halo, OH, CO₂H, carboxy, etc.; R₄ = (un)substituted alkyl, aryl, arylalkyl, heterocycle or heterocyclealkyl, or R₄ = halo or OH; R₅-R₇ = H, (un)substituted alkyl, aryl, arylalkyl, heterocycle or heterocyclealkyl; with the provisos] having activity as selective inhibitors of JNK, are disclosed. Such compds. I have utility in the treatment of a wide range of conditions that are responsive to JNK inhibition. Thus, methods of treating such conditions are also disclosed, as are pharmaceutical compns. containing one or more compds. of the above compds. Many of the claimed compds. have IC₅₀ values ≤0.5 μM in the JNK2 assay, e.g. 5-[3-(4-fluorophenyl)-1H-indazol-5-yl]-2H-1,2,3,4-tetrazole. Although the methods of preparation are not claimed, >400 example preps. are included.

IT 716322-54-2P 716322-98-4P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of indazole derivs. as JNK enzyme inhibitors)


RN 716322-54-2 CAPLUS

CN Carbamic acid, [3-[5-(aminocarbonyl)-1H-indazol-3-yl]phenyl]-, (4-fluorophenyl)methyl ester (9CI) (CA INDEX NAME)



RN 716322-98-4 CAPLUS

CN 1H-Indazole-5-carboxamide, 3-[3-[[[(4-fluorophenyl)methyl]amino]carbonyl]amino]phenyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 32 THERE ARE 32 CAPLUS RECORDS THAT CITE THIS RECORD (69 CITINGS)

REFERENCE COUNT: 79 THERE ARE 79 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L87 ANSWER 9 OF 84 CAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 2004:390211 CAPLUS Full-text

DOCUMENT NUMBER: 140:406638

TITLE: Preparation of arylamides as melanin concentrating hormone (MCH) receptor antagonists.

INVENTOR(S): Stenkamp, Dirk; Mueller, Stephan Georg; Roth, Gerald Juergen; Lustenberger, Philipp; Rudolf, Klaus; Lehmann-Lintz, Thorsten; Arndt, Kirsten; Lotz, Ralf R. H.; Lenter, Martin; Wieland, Heike-Andrea

PATENT ASSIGNEE(S): Boehringer Ingelheim Pharma GmbH & Co. Kg, Germany; et al.

SOURCE: PCT Int. Appl., 276 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004039764	A1	20040513	WO 2003-EP11933	20031028 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,				

FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

DE 10250743	A1	20040519	DE 2002-10250743	20021031 <--
CA 2504207	A1	20040513	CA 2003-2504207	20031028 <--
AU 2003285306	A1	20040525	AU 2003-285306	20031028 <--
EP 1558567	A1	20050803	EP 2003-778292	20031028 <--
EP 1558567	B1	20090624		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003015797	A	20050913	BR 2003-15797	20031028 <--
CN 1708476	A	20051214	CN 2003-80102236	20031028 <--
JP 2006504761	T	20060209	JP 2004-547576	20031028 <--
AT 434601	T	20090715	AT 2003-778292	20031028 <--
ES 2327329	T3	20091028	ES 2003-778292	20031028 <--
US 20040152742	A1	20040805	US 2003-699089	20031031 <--
US 7351719	B2	20080401		
ZA 2005001164	A	20061025	ZA 2005-1164	20050209 <--
NO 2005000745	A	20050523	NO 2005-745	20050211 <--
MX 2005002865	A	20050527	MX 2005-2865	20050315 <--
IN 2005DN01643	A	20090515	IN 2005-DN1643	20050421 <--
IN 248867	A1	20110909		
HR 2005000383	A2	20060831	HR 2005-383	20050429 <--
PRIORITY APPLN. INFO.:			DE 2002-10250743	A 20021031 <--
			US 2003-456482P	P 20030321

<--

WO 2003-EP11933 W 20031028

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 140:406638

AB R1R2NXYZNR3COWABb [R1, R2 = H, (substituted) alkyl, cycloalkyl, heterocyclyl, Ph, pyridyl; R1R2 = alkylene optionally interrupted by CH:N, CH:CH, O, S, SO, SO2, CO, imino, etc.; R3 = H, alkyl, cycloalkyl, cycloalkylalkyl; X = alkylene optionally interrupted by CH:CH, C.tplbond.C, O, S, SO, SO2, CO, imino; W = CR6aR6bO, CR7a:CR7c, etc.; Z = bond, (fused) (alkyl-substituted) alkylene; Y, A, B = Cy; b = 0, 1; Cy = (substituted) (unsatd.) carbocyclyl, Ph, (aromatic) heterocyclyl; R6a, R6b = H, alkyl, CF3; R7a, R7c = H, F, Cl, alkyl, CF3; with provisos and specific exceptions], were prepared for treatment of obesity, diabetes, heart failure, arteriosclerosis, hypertension, arthritis, mastocytosis, depression, anxiety, etc. Thus, Me aminoacetate hydrochloride, Et3N, and N-[3-chloro-4-(2-oxoethoxy)phenyl]-2-(2,4-dichlorophenoxy)acetamide in CH2Cl2/THF were treated with NaBH(OAc)3 followed by stirring for 3 h to give 78% Me [2-[2-chloro-4-[2-(2,4-dichlorophenoxy)acetylaminophenoxy]ethylamino]acetate. Tested title compds. bound to MCH-1 receptors with IC50 = 17-41 nM.

IT 689299-57-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(claimed compound; preparation of arylamides as melanin concentrating hormone (MCH)

receptor antagonists)

RN 689299-57-8 CAPLUS

CN Acetamide,

N-[3-chloro-4-[2-(dimethylamino)ethoxy]phenyl]-2-[2-chloro-4-(3-pyridinyl)phenoxy]- (CA INDEX NAME)



IT 689302-21-4P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of arylamides as melanin concentrating hormone (MCH) receptor antagonists)

RN 689302-21-4 CAPLUS

CN Acetamide,

N-[3-chloro-4-[2-(diethylamino)ethoxy]phenyl]-2-[2-chloro-4-(3-pyridinyl)phenoxy]- (CA INDEX NAME)



OS.CITING REF COUNT: 6 THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD (6 CITINGS)

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L87 ANSWER 10 OF 84 CAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 2004:60473 CAPLUS Full-text

DOCUMENT NUMBER: 140:128423

TITLE: Preparation of heterocyclylbenzoylureas for treating type 2 diabetes

INVENTOR(S): Schoenafinger, Karl; Defossa, Elisabeth; Kadereit, Dieter; Von Roedern, Erich; Klabunde, Thomas; Burger, Hans-Joerg; Herling, Andreas; Wendt, Karl-Ulrich

PATENT ASSIGNEE(S): Aventis Pharma Deutschland GmbH, Germany

SOURCE: PCT Int. Appl., 67 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004007455	A1	20040122	WO 2003-EP7078	20030703 <--

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW


RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

DE 10231627	A1	20040205	DE 2002-10231627	20020712 <--
DE 10231627	B4	20060309		
DE 10306503	A1	20040826	DE 2003-10306503	20030217 <--
DE 10320326	A1	20041202	DE 2003-10320326	20030506 <--
CA 2493374	A1	20040122	CA 2003-2493374	20030703 <--
AU 2003249937	A1	20040202	AU 2003-249937	20030703 <--
EP 1523475	A1	20050420	EP 2003-763692	20030703 <--
EP 1523475	B1	20091223		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003012697	A	20050426	BR 2003-12697	20030703 <--
CN 1668593	A	20050914	CN 2003-816581	20030703 <--
CN 1304371	C	20070314		
JP 2006502247	T	20060119	JP 2005-505058	20030703 <--
NZ 537603	A	20060929	NZ 2003-537603	20030703 <--
AT 452879	T	20100115	AT 2003-763692	20030703 <--
US 20040152743	A1	20040805	US 2003-617498	20030711 <--
US 7138414	B2	20061121		
ZA 2004010133	A	20051123	ZA 2004-10133	20041215 <--
IN 2004CN03014	A	20060217	IN 2004-CN3014	20041231 <--
MX 2005000053	A	20050408	MX 2005-53	20050103 <--
HR 2005000022	A2	20060331	HR 2005-22	20050111 <--
NO 2005000648	A	20050207	NO 2005-648	20050207 <--
US 20070021474	A1	20070125	US 2006-464907	20060816 <--
PRIORITY APPLN. INFO.:			DE 2002-10231627	A 20020712 <--
			DE 2003-10306503	A 20030217
<--			DE 2003-10320326	A 20030506
<--			US 2002-430782P	P 20021204
<--			WO 2003-EP7078	W 20030703
<--			US 2003-617498	A1 20030711 <--


ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 140:128423


GI



- AB Title compds. [I; R1, R2 = H, (substituted) A, OA, COA, CO2A, AlkCO2H, AlkCO2A; A = alkyl; Alk = alkylene; R3, R4 = F, Cl, Br, OH, NO2, CN, (substituted) A, OA, alkenyloxy, alkynyl; R5 = H, F, Cl, Br, OH, NO2, CN, (substituted) A, OA, COA, AlkCO2H, AlkCO2A, SO2A, alkenyloxy, alkynyl; X = H, F, Cl, Br, OH, NO2, CN, (substituted) A, COA, AlkCO2H, AlkCO2A, SO2A, alkenyl, alkynyl, OA, SO1-2A, NHA, NA2, CO2H, CO2A, CONH2, CONHA, CONA2, SO2NH2, SO2NHA, SO2NA2, NHCOR6; R6 = H, A, cycloalkyl, cycloalkylalkylene, alkenyl, alkynyl, AlkCO2A, AlkCOA, AlkCO2H, AlkCONH2, aryl, Alkaryl, heteroaryl, Alkheteroaryl, heteroarylcarbonyl; het = 4-7 membered (substituted) heterocyclyl, with the exception of pyrrole; m = 1-5; n, p = 0-3], were prepared Thus, 1-(4-amino-3-fluorophenyl)-1H-[1,2,4]triazole (preparation given) and 2-chloro-4,5-difluorobenzoylisocyanate were stirred 30 min in MeCN to give 1-(2-chloro-4,5-difluorobenzoyl)-3-(2-fluor-4-[1,2,4]triazol-1-ylphenyl)urea. The latter at 10 μ M gave 94% inhibition of activated glycogen phosphorylase.
- IT 648916-89-6P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of heterocyclylbenzoylureas for treating type 2 diabetes)
- RN 648916-89-6 CAPLUS
- CN Benzamide, 2-chloro-N-[[[2-chloro-4-(2H-tetrazol-5-yl)phenyl]amino]carbonyl]-4-fluoro- (CA INDEX NAME)




- IT 648916-81-8P 648916-82-9P 648916-83-0P
 648916-84-1P 648916-86-3P 648916-87-4P
 648916-88-5P 648916-90-9P 648916-91-0P
 648916-92-1P 648917-03-7P 648917-04-8P
 648917-05-9P 648917-07-1P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of heterocyclylbenzoylureas for treating type 2 diabetes)
- RN 648916-81-8 CAPLUS
- CN Benzamide, 2-chloro-4,5-difluoro-N-[[[2-fluoro-4-(1H-1,2,4-triazol-1-yl)phenyl]amino]carbonyl]- (CA INDEX NAME)



RN 648916-82-9 CAPLUS


CN Benzamide,

2-chloro-4-fluoro-N-[[[2-methoxy-4-(3-methyl-1H-1,2,4-triazol-5-yl)phenyl]amino]carbonyl]- (CA INDEX NAME)




RN 648916-83-0 CAPLUS

CN Benzamide, 2-chloro-4,5-difluoro-N-[[[2-methoxy-4-(3-methyl-1H-1,2,4-triazol-5-yl)phenyl]amino]carbonyl]- (CA INDEX NAME)




RN 648916-84-1 CAPLUS

CN 1H-1,2,4-Triazole-3-acetic acid, 5-[4-[[[(2-chloro-4-fluorobenzoyl)amino]carbonyl]amino]-3-methoxyphenyl]- (CA INDEX NAME)




RN 648916-86-3 CAPLUS

CN Benzamide, 2-chloro-N-[[[2-chloro-5-(3-methyl-1H-1,2,4-triazol-5-yl)phenyl]amino]carbonyl]-4,5-difluoro- (CA INDEX NAME)




RN 648916-87-4 CAPLUS

CN Benzamide, 2-chloro-N-[[[2-chloro-3-(1H-1,2,4-triazol-5-yl)phenyl]amino]carbonyl]-4,5-difluoro- (CA INDEX NAME)




RN 648916-88-5 CAPLUS

CN Benzamide, 2-chloro-N-[[[4-(2,5-dihydro-5-oxo-1H-1,2,4-triazol-3-yl)-2-(trifluoromethoxy)phenyl]amino]carbonyl]-4,5-difluoro- (CA INDEX NAME)




RN 648916-90-9 CAPLUS

CN Benzamide, 2-chloro-N-[[[2-chloro-4-(2H-tetrazol-5-yl)phenyl]amino]carbonyl]-4,5-difluoro- (CA INDEX NAME)




RN 648916-91-0 CAPLUS

CN Benzamide, 2-chloro-4-fluoro-N-[[[4-(2H-tetrazol-5-yl)-2-(trifluoromethoxy)phenyl]amino]carbonyl]- (CA INDEX NAME)




RN 648916-92-1 CAPLUS

CN Benzamide, 2-chloro-4,5-difluoro-N-[[[4-(2H-tetrazol-5-yl)-2-(trifluoromethoxy)phenyl]amino]carbonyl]- (CA INDEX NAME)




RN 648917-03-7 CAPLUS

CN Benzamide, 2-chloro-N-[[[4-(2,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl)-2-(trifluoromethoxy)phenyl]amino]carbonyl]-4,5-difluoro- (CA INDEX NAME)




RN 648917-04-8 CAPLUS

CN Benzamide, 2-chloro-N-[[[4-(2,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl)-2-(trifluoromethoxy)phenyl]amino]carbonyl]-4-fluoro- (CA INDEX NAME)




RN 648917-05-9 CAPLUS

CN Benzamide, 2-chloro-N-[[[2-chloro-4-(2,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl)phenyl]amino]carbonyl]-4-fluoro- (CA INDEX NAME)



RN 648917-07-1 CAPLUS

CN Benzamide, N-[[[2-(1H-benzimidazol-2-yl)phenyl]amino]carbonyl]-2-chloro-4,5-difluoro- (CA INDEX NAME)



OS.CITING REF COUNT: 9 THERE ARE 9 CAPLUS RECORDS THAT CITE THIS RECORD (13 CITINGS)

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L87 ANSWER 11 OF 84 CAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 2003:971891 CAPLUS Full-text

DOCUMENT NUMBER: 140:13098

TITLE: Pharmaceutically active compounds having a tricyclic pyrazolotriazolopyrimidine ring structure and methods of use

INVENTOR(S): Baraldi, Pier Giovanni; Borea, Pier Andrea

PATENT ASSIGNEE(S): King Pharmaceuticals Research & Development, Inc., USA

SOURCE: PCT Int. Appl., 80 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003101455	A2	20031211	WO 2003-US17313	20030530 <--
WO 2003101455	A3	20040521		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2454654	A1	20031211	CA 2003-2454654	20030530 <--
AU 2003245380	A1	20031219	AU 2003-245380	20030530 <--
US 20040039004	A1	20040226	US 2003-452788	20030530 <--
US 7064204	B2	20060620		
BR 2003004963	A	20040928	BR 2003-4963	20030530 <--
EP 1549319	A2	20050706	EP 2003-739019	20030530 <--

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

JP 2005527635	T	20050915	JP 2004-508812	20030530 <--
MX 2004000908	A	20040326	MX 2004-908	20040129 <--
ZA 2004000784	A	20050503	ZA 2004-784	20040130 <--

PRIORITY APPLN. INFO.: US 2002-384809P P 20020530 <--
WO 2003-US17313 W 20030530

<--

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 140:13098

AB Tricyclic pyrazolotriazolopyrimidines which possess antagonistic activity for adenosine receptors may be useful for modulating biol. function in the nervous, cardiovascular, renal, respiratory and immune systems. General synthetic schemes and examples of formulations for the compds. are presented.


IT 512845-34-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(tricyclic pyrazolotriazolopyrimidines with antagonistic activity for adenosine receptors)

RN 512845-34-0 CAPLUS

CN Acetamide, 2-[4-[5-amino-7-(2-phenylethyl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-2-yl]phenoxy]-N-(4-iodophenyl)- (CA INDEX NAME)



OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L87 ANSWER 12 OF 84 CAPLUS COPYRIGHT 2011 ACS on STN


ACCESSION NUMBER: 2003:633320 CAPLUS Full-text

DOCUMENT NUMBER: 139:180075

TITLE: Preparation of pyrrolopyrimidines as tyrosine kinase inhibitors
 INVENTOR(S): Hirst, Gavin C.; Calderwood, David; Munschauer, Rainer; Arnold, Lee D.; Johnston, David N.; Rafferty, Paul
 PATENT ASSIGNEE(S): Abbott GmbH & Co. KG, USA
 SOURCE: U.S. Pat. Appl. Publ., 166 pp., Cont.-in-part of Appl. No. PCT/US99/21560.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20030153752	A1	20030814	US 2000-537167	20000329 <--
US 6713474	B2	20040330		
WO 2000017203	A1	20000330	WO 1999-US21560	19990917 <--
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
ZA 2001002204	A	20020318	ZA 2001-2204	20010316 <--
PRIORITY APPLN. INFO.:			US 1998-100832P	P 19980918 <--
			US 1998-100833P	P 19980918
<--			US 1998-100834P	P 19980918
<--			US 1998-100946P	P 19980918
<--			WO 1999-US21560	A2 19990917 <--

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
 OTHER SOURCE(S): MARPAT 139:180075
 GI



AB The title compds. I [A = (un)substituted 6-membered aromatic ring, 5-6 membered heteroarom. ring; L = O, S, SO, SO₂, etc.; G = a direct bond, (CH₂)_j (wherein j = 1-6), alkenylene, cycloalkylene, oxaalkylene; R₁ = alkyl, cycloalkyl, bicycloalkyl, etc.; R₂ = H, alkyl, cycloalkyl, halo, etc.; R₃ = alkyl, alkenyl, cycloalkyl, etc.] and physiol. acceptable salts and metabolites thereof, are inhibitors of serine/threonine and tyrosine kinase activity. Several of the kinases, whose activity is inhibited by compds. I, are involved in immunol., hyperproliferative, or angiogenic processes. Thus, the compds. I can ameliorate disease states where angiogenesis or endothelial cell hyperproliferation is a factor. These compds. can be used to treat cancer and hyperproliferative disorders, rheumatoid arthritis, disorders of the immune system, transplant rejections and inflammatory disorders. All exemplified compds. I significantly inhibited either FGFR, PDGFR, KDR, Tie-2, Lck, Fyn, Blk, Lyn, or Src at ≤50 μM, and some significantly inhibited cdc2 at ≤50 μM. 546 Example preps. are included. For example, addition of piperidine to 4-[4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]cyclohexanone in DCE and AcOH, followed by treatment with Na[(AcO)₃BH], workup and chromatog., gave cis- and trans-II.

IT 262442-33-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(target compound; preparation of pyrrolopyrimidinamines as protein kinase inhibitors)

RN 262442-33-1 CAPLUS


CN Acetamide, N-[4-[4-amino-7-[cis-4-(4-methyl-1-piperazinyl)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl]-2-methoxyphenyl]-2-(4-chlorophenoxy)- (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A



PAGE 2-A



OS.CITING REF COUNT: 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD
(5 CITINGS)

L87 ANSWER 13 OF 84 CAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 2003:591153 CAPLUS [Full-text](#)

DOCUMENT NUMBER: 139:164789

TITLE: Preparation of phenylpyrazoles as 5-HT2A serotonin receptor modulators

INVENTOR(S): Teegarden, Bradley; Drouet, Keith; Jayakumar, Honnappa; Thomsen, William; Maffuid, Paul; Elwell, Katie; Foster, Richard; Lawless, Michael; Liu, Qian; Smith, Julian; Feichtinger, Konrad

PATENT ASSIGNEE(S): Arena Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 266 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent


LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003062206	A2	20030731	WO 2003-US2059	20030123 <--

WO 2003062206 A3 20040108
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
EP 1509505 A2 20050302 EP 2003-705889 20030123 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
PRIORITY APPLN. INFO.: US 2002-386198P P 20020123 <--
US 2002-386384P P 20020605
<--
US 2002-401467P P 20020805
<--
WO 2003-US2059 W 20030123
<--
OTHER SOURCE(S): MARPAT 139:164789
GI



AB Title compds. I [wherein R1 = H, halo, NR5R6, OH, or OR7; R2 = H, (cyclo)alkyl, or alkenyl; R3 = halo, carboxy, CN, or (un)substituted alkoxy carbonyl, (cyclo)alkyl, alkenyl, alkynyl, or (hetero)aryl; R4 = (cyclo)alkyl or alkenyl; R5 and R6 = independently H or (un)substituted (cyclo)alkyl, alkenyl, aryl(methyl); or NR5R6 = (un)substituted heterocyclyl; R7 = H or alkyl; A = CO, CS, or SO₂; B = (NR11)_q(CHR12)_m(1,2-cyclopropylidene)_nQ1 or OQ2; m, n, and q = independently 0-1; R11 and R12 = independently H,

(cyclo)alkyl, or alkenyl; Q = (un)substituted Ph; Q2 = (un)substituted (cyclo)alkyl, alkenyl, alkynyl, alkylaryl, or aryl(alkyl); and pharmaceutically acceptable salts thereof] were prepared as modulators of the 5-HT_{2A} serotonin receptor. For example, reaction of triphosgene with 3-(3-aminophenyl)-4-bromo-2-methylpyrazole in the presence of TEA in CH₂Cl₂, followed by addition of 4-(trifluoromethoxy)benzylamine provided the N-(pyrazolylphenyl)urea II (68%). The latter exhibited IC₅₀ values of 1.2 μ M, 0.45 μ M, and 0.0171 μ M for AP-1, WT 5-HT_{2A}, and AP-3, resp., in a competitive binding assay. A number of the compds. of the invention evidenced inverse agonist activity against AP-1 (data given). Thus, I and pharmaceutical compns. thereof are directed to methods useful in the prophylaxis or treatment of reducing platelet aggregation, coronary artery disease, myocardial infarction, transient ischemic attack, angina, stroke, atrial fibrillation, reducing the risk of blood clot formation, asthma or symptoms thereof, agitation or a symptom, behavioral disorders, drug induced psychosis, excitative psychosis, Gilles de la Tourette's syndrome, manic disorder, organic or NOS psychosis, psychotic disorder, psychosis, acute schizophrenia, chronic schizophrenia and NOS schizophrenia, and related disorders (no data). The present invention also relates to the method of prophylaxis or treatment of 5-HT_{2A} serotonin receptor mediated disorders in combination with a dopamine D₂ receptor antagonist such as haloperidol, administered sep. or together.


IT 573711-73-6P, 1-[3-(4-Bromo-2-methyl-2H-pyrazol-3-yl)phenyl]-3-[(4-fluorophenyl)methyl]urea

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(5-HT_{2A} receptor modulator; preparation of phenylpyrazoles as 5-HT_{2A} serotonin receptor modulators for treatment of heart disease, stroke, psychosis, and other disorders)

RN 573711-73-6 CAPLUS

CN Urea, N-[3-(4-bromo-1-methyl-1H-pyrazol-5-yl)phenyl]-N'-[(4-fluorophenyl)methyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 7 THERE ARE 7 CAPLUS RECORDS THAT CITE THIS RECORD (8 CITINGS)

L87 ANSWER 14 OF 84 CAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 2003:334911 CAPLUS Full-text


DOCUMENT NUMBER: 138:354000

TITLE: Preparation of dihydroxypyrimidine carboxamide inhibitors of HIV integrase

INVENTOR(S): Di Francesco, Maria Emilia; Gardelli, Cristina; Harper, Steven; Matassa, Victor Giulio; Muraglia, Ester; Nizi, Emanuela; Pace, Paola; Pacini, Barbara;

PATENT ASSIGNEE(S): Petrocchi, Alessia; Poma, Marco; Summa, Vincenzo
 Istituto Di Ricerche Di Biologia Molecolare P.
 Angeletti Spa, Italy
 SOURCE: PCT Int. Appl., 315 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003035076	A1	20030501	WO 2002-GB4742	20021021 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2463975	A1	20030501	CA 2002-2463975	20021021 <--
AU 2002334205	A1	20030506	AU 2002-334205	20021021 <--
AU 2002334205	B2	20070705		
EP 1441734	A1	20040804	EP 2002-801949	20021021 <--
EP 1441734	B1	20070228		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
JP 2005510500	T	20050421	JP 2003-537643	20021021 <--
JP 4351053	B2	20091028		
AT 355064	T	20060315	AT 2002-801949	20021021 <--
PT 1441734	E	20070531	PT 2002-801949	20021021 <--
ES 2281565	T3	20071001	ES 2002-801949	20021021 <--
US 20050075356	A1	20050407	US 2004-493279	20040420 <--
US 7232819	B2	20070619		
US 20070083045	A1	20070412	US 2006-516831	20060907 <--
US 7459452	B2	20081202		
PRIORITY APPLN. INFO.:			US 2001-348195P	P 20011026 <--
			WO 2002-GB4742	W 20021021
			US 2004-493279	A3 20040420
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT				
OTHER SOURCE(S):			MARPAT 138:354000	
GI				



AB The title 4,5-dihydroxypyrimidine-6-carboxamides [I; R1 = H, alkyl, haloalkyl, alkoxy, etc.; R2 = H, alkyl, haloalkyl, hydroxyalkyl, etc.; R3 = H, alkyl; R4 = H, alkyl, haloalkyl, etc.] which are inhibitors of HIV integrase and inhibitors of HIV replication, and therefore are useful in the prevention and treatment of infection by HIV and in the prevention, delay in the onset, and treatment of AIDS, were prepared Thus, refluxing N-hydroxythiophene-2-carboximidamide with di-Me acetylenedicarboxylate in CHCl₃ followed by reacting the resulting Me 5,6-dihydroxy-2-(2-thienyl)pyrimidine-4-carboxylate with 4-fluorobenzylamine in DMF afforded I [R1 = 2-thienyl; R2 = H; R3 = 4-FC₆H₄CH₂; R4 = H]. The compds. I are employed against HIV infection and AIDS as compds. per se or in the form of pharmaceutically acceptable salts. The compds. I and their salts can be employed as ingredients in pharmaceutical compns., optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.


IT 519023-70-2P 519023-73-5P 519024-20-5P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of dihydroxypyrimidine carboxamide inhibitors of HIV integrase)

RN 519023-70-2 CAPLUS

CN 4-Pyrimidinecarboxamide, 2-[2-[[[(2,3-


dichlorophenyl)methyl]amino]carbonyl]amino]phenyl]-1,6-dihydro-5-hydroxy-6-oxo-N-(phenylmethyl)- (CA INDEX NAME)



RN 519023-73-5 CAPLUS

CN 4-Pyrimidinecarboxamide, 2-[2-[[[(2,5-


dichlorophenyl)methyl]amino]carbonyl]amino]phenyl]-1,6-dihydro-5-hydroxy-6-oxo-N-(phenylmethyl)- (CA INDEX NAME)



RN 519024-20-5 CAPLUS

CN 4-Pyrimidinecarboxamide, 2-[3-[[[(3,4-

dichlorophenyl)methyl]amino]carbonyl]amino]phenyl]-1,6-dihydro-5-hydroxy-6-oxo-N-(phenylmethyl)- (CA INDEX NAME)



OS.CITING REF COUNT: 22 THERE ARE 22 CAPLUS RECORDS THAT CITE THIS RECORD (31 CITINGS)

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L87 ANSWER 15 OF 84 CAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 2003:254172 CAPLUS Full-text

DOCUMENT NUMBER: 138:281081

TITLE: Drug screening with non-endogenous, constitutively activated human serotonin receptors and small molecule modulators thereof

INVENTOR(S): Behan, Dominic P.; Chalmers, Derek T.; Liaw, Chen W.; Russo, Joseph F.; Thomsen, William J.

PATENT ASSIGNEE(S): Arena Pharmaceuticals, Inc., USA

SOURCE: U.S., 62 pp., Cont.-in-part of U.S. Ser. No. 60,188. CODEN: USXXAM

DOCUMENT TYPE: Patent


LANGUAGE: English

FAMILY ACC. NUM. COUNT: 17

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6541209	B1	20030401	US 1999-292072	19990414 <--
US 6140509	A	20001031	US 1999-292069	19990414 <--
US 6420541	B1	20020716	US 2000-767013	20001222 <--

US 20030224442	A1	20031204	US 2002-55555	20020123 <--
US 20030153004	A1	20030814	US 2002-176255	20020619 <--
US 6846919	B2	20050125		
AU 2004203102	A1	20040729	AU 2004-203102	20040708
AU 2004203102	B2	20071018		
US 20050119182	A1	20050602	US 2004-980560	20041102 <--
US 7368539	B2	20080506		
AU 2007202139	A1	20070531	AU 2007-202139	20070510
AU 2007202139	B2	20090521		
AU 2007202155	A1	20070607	AU 2007-202155	20070510
AU 2007202155	B2	20090507		
AU 2007202121	A1	20070607	AU 2007-202121	20070511
AU 2007202241	A1	20070607	AU 2007-202241	20070511
AU 2007216751	A1	20071004	AU 2007-216751	20070912 <--
AU 2007216752	A1	20071004	AU 2007-216752	20070912 <--
AU 2008200231	A1	20080207	AU 2008-200231	20080116
US 20090076254	A1	20090319	US 2008-51754	20080319 <--
US 7754866	B2	20100713		
PRIORITY APPLN. INFO.:			US 1997-839449	B2 19970414 <--
			US 1998-60188	A2 19980414 <--
			US 1998-90783P	P 19980626
<--			US 1998-112909P	P 19981218
<--			US 1999-123000P	P 19990305
<--			US 1999-292072	A3 19990414 <--
			US 2000-767013	A3 20001222 <--
			AU 2002-219890	A3 20011126 <--
			US 2002-176255	A1 20020619 <--
			AU 2004-202147	A3 20040512
			AU 2004-202476	A3 20040603
			AU 2004-203102	A3 20040708
			US 2004-980560	A3 20041102
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT				
AB	Disclosed herein are non-endogenous, constitutively activated forms of the human 5-HT2A and human 5-HT2C receptors and uses of such receptors to screen candidate compds. Further disclosed herein are candidate compds. identified by the screening method which act at the 5HT2A receptors. Yet further disclosed is a new class of compds. which act at the 5HT2A receptors.			
IT	247038-30-8P			
	RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)			
	(drug screening with non-endogenous, constitutively activated human serotonin receptors and small mol. modulators thereof)			
RN	247038-30-8 CAPLUS			
CN	Urea, N-[3-(4-bromo-1-methyl-1H-pyrazol-3-yl)phenyl]-N'-[(4-fluorophenyl)methyl]- (CA INDEX NAME)			



OS.CITING REF COUNT: 10 THERE ARE 10 CAPLUS RECORDS THAT CITE THIS RECORD (11 CITINGS)
 REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L87 ANSWER 16 OF 84 CAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 2003:221693 CAPLUS Full-text

DOCUMENT NUMBER: 138:238197

TITLE: Preparation of furo- and thienopyrimidines as TIE-2 and/or VEGFR-2 kinase inhibitors useful against hyperproliferative diseases

INVENTOR(S): Adams, Jerry Leroy; Bryan, Deborah Lynne; Feng, Yanhong; Matsunaga, Shinichiro; Maeda, Yutaka; Miyazaki, Yasushi; Nakano, Masato; Rocher, Jean-Philippe; Sato, Hideyuki; Semones, Marcus; Silva, Domingos J.; Tang, Jun

PATENT ASSIGNEE(S): Glaxosmithkline K.K., Japan; Smithkline Beecham Corporation

SOURCE: PCT Int. Appl., 265 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003022852	A2	20030320	WO 2002-US28650	20020910 <--
WO 2003022852	A3	20031127		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2002333524	A1	20030324	AU 2002-333524	20020910 <--
EP 1425284	A2	20040609	EP 2002-798181	20020910 <--
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, SK			
JP 2005508904	T	20050407	JP 2003-526926	20020910 <--
US 20050004142	A1	20050106	US 2004-489052	20040309 <--
US 7427623	B2	20080923		
US 20080287466	A1	20081120	US 2008-169800	20080709 <--

PRIORITY APPLN. INFO.:

US 2001-318766P
WO 2002-US28650P 20010911 <--
W 20020910


<--

US 2004-489052 A3 20040309

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 138:238197

GI




AB Furo- and thienopyrimidine derivs. (shown as I; variables defined below; e.g. 4-Amino-3-(4-methoxyphenyl)-2-[3-(methylsulfonylamino)phenyl]furo[2,3-d]pyrimidine), which are useful as TIE-2 (tyrosine kinase containing immunoglobulin and EGF homol. domains) and/or VEGFR-2 kinase inhibitors against hyperproliferative diseases are described herein. Enzyme inhibitions by .apprx.60 examples of I are included as ranges; also, 4-amino-3-[4-[[2-fluoro-5-(trifluoromethyl)phenyl]aminocarbonylamino]phenyl]thieno[2,3-d]pyrimidine exhibited IC₅₀ = 0.0018 μ M in the TIE-2 fluorescence polarization kinase activity assay. For I: X is O or S; A is H, halo, C1-C6 alkyl, aryl, heteroaryl, aryl or heteroaryl substituted with ≥ 1 R₃, heterocyclyl, -RR₃, -C(O)OR₄, -C(O)NR₅R₆, -C(O)R₄; D is H, halo, C1-C6 alkyl, aryl, heteroaryl, aryl or heteroaryl substituted with ≥ 1 R₃, heterocyclyl, -RR₃, -C(O)OR₄, -C(O)NR₅R₆, or -C(O)R₄. R is C1-C6 alkylene, C3-C7 cycloalkylene, C1-C6 alkenylene, or C1-C6 alkynylene; R₁ is H, C1-C6 alkyl, C1-C6 alkoxy, -SR₄, -S(O)₂R₄, -NR₇R₇, -NR'R''R''', -N(H)RR₃, -C(O)OR₇, or -C(O)NR₇R₇. R₂ is H, -OH, -NR₇R₇ or :NH; R₃ is halo, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C3-C7 cycloalkoxy, C1-C6 haloalkoxy, aryl, aralkyl, aryloxy, heteroaryl, heterocyclyl, -CN, -NHC(O)R₄, -N(R₈)HC(O)R₄, -NHC(S)R₄, -NR₅R₆, -RNR₅R₆, -SR₄, -S(O)₂R₄, -RC(O)OR₄, -C(O)OR₄, -C(O)R₄, -C(O)NR₅R₆, -NHS(O)₂R₄, -N(S(O)₂R₄)S(O)₂R₄, -S(O)₂NR₅R₆, or -NHC(:NH)R₄. R₄ is H, C1-C6 alkyl, aryl, heteroaryl, heterocyclyl, -RR₃, -NR''R''', or -NR'NR''R'''; R₅ is H, C1-C6 alkyl, C3-C7 cycloalkyl, cyanoalkyl, -R'R'', aryl, aralkyl, heteroaryl, -NHC(O)OR'', -R'NHC(O)OR'', -R'NHC(O)NR''R''', or -R'C(O)OR''. R₆ is H, C1-C6 alkyl, C3-C7 cycloalkyl, cyanoalkyl, -R'R'', aryl, aralkyl, heteroaryl, -C(O)OR'', or -R'C(O)NR''R'''; R₇ is H, C1-C6 alkyl, aryl, or -C(O)OR'''; R₈ is C1-C3 alkyl; R' is C1-C3 alkylene; R'' is heteroalkyl or NRR''R'''; R''' is H, C1-C6 alkyl, aryl, aralkyl, heteroaryl, or C3-C7 cycloalkyl; R'''' is H, C1-C6 alkyl, aryl, heteroaryl, or C3-C7 cycloalkyl. Although the methods of preparation are not claimed, several example preps. of I are included and characterization data is given for .apprx.480 examples of I.

IT 501695-83-6P, 4-Amino-5-[4-[[[2-fluoro-5-(trifluoromethyl)phenyl]aminocarbonylamino]methyl]phenyl]-6-(4-methoxyphenyl)furo[2,3-d]pyrimidine

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of furo- and thienopyrimidines as TIE-2 and/or

VEGFR-2 kinase inhibitors useful against hyperproliferative diseases)
 RN 501695-83-6 CAPLUS
 CN Urea, N-[[4-[4-amino-6-(4-methoxyphenyl)furo[2,3-d]pyrimidin-5-yl]phenyl]methyl]-N'-[2-fluoro-5-(trifluoromethyl)phenyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 14 THERE ARE 14 CAPLUS RECORDS THAT CITE THIS RECORD (15 CITINGS)
 REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L87 ANSWER 17 OF 84 CAPLUS COPYRIGHT 2011 ACS on STN
 ACCESSION NUMBER: 2003:153400 CAPLUS Full-text
 DOCUMENT NUMBER: 138:187776
 TITLE: Preparation of oxadiazolyl and thiadiazolyl benzoyl ureas as pesticides
 INVENTOR(S): Maurer, Fritz; Erdelen, Christoph; Reckmann, Udo
 PATENT ASSIGNEE(S): Bayer CropScience AG, Germany
 SOURCE: Ger. Offen., 20 pp.
 CODEN: GWXXBX
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 10139721	A1	20030227	DE 2001-10139721	20010813 <--
WO 2003016293	A1	20030227	WO 2002-EP8572	20020801 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002325929	A1	20030303	AU 2002-325929	20020801 <--
IN 2002MU00674	A	20050318	IN 2002-MU674	20020805 <--

PRIORITY APPLN. INFO.:

DE 2001-10139721

A 20010813 <--

WO 2002-EP8572


W 20020801

<--

OTHER SOURCE(S):

MARPAT 138:187776

GI



AB Title compds. [I; R1 = H, halo; R2 = halo; R3 = halo, (halo)alkyl; n = 0-2; Q = Q1, Q2, Q3; R4 = H, alkyl, alkoxyalkyl, alkoxycarbonylalkyl, alkylcarbonyloxyalkyl, (substituted) aryl, arylalkyl; X = O, S], were prepared Thus, 4-(5-ethyl-1,3,4-oxadiazol-2-yl)aniline (preparation given) was dropwise treated with 2,6-difluorobenzoyl isocyanate in MeCN at room temperature followed by stirring for 18 h at room temperature to give 86%

N-(2,6-difluorobenzoyl)-N'-[4-(5-ethyl-1,3,4-oxadiazol-2-yl)phenyl]urea. Several I at 0.05% gave 100% kill of *Heliothis virescens* caterpillars on Glycine max after 7 days.


IT 1053718-64-1 1053718-65-2 1053718-66-3
 1053718-69-6 1053718-71-0 1053718-80-1
 1053718-82-3 1053718-84-5 1053718-85-6
 1053718-99-2

RL: PRPH (Prophetic)

(Preparation of oxadiazolyl and thiadiazolyl benzoyl ureas as pesticides)


RN 1053718-64-1 CAPLUS

CN Benzamide, N-[[[2,5-dichloro-4-[5-(1,1-dimethylethyl)-1,2,4-oxadiazol-3-yl]phenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)




RN 1053718-65-2 CAPLUS

CN Benzamide, 2-chloro-N-[[[2,5-dichloro-4-[5-(1,1-dimethylethyl)-1,2,4-oxadiazol-3-yl]phenyl]amino]carbonyl]- (CA INDEX NAME)




RN 1053718-66-3 CAPLUS

CN Benzamide, 2-chloro-N-[[[4-[5-(1,1-dimethylethyl)-1,2,4-oxadiazol-3-yl]-2,3-difluorophenyl]amino]carbonyl]- (CA INDEX NAME)




RN 1053718-69-6 CAPLUS

CN Benzamide, 2-chloro-N-[[[2,3-dichloro-4-[5-(1,1-dimethylethyl)-1,2,4-oxadiazol-3-yl]phenyl]amino]carbonyl]- (CA INDEX NAME)




RN 1053718-71-0 CAPLUS

CN Benzamide, N-[[[2,3-dichloro-4-[5-(1,1-dimethylethyl)-1,2,4-oxadiazol-3-yl]phenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)




RN 1053718-80-1 CAPLUS

CN Benzamide, N-[[[2,5-dichloro-4-[3-(1,1-dimethylethyl)-1,2,4-oxadiazol-5-yl]phenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)




RN 1053718-82-3 CAPLUS

CN Benzamide, 2-chloro-N-[[[2,5-dichloro-4-[3-(1,1-dimethylethyl)-1,2,4-oxadiazol-5-yl]phenyl]amino]carbonyl]- (CA INDEX NAME)




RN 1053718-84-5 CAPLUS

CN Benzamide, N-[[[4-[3-(1,1-dimethylethyl)-1,2,4-oxadiazol-5-yl]-2,5-difluorophenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)




RN 1053718-85-6 CAPLUS

CN Benzamide, 2-chloro-N-[[[4-[3-(1,1-dimethylethyl)-1,2,4-oxadiazol-5-yl]-2,5-difluorophenyl]amino]carbonyl]- (CA INDEX NAME)



RN 1053718-99-2 CAPLUS

CN Benzamide, N-[[[4-[5-(1,1-dimethylethyl)-1,2,4-oxadiazol-3-yl]-2,3-difluorophenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)



IT 498547-80-1P 498547-82-3P 498547-84-5P
 498547-85-6P 498547-86-7P 498547-87-8P
 498547-88-9P 498547-95-8P


RL: AGR (Agricultural use); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of oxadiazolyl and thiadiazolyl benzoyl ureas as pesticides)

RN 498547-80-1 CAPLUS


CN Benzamide,

N-[[[4-(5-ethyl-1,2,4-oxadiazol-3-yl)phenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)




RN 498547-82-3 CAPLUS

CN Benzamide, 2-chloro-N-[[[4-[3-(1,1-dimethylethyl)-1,2,4-oxadiazol-5-yl]phenyl]amino]carbonyl]- (CA INDEX NAME)




RN 498547-84-5 CAPLUS

CN Benzamide, 2,6-difluoro-N-[[[4-(5-phenyl-1,2,4-oxadiazol-3-yl)phenyl]amino]carbonyl]- (CA INDEX NAME)




RN 498547-85-6 CAPLUS

CN Benzamide, N-[[[4-[5-(1,1-dimethylethyl)-1,2,4-oxadiazol-3-yl]phenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)




RN 498547-86-7 CAPLUS

CN Benzamide, 2-chloro-N-[[[4-[5-(1,1-dimethylethyl)-1,2,4-oxadiazol-3-yl]phenyl]amino]carbonyl]- (CA INDEX NAME)




RN 498547-87-8 CAPLUS

CN Benzamide, N-[[[4-[5-(1,1-dimethylethyl)-1,2,4-oxadiazol-3-yl]-2,5-difluorophenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)




RN 498547-88-9 CAPLUS

CN Benzamide, 2-chloro-N-[[[4-[5-(1,1-dimethylethyl)-1,2,4-oxadiazol-3-yl]-2,5-difluorophenyl]amino]carbonyl]- (CA INDEX NAME)



RN 498547-95-8 CAPLUS

CN Benzamide, N-[[[4-[3-(1,1-dimethylethyl)-1,2,4-oxadiazol-5-yl]phenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)



L87 ANSWER 18 OF 84 CAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 2003:151162 CAPLUS Full-text

DOCUMENT NUMBER: 138:321211

TITLE: Design, Synthesis, and Biological Evaluation of C9- and C2-Substituted

Pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines as New A2A and A3 Adenosine Receptor Antagonists

AUTHOR(S): Baraldi, Pier Giovanni; Fruttarolo, Francesca; Tabrizi, Mojgan Aghazadeh; Preti, Delia; Romagnoli, Romeo; El-Kashef, Hussein; Moorman, Allan; Varani, Katia; Gessi, Stefania; Merighi, Stefania; Borea, Pier Andrea

CORPORATE SOURCE: Dipartimento di Scienze Farmaceutiche and Dipartimento di Medicina Clinica e Sperimentale-Sezione di Farmacologia, Universita di Ferrara, Ferrara, 44100, Italy

SOURCE: Journal of Medicinal Chemistry (2003), 46(7), 1229-1241

CODEN: JMCMAR; ISSN: 0022-2623


PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 138:321211

GI



AB Pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines such as I are prepared as selective adenosine A2a and A3 receptor antagonists. Pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines substituted at the 9-position retain receptor affinity but lose selectivity for the adenosine A2a and A3 receptors over other adenosine receptors. Replacement of the furan moiety present in the pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine with a Ph or a substituted aromatic ring abolishes affinity at all the adenosine receptor subtypes, demonstrating that the furanyl ring is a necessary structural element to guarantee interaction with the adenosine receptor surface; replacement of the furan ring with an ortho-ethoxy-substituted aromatic ring did not enhance affinity. Introduction of a N-methylpiperazinomethyl or morpholinomethyl function at the 5' position of the furanyl ring of I or introduction of a methylsulfanyl moiety at the 9-position of pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines yields inhibitors with improved water solubilities but reduced affinities for adenosine A2a and A3 receptors.


IT 512845-34-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(preparation and structure-activity relationships of pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines as potential selective adenosine A2a and A3 receptor antagonists)

RN 512845-34-0 CAPLUS

CN Acetamide, 2-[4-[5-amino-7-(2-phenylethyl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-2-yl]phenoxy]-N-(4-iodophenyl)- (CA INDEX NAME)



OS.CITING REF COUNT:	50	THERE ARE 50 CAPLUS RECORDS THAT CITE THIS RECORD (51 CITINGS)
REFERENCE COUNT:	29	THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L87 ANSWER 19 OF 84 CAPLUS COPYRIGHT 2011 ACS on STN
 ACCESSION NUMBER: 2002:925396 CAPLUS Full-text
 DOCUMENT NUMBER: 138:17998
 TITLE: Photothermographic recording paper comprising
 polymerizable compound
 INVENTOR(S): Takashima, Masanobu; Sato, Hiroshi; Arai, Yoshimitsu;
 Hanasaki, Kyoko
 PATENT ASSIGNEE(S): Fuji Photo Film Co., Ltd., Japan
 SOURCE: Eur. Pat. Appl., 80 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1262828	A1	20021204	EP 2002-11662	20020531 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2003050442	A	20030221	JP 2002-98759	20020401 <--
US 20030073025	A1	20030417	US 2002-158210	20020531 <--
US 6720124	B2	20040413		
PRIORITY APPLN. INFO.:			JP 2001-166731	A 20010601 <--
			JP 2002-98759	A 20020401

<--

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 138:17998

AB A recording photothermog. paper includes a support having disposed thereon a recording layer comprising at least: a diazo compound having no diazonio group, as further described in the claims; a coupler compound that colors by reacting with the diazo compound; and a polymerizable compound. Since the photothermog. paper according to the present invention contains a polymerizable compound in the recording layer, it shows excellent image fastness, high sensitivity and fixing speed. A highly sensitive image can be recorded and photofixed at high speed using not only UV light but visible to IR light in a completely dry processing system that does not require a developing solution and therefore does not generate waste; there is excellent decoloring at non-image portions (background portions); and a sharp high-contrast black-and-white or color image can be formed.


IT 477704-73-7

RL: TEM (Technical or engineered material use); USES (Uses)
 (coupler; photothermog. recording paper comprising polymerizable thermoplasticizer compound and coupler that colors by reacting with diazo compound)


RN 477704-73-7 CAPLUS

CN Benzoic acid, 3-chloro-4-[2-[[4-[6-(1,1-dimethylethyl)-3H-pyrazolo[1,5-b][1,2,4]triazol-2-yl]phenyl]amino]-2-oxoethoxy]-, 6-[(2-methyl-1-oxo-2-propen-1-yl)oxy]hexyl ester (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L87 ANSWER 20 OF 84 CAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 2002:770129 CAPLUS Full-text

DOCUMENT NUMBER: 137:279184

TITLE: Preparation of 3-(hetero)aryl pyrazoles with 4,5(3,4)-bicyclic ring fusion as protein kinase inhibitors

INVENTOR(S): Doyle, Kevin J.; Rafferty, Paul; Steele, Robert W.; Wilkins, David J.; Arnold, Lee D.; Hockley, Michael; Ericsson, Anna M.; Iwasaki, Nobuhiko; Ogawa, Nobuo

PATENT ASSIGNEE(S): BASF Aktiengesellschaft, Germany

SOURCE: U.S., 69 pp., Cont.-in-part of WO 2000 27,822.

CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6462036	B1	20021008	US 2000-573366	20000517 <--
WO 2000027822	A2	20000518	WO 1999-US26105	19991104 <--
WO 2000027822	A3	20000810		
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
CA 2409225	A1	20011122	CA 2001-2409225	20010517 <--
WO 2001087846	A2	20011122	WO 2001-US16153	20010517 <--
WO 2001087846	A3	20020321		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT,
RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US,
UZ, VN, YU, ZA, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
EP 1289525 A2 20030312 EP 2001-937553 20010517 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
JP 2003533514 T 20031111 JP 2001-584242 20010517 <--
MX 2002011320 A 20040910 MX 2002-11320 20021115 <--
PRIORITY APPLN. INFO.: US 1998-107467P P 19981106 <--
WO 1999-US26105 A2 19991104 <--
US 2000-573366 A 20000517
<--
WO 2001-US16153 W 20010517
<--

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): CASREACT 137:279184; MARPAT 137:279184
GI



I



II

AB Title compds. I [$m = 1-10$; $X = \text{alkyl, CO, O, oximino, etc.}$; $B = \text{alkyl, cycloalkyl, aryl, pyridyl, thienyl, furyl, pyrrolyl}$; $R_1 = \text{H, halo, hydroxy, nitro, cyano, hydroxyamidino, etc.}$; $A = (\text{un})\text{substituted with one or more substituents selected from halo, alkyl, etc.}$] were prepared For instance, indan-1-one hydrazone (preparation given) was reacted with Me 3,4,5-trimethoxybenzoate (THF, $n\text{-BuLi}$, 0°) and subsequently acidified with HCl (3 M) and heated to reflux for 1 h to give II. I are inhibitors of protein

kinase activity and used for the treatment of, e.g., cancer, diabetic retinopathy, etc.


IT 268563-63-9P, N-(2,5-Difluorobenzyl)-N'-[4-(1,4-dihydroindeno[1,2-c]pyrazol-3-yl)phenyl]urea

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(kinase inhibitor; 3-(hetero)aryl pyrazoles with 4,5(3,4)-bicyclic ring fusion as protein kinase inhibitors)

RN 268563-63-9 CAPLUS

CN Urea, N-[(2,5-difluorophenyl)methyl]-N'-[4-(1,4-dihydroindeno[1,2-c]pyrazol-3-yl)phenyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 9 THERE ARE 9 CAPLUS RECORDS THAT CITE THIS RECORD (9 CITINGS)

REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L87 ANSWER 21 OF 84 CAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 2002:754342 CAPLUS Full-text

DOCUMENT NUMBER: 137:263068

TITLE: Preparation of aryl and biaryl derivatives having Melanin-concentrating hormone modulatory activity

INVENTOR(S): Hobbs, Douglas W.; Guo, Tao; Hunter, Rachael C.; Gu, Huizhong

PATENT ASSIGNEE(S): Pharmacoopia, Inc., USA

SOURCE: PCT Int. Appl., 180 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002076929	A1	20021003	WO 2002-US8300	20020319 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UZ, VN, YU, ZA, ZM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

CA 2441235	A1	20021003	CA 2002-2441235	20020319 <--
CA 2441235	C	20110524		
AU 2002247367	A1	20021008	AU 2002-247367	20020319 <--
AU 2002247367	B2	20051027		
US 20030092715	A1	20030515	US 2002-101136	20020319 <--
US 7034056	B2	20060425		
EP 1370520	A1	20031217	EP 2002-715150	20020319 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
CN 1498205	A	20040519	CN 2002-806895	20020319 <--
CN 100537527	C	20090909		
HU 2004000252	A2	20040830	HU 2004-252	20020319 <--
JP 2004526736	T	20040902	JP 2002-576192	20020319 <--
JP 4557492	B2	20101006		
NZ 527680	A	20050729	NZ 2002-527680	20020319 <--
ZA 2003006727	A	20041129	ZA 2003-6727	20030828 <--
MX 2003008484	A	20031208	MX 2003-8484	20030919 <--
JP 2010001316	A	20100107	JP 2009-232046	20091005 <--
PRIORITY APPLN. INFO.:			US 2001-277534P	P 20010321 <--
			JP 2002-576192	A3 20020319 <--
			WO 2002-US8300	W 20020319

<--

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 137:263068

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. [I; A = (un)substituted aryl, pyridinyl, pyrazinyl, pyridazinyl; Z = biphenylcarbonyl, biphenylcarbonyl, biphenoxycarbonyl, biphenyl, biphenylsulfonyl; M = H, Me, Et, iso-Pr, n-Pr, cyclobutyl; n = 2-4; p = 1-6; R1 = NH2, NHR, NR2, NOR2, NH(CH2)nNR2; R = Me, Et, n-Pr, iso-Pr, cyclobutyl; R2 = H, alkyl] are prepared as antagonists of the Melanin-concentrating hormone (MCH) receptor. In one embodiment, this invention provides methods of preparing title compds., pharmaceutical compns. containing one or more of title compds., methods of preparing pharmaceutical formulations comprising one or more title compds., and methods of treatment, prevention or amelioration or one or more of diseases associated with the MCH receptor. Thus, the title compound II was an illustrative inventive compound


IT ~~463936-60-9P~~ ~~463936-71-2P~~

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of aryl and biaryl derivs. having Melanin-concentrating hormone modulatory activity)


RN 463936-60-9 CAPLUS

CN Carbamic acid, (3,5-dichlorophenyl)-, 3-(dimethylamino)-1-[4-(4-pyridinyl)phenyl]propyl ester (9CI) (CA INDEX NAME)



RN 463936-71-2 CAPLUS

CN Carbamic acid, (3,5-dichlorophenyl)-,
3-(dimethylamino)-1-[4-(3-pyridinyl)phenyl]propyl ester (9CI) (CA INDEX
NAME)



OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD
(4 CITINGS)

REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L87 ANSWER 22 OF 84 CAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 2002:615623 CAPLUS Full-text

DOCUMENT NUMBER: 137:169517

TITLE: Oxazolyl-pyrazole derivatives as protein kinase
inhibitors, their preparation and combinatorial
libraries, and their pharmaceutical use in the
treatment of cancer and other diseases and disorders
INVENTOR(S): Berta, Daniela; Felder, Eduard; Vulpetti, Anna; Villa,
Marzia

PATENT ASSIGNEE(S): Pharmacia Italia S.p.A., Italy

SOURCE: PCT Int. Appl., 107 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002062804	A1	20020815	WO 2002-EP995	20020128 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,				
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,				
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,				
PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,				
UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,				

CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG


CA 2437260	A1	20020815	CA 2002-2437260	20020128 <--
AU 2002246076	A1	20020819	AU 2002-246076	20020128 <--
AU 2002246076	B2	20070614		
EP 1377589	A1	20040107	EP 2002-714136	20020128 <--
EP 1377589	B1	20050907		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004520394	T	20040708	JP 2002-563156	20020128 <--
NZ 527123	A	20050429	NZ 2002-527123	20020128 <--
AT 304017	T	20050915	AT 2002-714136	20020128 <--
ES 2248532	T3	20060316	ES 2002-714136	20020128 <--
MX 2003006863	A	20031113	MX 2003-6863	20030731 <--
US 20040180881	A1	20040916	US 2004-470859	20040415 <--
US 7105535	B2	20060912		
PRIORITY APPLN. INFO.:			GB 2001-2687	A 20010202 <--
			WO 2002-EP995	W 20020128

<--


ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 137:169517

GI



I



II

AB The method of treating protein kinase-linked diseases with oxazolyl-pyrazole derivs. I and their pharmaceutically acceptable salts is disclosed [wherein: R = H, alkyl, alkenyl, aryl, arylalkyl, (un)saturated cycloalkyl or cycloalkyloxy optionally condensed with 1 or 2 benzene rings, or optionally benzo-condensed 5- or 6-membered heterocyclyl or heterocyclylalkyl having 1 or 2 N/O/S atoms [all optionally substituted by one or more of: halo, NO₂, cyano, OH, oxo, alkyl, alkoxyalkyl, perfluoroalkyl, (un)substituted aryl or

5- or 6-membered heterocyclyl having 1 or 2 N/O/S atoms, alkoxy, alkoxyalkyloxy, (un)substituted arylalkyloxy or aryloxy, alkylthio, alkylsulfonyl, arylthio, or arylsulfonyl, cycloalkyl, amino, alkylamino, dialkylamino, arylamino, alkylcarbonyl, alkyloxycarbonyl, alkylaminocarbonyl, aminocarbonyl, (un)substituted arylcarbonyl or heterocyclylcarbonyl, alkylcarbonylamino, alkyloxycarbonylamino, arylalkyloxycarbonylamino, arylcarbonylamino, aryloxycarbonylamino, carboxy, alkylcarbonyloxy, or arylcarbonyloxy]; Y = bond, CO, NHCO, SO₂; WZ = benzo fusion, naphtho fusion, or an optionally benzocondensed 5- or 6-membered heterocycle having 1 or 2 N/O/S atoms, each optionally substituted by one or more of halo, nitro, cyano, alkyl, alkoxy, alkylsulfonyl, or aryl]. Also disclosed is a novel subset of I, including 382 individually named compds. I are useful in the treatment of diseases caused by and/or associated with an altered protein kinase activity, such as cancer, cell proliferative disorders, viral infections, autoimmune diseases and neurodegenerative disorders. Eleven examples are given, including solid-phase preparation of several compds. I and intermediates, and descriptions of 3 combinatorial libraries of 3874, 3172, and 2184 members, based on 4 claimed tables of reactants. For instance, Et 3-(3-nitrophenyl)pyrazole-4-carboxylate was bound to trityl chloride resin, saponified with NaOH in MeOH, and amidated with o-aminophenol. The resultant N-(2-hydroxyphenyl)amide was cyclized by Mitsunobu reaction to give a 1,3-benzoxazole derivative, followed by reduction of the nitro group to amino using SnCl₂, amidation with PhCH₂CO₂H, and resin cleavage with TFA, to give title compound II. Inhibition assays against various kinases are described (no data).

IT 448184-05-2P, N-[4-[4-(6-Methyl-1,3-benzoxazol-2-yl)pyrazol-3-yl]phenyl]-2-(2,3-dichlorophenoxy)acetamide 448185-96-4P,

N-[4-[4-(4-Methyl-7-isopropyl-1,3-benzoxazol-2-yl)pyrazol-3-yl]phenyl]-2-(2,3-dichlorophenoxy)acetamide 448187-45-9P,


N-[3-[4-(Naphth[2,3-d]-1,3-oxazol-2-yl)pyrazol-3-yl]phenyl]-2-(2,3-dichlorophenoxy)acetamide

RL: CPN (Combinatorial preparation); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); CMBI (Combinatorial study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of oxazolylypyrazole derivs. as protein kinase inhibitors, and their combinatorial libraries and use as anticancer agents)


RN 448184-05-2 CAPLUS

CN Acetamide, 2-(2,3-dichlorophenoxy)-N-[4-[4-(6-methyl-2-benzoxazolyl)-1H-pyrazol-3-yl]phenyl]- (CA INDEX NAME)




RN 448185-96-4 CAPLUS

CN Acetamide, 2-(2,3-dichlorophenoxy)-N-[4-[4-[4-methyl-7-(1-methylethyl)-2-benzoxazolyl]-1H-pyrazol-3-yl]phenyl]- (CA INDEX NAME)



RN 448187-45-9 CAPLUS

CN Acetamide, 2-(2,3-dichlorophenoxy)-N-[3-(4-naphth[2,3-d]oxazol-2-yl-1H-pyrazol-3-yl)phenyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 14 THERE ARE 14 CAPLUS RECORDS THAT CITE THIS RECORD (15 CITINGS)
 REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L87 ANSWER 23 OF 84 CAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 2002:555466 CAPLUS Full-text

DOCUMENT NUMBER: 137:125096

TITLE: Preparation of phenyl derivatives containing inhibitors of coagulation factor for prophylaxis and/or therapy of thromboembolic disorders

INVENTOR(S): Dorsch, Dieter; Mederski, Werner; Tsaklakidis, Christos; Cezanne, Bertram; Gleitz, Johannes; Barnes, Christopher

PATENT ASSIGNEE(S): Merck Patent G.m.b.H., Germany

SOURCE: PCT Int. Appl., 133 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002057236	A1	20020725	WO 2001-EP14296	20011205 <--
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
DE 10102322	A1	20020725	DE 2001-10102322	20010119 <--
CA 2434937	A1	20020725	CA 2001-2434937	20011205 <--
CA 2434937	C	20101109		
AU 2002227993	A1	20020730	AU 2002-227993	20011205 <--
AU 2002227993	B2	20070809		
EP 1351938	A1	20031015	EP 2001-989580	20011205 <--
EP 1351938	B1	20070411		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
BR 2001016804	A	20040217	BR 2001-16804	20011205 <--
CN 1518541	A	20040804	CN 2001-823061	20011205 <--

JP 2004535362	T	20041125	JP 2002-557917	20011205 <--
JP 4180375	B2	20081112		
HU 2005000110	A2	20050628	HU 2005-110	20011205 <--
AT 359271	T	20070515	AT 2001-989580	20011205 <--
ES 2284718	T3	20071116	ES 2001-989580	20011205 <--
MX 2003006483	A	20030922	MX 2003-6483	20030718 <--
IN 2003KN01033	A	20060602	IN 2003-KN1033	20030813 <--
ZA 2003006419	A	20041118	ZA 2003-6419	20030818 <--
US 20040087582	A1	20040506	US 2003-466680	20031218 <--
US 7273867	B2	20070925		
PRIORITY APPLN. INFO.:			DE 2001-10102322	A 20010119 <--
			WO 2001-EP14296	W 20011205

<--

OTHER SOURCE(S): MARPAT 137:125096

AB Novel compds. of the formula R1R2C6H3-W-X-Y-T in which W, X, Y, T, R1 and R2 are as defined in Patent Claim 1, are inhibitors of coagulation factor Xa and can be employed for the prophylaxis and/or therapy of thromboembolic disorders. Thus, 3-(5-methyl-1,2,4-oxadiazol-3-yl)phenol wa reacted with Et 2-bromovalerate, sodium hydroxide, thionyl chloride, 4-morpholin-4-ylaniline, followed a hydrogenation in acetic acid to give 2-(3-amidinophenoxy)-N-(4-morpholin-4-ylphenyl)valeramide acetate, showing IC50=3x10⁻⁷ M and IC50=4.9x10⁻⁷ M.

IT 444002-21-5P 444002-22-6P


RL: IMF (Industrial manufacture); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of Ph derivs. containing inhibitors of coagulation factor for prophylaxis and/or therapy of thromboembolic disorders)

RN 444002-21-5 CAPLUS


CN Pentanamide,

N-[4-(2,5-dioxo-1-pyrrolidinyl)-3-(trifluoromethyl)phenyl]-2-[3-(5-methyl-1,2,4-oxadiazol-3-yl)phenoxy]- (CA INDEX NAME)



RN 444002-22-6 CAPLUS

CN Pentanamide, N-[3-chloro-4-(2,5-dioxo-1-pyrrolidinyl)phenyl]-2-[3-(5-methyl-1,2,4-oxadiazol-3-yl)phenoxy]- (CA INDEX NAME)



OS.CITING REF COUNT: 18 THERE ARE 18 CAPLUS RECORDS THAT CITE THIS
RECORD (18 CITINGS)
REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L87 ANSWER 24 OF 84 CAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 2002:368463 CAPLUS Full-text

DOCUMENT NUMBER: 136:386109

TITLE: Preparation of amide derivatives as antiherpes agents

INVENTOR(S): Kontani, Toru; Miyata, Junji; Hamaguchi, Wataru;
Miyazaki, Yoji; Suzuki, Hiroshi; Nakai, Eiichi;
Kageyama, Shunji

PATENT ASSIGNEE(S): Yamanouchi Pharmaceutical Co., Ltd., Japan; Rational
Drug Design Laboratories

SOURCE: PCT Int. Appl., 71 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002038554	A1	20020516	WO 2001-JP9790	20011108 <--
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2428184	A1	20020516	CA 2001-2428184	20011108 <--
CA 2428184	C	20100330		
AU 2002012734	A	20020521	AU 2002-12734	20011108 <--
EP 1340750	A1	20030903	EP 2001-981033	20011108 <--
EP 1340750	B1	20050817		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
AT 302197	T	20050915	AT 2001-981033	20011108 <--
ES 2247177	T3	20060301	ES 2001-981033	20011108 <--
JP 3913172	B2	20070509	JP 2002-541089	20011108 <--
US 20040034232	A1	20040219	US 2003-416371	20030512 <--
US 6949543	B2	20050927		
PRIORITY APPLN. INFO.:			JP 2000-344354	A 20001110 <--
			WO 2001-JP9790	W 20011108

<--

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 136:386109

GI



AB The title compds. I [R1, R2 = H, alkyl, etc.; ring A = (un)substituted aryl, etc.; X = CO, SO2; R3 = (un)substituted cycloalkyl, etc.] are prepared These amide derivs. are useful as drugs and antiviral agents, in particular, preventives or remedies for various diseases caused by the infection with herpesviruses, more specifically, various herpesvirus infections such as pox (blister) caused by the infection with varicella zoster virus, herpes zoster caused by the recurrent infection with latent varicella zoster virus, herpes labialis and herpes encephalitis caused by the infection with HSV-1 and genital herpes caused by the infection with HSV-2.

N-([4-(2-Aminothiazol-4-yl)phenyl]carbamoyl)methyl)-4-fluoro-N-(2,3-dihydro-1H-indol-6-yl)benzamide dihydrochloride showed EC50 value of 0.046 μ M against varicella zoster virus, vs. EC50 value of 4.3 μ M shown by acyclovir.

IT 425688-62-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of amide derivs. as antiherpes agents)

RN 425688-62-6 CAPLUS

CN Benzamide, 4-fluoro-N-(4-fluorophenyl)-N-[2-oxo-2-[[4-[2-(2-pyridinylamino)-4-thiazolyl]phenyl]amino]ethyl]-, hydrochloride (1:2)

(CA

INDEX NAME)



● 2 HCl

OS.CITING REF COUNT: 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD (8 CITINGS)

REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L87 ANSWER 25 OF 84 CAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 2002:72061 CAPLUS Full-text

DOCUMENT NUMBER: 136:118465

TITLE: Preparation of 2-aryldihydroxypyrimidine-4-carboxylic acids as hepatitis C viral polymerase inhibitors

INVENTOR(S): Gardelli, Cristina; Giuliano, Claudio; Harper, Steven; Koch, Uwe; Narjes, Frank; Ontoria Ontoria, Jesus Maria; Poma, Marco; Ponzi, Simona; Stansfield, Ian; Summa, Vincenzo

PATENT ASSIGNEE(S): Istituto di Ricerche di Biologia Molecolare P. Angeletti S.p.A., Italy

SOURCE: PCT Int. Appl., 162 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002006246	A1	20020124	WO 2001-EP7955	20010711 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2418288	A1	20020124	CA 2001-2418288	20010711 <--
EP 1309566	A1	20030514	EP 2001-951664	20010711 <--
EP 1309566	B1	20091007		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004504304	T	20040212	JP 2002-512150	20010711 <--
AU 2001272530	B2	20060803	AU 2001-272530	20010711 <--
AT 444956	T	20091015	AT 2001-951664	20010711 <--
US 20040106627	A1	20040603	US 2003-333431	20030709 <--
US 7091209	B2	20060815		
PRIORITY APPLN. INFO.:			GB 2000-17676	A 20000719 <--
			WO 2001-EP7955	W 20010711

<--

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 136:118465

AB RR1 (R1 = 4-carboxy-5,6-dihydroxy-2-pyrimidinyl)[I; R = (un)substituted (hetero)aryl] were prepared Thus, 2-(O2N)C6H4C(:NOH)NH2 (preparation given) N-was alkenylated by MeO2CC.tplbond.CCO2Me and the product cyclized to give, after reduction, N-acylation, and saponification, I [R = 2-(2-ClC6H4CH2NHCONH)C6H4]. Data for biol. activity of I were given.

IT 865876-11-5 865876-12-6 865876-13-7
 866052-40-6 1102359-49-8 1102360-10-0
 1102360-16-6 1102360-19-9 1102360-21-3
 1102363-65-4 1102363-69-8 1102363-70-1
 1102363-71-2 1102363-72-3 1102363-75-6

1102363-77-8 1102363-82-5


RL: PRPH (Prophetic)

(Preparation of 2-aryldihydroxypyrimidine-4-carboxylic acids as hepatitis C viral polymerase inhibitors)

RN 865876-11-5 CAPLUS


CN 4-Pyrimidinecarboxylic acid, 2-[2-[[[(2-

fluorophenyl)methyl]amino]carbonyl]amino]phenyl]-1,6-dihydro-5-hydroxy-6-oxo- (CA INDEX NAME)



RN 865876-12-6 CAPLUS


CN 4-Pyrimidinecarboxylic acid, 2-[2-[[[(2-bromophenyl)methyl]amino]carbonyl]amino]phenyl]-1,6-dihydro-5-hydroxy-6-oxo- (CA INDEX NAME)



RN 865876-13-7 CAPLUS


CN 4-Pyrimidinecarboxylic acid, 2-[2-[[[(2-chloro-6-

methylphenyl)methyl]amino]carbonyl]amino]phenyl]-1,6-dihydro-5-hydroxy-6-oxo- (CA INDEX NAME)




RN 866052-40-6 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 2-[2-[[[(2-chlorophenyl)methyl]amino]carbonyl]amino]-5-[(2-thienylcarbonyl)amino]phenyl]-1,6-dihydro-5-hydroxy-6-oxo- (CA INDEX NAME)




RN 1102359-49-8 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 2-[3-[[[(3-fluorophenyl)methyl]amino]carbonyl]amino]phenyl]-1,6-dihydro-5-hydroxy-6-oxo- (CA INDEX NAME)




RN 1102360-10-0 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 2-[3-[[[(2-chlorophenyl)methyl]amino]carbonyl]amino]phenyl]-1,6-dihydro-5-hydroxy-6-oxo- (CA INDEX NAME)




RN 1102360-16-6 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1102360-19-9 CAPLUS
CN 4-Pyrimidinecarboxylic acid, 2-[3-[[[(3-

chlorophenyl)methyl]amino]carbonyl]amino]phenyl]-1,6-dihydro-5-hydroxy-6-oxo- (CA INDEX NAME)




RN 1102360-21-3 CAPLUS
CN 4-Pyrimidinecarboxylic acid, 2-[3-[[[(3,4-


dichlorophenyl)methyl]amino]carbonyl]amino]phenyl]-1,6-dihydro-5-hydroxy-6-oxo- (CA INDEX NAME)




RN 1102363-65-4 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1102363-69-8 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED




RN 1102363-70-1 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED




RN 1102363-71-2 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED




RN 1102363-72-3 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1102363-75-6 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1102363-77-8 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1102363-82-5 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




IT 391680-76-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 2-aryldihydroxypyrimidine-4-carboxylic acids as hepatitis C viral polymerase inhibitors)

RN 391680-76-5 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 2-[2-[[[(2-

chlorophenyl)methyl]amino]carbonyl]amino]phenyl]-1,6-dihydro-5-hydroxy-6-oxo- (CA INDEX NAME)



IT 391680-87-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(preparation of 2-aryldihydroxypyrimidine-4-carboxylic acids as hepatitis C

viral polymerase inhibitors)

RN 391680-87-8 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 2-[2-[[[(2-

chlorophenyl)methyl]amino]carbonyl]amino]phenyl]-1,6-dihydro-5-hydroxy-6-oxo-, methyl ester (CA INDEX NAME)



OS.CITING REF COUNT: 23 THERE ARE 23 CAPLUS RECORDS THAT CITE THIS RECORD (25 CITINGS)
 REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L87 ANSWER 26 OF 84 CAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 2001:851793 CAPLUS Full-text

DOCUMENT NUMBER: 136:5986

TITLE: Preparation of azole inhibitors of cytokine production
 INVENTOR(S): Bamaung, Nwe Y.; Basha, Anwer; Djuric, Stevan W.; Gubbins, Earl J.; Luly, Jay R.; Tu, Noah P.; Madar, David J.; Warrior, Usha; Wiedeman, Paul E.; Zhou, Xun; Sciotti, Richard J.; Wagenaar, Frank L.

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 124 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1



PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20010044445	A1	20011122	US 1999-289155	19990408 <--
PRIORITY APPLN. INFO.:			US 1999-289155	19990408 <--

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 136:5986

GI




AB The title compds. [I; R1, R3 = H, aryl, perfluoroalkyl, etc.; Z = N, C; R2 is absent or = H, alkyl, cycloalkyl, etc.; Q = (hetero)aryl (when Q = Ph, the Ph is 2-, 3-, or 4-substituted by E relative to the position of attachment of the pyrazole or 1,2,4-triazole ring to the Ph ring); R4, R5 = H, alkyl, haloalkyl, etc.; E = NO2, NH2, etc.], useful for inhibiting cytokine (Interleukin-2, Interleukin-4, or Interleukin-5) production and cellular proliferation in stimulated human T cell lines or human peripheral blood mononuclear cells (biol. data given) and therefore have utility in the treatment of diseases that are prevented by or ameliorated with cytokine inhibitors, were prepared General procedures for preparation of compds. I were described. Thus, the title compound II was prepared

IT 245746-03-6P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of azole inhibitors of cytokine production)

RN 245746-03-6 CAPLUS

CN Propanamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2-(4-chlorophenoxy)-2-methyl- (CA INDEX NAME)



OS.CITING REF COUNT: 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD (6 CITINGS)

L87 ANSWER 27 OF 84 CAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 2001:851123 CAPLUS Full-text

DOCUMENT NUMBER: 136:5985


TITLE: Preparation of tricyclic pyrazole derivatives as tyrosine kinase inhibitors for treatment of angiogenesis-related diseases

INVENTOR(S): Doyle, Kevin J.; Rafferty, Paul; Steele, Robert W.;

PATENT ASSIGNEE(S): Wilkins, David J.; Arnold, Lee D.; Hockley, Michael;
 SOURCE: Ericsson, Anna M.; Iwasaki, Nobuhiko; Ogawa, Nobuo
 Knoll G.m.b.H., Germany
 PCT Int. Appl., 183 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001087846	A2	20011122	WO 2001-US16153	20010517 <--
WO 2001087846	A3	20020321		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
US 6462036	B1	20021008	US 2000-573366	20000517 <--
CA 2409225	A1	20011122	CA 2001-2409225	20010517 <--
EP 1289525	A2	20030312	EP 2001-937553	20010517 <--
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
JP 2003533514	T	20031111	JP 2001-584242	20010517 <--
MX 2002011320	A	20040910	MX 2002-11320	20021115 <--
PRIORITY APPLN. INFO.:			US 2000-573366	A1 20000517 <--
			US 1998-107467P	P 19981106
<--			WO 1999-US26105	A2 19991104 <--
			WO 2001-US16153	W 20010517

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
 OTHER SOURCE(S): MARPAT 136:5985
 GI



AB Title compds. I [m = 1-10; X = (CH₂)_n, CO, O, C:NOR10, NR11, (CH₂)_n, S, SO, or SO₂; n = 1-3; R10 = alkyl; R11 = (un)substituted alkyl or Ph; B = (cyclo)alkyl, aryl, pyridyl, thienyl, furyl, or pyrrolyl; R1 = H, halo, OH, NO₂, CN, hydroxyamidino, CH₂NH₂, formamidomethyl, (un)substituted


alkenyl(oxy), alkynyl, or YW; Y = absent or alkyl, alkoxy, O, S, or CO; W = H, OH, (un)substituted Ph, alkoxy, or amino; ring A is optionally substituted with halo, OH, NO₂, CN, or (un)substituted alkyl, alkoxy, PhO, carboxy, carbamoyl, amino, amido, aralkyl, alkenyl, or alkynyl; with provisos; and racemic mixts., racemic diastereomeric mixts., tautomers, optical isomers, and pharmaceutically acceptable salts thereof] were prepared as protein kinase inhibitors, especially tyrosine kinase inhibitors. Thus, indan-1-one hydrazone (preparation given) in THF at 0° was treated with BuLi and then with Me 3,4,5-trimethoxybenzoate to give 3-(3,4,5-trimethoxyphenyl)-1,4-dihydroindeno[1,2-c]pyrazole. Example compds. significantly inhibited KDR kinase at concns. of ≤ 50 μM.

IT 268563-63-9P, N-(2,5-Difluorobenzyl)-N'-[4-(1,4-dihydroindeno[1,2-c]pyrazol-3-yl)phenyl]urea
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of tricyclic pyrazole derivs. as tyrosine kinase inhibitors for treatment of angiogenesis-related diseases)

RN 268563-63-9 CAPLUS

CN Urea, N-[(2,5-difluorophenyl)methyl]-N'-[4-(1,4-dihydroindeno[1,2-c]pyrazol-3-yl)phenyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 8 THERE ARE 8 CAPLUS RECORDS THAT CITE THIS RECORD (8 CITINGS)
 REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L87 ANSWER 28 OF 84 CAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 2001:833294 CAPLUS Full-text

DOCUMENT NUMBER: 135:357934

TITLE: Preparation of tetrazolylbenzoylureas as pesticides and herbicides.

INVENTOR(S): Maurer, Fritz; Erdelen, Christoph

PATENT ASSIGNEE(S): Bayer Aktiengesellschaft, Germany

SOURCE: PCT Int. Appl., 85 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent


LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----

WO 2001085705 A1 20011115 WO 2001-EP4899 20010502 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM,
HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS,
LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO,
RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ,
VN, YU, ZA, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
DE 10023430 A1 20011115 DE 2000-10023430 20000512 <--
BR 2001010710 A 20030211 BR 2001-10710 20010502 <--
EP 1289969 A1 20030312 EP 2001-945069 20010502 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
JP 2003532717 T 20031105 JP 2001-582306 20010502 <--
CN 1200933 C 20050511 CN 2001-809261 20010502 <--
AU 783546 B2 20051110 AU 2001-67395 20010502 <--
IN 2001MU00420 A 20050304 IN 2001-MU420 20010503 <--
IN 210925 A1 20071026
EG 22778 A 20030831 EG 2001-479 20010508 <--
ZA 2002008199 A 20031110 ZA 2002-8199 20021011 <--
US 20030187043 A1 20031002 US 2002-275829 20021108 <--
US 6911416 B2 20050628
MX 2002011131 A 20030425 MX 2002-11131 20021112 <--
US 20040192747 A1 20040930 US 2004-823855 20040414 <--
IN 2007MU02243 A 20090605 IN 2007-MU2243 20071113 <--
PRIORITY APPLN. INFO.: DE 2000-10023430 A 20000512 <--
WO 2001-EP4899 W 20010502
<--
IN 2001-MU402 A3 20010503 <--
US 2002-275829 A3 20021108 <--
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): MARPAT 135:357934
GI



AB Title compds. [I; R1 = halo; R2 = H, halo; R3 = halo, alkyl, haloalkyl; n = 0-2; R4 = H, (substituted) alkyl, alkenyl, alkoxyalkyl, alkoxycarbonylalkyl, alkylsulfonyl, aryl, aralkyl, arylsulfonyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl], were prepared Thus, 5-(3-chloro-4-aminophenyl)tetrazole (preparation given) in MeCN was treated with 2,6-difluorobenzoyl isocyanate in MeCN to precipitate 53% N-(2,6-difluorobenzoyl)-N'-(2-chloro-4-tetrazol-5-ylphenyl)urea. Several I at 0.1% on cabbage leaves gave 100% kill of Spodoptera frugiperda after 7 days.


IT 1139482-69-1 1139482-71-5 1139482-72-6
 1139482-73-7 1139482-74-8 1139482-77-1
 1139482-78-2 1139482-79-3 1139482-80-6

RL: PRPH (Prophetic)

(Preparation of tetrazolylbenzoylureas as pesticides and herbicides.)


RN 1139482-69-1 CAPLUS

CN Benzamide, 2-chloro-N-[[[4-chloro-3-[1-(difluoromethyl)-1H-tetrazol-5-yl]phenyl]amino]carbonyl]- (CA INDEX NAME)




RN 1139482-71-5 CAPLUS

CN Benzamide, N-[[[3-[1-(difluoromethyl)-1H-tetrazol-5-yl]-5-(trifluoromethyl)phenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)




RN 1139482-72-6 CAPLUS

CN Benzamide, 2-chloro-N-[[[3-[1-(difluoromethyl)-1H-tetrazol-5-yl]-5-(trifluoromethyl)phenyl]amino]carbonyl]- (CA INDEX NAME)




RN 1139482-73-7 CAPLUS

CN Benzamide, N-[[[2-chloro-5-[1-(difluoromethyl)-1H-tetrazol-5-yl]phenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)




RN 1139482-74-8 CAPLUS

CN Benzamide, 2-chloro-N-[[[2-chloro-5-[1-(difluoromethyl)-1H-tetrazol-5-yl]phenyl]amino]carbonyl]- (CA INDEX NAME)




RN 1139482-77-1 CAPLUS

CN Benzamide, 2-chloro-N-[[[3-[1-(difluoromethyl)-1H-tetrazol-5-yl]phenyl]amino]carbonyl]- (CA INDEX NAME)




RN 1139482-78-2 CAPLUS

CN Benzamide, 2-chloro-N-[[[3-(2H-tetrazol-5-yl)phenyl]amino]carbonyl]- (CA INDEX NAME)




RN 1139482-79-3 CAPLUS

CN Benzamide, 2,6-difluoro-N-[[[3-(2H-tetrazol-5-yl)phenyl]amino]carbonyl]- (CA INDEX NAME)



RN 1139482-80-6 CAPLUS

CN Benzamide, N-[[[4-chloro-3-[1-(difluoromethyl)-1H-tetrazol-5-yl]phenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)




IT	372192-41-1P	372192-43-3P	372192-44-4P
	372192-46-6P	372192-47-7P	372192-48-8P
	372192-49-9P	372192-50-2P	372192-51-3P
	372192-52-4P	372192-53-5P	372192-54-6P
	372192-55-7P	372192-56-8P	372192-57-9P
	372192-58-0P	372192-59-1P	372192-60-4P
	372192-61-5P	372192-62-6P	372192-63-7P
	372192-64-8P	372192-65-9P	372192-66-0P
	372192-67-1P	372192-68-2P	372192-69-3P
	372192-70-6P	372192-71-7P	372192-72-8P
	372192-73-9P	372192-74-0P	372192-75-1P
	372192-76-2P	372192-77-3P	372192-78-4P
	372192-79-5P	372192-80-8P	372192-81-9P
	372192-82-0P	372192-83-1P	372192-84-2P
	372192-85-3P	372192-86-4P	372192-87-5P
	372192-88-6P	372192-89-7P	372192-90-0P
	372192-91-1P	372192-92-2P	372192-93-3P
	372192-94-4P	372192-95-5P	372192-96-6P
	372192-97-7P	372192-98-8P	372192-99-9P
	372193-00-5P	372193-01-6P	372193-02-7P
	372193-03-8P	372193-04-9P	372193-05-0P
	372193-06-1P	372193-07-2P	372193-08-3P
	372193-09-4P	372193-10-7P	372193-11-8P
	372193-12-9P	372193-13-0P	372193-14-1P
	372193-15-2P	372193-16-3P	

RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of tetrazolylbenzoylureas as pesticides and herbicides)


RN 372192-41-1 CAPLUS

CN Benzamide, N-[[[2-chloro-4-(2H-tetrazol-5-yl)phenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)




RN 372192-43-3 CAPLUS

CN Benzamide, N-[[[2-chloro-4-[2-(tetrahydro-2H-pyran-2-yl)-2H-tetrazol-5-yl]phenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)




RN 372192-44-4 CAPLUS

CN Benzamide, N-[[[2-chloro-4-(1-methyl-1H-tetrazol-5-yl)phenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)




RN 372192-46-6 CAPLUS

CN Benzamide, N-[[[2-chloro-4-[2-(1,1-dimethylethyl)-2H-tetrazol-5-yl]phenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)




RN 372192-47-7 CAPLUS

CN Benzamide, N-[[[2-chloro-4-(2-methyl-2H-tetrazol-5-yl)phenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)




RN 372192-48-8 CAPLUS

CN Benzamide, N-[[[4-chloro-2-(2H-tetrazol-5-yl)phenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)




RN 372192-49-9 CAPLUS

CN Benzamide, N-[[[2,5-dichloro-4-(2H-tetrazol-5-yl)phenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)



RN 372192-50-2 CAPLUS


CN Benzamide, N-[[[2-chloro-4-[2-(1-methylcyclohexyl)-2H-tetrazol-5-yl]phenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)



RN 372192-51-3 CAPLUS


CN Benzamide, N-[[[2-chloro-4-[2-[(tetrahydro-2H-pyran-2-yl)methyl]-2H-

tetrazol-5-yl]phenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)




RN 372192-52-4 CAPLUS

CN Benzamide, 2-chloro-N-[[[2-chloro-4-[2-(1,1-dimethylethyl)-2H-tetrazol-5-yl]phenyl]amino]carbonyl]-6-fluoro- (CA INDEX NAME)




RN 372192-53-5 CAPLUS

CN Benzamide, N-[[[4-chloro-2-[2-(1,1-dimethylethyl)-2H-tetrazol-5-yl]phenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)




RN 372192-54-6 CAPLUS

CN 2H-Tetrazole-2-acetic acid, 5-[3-chloro-4-[[[(2,6-difluorobenzoyl)amino]carbonyl]amino]phenyl]-, methyl ester (CA INDEX NAME)




RN 372192-55-7 CAPLUS

CN Benzamide, N-[[[4-[2-[2-(acetyloxy)ethyl]-2H-tetrazol-5-yl]-2-chlorophenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)




RN 372192-56-8 CAPLUS

CN Benzamide, N-[[[2-chloro-4-[2-(ethoxymethyl)-2H-tetrazol-5-yl]phenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)




RN 372192-57-9 CAPLUS

CN Benzamide, N-[[[2-chloro-4-(2-propyl-2H-tetrazol-5-yl)phenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)



RN 372192-58-0 CAPLUS


CN Benzamide, N-[[[2,5-dichloro-4-[2-(1,1-dimethylethyl)-2H-tetrazol-5-yl]phenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)



RN 372192-59-1 CAPLUS


CN Benzamide, N-[[[4-[2-[(4-bromophenyl)methyl]-2H-tetrazol-5-yl]-2-

chlorophenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)




RN 372192-60-4 CAPLUS

CN Benzamide, N-[[[2-chloro-4-[2-(difluoromethyl)-2H-tetrazol-5-yl]phenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)




RN 372192-61-5 CAPLUS

CN Benzamide, N-[[[2-chloro-4-(2-phenyl-2H-tetrazol-5-yl)phenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)




RN 372192-62-6 CAPLUS

CN Benzamide, N-[[[2-chloro-4-[1-(difluoromethyl)-1H-tetrazol-5-yl]phenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)



RN 372192-63-7 CAPLUS


CN Benzamide, N-[[[2-chloro-4-[2-(2-methylpropyl)-2H-tetrazol-5-yl]phenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)



RN 372192-64-8 CAPLUS


CN Benzamide,

N-[[[2-chloro-4-[2-(3,4,4-trifluoro-3-buten-1-yl)-2H-tetrazol-5-yl]phenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)




RN 372192-65-9 CAPLUS

CN Benzamide, N-[[[2,6-dichloro-4-[2-(1,1-dimethylethyl)-2H-tetrazol-5-yl]phenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)




RN 372192-66-0 CAPLUS

CN Benzamide, N-[[[2,6-dichloro-4-[2-(2-methylpropyl)-2H-tetrazol-5-yl]phenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)




RN 372192-67-1 CAPLUS

CN Benzamide, N-[[[2,5-dichloro-4-[2-(2-methylpropyl)-2H-tetrazol-5-yl]phenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)




RN 372192-68-2 CAPLUS

CN Benzamide, N-[[[2,5-dichloro-4-(2-propyl-2H-tetrazol-5-yl)phenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)




RN 372192-69-3 CAPLUS

CN Benzamide, N-[[[4-[2-(1,1-dimethylethyl)-2H-tetrazol-5-yl]phenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)




RN 372192-70-6 CAPLUS

CN Benzamide, 2-chloro-N-[[[4-[2-(1,1-dimethylethyl)-2H-tetrazol-5-yl]phenyl]amino]carbonyl]-6-fluoro- (CA INDEX NAME)




RN 372192-71-7 CAPLUS

CN Benzamide, N-[[[2,5-dichloro-4-[2-(difluoromethyl)-2H-tetrazol-5-yl]phenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)




RN 372192-72-8 CAPLUS

CN Benzamide, N-[[[2-chloro-4-[2-(2-methyl-2-propen-1-yl)-2H-tetrazol-5-yl]phenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)




RN 372192-73-9 CAPLUS

CN Benzamide, 2-chloro-N-[[[4-[2-(1,1-dimethylethyl)-2H-tetrazol-5-yl]phenyl]amino]carbonyl]- (CA INDEX NAME)




RN 372192-74-0 CAPLUS

CN Benzamide, 2-chloro-N-[[[2-chloro-4-[2-(1,1-dimethylethyl)-2H-tetrazol-5-yl]phenyl]amino]carbonyl]- (CA INDEX NAME)



RN 372192-75-1 CAPLUS


CN Benzamide, 2-chloro-N-[[[2,6-dichloro-4-[2-(1,1-dimethylethyl)-2H-tetrazol-5-yl]phenyl]amino]carbonyl]- (CA INDEX NAME)



RN 372192-76-2 CAPLUS


CN Benzamide,

2-chloro-N-[[[2,5-dichloro-4-[2-(1,1-dimethylethyl)-2H-tetrazol-5-yl]phenyl]amino]carbonyl]- (CA INDEX NAME)




RN 372192-77-3 CAPLUS

CN Benzamide, N-[[[3-chloro-4-[2-(1,1-dimethylethyl)-2H-tetrazol-5-yl]phenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)




RN 372192-78-4 CAPLUS

CN Benzamide, 2-chloro-N-[[[3-chloro-4-[2-(1,1-dimethylethyl)-2H-tetrazol-5-yl]phenyl]amino]carbonyl]-6-fluoro- (CA INDEX NAME)




RN 372192-79-5 CAPLUS

CN Benzamide, N-[[[4-[2-(1,1-dimethylethyl)-2H-tetrazol-5-yl]-3-fluorophenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)




RN 372192-80-8 CAPLUS

CN Benzamide, 2-chloro-N-[[[4-[2-(1,1-dimethylethyl)-2H-tetrazol-5-yl]-3-fluorophenyl]amino]carbonyl]- (CA INDEX NAME)




RN 372192-81-9 CAPLUS

CN Benzamide, N-[[[4-[2-(1,1-dimethylethyl)-2H-tetrazol-5-yl]-2,6-difluorophenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)




RN 372192-82-0 CAPLUS

CN Benzamide, 2-chloro-N-[[[4-[2-(1,1-dimethylethyl)-2H-tetrazol-5-yl]-2,5-difluorophenyl]amino]carbonyl]- (CA INDEX NAME)




RN 372192-83-1 CAPLUS

CN Benzamide, N-[[[4-[2-(1,1-dimethylethyl)-2H-tetrazol-5-yl]-2,5-difluorophenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)




RN 372192-84-2 CAPLUS

CN Benzamide, 2-chloro-N-[[[4-[2-(1,1-dimethylethyl)-2H-tetrazol-5-yl]-2,6-difluorophenyl]amino]carbonyl]- (CA INDEX NAME)




RN 372192-85-3 CAPLUS

CN Benzamide, N-[[[2,5-dichloro-4-[2-(1-ethyl-1-methylpropyl)-2H-tetrazol-5-yl]phenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)




RN 372192-86-4 CAPLUS

CN Benzamide, N-[[[4-[2-(1-ethyl-1-methylpropyl)-2H-tetrazol-5-yl]phenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)




RN 372192-87-5 CAPLUS

CN Benzamide, N-[[[4-[2-(1,1-dimethylpropyl)-2H-tetrazol-5-yl]phenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)




RN 372192-88-6 CAPLUS

CN Benzamide, N-[[[4-[2-(1-ethyl-1-methylpropyl)-2H-tetrazol-5-yl]-2-fluorophenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)




RN 372192-89-7 CAPLUS

CN Benzamide, N-[[[4-[2-(1,1-dimethylpropyl)-2H-tetrazol-5-yl]-2-fluorophenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)




RN 372192-90-0 CAPLUS

CN Benzamide, 2-chloro-N-[[[4-[2-(1,1-dimethylpropyl)-2H-tetrazol-5-yl]phenyl]amino]carbonyl]- (CA INDEX NAME)




RN 372192-91-1 CAPLUS

CN Benzamide, 2-chloro-N-[[[4-[2-(1-ethyl-1-methylpropyl)-2H-tetrazol-5-yl]phenyl]amino]carbonyl]- (CA INDEX NAME)




RN 372192-92-2 CAPLUS

CN Benzamide, 2-chloro-N-[[[4-[2-(1,1-dimethylpropyl)-2H-tetrazol-5-yl]phenyl]amino]carbonyl]-6-fluoro- (CA INDEX NAME)




RN 372192-93-3 CAPLUS

CN Benzamide, 2-chloro-N-[[[4-[2-(1-ethyl-1-methylpropyl)-2H-tetrazol-5-yl]phenyl]amino]carbonyl]-6-fluoro- (CA INDEX NAME)




RN 372192-94-4 CAPLUS

CN Benzamide, N-[[[4-[2-(1,1-dimethylethyl)-2H-tetrazol-5-yl]-3,5-difluorophenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)




RN 372192-95-5 CAPLUS

CN Benzamide, N-[[[4-[2-(1,1-dimethylethyl)-2H-tetrazol-5-yl]-2,3-difluorophenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)




RN 372192-96-6 CAPLUS

CN Benzamide, 2-chloro-N-[[[4-[2-(1,1-dimethylethyl)-2H-tetrazol-5-yl]-2,3-difluorophenyl]amino]carbonyl]- (CA INDEX NAME)




RN 372192-97-7 CAPLUS

CN Benzamide, N-[[[4-[2-(1,1-dimethylethyl)-2H-tetrazol-5-yl]-2-fluorophenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)




RN 372192-98-8 CAPLUS

CN Benzamide, 2-chloro-N-[[[4-[2-(1,1-dimethylethyl)-2H-tetrazol-5-yl]-2-fluorophenyl]amino]carbonyl]- (CA INDEX NAME)



RN 372192-99-9 CAPLUS


CN Benzamide, N-[[[3,5-dichloro-4-[2-(1,1-dimethylethyl)-2H-tetrazol-5-yl]phenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)



RN 372193-00-5 CAPLUS


CN Benzamide,

2-chloro-N-[[[3,5-dichloro-4-[2-(1,1-dimethylethyl)-2H-tetrazol-5-yl]phenyl]amino]carbonyl]- (CA INDEX NAME)



RN 372193-01-6 CAPLUS


CN Benzamide, N-[[[2,3-dichloro-4-[2-(1,1-dimethylethyl)-2H-tetrazol-5-yl]phenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)



RN 372193-02-7 CAPLUS


CN Benzamide,

2-chloro-N-[[[2,3-dichloro-4-[2-(1,1-dimethylethyl)-2H-tetrazol-5-yl]phenyl]amino]carbonyl]- (CA INDEX NAME)




RN 372193-03-8 CAPLUS

CN Benzamide, 2-chloro-N-[[[2-chloro-4-[2-(difluoromethyl)-2H-tetrazol-5-yl]phenyl]amino]carbonyl]- (CA INDEX NAME)




RN 372193-04-9 CAPLUS

CN Benzamide, 2-chloro-N-[[[2-chloro-4-[1-(difluoromethyl)-1H-tetrazol-5-yl]phenyl]amino]carbonyl]- (CA INDEX NAME)




RN 372193-05-0 CAPLUS

CN Benzamide, N-[[[4-[2-(difluoromethyl)-2H-tetrazol-5-yl]phenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)




RN 372193-06-1 CAPLUS

CN Benzamide, 2-chloro-N-[[[4-[2-(difluoromethyl)-2H-tetrazol-5-yl]phenyl]amino]carbonyl]- (CA INDEX NAME)




RN 372193-07-2 CAPLUS

CN Benzamide, 2-chloro-N-[[[4-[1-(difluoromethyl)-1H-tetrazol-5-yl]phenyl]amino]carbonyl]- (CA INDEX NAME)




RN 372193-08-3 CAPLUS

CN Benzamide, N-[[[4-[1-(difluoromethyl)-1H-tetrazol-5-yl]phenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)




RN 372193-09-4 CAPLUS

CN Benzamide,
2-chloro-N-[[[2,5-dichloro-4-[2-(difluoromethyl)-2H-tetrazol-5-yl]phenyl]amino]carbonyl]- (CA INDEX NAME)




RN 372193-10-7 CAPLUS

CN Benzamide, N-[[[3-chloro-4-[2-(difluoromethyl)-2H-tetrazol-5-yl]phenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)




RN 372193-11-8 CAPLUS

CN Benzamide, 2-chloro-N-[[[3-chloro-4-[2-(difluoromethyl)-2H-tetrazol-5-yl]phenyl]amino]carbonyl]- (CA INDEX NAME)




RN 372193-12-9 CAPLUS

CN Benzamide, N-[[[4-[2-(difluoromethyl)-2H-tetrazol-5-yl]-3-fluorophenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)




RN 372193-13-0 CAPLUS

CN Benzamide, N-[[[3-[2-(1,1-dimethylethyl)-2H-tetrazol-5-yl]phenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)




RN 372193-14-1 CAPLUS

CN Benzamide, 2-chloro-N-[[[3-[2-(1,1-dimethylethyl)-2H-tetrazol-5-yl]phenyl]amino]carbonyl]- (CA INDEX NAME)




RN 372193-15-2 CAPLUS

CN Benzamide, N-[[[3-[2-(difluoromethyl)-2H-tetrazol-5-yl]phenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)



RN 372193-16-3 CAPLUS

CN Benzamide, N-[[[3-[1-(difluoromethyl)-1H-tetrazol-5-yl]phenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (5 CITINGS)

REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L87 ANSWER 29 OF 84 CAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 2001:730744 CAPLUS Full-text

DOCUMENT NUMBER: 135:288790

TITLE: Pyrrolopyrimidines as tyrosine kinase inhibitors

INVENTOR(S): Hirst, Gavin C.; Calderwood, David; Munschauer, Rainer; Arnold, Lee D.; Johnston, David N.; Rafferty, Paul

PATENT ASSIGNEE(S): Basf Aktiengesellschaft, Germany

SOURCE: PCT Int. Appl., 453 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001072751	A1	20011004	WO 2000-US8593	20000329 <--
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			


PRIORITY APPLN. INFO.: WO 2000-US8593 20000329 <--

OTHER SOURCE(S): MARPAT 135:288790


GI




I



II



IV



III

AB Chemical compds. having structural formula I and physiol. acceptable salts and metabolites thereof, are inhibitors of serine/threonine and tyrosine kinase activity. Several of the kinases, whose activity is inhibited by these chemical compds., are involved in immunol., hyperproliferative, or angiogenic processes. Thus, these chemical compds. can ameliorate disease states where angiogenesis or endothelial cell hyperproliferation is a factor. These compds. can be used to treat cancer and hyperproliferative disorders, rheumatoid arthritis, disorders of the immune system, transplant rejections and inflammatory disorders. All exemplified compds. significantly inhibited either FGFR, PDGFR, KDR, Tie-2, Lck, Fyn, Blk, Lyn, or Src at $\leq 50 \mu\text{M}$, and some significantly inhibited cdc2 at $\leq 50 \mu\text{M}$. In I, ring A is a six membered aromatic ring or a five or six membered heteroarom. ring which is optionally substituted. L is -O-, -S-, -S(O)-, -S(O)₂-, -N(R)-, -N[C(O)OR]-, -N[C(O)R]-, -N(SO₂R)-, -CH₂O-, -CH₂S-, -CH₂N(R)-, -C(NR)-, -CH₂N[C(O)R]-, -CH₂N[C(O)OR]-, -CH₂N(SO₂R)-, -CH(NHR)-, -CH[NHC(O)R]-, -CH(NHSO₂R)-, -CH[NHC(O)OR]-, -CH[OC(O)R]-, -CH[OC(O)NHR]-, -CH:CH-, -C(:NOR)-, -C(O)-, -CH(OR)-, -C(O)N(R)-, -N(R)C(O)-, -N(R)S(O)-, -N(R)S(O)₂-, -OC(O)N(R)-, -N(R)C(O)N(R)-, -NRC(O)O-, -S(O)N(R)-, -S(O)₂N(R)-, -N[C(O)R]S(O)-, -N[C(O)R]S(O)₂-, -N(R)S(O)N(R)-, -N(R)S(O)₂N(R)-, -C(O)N(R)C(O)-, -S(O)N(R)C(O)-, -S(O)₂N(R)C(O)-, -OS(O)N(R)-, -OS(O)₂N(R)-, -N(R)S(O)O-, -N(R)S(O)₂O-, -N(R)S(O)C(O)-, -N(R)S(O)₂C(O)-, -SON[C(O)R]-, -SO₂N[C(O)R]-, -N(R)SON(R)-, -N(R)SO₂N(R)-, -C(O)O-, -N(R)P(OR')O-, -N(R)P(OR')-, -N(R)P(O)(OR')O-, -N(R)P(O)(OR')-, -N[C(O)R]P(OR')O-, -N[C(O)R]P(OR')-, -N[C(O)R]P(O)(OR')O-, -N[C(O)R]P(OR')-, -CH(R)S(O)-, or -CH(R)S(O)₂-. L is also -CH(R)N[C(O)OR]-, -CH(R)N[C(O)R]-, -CH(R)N(SO₂R)-, -CH(R)O-, -CH(R)S-, -CH(R)N(R)-, -CH(R)N[C(O)R]-, -CH(R)N[C(O)OR]-, -CH(R)N(SO₂R)-, -CH(R)C(:NOR)-, -CH(R)C(O)-, -CH(R)CH(OR)-, -CH(R)C(O)N(R)-,

-CH(R)N(R)C(O)-, -CH(R)N(R)S(O)-, -CH(R)N(R)S(O)2-, -CH(R)OC(O)N(R)-, -CH(R)N(R)C(O)N(R)-, -CH(R)N(R)C(O)O-, -CH(R)S(O)N(R)-, -CH(R)S(O)2N(R)-, -CH(R)N[C(O)R]S(O)-, -CH(R)N[C(O)R]S(O)2-, -CH(R)N(R)S(O)N(R)-, -CH(R)N(R)S(O)2N(R)-, -CH(R)C(O)N(R)C(O)-, -CH(R)S(O)N(R)C(O)-, -CH(R)S(O)2N(R)C(O)-, -CH(R)OS(O)N(R)-, -CH(R)OS(O)2N(R)-, -CH(R)N(R)S(O)O-, -CH(R)N(R)S(O)2O-, -CH(R)N(R)S(O)C(O)-, -CH(R)N(R)S(O)2C(O)-, -CH(R)SON[C(O)R]-, -CH(R)S(O)2N[C(O)R]-, -CH(R)N(R)SON(R)-, -CH(R)N(R)S(O)2N(R)-; -CH(R)C(O)O-, -CH(R)N(R)P(OR')O-, -CH(R)N(R)P(OR')-, -CH(R)N(R)P(O)(OR')O-, -CH(R)N(R)P(O)(OR')-, -CH(R)N[C(O)R]P(OR')O-, -CH(R)N[C(O)R]P(OR')-, -CH(R)N[C(O)R]P(O)(OR')O- or -CH(R)N[C(O)R]P(OR')-. In L, each R and R' is, independently, -H, acyl, substituted or unsubstituted aliphatic, aromatic, arylalkyl, heteroarom., cycloalkyl or arylalkyl; or L is -RbN(R)S(O)2-, -RbN(R)P(O)-, or -RbN(R)P(O)O-, wherein Rb is an alkylene group which when taken together with the sulfonamide, phosphinamide, or phosphonamide group to which it is bound forms a five or six membered ring fused to ring A; or L is II (X = O or nil; Y = O or nil) or III (Y = O, nil) wherein R85 taken together with the phosphinamide, or phosphonamide is a 5-, 6-, or 7-membered, aromatic, heteroarom. or heterocycloalkyl ring system. G is a direct bond, -(CH2)j- (j = 1-6), C2-C6-alkenylene, C3-C8-cycloalkylene or C1-C6-oxaalkylene group. R1 is substituted or optionally substituted aliphatic, cycloalkyl, bicycloalkyl, cycloalkenyl, aromatic, heteroarom., heteroaralkyl, heterocycloalkyl, heterobicycloalkyl, alkylamido, arylamido, -S(O)2-alkyl, -S(O)2-cycloalkyl, -C(O)alkyl, or -B-E, wherein B is substituted or unsubstituted cycloalkyl, heterocycloalkyl, aromatic, heteroarom., alkylene, aminoalkyl, alkylencarbonyl, or aminoalkylcarbonyl and E is substituted or unsubstituted azacycloalkyl, azacycloalkylcarbonyl, azacycloalkylsulfonyl, azacycloalkylalkyl, heteroaryl, heteroarylcarbonyl, heteroarylsulfonyl, heteroaralkyl, alkyl sulfonamido, aryl sulfonamido, bicycloalkyl, ureido, thioureido or aryl. R2 is -H or substituted or unsubstituted aliphatic, cycloalkyl, halogen, -OH, cyano, aromatic, heteroarom., heterocycloalkyl, aralkyl, heteroaralkyl, -(CH2)0-3NR4R5, or -(CH2)0-3C(O)NR4R5. R3 is substituted or unsubstituted aliphatic, alkenyl, cycloalkyl, aromatic, heteroarom., or heterocycloalkyl with provisos. R4, R5 and the N atom together form a 3, 4, 5, 6 or 7-membered, substituted or unsubstituted heterocycloalkyl, heterobicycloalkyl or heteroarom.; or R4 and R5 are each, independently, -H, azabicycloalkyl, heterocycloalkyl, substituted or unsubstituted alkyl or Y-Z; Y is -C(O)-, -(CH2)p-, -S(O)2-, -C(O)O-, -SO2NH-, -CONH-, -(CH2)pO-, -(CH2)pNH-, -(CH2)pS-, -(CH2)pS(O)-, and -(CH2)pS(O)2-; p = 0-6; and Z is -H, or substituted or unsubstituted alkyl, amino, aryl, heteroaryl or heterocycloalkyl. 546 Example preps. are included. For example, addition of piperidine to 4-[4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]cyclohexanone in DCE and AcOH, followed by treatment with Na[(AcO)3BH], workup and chromatog., gave cis- and trans-IV.

IT 262442-33-1P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(target compound; preparation of pyrrolopyrimidinamines as protein kinase inhibitors)


RN 262442-33-1 CAPLUS

CN Acetamide, N-[4-[4-amino-7-[cis-4-(4-methyl-1-piperazinyl)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl]-2-methoxyphenyl]-2-(4-chlorophenoxy)- (CA


INDEX NAME)

Relative stereochemistry.

PAGE 1-A



PAGE 2-A



OS.CITING REF COUNT: 14 THERE ARE 14 CAPLUS RECORDS THAT CITE THIS RECORD (14 CITINGS)

REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L87 ANSWER 30 OF 84 CAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 2001:395257 CAPLUS Full-text

DOCUMENT NUMBER: 135:152703

TITLE: A convenient method for the preparation of 3-phenoxy/thiophenoxy-2(1H)quinolinones

AUTHOR(S): Hashim, S. Riaz; Reddy, P. Tirupathy

CORPORATE SOURCE: Organic Chemistry Division-I, Indian Institute of Chemical Technology, Hyderabad, 500 007, India


SOURCE: Indian Journal of Chemistry, Section B: Organic Chemistry Including Medicinal Chemistry (2001), 40B(5), 357-360

CODEN: IJSBDB; ISSN: 0376-4699

PUBLISHER: National Institute of Science Communication, CSIR

DOCUMENT TYPE: Journal

LANGUAGE: English
 OTHER SOURCE(S): CASREACT 135:152703
 AB A number of new 4-methyl-3-phenoxy(or thiophenoxy)-2(1H)quinolinones have been synthesized in excellent yields through a simple and efficient procedure involving reaction of N-(2-acetylphenyl)chloroacetamide with phenols and thiophenols and cyclization of N-(2-acetylphenyl)phenoxy/thiophenoxyacetamide intermediates under basic conditions.
 IT 352353-28-7P
 RL: BYP (Byproduct); PREP (Preparation)
 (preparation of (thio)phenoxyquinolinones)
 RN 352353-28-7 CAPLUS
 CN Acetamide, 2-(2,6-dichlorophenoxy)-N-[2-(4-methyl-2-quinolinyl)phenyl]-
 (CA INDEX NAME)




REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L87 ANSWER 31 OF 84 CAPLUS COPYRIGHT 2011 ACS on STN
 ACCESSION NUMBER: 2001:300689 CAPLUS Full-text
 DOCUMENT NUMBER: 134:311208
 TITLE: Preparation of pyrazolylphenylureas as 5-HT_{2A} receptor ligands
 INVENTOR(S): Behan, Dominic P.; Beeley, Nigel R. A.; Chalmers, Derek T.; Foster, Richard J.; Glen, Robert C.; Lawless, Michael S.; Liaw, Chen W.; Liu, Quin; Menzaghi, Frederique; Russo, Joseph F.; Smith, Julian R.; Thomsen, William J.
 PATENT ASSIGNEE(S): Arena Pharmaceuticals, Inc., USA; Tripos, Inc.; et al.
 SOURCE: PCT Int. Appl., 95 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 17
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001029008	A1	20010426	WO 2000-US28347	20001013 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,				

SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,
YU, ZA, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ,
CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

US 6150393	A	20001121	US 1999-418721	19991015 <--
CA 2387031	A1	20010426	CA 2000-2387031	20001013 <--
AU 2001012010	A	20010430	AU 2001-12010	20001013 <--
EP 1244632	A1	20021002	EP 2000-973507	20001013 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
MX 2002003792	A	20040906	MX 2002-3792	20020415 <--
AU 2004203102	A1	20040729	AU 2004-203102	20040708
AU 2004203102	B2	20071018		
AU 2007202139	A1	20070531	AU 2007-202139	20070510
AU 2007202139	B2	20090521		
AU 2007202155	A1	20070607	AU 2007-202155	20070510
AU 2007202155	B2	20090507		
AU 2007202121	A1	20070607	AU 2007-202121	20070511
AU 2007202241	A1	20070607	AU 2007-202241	20070511
AU 2007216751	A1	20071004	AU 2007-216751	20070912 <--
AU 2007216752	A1	20071004	AU 2007-216752	20070912 <--
AU 2008200231	A1	20080207	AU 2008-200231	20080116
PRIORITY APPLN. INFO.:			US 1999-418721	A 19991015 <--
			US 1998-112909P	P 19981218
<--				
			US 1999-123000P	P 19990305
<--				
			US 1999-292069	A2 19990414 <--
			US 1999-152708P	P 19990907
<--				
			WO 2000-US28347	W 20001013
<--				
			AU 2002-219890	A3 20011126 <--
			AU 2004-202147	A3 20040512
			AU 2004-202476	A3 20040603
			AU 2004-203102	A3 20040708
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT				
OTHER SOURCE(S): MARPAT 134:311208				
GI				



AB Title compds. [I; R = C₆H₄[NR₁C(:X)R₉]-3; X = O, S, NR₂; R₉ = NR₃R₄, (CH₂)_mR₅, O(CH₂)_nR₆; R₁-R₃, R₇ = H, alk(en)yl, cycloalkyl, etc.; R₄-R₆ = (cyclo)alkyl, aryl(methyl), etc.; R₈ = halo, alk(en)yl, cycloalkyl, etc.; m, n = 0-4] were prepared Thus, I [R = C₆H₄(NHR₁₀)-3, R₇ = Me, R₈ = Br] (II; R₁₀ = H) was

amidated by 4-(MeS)C₆H₄NCS to give II [R10 = CSNHC₆H₄(SMe)-4]. Data for biol. activity of I were given.


IT 247038-30-8P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrazolylphenylureas as 5-HT_{2A} receptor ligands)

RN 247038-30-8 CAPLUS

CN Urea, N-[3-(4-bromo-1-methyl-1H-pyrazol-3-yl)phenyl]-N'-[(4-fluorophenyl)methyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 10 THERE ARE 10 CAPLUS RECORDS THAT CITE THIS RECORD (10 CITINGS)
 REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L87 ANSWER 32 OF 84 CAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 2001:185739 CAPLUS Full-text

DOCUMENT NUMBER: 134:237301

TITLE: Preparation of benzophenones and phenyl heteroaryl ketones as inhibitors of reverse transcriptase

INVENTOR(S): Andrews, Clarence Webster; Chan, Joseph Howing; Freeman, George Andrew; Romines, Karen Rene; Tidwell, Jeffrey H.

PATENT ASSIGNEE(S): Glaxo Group Limited, UK; Pianetti, Pascal Maurice Charles

SOURCE: PCT Int. Appl., 436 pp.
 CODEN: PIXXD2

DOCUMENT TYPE: Patent


LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001017982	A1	20010315	WO 2000-EP8487	20000831 <--
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
CA 2383782	A1	20010315	CA 2000-2383782	20000831 <--

BR 2000013771	A	20020514	BR 2000-13771	20000831 <--
EP 1208091	A1	20020529	EP 2000-967637	20000831 <--
EP 1208091	B1	20060503		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				
IE, SI, LT, LV, FI, RO, MK, CY, AL				
TR 2002001187	T2	20020821	TR 2002-1187	20000831 <--
HU 2002002593	A2	20021228	HU 2002-2593	20000831 <--
HU 2002002593	A3	20041028		
JP 2003510252	T	20030318	JP 2001-521729	20000831 <--
JP 3739704	B2	20060125		
NZ 517451	A	20040130	NZ 2000-517451	20000831 <--
AU 770302	B2	20040219	AU 2000-77743	20000831 <--
CN 1636984	A	20050713	CN 2004-10095621	20000831 <--
CN 1636985	A	20050713	CN 2004-10095622	20000831 <--
CN 1636986	A	20050713	CN 2004-10097470	20000831 <--
CN 1213038	C	20050803	CN 2000-815249	20000831 <--
AT 325106	T	20060615	AT 2000-967637	20000831 <--
EP 1710238	A1	20061011	EP 2006-75956	20000831 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				
IE, SI, FI, CY				
ES 2261242	T3	20061116	ES 2000-967637	20000831 <--
TW 286550	B	20070911	TW 2000-117846	20000901 <--
IN 2002KN00280	A	20050311	IN 2002-KN280	20020225 <--
ZA 2002001664	A	20030527	ZA 2002-1664	20020227 <--
NO 2002001042	A	20020430	NO 2002-1042	20020301 <--
NO 323156	B1	20070108		
MX 2002002347	A	20020812	MX 2002-2347	20020304 <--
US 7273863	B1	20070925	US 2002-70084	20020307 <--
JP 2006077019	A	20060323	JP 2005-272533	20050920 <--
KR 2007093152	A	20070917	KR 2007-7019984	20070831 <--
PRIORITY APPLN. INFO.:			GB 1999-20872	A 19990904 <--
			EP 2000-967637	A3 20000831 <--
			JP 2001-521729	A3 20000831 <--
			WO 2000-EP8487	W 20000831
<--				
			KR 2002-7002871	A3 20020302 <--
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT				
OTHER SOURCE(S): MARPAT 134:237301				
GI				



I




II

AB The title compds. [I; X = C, O, N; R1 = alkyl, cycloalkyl, (un)substituted aryl, etc.; R2 = H, halo, alkyl; R3, R4 = H, OH, (un)substituted heterocyclyl, etc.; R5 = H, halo, alkyl, etc.], useful in the treatment of HIV infections, were prepared E.g., a 4-step synthesis of the ketone II which showed IC50 of between 101 nM and 1,000 nM against HIV-1 in MT4 cell assay, was described.

IT 329936-79-0P 329936-85-8P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of benzophenones and Ph heteroaryl ketones as inhibitors of reverse transcriptase)


RN 329936-79-0 CAPLUS

CN Acetamide, 2-(2-benzoyl-4-chlorophenoxy)-N-[4-(1H-1,2,4-triazol-1-yl)phenyl]- (CA INDEX NAME)



RN 329936-85-8 CAPLUS

CN Acetamide, 2-(2-benzoyl-4-chlorophenoxy)-N-[4-(1,2,3-thiadiazol-4-yl)phenyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 18 THERE ARE 18 CAPLUS RECORDS THAT CITE THIS RECORD (18 CITINGS)

REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L87 ANSWER 33 OF 84 CAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 2000:384159 CAPLUS Full-text

DOCUMENT NUMBER: 133:30670



TITLE: Preparation of substituted benzo[de]isoquinoline-1,3-diones as glycoprotein IbIX antagonists

INVENTOR(S): Mederski, Werner; Devant, Ralf; Barnickel, Gerhard; Bernotat-Danielowski, Sabine; Melzer, Guido; Raddatz, Peter; Wu, Zhengdong; Dhanoa, Daljit; Soll, Richard; Rinker, James; Graybill, Todd

PATENT ASSIGNEE(S): Merck Patent G.m.b.H., Germany

SOURCE: PCT Int. Appl., 278 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000032577	A2	20000608	WO 1999-EP8561	19991109 <--
WO 2000032577	A3	20000921		
W:				
AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ,				
DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS,				
JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK,				
MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ,				
TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW				
RW:				
GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,				
DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,				
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2352045	A1	20000608	CA 1999-2352045	19991109 <--
BR 9915648	A	20010814	BR 1999-15648	19991109 <--
EP 1144381	A2	20011017	EP 1999-968783	19991109 <--
R:				
AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				
IE, SI, LT, LV, FI, RO				
HU 2001004520	A2	20020429	HU 2001-4520	19991109 <--
HU 2001004520	A3	20021028		
JP 2002537225	T	20021105	JP 2000-585219	19991109 <--
AU 760136	B2	20030508	AU 2000-26603	19991109 <--
TW 473474	B	20020121	TW 1999-120540	19991124 <--
NO 2001002544	A	20010523	NO 2001-2544	20010523 <--
MX 2001005227	A	20011203	MX 2001-5227	20010524 <--
ZA 2001005191	A	20021213	ZA 2001-5191	20010622 <--
IN 2001KN00647	A	20050311	IN 2001-KN647	20010626 <--
PRIORITY APPLN. INFO.:			US 1998-199413	A 19981125 <--
			US 1999-398783	A 19990920
<--			WO 1999-EP8561	W 19991109
<--				
OTHER SOURCE(S):		MARPAT 133:30670		
GI				



AB The title compds. [I; R = H, NO₂; R₁ = Het, -HetSO₂Ar, NO₂, etc.; R₂ = Ar, Het₁, -Het₁Ar, etc.; Ar = Ph, biphenyl, pyridyl, etc.; Het, Het₁ = (un)substituted (un)saturated mono-, bi- or tricyclic 5-13 membered heterocycl[yl], useful as glycoprotein IbIX antagonists (no data) for the control of thrombotic disorders, were prepared and formulated. E.g., preparation of II was given. Compds. I are effective at 0.02-10 mg/kg/day.

IT 1098872-73-1 1098872-76-4 1098872-84-4
 1098872-88-8 1098872-89-9 1098872-90-2
 1098873-22-3 1098873-23-4 1098873-24-5
 1098873-29-0 1098873-33-6 1098873-40-5
 1098873-44-9 1098873-67-6 1098873-68-7
 1098873-73-4 1098873-74-5 1098873-75-6
 1098874-28-2 1098874-41-9 1098876-45-9
 1098876-48-2 1098876-57-3 1098877-65-6
 1098879-51-6 1098879-52-7 1098880-47-7
 1098880-51-3 1098880-53-5 1098880-57-9


RL: PRPH (Prophetic)

(Preparation of substituted benzo[de]isoquinoline-1,3-diones as glycoprotein IbIX antagonists)


RN 1098872-73-1 CAPLUS

CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 2-A




RN 1098872-76-4 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 2-A




RN 1098872-84-4 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 2-A




RN 1098872-88-8 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 2-A




RN 1098872-89-9 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 2-A




RN 1098872-90-2 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 2-A




RN 1098873-22-3 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 2-A




RN 1098873-23-4 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 2-A




RN 1098873-24-5 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 2-A




RN 1098873-29-0 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 2-A




RN 1098873-33-6 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 2-A




RN 1098873-44-9 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 2-A




RN 1098873-67-6 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 2-A




RN 1098873-68-7 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 2-A




RN 1098873-73-4 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 2-A




RN 1098873-74-5 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 2-A




RN 1098873-75-6 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 2-A




RN 1098874-28-2 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 2-A




RN 1098874-41-9 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 2-A




RN 1098876-45-9 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 2-A




RN 1098876-48-2 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 2-A




RN 1098876-57-3 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 2-A




RN 1098877-65-6 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 2-A




RN 1098879-51-6 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 2-A




RN 1098879-52-7 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 2-A




RN 1098880-47-7 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 2-A




RN 1098880-51-3 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 2-A




RN 1098880-53-5 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 2-A




RN 1098880-57-9 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A



PAGE 2-A



OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD
(4 CITINGS)
REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L87 ANSWER 34 OF 84 CAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 2000:335390 CAPLUS Full-text

DOCUMENT NUMBER: 132:347566

TITLE: Preparation of tricyclic pyrazole derivatives as
protein kinase inhibitors.

INVENTOR(S): Doyle, Kevin J.; Rafferty, Paul; Steele, Robert W.;
Wilkins, David J.; Hockley, Michael; Arnold, Lee D.;
Ericsson, Anna M.

PATENT ASSIGNEE(S): Basf Aktiengesellschaft, Germany

SOURCE: PCT Int. Appl., 210 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000027822	A2	20000518	WO 1999-US26105	19991104 <--
WO 2000027822	A3	20000810		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2350235	A1	20000518	CA 1999-2350235	19991104 <--
BR 9915132	A	20010807	BR 1999-15132	19991104 <--
EP 1127051	A2	20010829	EP 1999-962700	19991104 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
TR 2001002277	T2	20020121	TR 2001-2277	19991104 <--
HU 2002000310	A2	20021128	HU 2002-310	19991104 <--
HU 2002000310	A3	20021228		
JP 2003517447	T	20030527	JP 2000-581002	19991104 <--
AU 762992	B2	20030710	AU 2000-19091	19991104 <--
US 6462036	B1	20021008	US 2000-573366	20000517 <--
MX 2001004211	A	20010731	MX 2001-4211	20010427 <--
BG 105481	A	20011231	BG 2001-105481	20010427 <--
NO 2001002219	A	20010613	NO 2001-2219	20010504 <--
ZA 2001003610	A	20020923	ZA 2001-3610	20010504 <--
IN 2001CN00627	A	20050304	IN 2001-CN627	20010504 <--
PRIORITY APPLN. INFO.:			US 1998-107467P	P 19981106 <--
			WO 1999-US26105	W 19991104

<--

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 132:347566

GI



AB A method of inhibiting protein kinase activity comprises administration of title compds. [I; X = substituted methylene, CO, O, C:NOR7, NR8, (CH2)n, S,


SO, SO₂; n = 1-3; R₁ = H; R₂ = (substituted) aryl, pyridyl, thienyl, furyl, pyrrolyl; R₃-R₆ = H, OH, halo, CO₂H, alkoxycarbonyl, (substituted) alkyl, alkoxy, PhO, etc.; R₇ = H, alkyl; with provisos]. Thus, indan-1-one hydrazone (preparation given) in THF at 0° was treated with BuLi and then with Me 3,4,5-trimethoxybenzoate to give 3-(3,4,5-trimethoxyphenyl)-1,4-dihydroindeno[1,2-c]pyrazole.

IT 268563-63-9P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of tricyclic pyrazole derivs. as protein kinase inhibitors)

RN 268563-63-9 CAPLUS

CN Urea, N-[(2,5-difluorophenyl)methyl]-N'-[4-(1,4-dihydroindeno[1,2-c]pyrazol-3-yl)phenyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 23 THERE ARE 23 CAPLUS RECORDS THAT CITE THIS RECORD (31 CITINGS)
REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L87 ANSWER 35 OF 84 CAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 2000:247417 CAPLUS Full-text

DOCUMENT NUMBER: 132:265193

TITLE: Preparation of phenylpyrazoles and hypolipidemic agents

INVENTOR(S): Yamada, Hiroichi; Mochizuki, Nobuo; Uchida, Seiichi; Umeda, Nobuhiro

PATENT ASSIGNEE(S): Nippon Soda Co., Ltd., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 19 pp.
CODEN: JKXXAF



DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
JP 2000109465	A	20000418	JP 1999-221791	19990804 <--
PRIORITY APPLN. INFO.:			JP 1998-222159	A 19980805 <--
OTHER SOURCE(S):		CASREACT 132:265193; MARPAT 132:265193		
GI				



AB Title compds. I [R1 = H, C1-6 alkyl; X = CO, SO₂; A = (CR₃R₂)p(CR₄:CR₅)q; B = (CR₆R₇)r; R₂, R₃, R₆, R₇ = H, cyano, OH, halo, C1-6 alkyl, C1-6 alkoxy etc.; R₄, R₅ = H, C1-6 alkyl, C1-6 haloalkyl, (un)substituted benzyl; p, r = 0-6; q = 0-1; Y = O, S, SO, SO₂, CO, etc.; n = 0-1; D = (un)substituted Ph; naphthyl, tetrahydronaphthyl, indanyl; R₁₁ = halo, C1-6 alkyl, C1-6 alkoxy; m = 0-2; R₁₂ = H, C1-6 alkyl] or their pharmaceutically acceptable salts are prepared by dehydration of pyrazoles II (R₁, R₁₁, R₁₂, m = same as I) with HO₂CAYlBD (A, B, Y, D, n = same as I). 5-(4-Aminophenyl)pyrazole (1.59 g) was reacted with 3.09 g benzoyl chloride in the presence of NEt₃ in DMF at room temperature for 20 h to give 1.31 g phenyl-N-[4-(pyrazol-5-yl)phenyl]carboxamide showing in vivo good hypolipidemic activity.


IT 263257-79-QP

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); IMF (Industrial manufacture); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of phenylpyrazoles by dehydration of aminophenylpyrazoles and carboxylic acids)

RN 263257-79-0 CAPLUS

CN Propanamide, 2-(4-chlorophenoxy)-2-methyl-N-[4-(1H-pyrazol-3-yl)phenyl]- (CA INDEX NAME)



L87 ANSWER 36 OF 84 CAPLUS COPYRIGHT 2011 ACS on STN


ACCESSION NUMBER: 2000:210172 CAPLUS Full-text

DOCUMENT NUMBER: 132:251160


TITLE: Preparation of pyrrolopyrimidines as protein kinase

INVENTOR(S): inhibitors
 Hirst, Gavin C.; Calderwood, David; Wishart, Neil;
 Ritter, Kurt; Arnold, Lee D.
 PATENT ASSIGNEE(S): Basf A.-G., Germany
 SOURCE: PCT Int. Appl., 304 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000017203	A1	20000330	WO 1999-US21560	19990917 <--
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2344249	A1	20000330	CA 1999-2344249	19990917 <--
AU 9960484	A	20000410	AU 1999-60484	19990917 <--
AU 753555	B2	20021024		
EP 1114053	A1	20010711	EP 1999-969415	19990917 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
TR 2001001186	T2	20011022	TR 2001-1186	19990917 <--
BR 9913887	A	20011023	BR 1999-13887	19990917 <--
HU 2002000403	A2	20020629	HU 2002-403	19990917 <--
HU 2002000403	A3	20040728		
JP 2002526500	T	20020820	JP 2000-574112	19990917 <--
NZ 510588	A	20030829	NZ 1999-510588	19990917 <--
US 20030153752	A1	20030814	US 2000-537167	20000329 <--
US 6713474	B2	20040330		
BG 105346	A	20011231	BG 2001-105346	20010315 <--
NO 2001001356	A	20010516	NO 2001-1356	20010316 <--
ZA 2001002204	A	20020318	ZA 2001-2204	20010316 <--
IN 2001CN00376	A	20050304	IN 2001-CN376	20010316 <--
PRIORITY APPLN. INFO.:			US 1998-100832P	P 19980918 <--
<--			US 1998-100833P	P 19980918
<--			US 1998-100834P	P 19980918
<--			US 1998-100946P	P 19980918
<--			WO 1999-US21560	W 19990917
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT				
OTHER SOURCE(S):			MARPAT 132:251160	
GI				



I



II

AB 7H-Pyrrolo[2,3-d]pyrimidin-4-amines (I) [wherein A = (un)substituted 6-membered aromatic ring or 5- or 6-membered heteroarom. ring; L = RbN(R)S(O)₂, RbN(R)P(O), or RbN(R)P(O)O, where Rb = alkylene group which when taken together with the sulfonamide, phosphinamide or phosphonamide group to which it is bound forms a 5- or 6-membered ring fused to ring A, or L = 5-, 6-, or 7-membered (oxa)azaphosphaarom. or (oxa)azaphosphacycloalkyl ring; R = H, acyl, or (un)substituted aliphatic, (hetero)aromatic, or cycloalkyl; R1 = (un)substituted (hetero)cyclic, (hetero)aromatic, amido, acyl, or (cyclo)alkylsulfonyl; R2 = H, halo, OH, CN, (un)substituted aliphatic, cycloalkyl, (hetero)aromatic, (hetero)aralkyl, amino, or amido; R3 (un)substituted aliphatic, alkenyl, (hetero)cycloalkyl, or (hetero)aromatic; n = 0-6], and physiol. acceptable salts and metabolites thereof, were prepared For example, addition of piperidine to 4-[4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]cyclohexanone in DCE and AcOH, followed by workup and chromatog., gave cis- and trans-II. I inhibit serine/threonine and tyrosine kinase activity, which are involved in immunol., hyperproliferative, and angiogenic processes. All exemplified compds. significantly inhibited either FGFR, PDGFR, KDR, Tie-2, Lck, Fyn, Blk, Lyn, or Src at concns. of $\leq 50 \mu\text{M}$, and some significantly inhibited cdc2 at concns. of $50 \leq \mu\text{M}$. Thus, these compds. are useful in the treatment of cancer and hyperproliferative disorders, rheumatoid arthritis, disorders of the immune system, transplant rejections, and inflammatory disorders.

IT 262442-33-1P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(target compound; preparation of 7H-pyrrolo[2,3-d]pyrimidin-4-amines as protein kinase inhibitors)

RN 262442-33-1 CAPLUS


CN Acetamide, N-[4-[4-amino-7-[cis-4-(4-methyl-1-piperazinyl)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl]-2-methoxyphenyl]-2-(4-chlorophenoxy)- (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A



PAGE 2-A



OS.CITING REF COUNT: 15 THERE ARE 15 CAPLUS RECORDS THAT CITE THIS
RECORD (15 CITINGS)
REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L87 ANSWER 37 OF 84 CAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 1999:672842 CAPLUS Full-text

DOCUMENT NUMBER: 131:317743

TITLE: Drug screening with non-endogenous, constitutively
activated human serotonin receptors and small molecule
modulators thereof

INVENTOR(S): Behan, Dominic P.; Chalmers, Derek T.; Foster, Richard
J.; Glen, Robert C.; Lawless, Michael S.; Liaw, Chen
W.; Liu, Qian; Russo, Joseph F.; Smith, Julian R.;
Thomsen, William J.

PATENT ASSIGNEE(S): Arena Pharmaceuticals, Inc., USA; Tripos, Inc.

SOURCE: PCT Int. Appl., 142 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 17


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9952927	A1	19991021	WO 1999-US8168	19990414 <--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2325559	A1	19991021	CA 1999-2325559	19990414 <--
AU 9937466	A	19991101	AU 1999-37466	19990414 <--
AU 764766	B2	20030828		
US 6107324	A	20000822	US 1999-292071	19990414 <--
US 6140509	A	20001031	US 1999-292069	19990414 <--
EP 1071701	A1	20010131	EP 1999-919835	19990414 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2003514763	T	20030422	JP 2000-543483	19990414 <--
MX 2000010060	A	20040423	MX 2000-10060	20001013 <--
AU 2003257531	A1	20031120	AU 2003-257531	20031024 <--
AU 2004203102	A1	20040729	AU 2004-203102	20040708
AU 2004203102	B2	20071018		
AU 2007202139	A1	20070531	AU 2007-202139	20070510
AU 2007202139	B2	20090521		
AU 2007202155	A1	20070607	AU 2007-202155	20070510
AU 2007202155	B2	20090507		
AU 2007202121	A1	20070607	AU 2007-202121	20070511
AU 2007202241	A1	20070607	AU 2007-202241	20070511
AU 2007216751	A1	20071004	AU 2007-216751	20070912 <--
AU 2007216752	A1	20071004	AU 2007-216752	20070912 <--
AU 2008200231	A1	20080207	AU 2008-200231	20080116
PRIORITY APPLN. INFO.:			US 1998-60188	A 19980414 <--
			US 1998-90783P	P 19980626
<--			US 1998-112909P	P 19981218
<--			US 1999-123000P	P 19990305
<--			WO 1999-US8168	W 19990414
<--			AU 2002-219890	A3 20011126 <--
			AU 2004-202147	A3 20040512
			AU 2004-202476	A3 20040603
			AU 2004-203102	A3 20040708
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT				
OTHER SOURCE(S): MARPAT 131:317743				
AB	Disclosed herein are non-endogenous, constitutively activated forms of the human 5-HT2A and human 5-HT2C receptors and uses of such receptors to screen candidate compds. Further disclosed herein are candidate compds. identified by the screening method which act at the 5HT2A receptors. Yet further disclosed is a new class of compds. which act at the 5HT2A receptors.			
IT	247038-30-8P			
	RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);			

BIOL (Biological study); PREP (Preparation); USES (Uses)
 (drug screening with non-endogenous, constitutively activated human
 serotonin receptors and small mol. modulators thereof)

RN 247038-30-8 CAPLUS

CN Urea, N-[3-(4-bromo-1-methyl-1H-pyrazol-3-yl)phenyl]-N'-[(4-fluorophenyl)methyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 19 THERE ARE 19 CAPLUS RECORDS THAT CITE THIS
 RECORD (20 CITINGS)
 REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L87 ANSWER 38 OF 84 CAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 1999:659365 CAPLUS Full-text

DOCUMENT NUMBER: 131:271873

TITLE: Preparation of pyrazoles and triazoles as inhibitors
 of cytokine production

INVENTOR(S): Ba Maung, Nwe Y.; Basha, Anwer; Djuric, Stevan W.;
 Gubbins, Earl J.; Luly, Jay R.; Tu, Noah P.; Madar,
 David J.; Warrior, Usha; Wiedeman, Paul E.; Zhou, Xun;
 Wagenaar, Frank L.; Sciotti, Richard J.

PATENT ASSIGNEE(S): Abbott Laboratories, USA

SOURCE: PCT Int. Appl., 319 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9951580	A1	19991014	WO 1999-US7766	19990408 <--
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
CA 2327185	A1	19991014	CA 1999-2327185	19990408 <--
AU 9933879	A	19991025	AU 1999-33879	19990408 <--
EP 1068187	A1	20010117	EP 1999-915341	19990408 <--
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI			
JP 2002510679	T	20020409	JP 2000-542301	19990408 <--
MX 2000009837	A	20010405	MX 2000-9837	20001006 <--

PRIORITY APPLN. INFO.:

US 1998-56996

A 19980408 <--

WO 1999-US7766



W 19990408

<--

OTHER SOURCE(S):

MARPAT 131:271873

GI



AB Title compds. [I; R1 = H, NH2, OCONH2, CN, NO2, OH, CO2H, F, Cl, Br, I, aryl, perfluoroalkyl, heterocyclyloxy, heterocyclylsulfonyl; R2 = H, alkyl, cycloalkyl, alkylcarbonyl, heterocyclyl; R3 = H, NH2, OCONH2, CN, NO2, OH, CO2H, F, Cl, Br, I, aryl, perfluoroalkyl, heterocyclyloxy, heterocyclylsulfonyl; R4 and R5 are independently selected from H, alkyl, alkoxy, halo, perfluoroalkyl, CN, heterocycle; E = LB; B = alkyl, alkenyl, alkynyl; L = N:N, N:CH, CH:N, ON:CH, O, CO, NH, NHCO, NHSO2, NHCH2, alkenylene; Q = benzene ring with 2, 3, or 4 substituted E, heterocycle; Z = C; R2Z = N], E, Z isomers, stereoisomers, pharmaceutical acceptable salts, and prodrugs are prepared and tested as cytokine production inhibitors and are useful for treating diseases that are prevented by or ameliorated with Interleukin-2, Interleukin-4, or Interleukin-5 production inhibitors. Thus, the title compound II was prepared


IT 245746-03-6P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(preparation of pyrazoles and triazoles as inhibitors of cytokine production)

RN 245746-03-6 CAPLUS

CN Propanamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2-(4-chlorophenoxy)-2-methyl- (CA INDEX NAME)



OS.CITING REF COUNT: 14 THERE ARE 14 CAPLUS RECORDS THAT CITE THIS RECORD (19 CITINGS)
 REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L87 ANSWER 39 OF 84 CAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 1999:659233 CAPLUS Full-text

DOCUMENT NUMBER: 131:286505

TITLE: Preparation of isoxazoloquinolinones as multidrug resistance protein (MRP1) inhibitors

INVENTOR(S): Gruber, Joseph Michael; Kroin, Julian Stanley; Norman, Bryan Hurst

PATENT ASSIGNEE(S): Eli Lilly and Company, USA

SOURCE: PCT Int. Appl., 126 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9951228	A1	19991014	WO 1999-US7613	19990407 <--
W:			AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW	
RW:			GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG	
CA 2327617	A1	19991014	CA 1999-2327617	19990407 <--
AU 9934769	A	19991025	AU 1999-34769	19990407 <--
TR 2000002851	T2	20001221	TR 2000-2851	19990407 <--
BR 9910112	A	20001226	BR 1999-10112	19990407 <--
EP 1067928	A1	20010117	EP 1999-916456	19990407 <--
R:			AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO	
HU 2001001508	A2	20011028	HU 2001-1508	19990407 <--
HU 2001001508	A3	20020429		
JP 2002510625	T	20020409	JP 2000-541999	19990407 <--
US 6369070	B1	20020409	US 2000-646062	20000913 <--
MX 2000009655	A	20010316	MX 2000-9655	20001002 <--
HR 2000000646	A2	20010630	HR 2000-646	20001003 <--
NO 2000005023	A	20001205	NO 2000-5023	20001005 <--
PRIORITY APPLN. INFO.:			US 1998-81080P	P 19980408 <--

WO 1999-US7613



W 19990407

<--

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 131:286505

GI



AB The title compds. (I) [where R = (un)substituted amino(alkyl) or aminoethoxy, or $(CH_2)_mR_3$; m and m' = independently 0, 1, or 2; R_3 = H, OH, alkoxy, amino ester, amino acid, or (un)substituted amino; R' = H, OH, or (un)substituted alkoxy] were prepared as inhibitors of 190 kDa multidrug resistance protein (MRP1) for inhibiting resistant neoplasms (14 specific neoplasm types claimed). Selected invention compds. were prepared via solution and solid phase combinatorial synthetic methods. For example, 3-(2-chloro-6-fluorophenyl)-5-methyl-4-isoxazolyl chloride was coupled with N-(5-methylisoxaz-3-oyl)-3-aminobenzylamine to form the amide followed by treatment with NaOH to yield the cyclized title compound (II). Several general procedures using substituted polystyrene resins for combinatorial preparation of title compds. were given. Representative compds. demonstrated significant reversal of MRP1 multiple drug resistance, and many compds. gave significant enhancement of oncolytic agent activities (no data). A large majority of the compds. tested were also said to have displayed a significant degree of selective inhibition of the HL60/ADR cell line over the HL60/VCR cell line in an assay for reversal of MRP1-mediated doxorubicin and vincristine resistance (no data).


IT 1101885-24-8 1101885-26-0

RL: PRPH (Prophetic)

(Preparation of isoxazoloquinolinones as multidrug resistance protein (MRP1) inhibitors)


RN 1101885-24-8 CAPLUS

CN Urea, N-[3,5-bis(trifluoromethyl)phenyl]-N'-[[3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)phenyl]methyl]- (CA INDEX NAME)



RN 1101885-26-0 CAPLUS

CN Urea, N-[[3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)phenyl]methyl]-N'-(4-chlorophenyl)- (CA INDEX NAME)



OS.CITING REF COUNT: 10 THERE ARE 10 CAPLUS RECORDS THAT CITE THIS RECORD (10 CITINGS)

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L87 ANSWER 40 OF 84 CAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 1999:388522 CAPLUS Full-text

DOCUMENT NUMBER: 131:80699

TITLE: Photographic couplers having UV-absorbing function and silver halide photographic material using same

INVENTOR(S): Nakamura, Kazuaki; Chen, Zuliou; Kita, Hiroshi; Kaneko, Yutaka

PATENT ASSIGNEE(S): Konica Co., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 68 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 11160840	A	19990618	JP 1997-340814	19971127 <--
PRIORITY APPLN. INFO.:			JP 1997-340814	19971127 <--
OTHER SOURCE(S):	MARPAT	131:80699		

AB The title couplers have UV-absorbing function and molar absorption coefficient of $\geq 10,000$ at 350 nm and ≤ 100 at 420 nm in MeOH.. Cyan, magenta, and yellow couplers with specified structures and above conditions are also

claimed. A Ag halide photog. material containing ≥ 1 of the above couplers is also claimed. The photog. material shows improved processability in rapid process and provides high quality color images with excellent lightfastness.

IT 228415-90-5 228415-91-6


RL: TEM (Technical or engineered material use); USES (Uses)

(photog. coupler having UV-absorbing property and specified mol.

absorption coefficient for emulsion providing image with light fastness)

RN 228415-90-5 CAPLUS

CN Dodecanamide, 2-[3-(2H-benzotriazol-2-yl)-5-(1,1-dimethylethyl)-2-hydroxyphenoxy]-N-[4-chloro-3-[[4,5-dihydro-5-oxo-1-(2,3,4,5,6-pentachlorophenyl)-1H-pyrazol-3-yl]amino]phenyl]- (CA INDEX NAME)




PAGE 1-B

—Cl

—Cl

RN 228415-91-6 CAPLUS

CN 1-Imidazolidineacetamide, N-[5-[[2-[4-(2H-benzotriazol-2-yl)-3-hydroxyphenoxy]-1-oxotetradecyl]amino]-2-chlorophenyl]- α -(2,2-dimethyl-1-oxopropyl)-2,5-dioxo-3-(phenylmethyl)- (CA INDEX NAME)



PAGE 1-B

CH₂—Ph

L87 ANSWER 41 OF 84 CAPLUS COPYRIGHT 2011 ACS on STN
 ACCESSION NUMBER: 1998:268348 CAPLUS Full-text
 DOCUMENT NUMBER: 128:321662
 ORIGINAL REFERENCE NO.: 128:63765a
 TITLE: Compositions and methods for treating bone deficit conditions
 INVENTOR(S): Orme, Mark W.; Baidur, Nand; Robbins, Kirk G.; et al.
 PATENT ASSIGNEE(S): Zymogenetics, Inc., USA; Osteoscreen, Inc.
 SOURCE: PCT Int. Appl., 215 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9817267	A1	19980430	WO 1997-US18864	19971023 <--
W: AL, AM, AU, BB, BG, BR, CA, CN, CZ, EE, FI, GE, HU, IL, IS, JP, KG, KP, KR, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, US, UZ, VN, AZ, BY, KZ, RU, TJ, TM				
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
US 5990169	A	19991123	US 1997-806771	19970226 <--
US 6153631	A	20001128	US 1997-806768	19970226 <--
US 6251901	B1	20010626	US 1997-806769	19970226 <--
US 5919808	A	19990706	US 1997-808743	19970228 <--
US 5922753	A	19990713	US 1997-808742	19970228 <--
US 5948776	A	19990907	US 1997-808739	19970228 <--
US 5994358	A	19991130	US 1997-808744	19970228 <--
US 6342514	B1	20020129	US 1997-808741	19970228 <--
US 5965573	A	19991012	US 1997-812141	19970306 <--
AU 9749889	A	19980515	AU 1997-49889	19971023 <--
EP 973513	A1	20000126	EP 1997-912787	19971023 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2001510450	T	20010731	JP 1998-519529	19971023 <--
US 6649631	B1	20031118	US 1999-297188	19991119 <--
PRIORITY APPLN. INFO.:			US 1996-735870	A2 19961023 <--
			US 1996-735873	A2 19961023 <--
			US 1996-735874	A2 19961023 <--
			US 1996-735876	A2 19961023 <--
			US 1996-735881	A2 19961023 <--


US 1996-736220	A2 19961023 <--
US 1996-736221	A2 19961023 <--
US 1996-736222	A2 19961023 <--
US 1996-736228	A2 19961023 <--
US 1996-736318	A2 19961023 <--
US 1996-736319	A2 19961023 <--
WO 1997-US18864	W 19971023

<--

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 128:321662

GI



AB Compds. containing 2 covalently linked aromatic systems, i.e. Ar1LAR2 [I; Ar1, Ar2 = (un)substituted Ph, naphthyl, or 5- or 6-membered aromatic heterocyclyl; L = linker (atoms or covalent bond per se) so as to space the aromatic systems at a distance of 1.5-15 Å] are effective in treating conditions associated with bone deficits. The compds. can be administered to vertebrate subjects alone or in combination with addnl. agents that promote bone growth or that inhibit bone resorption. They can be screened for activity prior to administration by assessing their ability to effect the transcription of a reporter gene coupled to a promoter associated with a bone morphogenetic protein and/or their ability to stimulate calvarial growth in model animal systems. A variety of compds. were prepared and/or tested by high-throughput screening. For instance, title compound II was prepared by condensation of 2-chloro-5-(trifluoromethyl)pyridine with ethylenediamine in the presence of EtN(Pr-iso)2 at reflux. At 5-50 µg/kg/day in ovariectomized rats, II stimulated bone growth with volume increases of 21-71% observed. In a calvarial bone growth assay, another compound I induced a 4-fold increase in width of new calvarial bone vs. controls.

IT 206983-31-5


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(preparation and/or use of linked aromatic and heteroarom. compds. for treating

bone deficit conditions)

RN 206983-31-5 CAPLUS

CN Acetamide, 2-[2,3-dichloro-4-(2-methylene-1-oxobutyl)phenoxy]-N-[4-(6-methyl-2-benzothiazolyl)phenyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 28 THERE ARE 28 CAPLUS RECORDS THAT CITE THIS
RECORD (42 CITINGS)
REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L87 ANSWER 42 OF 84 CAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 1998:250738 CAPLUS Full-text

DOCUMENT NUMBER: 128:294606

ORIGINAL REFERENCE NO.: 128:58387a,58390a

TITLE: Preparation of aniline derivatives having
antihyperglycemic activity

INVENTOR(S): Bierer, Donald E.; Dubenko, Larisa G.

PATENT ASSIGNEE(S): Shaman Pharmaceuticals, Inc., USA

SOURCE: U.S., 41 pp.
CODEN: USXXAM



DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5741926	A	19980421	US 1997-799745	19970212 <--
PRIORITY APPLN. INFO.:			US 1997-799745	19970212 <--
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT				
OTHER SOURCE(S):		MARPAT 128:294606		
GI				




AB The title compds. [I; R1-R5 = H, halo, C1-6 alkyl, etc.; R7-R10 = H, halo, Ph, etc.; A = C(O), CH2; B = NH, O, S], useful for the treatment of insulin-dependent diabetes mellitus (IDDM or Type I) and non-insulin dependent diabetes mellitus (NIDDM or Type II), were prepared. Thus, treatment of anthranilic acid with bromoacetyl bromide in DMF and dioxane followed by reaction of the resulting 2-[(2-bromoacetyl)amino]benzoic acid with o-fluoroaniline in DMF afforded the title compound II which showed stimulatory effect (128% basal) on 2-deoxy-D-glucose uptake in 3T3-L1 adipocytes in the absence of insulin.

IT 195393-81-8P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of aniline derivs. having antihyperglycemic activity)

RN 195393-81-8 CAPLUS

CN Acetamide, 2-[(2-fluorophenyl)amino]-N-[4-(2H-tetrazol-5-yl)phenyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)

REFERENCE COUNT: 53 THERE ARE 53 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L87 ANSWER 43 OF 84 CAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 1997:574584 CAPLUS Full-text

DOCUMENT NUMBER: 127:212475

ORIGINAL REFERENCE NO.: 127:41189a, 41192a

TITLE: N-(Heterocyclylaryl)hydrazine derivative for a principal color developer, silver halide photographic light-sensitive material and imaging method

INVENTOR(S): Okawa, Atsuhiro; Makuta, Toshiyuki; Taguchi, Toshiki

PATENT ASSIGNEE(S): Fuji Photo Film Co., Ltd., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 82 pp.
CODEN: JKXXAF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 09211818	A	19970815	JP 1996-331409	19961128 <--
US 5851749	A	19981222	US 1996-757730	19961126 <--
			JP 1995-334183	A 19951130 <--

PRIORITY APPLN. INFO.:
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 127:212475

GI



AB The title compds. [I; Z1 = acyl, CONH2, alkoxycarbonyl, aryloxy carbonyl, R1SO2, C(X):NR2; wherein R1 = alkyl, alkenyl, alkynyl, aryl, heterocyclyl; X = OR3, NR4R5; R2, R4, R5 = H, alkyl, alkenyl, alkynyl, aryl, heterocyclyl; R3 = same as R1; or R2 and R3, or R4 and R5 are bonded together to form a ring; Q1 = a group of nonmetal atoms necessary to form a 5- or 6-membered ring together with the C atom; Q2 = heterocyclyl; Y = substitutable group; m = 1,2; n = 0-3] (e.g. II) are prepared. An imaging method involves development of an imagewise-exposed silver halide photog. light-sensitive material in the presence of above color developer I, in particular with a processing liquid containing above color developer I. A silver halide photog. light-sensitive material comprises at least one hydrophilic colloidal layer containing above color developer I formed on a support. Another imaging method involves development of the latter photog. material (1) by heat-treatment at 50-200° or (2) in a solution. These compds. provide new principal developers which form dyes excellent in coloration during development and give images of good coloration and stability and stable in hue even when couplers substituted at the coupling position are used.


IT 194790-64-2

RL: TEM (Technical or engineered material use); USES (Uses)
 (photog. color developer; N-(heterocyclaryl)hydrazine derivs. for
 principal color developers, silver halide photog. light-sensitive
 material, and imaging method)

RN 194790-64-2 CAPLUS

CN Hydrazinecarboxamide, 2-[2,4-bis(1-methyl-1H-benzimidazol-2-yl)phenyl]-N-[2-chloro-5-[(dioctylamino)sulfonyl]phenyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

U

L87 ANSWER 44 OF 84 CAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 1997:563089 CAPLUS Full-text

DOCUMENT NUMBER: 127:247927

ORIGINAL REFERENCE NO.: 127:48437a,48440a

TITLE: Aniline derivatives having antihyperglycemic activity

INVENTOR(S): Bierer, Donald E.; Dubenko, Larisa G.

PATENT ASSIGNEE(S): Shaman Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 129 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent



LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----

WO 9730019 A1 19970821 WO 1997-US2289 19970213 <--
W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, HU,
IL, IS, JP, KG, KP, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN,
MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, UZ, VN, YU
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR,
IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML,
MR, NE, SN, TD, TG
AU 9721241 A 19970902 AU 1997-21241 19970213 <--
PRIORITY APPLN. INFO.: US 1996-600725 A 19960213 <--
WO 1997-US2289 W 19970213
<--
OTHER SOURCE(S): MARPAT 127:247927
GI




AB Aniline derivs. useful as antihyperglycemic agents, pharmaceutical compns. comprising the aniline derivs., and methods for their use are described. For instance, the novel compds. I [R1-R5 = H, halo, OR11, CX3, alkyl, (CH2)_nCH2OH, (CH2)_nCO2R12, (CH2)_nT; one and only one of R1-R5 = one of the latter 2 groups; R11, R12 = H, alkyl; X = halo; n = 0, 1; R7-R10 = H, halo, OR13, SR14, CY3, alkyl, Ph; R13, R14 = H, alkyl, Ph; Y = halo; A = CO, CH2; B = NH, O, S; T = 5-tetrazolyl] are described. The aniline derivs. are useful for the treatment of insulin-dependent and non-insulin-dependent diabetes mellitus. For instance, amidation of anthranilic acid with BrCH2COBr in DMF/dioxane (87.8% yield) and condensation of the intermediate bromo compound with o-fluoroaniline in DMF (85% yield) gave title compound II, a preferred compound. At 100 mg/kg orally in diabetic db/db mice, II reduced blood glucose by 61.3 mg/dL at 27 h, vs. 116.4 mg/dL for metformin at the same dosage.

IT 195393-81-8F, 4-(Tetrazol-5-yl)-1-[[2-[(2-fluorophenyl)amino]acetyl]amino]benzene
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of aniline derivs. with antihyperglycemic activity)

RN 195393-81-8 CAPLUS

CN Acetamide, 2-[(2-fluorophenyl)amino]-N-[4-(2H-tetrazol-5-yl)phenyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)

L87 ANSWER 45 OF 84 CAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 1996:116243 CAPLUS Full-text

DOCUMENT NUMBER: 124:260935

ORIGINAL REFERENCE NO.: 124:48343a,48346a

TITLE: Synthesis and antimicrobial activities of some new benzimidazoles, Part I

AUTHOR(S): El-Sherief, H. A.; El-Ezbawy, S. R.; Mahmoud, A. M.; Sarhan, Abd El-Wareth A. O.

CORPORATE SOURCE: Faculty Science, Assiut University, Assiut, Egypt

SOURCE: Bulletin of the Faculty of Science, Assiut University, B: Chemistry (1995), 24(1), 111-23

CODEN: BFSAE6; ISSN: 1010-2671

PUBLISHER: Assiut University

DOCUMENT TYPE: Journal

LANGUAGE: English


AB Reaction of Et p-(2-benzimidazolyl)phenoxyacetate (1) with aromatic amines gave the corresponding acetanilides. Reaction of 1 with hydrazine hydrate gave the hydrazide, which reacted with aromatic aldehydes, acetylacetone, Et acetoacetate, CS₂, etc. Antibacterial activity of several derivs. was determined

IT 175028-44-1P

RL: SPN (Synthetic preparation); PREP (Preparation)
(synthesis and antimicrobial activities of benzimidazole derivs.)

RN 175028-44-1 CAPLUS

CN Acetamide, 2-[4-(1H-benzimidazol-2-yl)phenoxy]-N-(4-bromophenyl)- (CA INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)


L87 ANSWER 46 OF 84 CAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 1994:148835 CAPLUS Full-text
 DOCUMENT NUMBER: 120:148835
 ORIGINAL REFERENCE NO.: 120:25989a,25992a
 TITLE: Photographic coupler and silver halide color
 photographic material
 INVENTOR(S): Mizukawa, Yuki; Motoki, Masuji; Sato, Tadahisa;
 Takahashi, Osamu
 PATENT ASSIGNEE(S): Fuji Photo Film Co., Ltd., Japan
 SOURCE: Eur. Pat. Appl., 126 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 571959	A2	19931201	EP 1993-108447	19930525 <--
EP 571959	A3	19940316		
EP 571959	B1	19970409		
R: DE, FR, GB, NL				
JP 06043611	A	19940218	JP 1992-234120	19920811 <--
EP 688774	A1	19951227	EP 1995-112304	19930525 <--
EP 688774	B1	19991222		
R: DE, FR, GB, NL				
US 5451501	A	19950919	US 1993-67111	19930526 <--
JP 08109181	A	19960430	JP 1995-158770	19950602 <--
US 5532377	A	19960702	US 1995-467833	19950606 <--
PRIORITY APPLN. INFO.:			JP 1992-157405	A 19920526 <--
			JP 1992-234120	A 19920811
<--				
			EP 1993-108447	A3 19930525 <--
			US 1993-67111	A3 19930526 <--

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): CASREACT 120:148835
 GI



AB A 1H-pyrazolo[1,5-b][1,2,4]triazole magenta coupler having a t-alkyl group at the position-6 and an amido group-substituted Ph group at the position-2 is disclosed having the formula I [R1 = tert-alkyl; R2, R3 = H, substituent; Y = H, halogen, aryloxy; A, B = CO, SO2; n = 0, 1; R4 = H, alkyl, aryl; R5


= alkyl, aryl, alkoxy, alkylamino, arylamino; R4-R5 may be combined to form a ring]. There is also disclosed a Ag halide color photog. material containing the same. The couplers provide excellent latent image stability, cause no lowering of sensitivity, and have excellent color developability.

IT 152828-07-4P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and use of, as photog. magenta coupler)

RN 152828-07-4 CAPLUS

CN Hexanamide, N-[4-[7-chloro-6-(1,1-dimethylethyl)-3H-pyrazolo[1,5-b][1,2,4]triazol-2-yl]phenyl]-2-[2-chloro-4-(1,1,3,3-tetramethylbutyl)phenoxy]- (CA INDEX NAME)



OS.CITING REF COUNT: 6 THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD
(6 CITINGS)

L87 ANSWER 47 OF 84 CAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 1993:29854 CAPLUS Full-text

DOCUMENT NUMBER: 118:29854

ORIGINAL REFERENCE NO.: 118:5361a,5364a

TITLE: Silver halide color photographic material

INVENTOR(S): Shimada, Yasuhiro; Ishii, Yoshio

PATENT ASSIGNEE(S): Fuji Photo Film Co., Ltd., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 37 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent


LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 04190348	A	19920708	JP 1990-322051	19901126 <--
US 5272051	A	19931221	US 1991-788432	19911106 <--
PRIORITY APPLN. INFO.:			JP 1990-322051	A 19901126 <--

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
GI




AB In the title material comprising a support having thereon one or more red-sensitive silver halide emulsion layers, at least one of the said red-sensitive silver halide emulsion layers contains a cyan coupler represented by general structure I. For I, R = a substituent group; Z1 = an electron-attracting substituent group which is not released upon reaction with an oxidized aromatic primary amine developing agent; Z2 = an electron-attracting substituent group; T = H or a group to be released upon reaction with an oxidized aromatic primary amine developing agent. The title material provides excellent color reproduction

IT 145130-89-8

RL: TEM (Technical or engineered material use); USES (Uses)
(photog. cyan coupler)

RN 145130-89-8 CAPLUS

CN 1H-Imidazo[1,2-b]pyrazole-7-carboxamide,
3-[[2-butoxy-4-(1,1,3,3-tetramethylbutyl)phenyl]thio]-6-[4-[[2-(2-chlorophenoxy)-1-oxotetradecyl]amino]phenyl]-2-cyano- (CA INDEX NAME)



L87 ANSWER 48 OF 84 CAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 1992:521410 CAPLUS Full-text

DOCUMENT NUMBER: 117:121410

ORIGINAL REFERENCE NO.: 117:20933a,20936a

TITLE: Photographic material using diffusion-resisting dye

INVENTOR(S): Ohashi, Hirobumi; Kagawa, Nobuaki; Kaguchi, Hiroyuki

PATENT ASSIGNEE(S): Konica K. K., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 20 pp.

CODEN: JKXXAF


DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
JP 04046337	A	19920217	JP 1990-154834	19900613 <--
JP 2852455	B2	19990203		
PRIORITY APPLN. INFO.:			JP 1990-154834	19900613 <--
GI				



AB The title photog. material contains a dispersion of ≥ 1 oil-soluble dye I [R1, R2 = alkyl, aryl, aralkyl, alkenyl, heterocyclyl; L1-3 = methine; n = 0-2; M = H, monovalent metal atom] in its photog. component layers. The photog. material shows reduced fog and improved long-term stability.

IT 142966-19-6

RL: TEM (Technical or engineered material use); USES (Uses)
(photog. materials containing)


RN 142966-19-6 CAPLUS

CN Octanamide,


2-[2-chloro-4-(1,1-dimethylpropyl)phenoxy]-N-[4-[4-[[1-[4-[[2-

[2-chloro-4-(1,1-dimethylpropyl)phenoxy]-1-oxooctyl]amino]phenyl]-3-cyano-1,5-dihydro-5-oxo-4H-pyrazol-4-ylidene]methyl]-3-cyano-5-hydroxy-1H-pyrazol-1-yl]phenyl]- (CA INDEX NAME)


PAGE 1-A



PAGE 2-A



PAGE 3-A



L87 ANSWER 49 OF 84 CAPLUS COPYRIGHT 2011 ACS on STN
 ACCESSION NUMBER: 1991:460720 CAPLUS Full-text
 DOCUMENT NUMBER: 115:60720
 ORIGINAL REFERENCE NO.: 115:10299a,10302a
 TITLE: High-contrast high-sensitivity rapidly processable
 photographic material
 INVENTOR(S): Hirano, Shigeo; Ichijima, Yasushi; Deguchi, Hisayasu
 PATENT ASSIGNEE(S): Fuji Photo Film Co., Ltd., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 64 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 02213838	A	19900824	JP 1989-35871	19890215 <--
PRIORITY APPLN. INFO.:			JP 1989-35871	19890215 <--


AB The title photog. material utilizes ≥ 1 A-(L1)v-B-(L2)w-FA [A = group releasing (L1)v-B-(L2)w-FA on reacting with oxidized developing agent; L1 = group releasing B-(L2)w-FA following its separation from A; B = group releasing (L2)w-FA on reacting with oxidized developing agent; L2 = group releasing FA following its separation from B; FA = nucleating agent, development accelerator; v,w = 0, 1]. The above compound releases a fogging agent on development accelerator in an imagewise manner and has a high maximum d.

IT 134889-42-2
RL: USES (Uses)
(photog. additive, high maximum d. materials using)


RN 134889-42-2 CAPLUS

CN Benzoic acid, 4-chloro-3-[[2-[[6-[(dodecylamino)carbonyl]-7-[[[4-(2-formylhydrazino)phenyl]amino]carbonyl]-1H-benzotriazol-1-yl]-1,2,3,4-tetrahydro-1,4-methanonaphthalen-5-yl]oxy]-3-(4-methoxyphenyl)-1,3-dioxopropyl]amino]-, 2-(dodecyloxy)-1-methyl-2-oxoethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



L87 ANSWER 50 OF 84 CAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 1991:81825 CAPLUS Full-text

DOCUMENT NUMBER: 114:81825

ORIGINAL REFERENCE NO.: 114:13973a,13976a

TITLE: Substituted N-(heterocyclic-substituted phenyl)-N'-benzylureas as pesticides

INVENTOR(S): Carney, Robert L.; Gruber, John M.; Lui, Alfred S. T.

PATENT ASSIGNEE(S): Sandoz A.-G., Switz.

SOURCE: U.S., 16 pp. Cont.-in-part of U.S. Ser. No. 187,164.


CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4950678	A	19900821	US 1989-386333	19890727 <--
PRIORITY APPLN. INFO.:			US 1986-840814	B2 19860318 <--
			US 1987-12577	B2 19870209 <--
			US 1988-187164	A2 19880428 <--

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 114:81825

GI



AB Title compds. I (X1,X2,X3,X5 = H, halo, C1-8 alkyl, C1-8 alkoxy; X4 = H, halo, (substituted) (halo) C1-8 alkyl, etc.; R6 = H, halo, C1-8 alkyl, etc.; Y = O, S; A = R4C, R4 = H, halo, (halo) C1-8 alkyl, (substituted) (halo) C1-8 alkoxy, (halo) C1-8 alkylthio, etc.; B = R3C, R3 = R4; R1 = R4; R2 = R3) and salts thereof, useful as pesticides in particular acaricides and insecticides (no data), are prepared 2,6-F2C3H3CONCO was added to 4-(4-chloro-1-pyrazolyl)aniline (preparation given) in CH2Cl2 to give I (X1 = X2 = F, X3 - X6 = R1 = H, R2 = Cl, Y = O, A = N, B = CH).


IT 112736-96-6P 112736-97-7P 112736-98-8P
 112736-99-9P 112737-00-5P 112737-01-6P
 112737-02-7P 112737-03-8P 112737-04-9P
 112737-05-0P 112737-06-1P 112737-07-2P
 112737-08-3P 112737-09-4P 112737-10-7P
 112737-11-8P 112737-12-9P 112737-13-0P
 112737-14-1P 112737-15-2P 112737-16-3P
 112737-17-4P 112737-18-5P 112737-19-6P
 112737-20-9P 112737-21-0P 112737-22-1P
 112737-23-2P 112737-24-3P 112737-25-4P
 112737-26-5P 112737-27-6P 112737-28-7P
 112737-29-8P 112737-30-1P 112737-31-2P
 112737-32-3P 112737-33-4P 112737-34-5P
 112737-35-6P 112737-37-8P 112737-38-9P
 112737-39-0P 112737-40-3P 112737-41-4P
 112737-42-5P 112737-43-6P 112737-44-7P
 112737-45-8P 112737-46-9P 112737-47-0P
 112737-48-1P 112737-50-5P 112737-51-6P
 112737-52-7P 112737-53-8P 112737-54-9P

112737-55-0P	112737-56-1P	112737-59-4P
112737-60-7P	112737-61-8P	112737-62-9P
112737-63-0P	112737-64-1P	112737-65-2P
112737-66-3P	112737-67-4P	112737-68-5P
112737-69-6P	112737-70-9P	112737-71-0P
112737-72-1P	112737-73-2P	112737-74-3P
112737-75-4P	112737-76-5P	112737-77-6P
112737-78-7P	112737-79-8P	112737-80-1P
112737-81-2P	112737-82-3P	112737-83-4P
112737-84-5P	112737-85-6P	112737-87-8P
112737-88-9P	112737-89-0P	112737-90-3P
112737-91-4P	112737-92-5P	112737-93-6P
112737-94-7P	112737-96-9P	112737-97-0P
112738-00-8P	112738-01-9P	112738-02-0P
112738-03-1P	112738-04-2P	112738-06-4P
112738-07-5P	112762-62-6P	112762-63-7P
112762-64-8P	112762-65-9P	112762-66-0P
112762-67-1P	112785-82-7P	131778-69-3P
131778-70-6P	131778-71-7P	131778-72-8P
131778-73-9P	131778-74-0P	131778-75-1P
131778-76-2P	131778-77-3P	131778-78-4P
131778-79-5P	131778-80-8P	131778-81-9P
131778-82-0P	131778-83-1P	131778-84-2P
131778-85-3P	131778-86-4P	131778-87-5P
131778-90-0P	131778-91-1P	131778-92-2P
131778-93-3P	131778-94-4P	131778-95-5P
131778-96-6P	131778-97-7P	131778-98-8P
131778-99-9P	131779-00-5P	131779-01-6P
131797-31-4P	131797-32-5P	131797-33-6P
131797-34-7P		

RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as insecticide)


RN 112736-96-6 CAPLUS

CN Benzamide, N-[[[3,5-dichloro-4-[4-chloro-3-(4-chlorophenyl)-1H-pyrazol-1-yl]phenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)




RN 112736-97-7 CAPLUS

CN Benzamide, N-[[[4-[4-chloro-3-(4-chlorophenyl)-1H-pyrazol-1-yl]-3,5-dimethylphenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)




RN 112736-98-8 CAPLUS

CN Benzamide, N-[[[4-(4-bromo-1H-pyrazol-1-yl)-3,5-dichlorophenyl]amino]carbonyl]-2-chloro- (CA INDEX NAME)




RN 112736-99-9 CAPLUS

CN Benzamide, 2-chloro-N-[[[3,5-dichloro-4-(3,4-dibromo-1H-pyrazol-1-yl)phenyl]amino]carbonyl]- (CA INDEX NAME)




RN 112737-00-5 CAPLUS

CN Benzamide, 2-chloro-N-[[[3,5-dichloro-4-[4,5-dichloro-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]amino]carbonyl]- (CA INDEX NAME)




RN 112737-01-6 CAPLUS

CN Benzamide, 2-chloro-N-[[[3,5-dichloro-4-[3-(4-chlorophenyl)-1H-pyrazol-1-




RN 112737-06-1 CAPLUS

CN Benzamide, N-[[[3,5-dichloro-4-(4-chloro-1H-pyrazol-1-yl)phenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)




RN 112737-07-2 CAPLUS

CN Benzamide, N-[[[4-(4-bromo-1H-pyrazol-1-yl)-3,5-dichlorophenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)



RN 112737-08-3 CAPLUS


CN Benzamide, N-[[[4-[3,4-bis(trifluoromethyl)-1H-pyrazol-1-yl]-3,5-dichlorophenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)



RN 112737-09-4 CAPLUS


CN Benzamide, N-[[[3,5-dichloro-4-(3-chloro-1H-pyrazol-1-

yl)phenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)




RN 112737-10-7 CAPLUS

CN Benzamide, N-[[[3,5-dichloro-4-(3,4-dibromo-1H-pyrazol-1-yl)phenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)



RN 112737-11-8 CAPLUS


CN Benzamide, N-[[[3,5-dichloro-4-[3-(4-chlorophenyl)-1H-pyrazol-1-yl]phenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)




RN 112737-12-9 CAPLUS

CN Benzamide, N-[[[3,5-dichloro-4-[4-(4-chlorophenyl)-1H-pyrazol-1-yl]phenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)


PAGE 1-A




PAGE 2-A



RN 112737-13-0 CAPLUS
 CN Benzamide, N-[[[3,5-dichloro-4-[3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)




RN 112737-14-1 CAPLUS
 CN Benzamide, N-[[[3,5-dichloro-4-[4-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)



RN 112737-15-2 CAPLUS


CN Benzamide,

N-[[[3,5-dichloro-4-[5-chloro-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)




RN 112737-16-3 CAPLUS

CN Benzamide, N-[[[3,5-dichloro-4-[3-(1,1-dimethylethyl)-1H-pyrazol-1-yl]phenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)



RN 112737-17-4 CAPLUS

CN Benzamide, N-[[[3,5-dichloro-4-(3,4-dichloro-1H-pyrazol-1-yl)phenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)




RN 112737-18-5 CAPLUS

CN Benzamide,


N-[[[3,5-dichloro-4-[4-chloro-3-(trifluoromethyl)-1H-pyrazol-1-

yl]phenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)




RN 112737-19-6 CAPLUS

CN Benzamide, N-[[[3,5-dichloro-4-[4,5-dichloro-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)




RN 112737-20-9 CAPLUS

CN Benzamide, N-[[[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]-3,5-dichlorophenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)



RN 112737-21-0 CAPLUS


CN Benzamide, N-[[[4-[5-chloro-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)



RN 112737-22-1 CAPLUS


CN Benzamide, N-[[[3-chloro-4-(4-chloro-1H-pyrazol-1-

yl)phenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)




RN 112737-23-2 CAPLUS

CN Benzamide, N-[[[4-[4-chloro-3-(4-chlorophenyl)-1H-pyrazol-1-yl]-3-(trifluoromethyl)phenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)




RN 112737-24-3 CAPLUS

CN Benzamide, N-[[[4-[5-chloro-3-(trifluoromethyl)-1H-pyrazol-1-yl]-3-(trifluoromethyl)phenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)




RN 112737-25-4 CAPLUS

CN Benzamide, N-[[[3,5-dichloro-4-(3,4,5-trichloro-1H-pyrazol-1-yl)phenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)




RN 112737-26-5 CAPLUS

CN Benzamide, N-[[[4-[4-bromo-3-(4-chlorophenyl)-1H-pyrazol-1-yl]-3,5-dichlorophenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)




RN 112737-27-6 CAPLUS

CN Benzamide, N-[[[3,5-dichloro-4-(3,4,5-tribromo-1H-pyrazol-1-yl)phenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)




RN 112737-28-7 CAPLUS

CN Benzamide, N-[[[3,5-dichloro-4-[3-chloro-5-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)



RN 112737-29-8 CAPLUS


CN Benzamide, N-[[[4-[4-chloro-3-(4-chlorophenyl)-1H-pyrazol-1-yl]-2-fluorophenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)



RN 112737-30-1 CAPLUS


CN Benzamide,

N-[[[5-chloro-4-[4-chloro-3-(4-chlorophenyl)-1H-pyrazol-1-yl]-2-fluorophenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)



RN 112737-31-2 CAPLUS


CN Benzamide, N-[[[4-[4-chloro-3-(4-chlorophenyl)-1H-pyrazol-1-yl]-3-methylphenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)



RN 112737-32-3 CAPLUS

CN Benzamide,


N-[[[5-chloro-4-[4-chloro-3-(4-chlorophenyl)-1H-pyrazol-1-yl]-2-methylphenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)




RN 112737-33-4 CAPLUS

CN Benzamide, N-[[[3,5-dichloro-4-[4-(2,4-dichlorophenyl)-1H-pyrazol-1-yl]phenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 112737-34-5 CAPLUS
 CN Benzamide, N-[[[4-[[4-(4-bromophenyl)-1H-pyrazol-1-yl]-3,5-dichlorophenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)


PAGE 1-A




PAGE 2-A



RN 112737-35-6 CAPLUS
 CN Benzamide, N-[[[3,5-dichloro-4-[[4-chloro-3-(4-chlorophenyl)-5-methoxy-1H-pyrazol-1-yl]phenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)




RN 112737-37-8 CAPLUS
 CN Benzoic acid, 2-[4-chloro-3-(4-chlorophenyl)-1H-pyrazol-1-yl]-5-[[[(2,6-difluorobenzoyl)amino]carbonyl]amino]-, methyl ester (CA INDEX NAME)




RN 112737-38-9 CAPLUS

CN Benzamide, N-[[[3-chloro-4-[5-chloro-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)




RN 112737-39-0 CAPLUS

CN Benzamide, N-[[[4-(4-bromo-1H-pyrazol-1-yl)-3-chlorophenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)




RN 112737-40-3 CAPLUS

CN Benzamide, N-[[[4-(4-bromo-1H-pyrazol-1-yl)-3-(trifluoromethyl)phenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)




RN 112737-41-4 CAPLUS

CN Benzamide, N-[[[3,5-dichloro-4-[3-(2,4-dichlorophenyl)-1H-pyrazol-1-yl]phenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)




RN 112737-42-5 CAPLUS

CN Benzamide, N-[[[3,5-dichloro-4-[3-(3,4-dichlorophenyl)-1H-pyrazol-1-yl]phenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)




RN 112737-43-6 CAPLUS

CN Benzamide, N-[[[4-[3-(4-bromophenyl)-1H-pyrazol-1-yl]-3,5-dichlorophenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)



RN 112737-44-7 CAPLUS


CN Benzamide, N-[[[3,5-dichloro-4-[3-(4-fluorophenyl)-1H-pyrazol-1-yl]phenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)



RN 112737-45-8 CAPLUS


CN Benzamide,

N-[[[3,5-dichloro-4-[3-[3-(trifluoromethyl)phenyl]-1H-pyrazol-1-yl]phenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)




RN 112737-46-9 CAPLUS

CN Benzamide, N-[[[3,5-dichloro-4-[3-(5-chloro-2-thienyl)-1H-pyrazol-1-yl]phenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)




RN 112737-47-0 CAPLUS

CN Benzamide, N-[[[3,5-dichloro-4-[3-(2-naphthalenyl)-1H-pyrazol-1-yl]phenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)




RN 112737-48-1 CAPLUS

CN Benzamide, N-[[[3,5-dichloro-4-(4-cyano-1H-pyrazol-1-yl)phenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)




RN 112737-50-5 CAPLUS

CN Benzamide, N-[[[3-chloro-4-[5-chloro-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]amino]carbonyl]-2-fluoro- (CA INDEX NAME)




RN 112737-51-6 CAPLUS

CN Benzamide, N-[[[4-(4-bromo-1H-pyrazol-1-yl)-3-chlorophenyl]amino]carbonyl]-2-fluoro- (CA INDEX NAME)




RN 112737-52-7 CAPLUS

CN Benzamide, N-[[[4-(4-bromo-1H-pyrazol-1-yl)-3-(trifluoromethyl)phenyl]amino]carbonyl]-2-fluoro- (CA INDEX NAME)




RN 112737-53-8 CAPLUS

CN Benzamide, N-[[[3,5-dichloro-4-[3-(2,4-dichlorophenyl)-1H-pyrazol-1-yl]phenyl]amino]carbonyl]-2-fluoro- (CA INDEX NAME)




RN 112737-54-9 CAPLUS

CN Benzamide, N-[[[3,5-dichloro-4-[3-(3,4-dichlorophenyl)-1H-pyrazol-1-yl]phenyl]amino]carbonyl]-2-fluoro- (CA INDEX NAME)




RN 112737-55-0 CAPLUS

CN Benzamide, N-[[[3,5-dichloro-4-[3-(4-fluorophenyl)-1H-pyrazol-1-yl]phenyl]amino]carbonyl]-2-fluoro- (CA INDEX NAME)



RN 112737-56-1 CAPLUS


CN Benzamide, N-[[[3,5-dichloro-4-[3-[3-(trifluoromethyl)phenyl]-1H-pyrazol-1-yl]phenyl]amino]carbonyl]-2-fluoro- (CA INDEX NAME)



RN 112737-59-4 CAPLUS

CN Benzamide, 2-chloro-N-[[[3,5-dichloro-4-[4,5-dichloro-3-(trifluoromethyl)-


1H-pyrazol-1-yl]phenyl]amino]carbonyl]-5-fluoro- (CA INDEX NAME)



RN 112737-60-7 CAPLUS


CN Benzamide,

2-chloro-N-[[[3,5-dichloro-4-[4,5-dichloro-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]amino]carbonyl]-6-fluoro- (CA INDEX NAME)




RN 112737-61-8 CAPLUS

CN Benzamide, 2,6-dichloro-N-[[[3,5-dichloro-4-[4,5-dichloro-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]amino]carbonyl]- (CA INDEX NAME)




RN 112737-62-9 CAPLUS

CN Benzamide, 2-chloro-N-[[[3,5-dichloro-4-(1H-pyrazol-1-yl)phenyl]amino]carbonyl]- (CA INDEX NAME)




RN 112737-63-0 CAPLUS

CN Benzamide, 2-chloro-N-[[[3,5-dichloro-4-(4-chloro-1H-pyrazol-1-yl)phenyl]amino]carbonyl]- (CA INDEX NAME)




RN 112737-64-1 CAPLUS

CN Benzamide, N-[[[4-[3,4-bis(trifluoromethyl)-1H-pyrazol-1-yl]-3,5-dichlorophenyl]amino]carbonyl]-2-chloro- (CA INDEX NAME)



RN 112737-65-2 CAPLUS


CN Benzamide, 2-chloro-N-[[[3,5-dichloro-4-(3-chloro-1H-pyrazol-1-yl)phenyl]amino]carbonyl]- (CA INDEX NAME)




RN 112737-66-3 CAPLUS

CN Benzamide, 2-chloro-N-[[[3,5-dichloro-4-[4-(4-chlorophenyl)-1H-pyrazol-1-yl]phenyl]amino]carbonyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 112737-67-4 CAPLUS


CN Benzamide,

2-chloro-N-[[[3,5-dichloro-4-[4-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]amino]carbonyl]- (CA INDEX NAME)



RN 112737-68-5 CAPLUS


CN Benzamide, 2-chloro-N-[[[3,5-dichloro-4-[5-chloro-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]amino]carbonyl]- (CA INDEX NAME)



RN 112737-69-6 CAPLUS


CN Benzamide,

2-chloro-N-[[[3,5-dichloro-4-[3-(1,1-dimethylethyl)-1H-pyrazol-1-yl]phenyl]amino]carbonyl]- (CA INDEX NAME)




RN 112737-70-9 CAPLUS

CN Benzamide, 2-chloro-N-[[[3,5-dichloro-4-[4-chloro-3-(4-chlorophenyl)-1H-pyrazol-1-yl]phenyl]amino]carbonyl]- (CA INDEX NAME)




RN 112737-71-0 CAPLUS

CN Benzamide, 2-chloro-N-[[[3,5-dichloro-4-[4-chloro-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]amino]carbonyl]- (CA INDEX NAME)




RN 112737-72-1 CAPLUS

CN Benzamide, N-[[[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]-3,5-dichlorophenyl]amino]carbonyl]-2-chloro- (CA INDEX NAME)




RN 112737-73-2 CAPLUS

CN Benzamide, N-[[[4-bromo-3-(4-chlorophenyl)-1H-pyrazol-1-yl]-3,5-dichlorophenyl]amino]carbonyl]-2-chloro- (CA INDEX NAME)




RN 112737-74-3 CAPLUS

CN Benzamide, 2-chloro-N-[[[3,5-dichloro-4-(3,4,5-tribromo-1H-pyrazol-1-yl)phenyl]amino]carbonyl]- (CA INDEX NAME)




RN 112737-75-4 CAPLUS

CN Benzamide, 2-chloro-N-[[[3,5-dichloro-4-[3-chloro-5-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]amino]carbonyl]- (CA INDEX NAME)




RN 112737-76-5 CAPLUS

CN Benzamide, 2-chloro-N-[[[3,5-dichloro-4-(3,4,5-trichloro-1H-pyrazol-1-yl)phenyl]amino]carbonyl]- (CA INDEX NAME)




RN 112737-77-6 CAPLUS

CN Benzamide, 2-chloro-N-[[[4-[4-chloro-3-(4-chlorophenyl)-1H-pyrazol-1-yl]-3,5-dimethylphenyl]amino]carbonyl]- (CA INDEX NAME)




RN 112737-78-7 CAPLUS

CN Benzamide,
N-[[[4-(4-bromo-1H-pyrazol-1-yl)-3-chlorophenyl]amino]carbonyl]-
2-chloro- (CA INDEX NAME)




RN 112737-79-8 CAPLUS

CN Benzamide, N-[[[4-(4-bromo-1H-pyrazol-1-yl)-3-(trifluoromethyl)phenyl]amino]carbonyl]-2-chloro- (CA INDEX NAME)




RN 112737-80-1 CAPLUS

CN Benzamide, 2-chloro-N-[[[3,5-dichloro-4-[3-(2-chlorophenyl)-1H-pyrazol-1-yl]phenyl]amino]carbonyl]- (CA INDEX NAME)




RN 112737-81-2 CAPLUS

CN Benzamide,
2-chloro-N-[[[3,5-dichloro-4-[3-(2,4-dichlorophenyl)-1H-pyrazol-1-yl]phenyl]amino]carbonyl]- (CA INDEX NAME)




RN 112737-82-3 CAPLUS

CN Benzamide,
2-chloro-N-[[[3,5-dichloro-4-[3-(3,4-dichlorophenyl)-1H-pyrazol-1-yl]phenyl]amino]carbonyl]- (CA INDEX NAME)




RN 112737-83-4 CAPLUS

CN Benzamide, N-[[[4-[3-(4-bromophenyl)-1H-pyrazol-1-yl]-3,5-dichlorophenyl]amino]carbonyl]-2-chloro- (CA INDEX NAME)




RN 112737-84-5 CAPLUS

CN Benzamide, 2-chloro-N-[[[3-chloro-4-[4-chloro-3-(4-chlorophenyl)-1H-pyrazol-1-yl]-5-methylphenyl]amino]carbonyl]- (CA INDEX NAME)




RN 112737-85-6 CAPLUS

CN Benzamide, 2-chloro-N-[[[3,5-dichloro-4-[3-(4-fluorophenyl)-1H-pyrazol-1-yl]phenyl]amino]carbonyl]- (CA INDEX NAME)




RN 112737-87-8 CAPLUS

CN Benzamide, 2-chloro-N-[[[3,5-dichloro-4-[3-(5-chloro-2-thienyl)-1H-pyrazol-1-yl]phenyl]amino]carbonyl]- (CA INDEX NAME)




RN 112737-88-9 CAPLUS

CN Benzamide, 2-chloro-N-[[[3,5-dichloro-4-[3-(2-naphthalenyl)-1H-pyrazol-1-yl]phenyl]amino]carbonyl]- (CA INDEX NAME)




RN 112737-89-0 CAPLUS

CN Benzamide, 2-chloro-N-[[[3-chloro-4-[5-chloro-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]amino]carbonyl]- (CA INDEX NAME)




RN 112737-90-3 CAPLUS

CN Benzamide, N-[[[4-[5-(4-bromophenyl)-1H-pyrazol-1-yl]-3,5-dichlorophenyl]amino]carbonyl]-2-chloro- (CA INDEX NAME)



RN 112737-91-4 CAPLUS


CN Benzamide, N-[[[4-[5-(4-bromophenyl)-1H-pyrazol-1-yl]-3,5-dichlorophenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)



RN 112737-92-5 CAPLUS

CN Benzamide, N-[[[4-[5-(4-bromophenyl)-4-chloro-1H-pyrazol-1-yl]-3,5-dichlorophenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A

Cl


RN 112737-93-6 CAPLUS

CN Benzamide, N-[[[3,5-dichloro-4-[3-(4-methylphenyl)-1H-pyrazol-1-yl]phenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)




RN 112737-94-7 CAPLUS

CN Benzamide, 2-chloro-N-[[[3,5-dichloro-4-[3-(4-methylphenyl)-1H-pyrazol-1-yl]phenyl]amino]carbonyl]- (CA INDEX NAME)




RN 112737-96-9 CAPLUS

CN Benzamide, N-[[[3,5-dichloro-4-(3-chloro-1H-indazol-1-yl)phenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)




RN 112737-97-0 CAPLUS

CN Benzamide, N-[[[3,5-dichloro-4-(5,6-dichloro-1H-benzimidazol-1-yl)phenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)




RN 112738-00-8 CAPLUS

CN Benzamide, N-[[[3,5-dichloro-4-(5,6-dichloro-1H-benzotriazol-1-yl)phenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)




RN 112738-01-9 CAPLUS

CN Benzamide, 2-chloro-N-[[[3,5-dichloro-4-(5,6-dichloro-1H-benzimidazol-1-yl)phenyl]amino]carbonyl]- (CA INDEX NAME)




RN 112738-02-0 CAPLUS

CN Benzamide, 2-chloro-N-[[[3-chloro-4-(5,6-dichloro-1H-benzimidazol-1-yl)phenyl]amino]carbonyl]- (CA INDEX NAME)




RN 112738-03-1 CAPLUS

CN Benzamide, 2-chloro-N-[[[3,5-dichloro-4-(5-chloro-1H-benzotriazol-1-yl)phenyl]amino]carbonyl]- (CA INDEX NAME)




RN 112738-04-2 CAPLUS

CN Benzamide, 2-chloro-N-[[[3,5-dichloro-4-(5,6-dichloro-1H-benzotriazol-1-yl)phenyl]amino]carbonyl]- (CA INDEX NAME)




RN 112738-06-4 CAPLUS

CN Benzamide,
N-[[[3,5-dichloro-4-(2H-indazol-2-yl)phenyl]amino]carbonyl]-2,6-
difluoro- (CA INDEX NAME)




RN 112738-07-5 CAPLUS

CN Benzamide, 2-chloro-N-[[[3,5-dichloro-4-(2H-indazol-2-yl)phenyl]amino]carbonyl]- (CA INDEX NAME)




RN 112762-62-6 CAPLUS

CN Benzamide, N-[[[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)




RN 112762-63-7 CAPLUS

CN Benzamide, 2-chloro-N-[[[3,5-dichloro-4-(3,4-dichloro-1H-pyrazol-1-yl)phenyl]amino]carbonyl]- (CA INDEX NAME)




RN 112762-64-8 CAPLUS

CN Benzamide, 2-chloro-N-[[[3-chloro-4-[4-chloro-3-(4-chlorophenyl)-1H-pyrazol-1-yl]phenyl]amino]carbonyl]- (CA INDEX NAME)



RN 112762-65-9 CAPLUS


CN Benzamide, 2-chloro-N-[[[4-[4-chloro-3-(4-chlorophenyl)-1H-pyrazol-1-yl]-3-(trifluoromethyl)phenyl]amino]carbonyl]- (CA INDEX NAME)



RN 112762-66-0 CAPLUS

CN Benzamide,


2-chloro-N-[[[4-[5-chloro-3-(trifluoromethyl)-1H-pyrazol-1-yl]-
3-(trifluoromethyl)phenyl]amino]carbonyl]- (CA INDEX NAME)



RN 112762-67-1 CAPLUS

CN Benzamide, N-[[[4-[5-(4-bromophenyl)-4-chloro-1H-pyrazol-1-yl]-3,5-dichlorophenyl]amino]carbonyl]-2-chloro- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A

Cl


RN 112785-82-7 CAPLUS

CN Benzamide, N-[[[3,5-dichloro-4-[3-(2-chlorophenyl)-1H-pyrazol-1-yl]phenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)




RN 131778-69-3 CAPLUS

CN 1H-Pyrazole-4-carboxylic acid, 1-[2,6-dichloro-4-[[[(2,6-difluorobenzoyl)amino]carbonyl]amino]phenyl]-, ethyl ester (CA INDEX NAME)




RN 131778-70-6 CAPLUS

CN Benzamide, N-[[[3,5-dichloro-4-[4-chloro-3-(4-fluorophenyl)-1H-pyrazol-1-yl]phenyl]amino]carbonyl]-2-fluoro- (CA INDEX NAME)



RN 131778-71-7 CAPLUS


CN Benzamide, 2-chloro-N-[[[3,5-dichloro-4-[3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]amino]carbonyl]- (CA INDEX NAME)



RN 131778-72-8 CAPLUS

CN Benzamide, N-[[[4-(4-bromo-1H-pyrazol-1-yl)phenyl]amino]carbonyl]-2,6-


difluoro- (CA INDEX NAME)



RN 131778-73-9 CAPLUS

CN Benzamide,


N-[[[4-(4-bromo-1H-pyrazol-1-yl)phenyl]amino]carbonyl]-2-fluoro-
(CA INDEX NAME)



RN 131778-74-0 CAPLUS

CN Benzamide,


N-[[[4-(4-bromo-1H-pyrazol-1-yl)phenyl]amino]carbonyl]-2-chloro-
(CA INDEX NAME)



RN 131778-75-1 CAPLUS

CN Benzamide,


N-[[[4-(4-bromo-3-fluoro-1H-pyrazol-1-yl)phenyl]amino]carbonyl]-
2,6-difluoro- (CA INDEX NAME)



RN 131778-76-2 CAPLUS

CN Benzamide,


N-[[[4-(4-bromo-3-fluoro-1H-pyrazol-1-yl)phenyl]amino]carbonyl]-
2-fluoro- (CA INDEX NAME)



RN 131778-77-3 CAPLUS


CN Benzamide,

N-[[[4-(4-bromo-3-fluorophenyl)phenyl]amino]carbonyl]-
2-chloro- (CA INDEX NAME)




RN 131778-78-4 CAPLUS

CN Benzamide, N-[[[4-[4-bromo-3-(4-methoxyphenyl)-1H-pyrazol-1-yl]-3,5-dichlorophenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)




RN 131778-79-5 CAPLUS

CN Benzamide, N-[[[4-[4-bromo-3-(4-methoxyphenyl)-1H-pyrazol-1-yl]-3,5-dichlorophenyl]amino]carbonyl]-2-chloro- (CA INDEX NAME)




RN 131778-80-8 CAPLUS

CN Benzamide, N-[[[3,5-dichloro-4-(3,4-diphenyl-1H-pyrazol-1-yl)phenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)




RN 131778-81-9 CAPLUS

CN Benzamide, 2-chloro-N-[[[3,5-dichloro-4-(3,4-diphenyl-1H-pyrazol-1-yl)phenyl]amino]carbonyl]- (CA INDEX NAME)




RN 131778-82-0 CAPLUS

CN Benzamide, N-[[[4-[3,4-bis(4-chlorophenyl)-1H-pyrazol-1-yl]-3,5-dichlorophenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)




RN 131778-83-1 CAPLUS

CN Benzamide, N-[[[4-[3,4-bis(4-chlorophenyl)-1H-pyrazol-1-yl]-3,5-dichlorophenyl]amino]carbonyl]-2-chloro- (CA INDEX NAME)




RN 131778-84-2 CAPLUS

CN Benzamide, N-[[[4-[4,5-dichloro-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)




RN 131778-85-3 CAPLUS

CN Benzamide, 2-chloro-N-[[[4-[4,5-dichloro-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]amino]carbonyl]- (CA INDEX NAME)




RN 131778-86-4 CAPLUS


CN Benzamide, N-[[[4-[4,5-dichloro-3-(trifluoromethyl)-1H-pyrazol-1-yl]-3-(trifluoromethyl)phenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)




RN 131778-87-5 CAPLUS
 CN Benzamide,
 2-chloro-N-[[[4-[4,5-dichloro-3-(trifluoromethyl)-1H-pyrazol-1-yl]-3-(trifluoromethyl)phenyl]amino]carbonyl]- (CA INDEX NAME)



RN 131778-90-0 CAPLUS
 CN Benzamide,
 N-[[[3,5-dichloro-4-[4-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)



PAGE 1-A




PAGE 2-A

RN 131778-91-1 CAPLUS


CN Benzamide,

N-[[[2,5-dichloro-4-[5-chloro-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)




RN 131778-92-2 CAPLUS

CN Benzamide, 2-chloro-N-[[[2,5-dichloro-4-[5-chloro-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]amino]carbonyl]- (CA INDEX NAME)



RN 131778-93-3 CAPLUS


CN Benzamide, 2-chloro-N-[[[2,3-dichloro-4-[5-chloro-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]amino]carbonyl]- (CA INDEX NAME)



RN 131778-94-4 CAPLUS


CN Benzamide,

N-[[[2,3-dichloro-4-[5-chloro-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)




RN 131778-95-5 CAPLUS

CN Benzamide, N-[[[2,3-dichloro-4-(3,4,5-trichloro-1H-pyrazol-1-yl)phenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)




RN 131778-96-6 CAPLUS

CN Benzamide, 2-chloro-N-[[[2,5-dichloro-4-(3,4,5-trichloro-1H-pyrazol-1-yl)phenyl]amino]carbonyl]- (CA INDEX NAME)




RN 131778-97-7 CAPLUS

CN Benzamide, N-[[[3,5-dichloro-2-fluoro-4-(3,4,5-trichloro-1H-pyrazol-1-yl)phenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)



RN 131778-98-8 CAPLUS


CN Benzamide, 2-chloro-N-[[[3,5-dichloro-2-fluoro-4-(3,4,5-trichloro-1H-pyrazol-1-yl)phenyl]amino]carbonyl]- (CA INDEX NAME)



RN 131778-99-9 CAPLUS


CN Benzamide,

2-chloro-N-[[[3-chloro-2-fluoro-4-(3,4,5-trichloro-1H-pyrazol-1-yl)phenyl]amino]carbonyl]- (CA INDEX NAME)



RN 131779-00-5 CAPLUS


CN Benzamide, 2-chloro-N-[[[2,3,5-trichloro-4-(3,4,5-trichloro-1H-pyrazol-1-yl)phenyl]amino]carbonyl]- (CA INDEX NAME)



RN 131779-01-6 CAPLUS


CN Benzamide,

2,6-difluoro-N-[[[2,3,5-trichloro-4-(3,4,5-trichloro-1H-pyrazol-1-yl)phenyl]amino]carbonyl]- (CA INDEX NAME)




RN 131797-31-4 CAPLUS

CN Benzamide, N-[[[3-chloro-4-(2,5,6-trichloro-1H-benzimidazol-1-yl)phenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)




RN 131797-32-5 CAPLUS

CN Benzamide, 2-chloro-N-[[[3,5-dichloro-4-[3-(trifluoromethyl)-4-[4-(trifluoromethyl)phenyl]-1H-pyrazol-1-yl]phenyl]amino]carbonyl]- (CA INDEX NAME)



PAGE 1-A




PAGE 2-A

RN 131797-33-6 CAPLUS


CN Benzamide, 2-chloro-N-[[[2,3-dichloro-4-(3,4,5-trichloro-1H-pyrazol-1-

yl)phenyl]amino]carbonyl]- (CA INDEX NAME)



RN 131797-34-7 CAPLUS

CN Benzamide, N-[[[3-chloro-2-fluoro-4-(3,4,5-trichloro-1H-pyrazol-1-yl)phenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L87 ANSWER 51 OF 84 CAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 1991:72228 CAPLUS Full-text

DOCUMENT NUMBER: 114:72228

ORIGINAL REFERENCE NO.: 114:12161a,12164a

TITLE: Color photographic material with wide exposure latitude

INVENTOR(S): Hirabayashi, Shigeto; Matsuzaka, Syoji; Ohya, Yukio; Nakayama, Tomoyuki; Hoshino, Hiroyuki

PATENT ASSIGNEE(S): Konica Co., Japan

SOURCE: Eur. Pat. Appl., 158 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
EP 365348	A2	19900425	EP 1989-310819	19891020 <--
EP 365348	A3	19901114		
R: DE, GB				
JP 02110551	A	19900423	JP 1988-264591	19881020 <--
JP 02131234	A	19900521	JP 1988-286538	19881111 <--
JP 02219053	A	19900831	JP 1989-40920	19890220 <--


AB Color photog. materials having a wide exposure latitude, which can provide an image with excellent graininess and sharpness, and which have high stability under variable processing conditions, consist of blue-sensitive, green-sensitive, and red-sensitive Ag halide emulsion layers on a support and ≥ 1 of the color-sensitive emulsion layers has a single-layer structure. The emulsion layer having a single-layer structure comprises ≥ 2 types of Ag halide grains differing in average grain size and contains a development-inhibitor-releasing compound. The exposure latitude of the Ag halide emulsion layer with a single-layer structure is ≥ 3.0 .

(photog. yellow shift coupler, color materials containing, with wide exposure latitude)

chloro-5-[(dodecyloxy)carbonyl]phenyl]amino]carbonyl]-2-(4-methoxyphenyl)-
2-oxoethoxy]phenyl]-3-methyl-, iodide (9CI) (CA INDEX NAME)

COCC(=O)Nc1ccc(cc1)C(=O)Oc2ccc(cc2)C(=O)Nc3ccc(cc3)C(=O)OC

PAGE 2-A

● I⁻

L87 ANSWER 52 OF 84 CAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 1990:468229 CAPLUS Full-text

DOCUMENT NUMBER: 113:68229

ORIGINAL REFERENCE NO.: 113:11357a,11360a

TITLE: Rapid processing of color photographic material for stable images

INVENTOR(S): Ezaki, Atsuo; Yoshimoto, Hiroshi

PATENT ASSIGNEE(S): Konica Co., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 36 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 01230045	A	19890913	JP 1988-57232	19880310 <--

PRIORITY APPLN. INFO.: JP 1988-57232 19880310 <--

AB In processing an exposed color photog. material by treating with a color developing agent, bleaching, and fixing, the bleaching time plus fixing time is ≤3 min 45 s and the photog. material contains a complex having a dye or its precursor bonded directly or via a timing group to the reactive site at which reaction occurs with the oxidized primary aromatic amine developer, the dye or its precursor released above having an absorption maximum shifted to a lower wavelength prior to its release.


IT 125329-20-6

RL: USES (Uses)
(yellow photog. coupler)


RN 125329-20-6 CAPLUS

CN Benzothiazolium,
[[2,4-bis(1,1-dimethylpropyl)phenyl]methoxy]-2-[4-[1-[[[2-chloro-5-[(dodecyloxy)carbonyl]phenyl]amino]carbonyl]-2-(4-methoxyphenyl)-2-oxoethoxy]phenyl]-3-methyl-, iodide (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

● I⁻

L87 ANSWER 53 OF 84 CAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 1990:449660 CAPLUS Full-text

DOCUMENT NUMBER: 113:49660

ORIGINAL REFERENCE NO.: 113:8265a,8268a

TITLE: Silver halide color photographic material containing shift coupler

INVENTOR(S): Ueda, Eiichi; Nakagawa, Satoshi; Shimazaki, Hiroshi

PATENT ASSIGNEE(S): Konica Co., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 24 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 01217460	A	19890831	JP 1988-43440	19880226 <--
PRIORITY APPLN. INFO.:			JP 1988-43440	19880226 <--
AB The title photog. material contains a shift coupler in which the wavelength of the absorption maximum of the dye released is shorter in the bonded state before release in comparison with that in the free state and has hydrophilic				

colloidal layers hardened by a hardening agent through activation of carboxylic groups.

IT 125329-20-6

RL: USES (Uses)

(photog. yellow shift coupler)


RN 125329-20-6 CAPLUS

CN Benzothiazolium,


[[2,4-bis(1,1-dimethylpropyl)phenyl]methoxy]-2-[4-[1-[[[2-

chloro-5-[(dodecyloxy)carbonyl]phenyl]amino]carbonyl]-2-(4-methoxyphenyl)-2-oxoethoxy]phenyl]-3-methyl-, iodide (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



● I⁻

L87 ANSWER 54 OF 84 CAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 1990:431810 CAPLUS Full-text

DOCUMENT NUMBER: 113:31810

ORIGINAL REFERENCE NO.: 113:5319a, 5322a

TITLE: Silver halide color photographic material containing azole compound as cyan coupler



INVENTOR(S): Fukunaga, Hiroo; Yamakawa, Kazuyoshi; Furusawa, Genichi

PATENT ASSIGNEE(S): Fuji Photo Film Co., Ltd., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 44 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 01250949	A	19891005	JP 1988-76403	19880331 <--
PRIORITY APPLN. INFO.:			JP 1988-76403	19880331 <--
OTHER SOURCE(S):	MARPAT 113:31810			

GI




AB A Ag halide color photog. material having excellent color reproducibility contains an azole compound [I; R = H, blocking group; Z, Z1, Z2 = (substituted) methine, N, but the substituent ≠ OH, acyloxy, sulfonyloxy] as a cyan coupler. A color photog. film having II as a cyan coupler was processed to give images showing excellent color reproducibility and colorfastness on storage at 60° and 70% relative humidity.

IT 127828-92-6

RL: TEM (Technical or engineered material use); USES (Uses)
 (cyan photog. coupler)

RN 127828-92-6 CAPLUS

CN Tetradecanamide, 2-[2-chloro-4-[(3-chloro-4-hydroxyphenyl)sulfonyl]phenoxy]-N-[2-(3-chloro-5-ethyl-1H-pyrazol-4-yl)phenyl]- (CA INDEX NAME)



ACCESSION NUMBER: 1990:188876 CAPLUS Full-text
 DOCUMENT NUMBER: 112:188876
 ORIGINAL REFERENCE NO.: 112:31745a,31748a
 TITLE: High-sensitivity color photographic material with improved image sharpness and shelf life
 INVENTOR(S): Hirabayashi, Shigeto
 PATENT ASSIGNEE(S): Konica Co., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 14 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 01191142	A	19890801	JP 1988-15453	19880126 <--
PRIORITY APPLN. INFO.:			JP 1988-15453	19880126 <--

AB In the title photog. material, ≥ 1 of the Ag halide emulsion layers contains a benzoylacetanilide derivative yellow photog. coupler and another yellow photog. coupler which, upon reaction with an oxidized aromatic primary amine color developer, releases a dye whose absorption maximum is at a shorter wavelength prior to its release.

IT 125329-20-6

RL: USES (Uses)

(yellow photog. coupler)


RN 125329-20-6 CAPLUS

CN Benzothiazolium,


[[2,4-bis(1,1-dimethylpropyl)phenyl]methoxy]-2-[4-[1-[[[2-

chloro-5-[(dodecyloxy)carbonyl]phenyl]amino]carbonyl]-2-(4-methoxyphenyl)-2-oxoethoxy]phenyl]-3-methyl-, iodide (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



L87 ANSWER 56 OF 84 CAPLUS COPYRIGHT 2011 ACS on STN
 ACCESSION NUMBER: 1990:188873 CAPLUS Full-text
 DOCUMENT NUMBER: 112:188873
 ORIGINAL REFERENCE NO.: 112:31745a, 31748a
 TITLE: Silver halide photographic material with improved sharpness
 INVENTOR(S): Yagi, Toshihiko; Nakagawa, Satoshi
 PATENT ASSIGNEE(S): Konica Co., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 22 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 01188847	A	19890728	JP 1988-13929	19880125 <--

PRIORITY APPLN. INFO.: JP 1988-13929 19880125 <--


AB In a Ag halide photog. material containing ≥ 1 Ag halide emulsion layer containing a coupler, ≥ 1 of the emulsion layers contains Ag halide grains containing ≥ 2 phases differing in AgI content with an. AgI content 2-20 mol% and the average AgI content higher than that in the peripheral regions and a coupler which contains a dye- or dye precursor-releasing group bonded directly or via a timing group to the active site with the above dye showing a shorter absorption maximum wave length before its release.

IT 125329-20-6
 RL: TEM (Technical or engineered material use); USES (Uses)
 (photog. coupler)


RN 125329-20-6 CAPLUS

CN Benzothiazolium,
 [[2,4-bis(1,1-dimethylpropyl)phenyl]methoxy]-2-[4-[1-[[[2-chloro-5-[(dodecyloxy)carbonyl]phenyl]amino]carbonyl]-2-(4-methoxyphenyl)-2-oxoethoxy]phenyl]-3-methyl-, iodide (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

● I⁻

L87 ANSWER 57 OF 84 CAPLUS COPYRIGHT 2011 ACS on STN
 ACCESSION NUMBER: 1990:174016 CAPLUS Full-text
 DOCUMENT NUMBER: 112:174016
 ORIGINAL REFERENCE NO.: 112:29279a,29282a
 TITLE: Stable pesticidal emulsions
 AUTHOR(S): Curtis, Ralston
 CORPORATE SOURCE: Sandoz Crop Prot., USA
 SOURCE: Research Disclosure (1989), 308, 981-2 (No. 308103)
 CODEN: RSDSBB; ISSN: 0374-4353
 DOCUMENT TYPE: Journal; Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
RD 308103		19891210	RD 1989-308103	19891210 <--
PRIORITY APPLN. INFO.:			RD 1989-308103	19891210 <--
AB Stable emulsifiable concs. containing 1-20% by weight of a difficult-to-dissolve crystalline pesticide, 45-90% by weight of 1-octyl-2-pyrrolidinone, 5-30% by weight of 1-methyl-2-pyrrolidinone, cyclohexanone, or α -butyrolactone, 10-50% by weight of methylated				

naphthalene or a xylene-range aromatic solvent or a mixture of 2 or more xylene-range aromatic solvents and 1-10% by weight of a surfactant are prepared. Pesticides prepared from these concs. were effective for controlling beet armyworm (*Spodoptera exigua*) on lima bean plants.


IT 112737-76-5 126353-95-5

RL: BIOL (Biological study)

(stable pesticidal emulsion containing)

RN 112737-76-5 CAPLUS


CN Benzamide, 2-chloro-N-[[[3,5-dichloro-4-(3,4,5-trichloro-1H-pyrazol-1-yl)phenyl]amino]carbonyl]- (CA INDEX NAME)



RN 126353-95-5 CAPLUS

CN Benzamide,

2-chloro-N-[[[2,5-dichloro-4-[4,5-dichloro-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]amino]carbonyl]- (CA INDEX NAME)



L87 ANSWER 58 OF 84 CAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 1990:88181 CAPLUS Full-text

DOCUMENT NUMBER: 112:88181

ORIGINAL REFERENCE NO.: 112:14831a,14834a

TITLE: Fog-resistant silver halide photographic material

INVENTOR(S): Sakamoto, Hidekazu

PATENT ASSIGNEE(S): Konica Co., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 18 pp.

CODEN: JKXXAF


DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
JP 01196045	A	19890807	JP 1988-20871	19880130 <--
PRIORITY APPLN. INFO.:			JP 1988-20871	19880130 <--



AB The material contains I (Z = group forming C-, N-, and/or S-containing 5- or 6-membered heterocycle; M = H, alkali metal, NH₄, protective group) and ≥1 coupler bound with a dye or its precursor, released by the reaction with an oxidant of aromatic primary amine coloring developer, directly or via timing group at the activation position, and the absorption maximum of the dye or its precursor shows blue shift before it is released. A Ag halide photog. emulsion containing II and III was applied on a cellulose triacetate film support to give a color photog. material which showed high durability and fog resistance.

IT 125329-20-6

RL: TEM (Technical or engineered material use); USES (Uses)
(photog. yellow coupler)


RN 125329-20-6 CAPLUS

CN Benzothiazolium,


[[2,4-bis(1,1-dimethylpropyl)phenyl]methoxy]-2-[4-[1-[[[2-

chloro-5-[(dodecyloxy)carbonyl]phenyl]amino]carbonyl]-2-(4-methoxyphenyl)-
2-oxoethoxy]phenyl]-3-methyl-, iodide (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

● I⁻

L87 ANSWER 59 OF 84 CAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 1990:55721 CAPLUS Full-text

DOCUMENT NUMBER: 112:55721

ORIGINAL REFERENCE NO.: 112:9571a,9574a

TITLE: Synthesis and antibacterial activity of some new selenadiazoles and thiadiazoles containing amino acid moieties

AUTHOR(S): Bayoumy, B. E.; Deeb, A.; El-Mobayed, M.; Abd-Alla, M. A.

CORPORATE SOURCE: Fac. Sci., Zagazig Univ., Zagazig, Egypt

SOURCE: Egyptian Journal of Chemistry (1988), Volume Date 1987, 30(1), 53-61


CODEN: EGJCA3; ISSN: 0367-0422

DOCUMENT TYPE: Journal


LANGUAGE: English

OTHER SOURCE(S): CASREACT 112:55721

GI



I




II

AB Title compds. I (R = piperazino, morpholino, piperidino, 2-pyridylamino, ethylamino, etc.; Z = Se, S) were prepared by treating semicarbazones II with SeO₂/AcOH or SOCl₂ resp. Bactericidal and fungicidal activity of I were determined

IT 111281-88-QP


RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation, bactericidal, and fungicidal activity of)
 RN 111281-88-0 CAPLUS
 CN Acetamide, 2-[(4-chlorophenyl)amino]-N-[4-(1,2,3-thiadiazol-4-yl)phenyl]-
 (CA INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
 (1 CITINGS)

L87 ANSWER 60 OF 84 CAPLUS COPYRIGHT 2011 ACS on STN
 ACCESSION NUMBER: 1990:14188 CAPLUS Full-text
 DOCUMENT NUMBER: 112:14188
 ORIGINAL REFERENCE NO.: 112:2443a,2446a
 TITLE: Silver halide color photographic material containing
 cyan coupler
 INVENTOR(S): Tachibana, Kimie; Kaneko, Yutaka
 PATENT ASSIGNEE(S): Konica Co., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 13 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 01028638	A	19890131	JP 1987-184554	19870723 <--
PRIORITY APPLN. INFO.: GI			JP 1987-184554	19870723 <--



AB In the title photog. material, ≥ 1 of red-sensitive Ag halide emulsion layer contains a coupler I [R1, R2 = substituent; Y, R3 = H, substituent; X = H, group to be released upon reaction with an oxidized developer]. The coupler is a pyrazoloimidazole cyan coupler. Cyan images show excellent spectral characteristics, and heat- and moisture-resistance. II was an example of I.

IT 124171-49-9


RL: USES (Uses)

(cyan coupler, color photog. material containing)

RN 124171-49-9 CAPLUS

CN 1H-Imidazo[1,2-b]pyrazole-6-carboxamide,

2-[4-[[2-(2-chlorophenoxy)-1-oxotetradecyl]amino]phenyl]-3-cyano-N-ethyl-
(CA INDEX NAME)




IT 124171-39-7F

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and use of, as cyan coupler)

RN 124171-39-7 CAPLUS

CN 1H-Imidazo[1,2-b]pyrazole-6-carboxamide,

7-chloro-2-[4-[[2-(2-chlorophenoxy)-1-oxotetradecyl]amino]phenyl]-N-ethyl-3-methyl- (CA INDEX NAME)



L87 ANSWER 61 OF 84 CAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 1989:574087 CAPLUS [Full-text](#)

DOCUMENT NUMBER: 111:174087

ORIGINAL REFERENCE NO.: 111:29006h, 29007a

TITLE: Preparation of
N-benzoyl-N'-(4-pyrazol-1-yl-phenyl)ureas as
pesticides

INVENTOR(S): Neubauer, Hans Juergen; Kuenast, Christoph;
Hofmeister, Peter


PATENT ASSIGNEE(S): BASF A.-G., Fed. Rep. Ger.

SOURCE: Ger. Offen., 14 pp.

CODEN: GWXXBX

DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 3732541	A1	19890413	DE 1987-3732541	19870926 <--
PRIORITY APPLN. INFO.:			DE 1987-3732541	19870926 <--
OTHER SOURCE(S):			CASREACT 111:174087; MARPAT 111:174087	
GI				




AB The title compds. (I; R1, R3, R4 = H, halo; R2 = halo; R5-R7 = R1, C1-8 alkyl, C1-4 haloalkyl) were prepared 4-(O2N)C6H4NHNH2.HCl was refluxed 1 h with (CF3CO)2CH2 in EtOH and the product mixture stirred 8 h with MeSO2Cl in CH2Cl2 containing Et3N to give phenylpyrazole II (R = NO2) which was heated 2 h at 60° with ZnCl2 and HCl in EtOH to give II (R = NH2). The latter was stirred 2 h at 40° with 2,6-F2C6H3CONCO in THF to give II (R = 2,6-F2C6H3CONHCONH) which was lethal to larvae of Aedes aegypti at 0.002 ppm.

IT 112737-04-9P 112737-05-0P 112737-21-0P
 112737-22-1P 112737-62-9P 112762-62-6P
 123066-42-2P 123066-43-3P 123066-44-4P
 123066-45-5P 123066-46-6P 123066-47-7P
 123066-48-8P 123066-49-9P 123066-50-2P
 123066-51-3P 123066-52-4P 123066-53-5P
 123066-54-6P 123066-55-7P 123066-56-8P
 123066-57-9P 123066-58-0P 123066-59-1P
 123066-60-4P 123066-61-5P 123066-62-6P

RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of, as pesticide)

RN 112737-04-9 CAPLUS


CN Benzamide, N-[[[4-(4-chloro-1H-pyrazol-1-yl)phenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)



RN 112737-05-0 CAPLUS


CN Benzamide,

N-[[[3,5-dichloro-4-(1H-pyrazol-1-yl)phenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)




RN 112737-21-0 CAPLUS

CN Benzamide, N-[[[4-[5-chloro-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)




RN 112737-22-1 CAPLUS

CN Benzamide, N-[[[3-chloro-4-(4-chloro-1H-pyrazol-1-yl)phenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)




RN 112737-62-9 CAPLUS

CN Benzamide, 2-chloro-N-[[[3,5-dichloro-4-(1H-pyrazol-1-yl)phenyl]amino]carbonyl]- (CA INDEX NAME)




RN 112762-62-6 CAPLUS

CN Benzamide, N-[[[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)




RN 123066-42-2 CAPLUS

CN Benzamide, 2-chloro-N-[[[3-chloro-4-(1H-pyrazol-1-yl)phenyl]amino]carbonyl]- (CA INDEX NAME)




RN 123066-43-3 CAPLUS

CN Benzamide, 2,6-difluoro-N-[[[4-(1H-pyrazol-1-yl)phenyl]amino]carbonyl]- (CA INDEX NAME)




RN 123066-44-4 CAPLUS

CN Benzamide, 2-chloro-N-[[[3-chloro-4-(4-chloro-1H-pyrazol-1-yl)phenyl]amino]carbonyl]- (CA INDEX NAME)




RN 123066-45-5 CAPLUS

CN Benzamide, 2-chloro-N-[[[4-(4-chloro-1H-pyrazol-1-yl)phenyl]amino]carbonyl]- (CA INDEX NAME)




RN 123066-46-6 CAPLUS

CN Benzamide, N-[[[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]amino]carbonyl]-2-chloro- (CA INDEX NAME)




RN 123066-47-7 CAPLUS

CN Benzamide, 2,6-difluoro-N-[[[4-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]amino]carbonyl]- (CA INDEX NAME)



RN 123066-48-8 CAPLUS


CN Benzamide, 2-chloro-N-[[[4-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]amino]carbonyl]- (CA INDEX NAME)



RN 123066-49-9 CAPLUS


CN Benzamide,

2,6-difluoro-N-[[[4-[3-methyl-5-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]amino]carbonyl]- (CA INDEX NAME)



RN 123066-50-2 CAPLUS


CN Benzamide, 2-chloro-N-[[[4-[3-methyl-5-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]amino]carbonyl]- (CA INDEX NAME)



RN 123066-51-3 CAPLUS


CN Benzamide,

N-[[[4-(3,5-dimethyl-1H-pyrazol-1-yl)phenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)




RN 123066-52-4 CAPLUS

CN Benzamide, 2,6-dichloro-N-[[[4-(3,5-dimethyl-1H-pyrazol-1-yl)phenyl]amino]carbonyl]- (CA INDEX NAME)




RN 123066-53-5 CAPLUS

CN Benzamide, 2-chloro-N-[[[4-(3,5-dimethyl-1H-pyrazol-1-yl)phenyl]amino]carbonyl]- (CA INDEX NAME)




RN 123066-54-6 CAPLUS

CN Benzamide, N-[[[3-chloro-4-(3-methyl-1H-pyrazol-1-yl)phenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)




RN 123066-55-7 CAPLUS

CN Benzamide, 2-chloro-N-[[[3-chloro-4-(3-methyl-1H-pyrazol-1-yl)phenyl]amino]carbonyl]- (CA INDEX NAME)




RN 123066-56-8 CAPLUS

CN Benzamide, 2,6-difluoro-N-[[[4-(3-methyl-1H-pyrazol-1-yl)phenyl]amino]carbonyl]- (CA INDEX NAME)




RN 123066-57-9 CAPLUS

CN Benzamide, 2-chloro-N-[[[4-(3-methyl-1H-pyrazol-1-yl)phenyl]amino]carbonyl]- (CA INDEX NAME)




RN 123066-58-0 CAPLUS

CN Benzamide, N-[[[4-(5-chloro-3-methyl-1H-pyrazol-1-yl)phenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)




RN 123066-59-1 CAPLUS

CN Benzamide, 2-chloro-N-[[[4-(5-chloro-3-methyl-1H-pyrazol-1-yl)phenyl]amino]carbonyl]- (CA INDEX NAME)




RN 123066-60-4 CAPLUS

CN Benzamide, N-[[[4-(3-ethyl-4-methyl-1H-pyrazol-1-yl)phenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)




RN 123066-61-5 CAPLUS

CN Benzamide, 2,6-dichloro-N-[[[4-(3-ethyl-4-methyl-1H-pyrazol-1-yl)phenyl]amino]carbonyl]- (CA INDEX NAME)



RN 123066-62-6 CAPLUS

CN Benzamide, 2-chloro-N-[[[4-(3-ethyl-4-methyl-1H-pyrazol-1-yl)phenyl]amino]carbonyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)

L87 ANSWER 62 OF 84 CAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 1988:619497 CAPLUS Full-text

DOCUMENT NUMBER: 109:219497

ORIGINAL REFERENCE NO.: 109:36159a,36162a

TITLE: Silver halide color photographic light-sensitive material containing pyrazoloazole type cyan coupler

INVENTOR(S): Tachibana, Kimie; Kaneko, Yutaka; Ishii, Fumio

PATENT ASSIGNEE(S): Konica Co., Japan

SOURCE: Eur. Pat. Appl., 168 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent


LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
EP 269436	A2	19880601	EP 1987-310417	19871125 <--

EP 269436 A3 19880914
 EP 269436 B1 19910306
 EP 269436 B2 19941102
 R: DE, FR, GB, IT, NL
 JP 64000554 A 19890105 JP 1987-294701 19871121 <--
 JP 2517334 B2 19960724
 JP 64000555 A 19890105 JP 1987-294702 19871121 <--
 JP 2535569 B2 19960918
 JP 64000552 A 19890105 JP 1987-294592 19871122 <--
 JP 64000557 A 19890105 JP 1987-326832 19871225 <--
 JP 2535575 B2 19960918
 JP 01105251 A 19890421 JP 1987-326833 19871225 <--
 US 4873183 A 19891010 US 1988-291351 19881229 <--
 PRIORITY APPLN. INFO.: JP 1986-280164 A 19861125 <--
 JP 1986-313455 A 19861227
 <--
 JP 1987-47323 A 19870302
 <--
 JP 1987-53417 A 19870309
 <--
 JP 1987-62162 A 19870317
 <--
 JP 1987-62163 A 19870317
 <--
 JP 1987-184552 A 19870723
 <--
 JP 1986-313458 A1 19861227 <--
 US 1987-124987 A1 19871124 <--
 GI For diagram(s), see printed CA Issue.
 AB A light-sensitive Ag halide color photog. material comprises a support, a red light-sensitive Ag halide emulsion layer containing a pyrazoloazole-type cyan dye-forming coupler having ≥ 1 electron-attracting group in a substitutable position except the active site of the coupler. The cyan dye-forming coupler is I [R1 = H, substituent; R2 = H, substituent provided that ≥ 1 of R1 and R2 (≥ 1 of R2 when there are more than 2 R2 s) is electron-attracting group; Z = group of nonmetal atoms necessary to complete a N-containing heterocyclic ring; R2 being connected with a C atom of the heterocyclic ring; X = H, substituent capable of being split off upon reaction with the oxidized product of a color developing agent; n = 1, 2]. The absorption maximum of the cyan dye-forming coupler is 580-710 nm. The red light-sensitive emulsion layer may contain a spectral sensitizing dye. A color photog. material containing the coupler provides excellent color reproduction
 IT 117507-87-6 117507-99-0 117543-05-2
 RL: TEM (Technical or engineered material use); USES (Uses)
 (cyan photog. coupler)
 RN 117507-87-6 CAPLUS
 CN Tetradecanamide,
 2-(2-chlorophenoxy)-N-[4-[6-(2,3,4,5,6-pentafluorophenyl)-
 1H-pyrazolo[5,1-c]-1,2,4-triazol-3-yl]phenyl]- (CA INDEX NAME)




RN 117507-99-0 CAPLUS

CN Tetradecanamide,
2-(2-chlorophenoxy)-N-[4-[7-chloro-6-(trifluoromethyl)-3H-
pyrazolo[1,5-b][1,2,4]triazol-2-yl]phenyl]- (CA INDEX NAME)



RN 117543-05-2 CAPLUS


CN Tetradecanamide, 2-[2-chloro-4-[(3-chloro-4-
hydroxyphenyl)sulfonyl]phenoxy]-N-[3-[3-methyl-5-(phenylsulfonyl)-1H-
pyrazolo[1,5-b]pyrazol-2-yl]phenyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD
(2 CITINGS)

L87 ANSWER 63 OF 84 CAPLUS COPYRIGHT 2011 ACS on STN
ACCESSION NUMBER: 1988:221637 CAPLUS Full-text
DOCUMENT NUMBER: 108:221637

ORIGINAL REFERENCE NO.: 108:36383a,36386a
 TITLE: Synthesis and antibacterial testing of some new
 selenadiazole and thiadiazole containing amino acid
 moieties
 AUTHOR(S): Bayoumi, B. E.; Abd-Alla, M. A.; Ahmed, A. N.
 CORPORATE SOURCE: Fac. Sci., Zagazig Univ., Assiut, Egypt
 SOURCE: Bulletin of Pharmaceutical Sciences, Assiut University
 (1986), 9(2), 66-77
 CODEN: BPAUEC; ISSN: 1110-0052
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI




AB A number of glycyaminophenylselenadiazoles and -thiadiazoles (e.g., I; RR1N = morpholino, piperidino, EtNH; X = Se, S) were prepared and evaluated for antimicrobial activity. Thus, 4-MeCOC6H4NHCOCH2Cl was treated with RR1NH to give 4-MeCOC6H4NHCOCH2NRR1. Treating the latter compds. with H2NCONHNH2 gave 4-H2NCONHN:CMc6H4NHCOCH2NRR1, which underwent oxidative cyclization with SeO2 in AcOH or SOCl2 to give I. The min. inhibitory concentration for I (RR1N = 2-thiazolylamino; X = Se, S) against several bacteria including Staphylococcus aureus, Klebsiella pneumoniae, and Escherichia coli were lower than those for tetracycline.

IT 111281-88-0P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (preparation and antimicrobial activity of)

RN 111281-88-0 CAPLUS

CN Acetamide, 2-[(4-chlorophenyl)amino]-N-[4-(1,2,3-thiadiazol-4-yl)phenyl]-
 (CA INDEX NAME)




OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD
 (2 CITINGS)

L87 ANSWER 64 OF 84 CAPLUS COPYRIGHT 2011 ACS on STN
 ACCESSION NUMBER: 1988:94547 CAPLUS Full-text
 DOCUMENT NUMBER: 108:94547

ORIGINAL REFERENCE NO.: 108:15555a,15558a
 TITLE: Preparation of N-benzoyl-N'-(heterocyclylphenyl)ureas
 as insecticides and acaricides
 INVENTOR(S): Carney, Robert L.; Gruber, John M.; Lui, Alfred S.
 PATENT ASSIGNEE(S): Sandoz A.-G., Switz.; Sandoz-Patent-G.m.b.H.;
 Sandoz-Erfindungen Verwaltungsgesellschaft m.b.H.
 SOURCE: Eur. Pat. Appl., 26 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 242322	A2	19871021	EP 1987-810137	19870311 <--
EP 242322	A3	19890322		
EP 242322	B1	19921216		
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, NL				
AT 83477	T	19930115	AT 1987-810137	19870311 <--
ES 2053579	T3	19940801	ES 1987-810137	19870311 <--
DK 8701345	A	19870919	DK 1987-1345	19870316 <--
AU 8770048	A	19870924	AU 1987-70048	19870316 <--
AU 602884	B2	19901101		
IL 81900	A	19910610	IL 1987-81900	19870316 <--
CN 87102145	A	19870930	CN 1987-102145	19870317 <--
CN 1017397	B	19920715		
JP 62230765	A	19871009	JP 1987-65533	19870317 <--
BR 8701205	A	19880112	BR 1987-1205	19870317 <--
HU 43941	A2	19880128	HU 1987-1157	19870317 <--
HU 203945	B	19911128		
SU 1491333	A3	19890630	SU 1987-4202182	19870317 <--
ZA 8701996	A	19881026	ZA 1987-1996	19870318 <--
PRIORITY APPLN. INFO.:			US 1986-840814	A 19860318 <--
			EP 1987-810137	A 19870311

<--
 GI



AB The title compds. [I; A = N, R4C; B = N, R3C; R1, R4 = H, halo, C1-8 haloalkyl, C1-8 (halo)alkoxy, C1-8 (halo)alkylthio, (un)substituted aryl, aryloxy, arylthio; R2, R3 = H, halo, cyano, CO2R5, C1-8 (halo)alkyl, C1-8 (halo)alkoxy, C1-8 (halo)alkylthio, (un)substituted aryl, aryloxy, arylthio; R1R2, R2R3 = (un)substituted, (un)saturated C4 bridging group; R5


= H, C1-8 alkyl; X1-X3, X5 = H, halo, C1-4 alkyl; X4 = H, halo, C1-4 (halo)alkyl, CO2R5; X6 = H, halo, C1-8 alkyl, CO2R5; Y = O, S] were prepared as chitin inhibitors, useful as acaricides and insecticides. 2,6-F2C6H3CONCO was added dropwise to a solution of p-(4-chloropyrazol-1-yl)aniline in CH2Cl2 and the mixture stirred 30 min at room temperature to give I (A = N, B = CH, R1 = X3-X6 = H, R2 = Cl, X1 = X2 = F, Y = O). I showed insecticidal activity when applied topically at 0.004-0.070 µg/insect to third instar larvae of *Heliothis virescens*.

IT 112736-96-6P 112736-97-7P 112736-98-8P
 112736-99-9P 112737-00-5P 112737-01-6P
 112737-02-7P 112737-03-8P 112737-04-9P
 112737-05-0P 112737-06-1P 112737-07-2P
 112737-08-3P 112737-09-4P 112737-10-7P
 112737-11-8P 112737-12-9P 112737-13-0P
 112737-14-1P 112737-15-2P 112737-16-3P
 112737-17-4P 112737-18-5P 112737-19-6P
 112737-20-9P 112737-21-0P 112737-22-1P
 112737-23-2P 112737-24-3P 112737-25-4P
 112737-26-5P 112737-27-6P 112737-28-7P
 112737-29-8P 112737-30-1P 112737-31-2P
 112737-32-3P 112737-33-4P 112737-34-5P
 112737-35-6P 112737-36-7P 112737-37-8P
 112737-38-9P 112737-39-0P 112737-40-3P
 112737-41-4P 112737-42-5P 112737-43-6P
 112737-44-7P 112737-45-8P 112737-46-9P
 112737-47-0P 112737-48-1P 112737-49-2P
 112737-50-5P 112737-51-6P 112737-52-7P
 112737-53-8P 112737-54-9P 112737-55-0P
 112737-56-1P 112737-59-4P 112737-60-7P
 112737-61-8P 112737-62-9P 112737-63-0P
 112737-64-1P 112737-65-2P 112737-66-3P
 112737-67-4P 112737-68-5P 112737-69-6P
 112737-70-9P 112737-71-0P 112737-72-1P
 112737-73-2P 112737-74-3P 112737-75-4P
 112737-76-5P 112737-77-6P 112737-78-7P
 112737-79-8P 112737-80-1P 112737-81-2P
 112737-82-3P 112737-83-4P 112737-84-5P
 112737-85-6P 112737-86-7P 112737-87-8P
 112737-88-9P 112737-89-0P 112737-90-3P
 112737-91-4P 112737-92-5P 112737-93-6P
 112737-94-7P 112737-96-9P 112737-97-0P
 112737-98-1P 112737-99-2P 112738-00-8P
 112738-01-9P 112738-02-0P 112738-03-1P
 112738-04-2P 112738-05-3P 112738-06-4P
 112738-07-5P 112762-62-6P 112762-63-7P
 112762-64-8P 112762-65-9P 112762-66-0P
 112762-67-1P 112785-82-7P

RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of, as insecticide and acaricide)


RN 112736-96-6 CAPLUS

CN Benzamide, N-[[[3,5-dichloro-4-[4-chloro-3-(4-chlorophenyl)-1H-pyrazol-1-yl]phenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)




RN 112736-97-7 CAPLUS

CN Benzamide, N-[[[4-[4-chloro-3-(4-chlorophenyl)-1H-pyrazol-1-yl]-3,5-dimethylphenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)




RN 112736-98-8 CAPLUS

CN Benzamide, N-[[[4-(4-bromo-1H-pyrazol-1-yl)-3,5-dichlorophenyl]amino]carbonyl]-2-chloro- (CA INDEX NAME)



RN 112736-99-9 CAPLUS


CN Benzamide, 2-chloro-N-[[[3,5-dichloro-4-(3,4-dibromo-1H-pyrazol-1-yl)phenyl]amino]carbonyl]- (CA INDEX NAME)



RN 112737-00-5 CAPLUS


CN Benzamide,

2-chloro-N-[[[3,5-dichloro-4-[4,5-dichloro-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]amino]carbonyl]- (CA INDEX NAME)




RN 112737-01-6 CAPLUS

CN Benzamide, 2-chloro-N-[[[3,5-dichloro-4-[3-(4-chlorophenyl)-1H-pyrazol-1-yl]phenyl]amino]carbonyl]- (CA INDEX NAME)




RN 112737-02-7 CAPLUS

CN Benzamide, N-[[[3,5-dichloro-4-[4,5-dichloro-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]amino]carbonyl]-2-fluoro- (CA INDEX NAME)




RN 112737-03-8 CAPLUS

CN Benzamide, N-[[[4-[3-(4-bromophenyl)-1H-pyrazol-1-yl]-3,5-dichlorophenyl]amino]carbonyl]-2-fluoro- (CA INDEX NAME)




RN 112737-04-9 CAPLUS

CN Benzamide, N-[[[4-(4-chloro-1H-pyrazol-1-yl)phenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)




RN 112737-05-0 CAPLUS

CN Benzamide, N-[[[3,5-dichloro-4-(1H-pyrazol-1-yl)phenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)




RN 112737-06-1 CAPLUS

CN Benzamide, N-[[[3,5-dichloro-4-(4-chloro-1H-pyrazol-1-yl)phenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)




RN 112737-07-2 CAPLUS

CN Benzamide, N-[[[4-(4-bromo-1H-pyrazol-1-yl)-3,5-dichlorophenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)




RN 112737-08-3 CAPLUS

CN Benzamide, N-[[[4-[3,4-bis(trifluoromethyl)-1H-pyrazol-1-yl]-3,5-dichlorophenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)




RN 112737-09-4 CAPLUS

CN Benzamide, N-[[[3,5-dichloro-4-(3-chloro-1H-pyrazol-1-yl)phenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)




RN 112737-10-7 CAPLUS

CN Benzamide, N-[[[3,5-dichloro-4-(3,4-dibromo-1H-pyrazol-1-yl)phenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)



RN 112737-11-8 CAPLUS


CN Benzamide, N-[[[3,5-dichloro-4-[3-(4-chlorophenyl)-1H-pyrazol-1-yl]phenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)




RN 112737-12-9 CAPLUS

CN Benzamide, N-[[[3,5-dichloro-4-[4-(4-chlorophenyl)-1H-pyrazol-1-yl]phenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 112737-13-0 CAPLUS

CN Benzamide, N-[[[3,5-dichloro-4-[3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)



RN 112737-14-1 CAPLUS


CN Benzamide, N-[[[3,5-dichloro-4-[4-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)



RN 112737-15-2 CAPLUS


CN Benzamide,

N-[[[3,5-dichloro-4-[5-chloro-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)




RN 112737-16-3 CAPLUS

CN Benzamide, N-[[[3,5-dichloro-4-[3-(1,1-dimethylethyl)-1H-pyrazol-1-yl]phenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)



RN 112737-17-4 CAPLUS

CN Benzamide, N-[[[3,5-dichloro-4-(3,4-dichloro-1H-pyrazol-1-yl)phenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)




RN 112737-18-5 CAPLUS

CN Benzamide,


N-[[[3,5-dichloro-4-[4-chloro-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)

yl]phenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)




RN 112737-19-6 CAPLUS

CN Benzamide, N-[[[3,5-dichloro-4-[[4,5-dichloro-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)




RN 112737-20-9 CAPLUS

CN Benzamide, N-[[[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]-3,5-dichlorophenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)



RN 112737-21-0 CAPLUS


CN Benzamide, N-[[[4-[5-chloro-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)



RN 112737-22-1 CAPLUS


CN Benzamide, N-[[[3-chloro-4-(4-chloro-1H-pyrazol-1-

yl)phenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)




RN 112737-23-2 CAPLUS

CN Benzamide, N-[[[4-[4-chloro-3-(4-chlorophenyl)-1H-pyrazol-1-yl]-3-(trifluoromethyl)phenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)




RN 112737-24-3 CAPLUS

CN Benzamide, N-[[[4-[5-chloro-3-(trifluoromethyl)-1H-pyrazol-1-yl]-3-(trifluoromethyl)phenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)




RN 112737-25-4 CAPLUS

CN Benzamide, N-[[[3,5-dichloro-4-(3,4,5-trichloro-1H-pyrazol-1-yl)phenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)




RN 112737-26-5 CAPLUS

CN Benzamide, N-[[[4-[4-bromo-3-(4-chlorophenyl)-1H-pyrazol-1-yl]-3,5-dichlorophenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)




RN 112737-27-6 CAPLUS

CN Benzamide, N-[[[3,5-dichloro-4-(3,4,5-tribromo-1H-pyrazol-1-yl)phenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)




RN 112737-28-7 CAPLUS

CN Benzamide, N-[[[3,5-dichloro-4-[3-chloro-5-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)



RN 112737-29-8 CAPLUS


CN Benzamide, N-[[[4-[4-chloro-3-(4-chlorophenyl)-1H-pyrazol-1-yl]-2-fluorophenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)



RN 112737-30-1 CAPLUS


CN Benzamide,

N-[[[5-chloro-4-[4-chloro-3-(4-chlorophenyl)-1H-pyrazol-1-yl]-2-fluorophenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)



RN 112737-31-2 CAPLUS


CN Benzamide, N-[[[4-[4-chloro-3-(4-chlorophenyl)-1H-pyrazol-1-yl]-3-methylphenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)



RN 112737-32-3 CAPLUS

CN Benzamide,


N-[[[5-chloro-4-[4-chloro-3-(4-chlorophenyl)-1H-pyrazol-1-yl]-2-methylphenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)




RN 112737-33-4 CAPLUS

CN Benzamide, N-[[[3,5-dichloro-4-[4-(2,4-dichlorophenyl)-1H-pyrazol-1-yl]phenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 112737-34-5 CAPLUS
 CN Benzamide, N-[[[4-[[4-(4-bromophenyl)-1H-pyrazol-1-yl]-3,5-dichlorophenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)


PAGE 1-A




PAGE 2-A



RN 112737-35-6 CAPLUS
 CN Benzamide, N-[[[3,5-dichloro-4-[[4-chloro-3-(4-chlorophenyl)-5-methoxy-1H-pyrazol-1-yl]phenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)




RN 112737-36-7 CAPLUS
 CN 1H-Pyrazole-4-carboxylic acid, 1-[2,6-dichloro-4-[[[(2,6-difluorobenzoyl)amino]carbonyl]amino]phenyl]-, methyl ester (CA INDEX NAME)




RN 112737-37-8 CAPLUS

CN Benzoic acid, 2-[4-chloro-3-(4-chlorophenyl)-1H-pyrazol-1-yl]-5-[[[(2,6-difluorobenzoyl)amino]carbonyl]amino]-, methyl ester (CA INDEX NAME)




RN 112737-38-9 CAPLUS

CN Benzamide, N-[[[3-chloro-4-[5-chloro-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)




RN 112737-39-0 CAPLUS

CN Benzamide, N-[[[4-(4-bromo-1H-pyrazol-1-yl)-3-chlorophenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)




RN 112737-40-3 CAPLUS

CN Benzamide, N-[[[4-(4-bromo-1H-pyrazol-1-yl)-3-(trifluoromethyl)phenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)




RN 112737-41-4 CAPLUS

CN Benzamide, N-[[[3,5-dichloro-4-[3-(2,4-dichlorophenyl)-1H-pyrazol-1-yl]phenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)




RN 112737-42-5 CAPLUS

CN Benzamide, N-[[[3,5-dichloro-4-[3-(3,4-dichlorophenyl)-1H-pyrazol-1-yl]phenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)




RN 112737-43-6 CAPLUS

CN Benzamide, N-[[[4-[3-(4-bromophenyl)-1H-pyrazol-1-yl]-3,5-dichlorophenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)




RN 112737-44-7 CAPLUS

CN Benzamide, N-[[[3,5-dichloro-4-[3-(4-fluorophenyl)-1H-pyrazol-1-yl]phenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)




RN 112737-45-8 CAPLUS

CN Benzamide, N-[[[3,5-dichloro-4-[3-[3-(trifluoromethyl)phenyl]-1H-pyrazol-1-yl]phenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)




RN 112737-46-9 CAPLUS

CN Benzamide, N-[[[3,5-dichloro-4-[3-(5-chloro-2-thienyl)-1H-pyrazol-1-yl]phenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)




RN 112737-47-0 CAPLUS

CN Benzamide, N-[[[3,5-dichloro-4-[3-(2-naphthalenyl)-1H-pyrazol-1-yl]phenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)




RN 112737-48-1 CAPLUS

CN Benzamide, N-[[[3,5-dichloro-4-(4-cyano-1H-pyrazol-1-yl)phenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)




RN 112737-49-2 CAPLUS

CN Benzamide, N-[[[3,5-dichloro-4-[4-chloro-3-(4-chlorophenyl)-1H-pyrazol-1-yl]phenyl]amino]carbonyl]-2-fluoro- (CA INDEX NAME)




RN 112737-50-5 CAPLUS

CN Benzamide, N-[[[3-chloro-4-[5-chloro-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]amino]carbonyl]-2-fluoro- (CA INDEX NAME)




RN 112737-51-6 CAPLUS

CN Benzamide, N-[[[4-(4-bromo-1H-pyrazol-1-yl)-3-chlorophenyl]amino]carbonyl]-2-fluoro- (CA INDEX NAME)




RN 112737-52-7 CAPLUS

CN Benzamide, N-[[[4-(4-bromo-1H-pyrazol-1-yl)-3-(trifluoromethyl)phenyl]amino]carbonyl]-2-fluoro- (CA INDEX NAME)




RN 112737-53-8 CAPLUS

CN Benzamide, N-[[[3,5-dichloro-4-[3-(2,4-dichlorophenyl)-1H-pyrazol-1-yl]phenyl]amino]carbonyl]-2-fluoro- (CA INDEX NAME)




RN 112737-54-9 CAPLUS

CN Benzamide, N-[[[3,5-dichloro-4-[3-(3,4-dichlorophenyl)-1H-pyrazol-1-yl]phenyl]amino]carbonyl]-2-fluoro- (CA INDEX NAME)



RN 112737-55-0 CAPLUS


CN Benzamide, N-[[[3,5-dichloro-4-[3-(4-fluorophenyl)-1H-pyrazol-1-yl]phenyl]amino]carbonyl]-2-fluoro- (CA INDEX NAME)



RN 112737-56-1 CAPLUS

CN Benzamide,


N-[[[3,5-dichloro-4-[3-[3-(trifluoromethyl)phenyl]-1H-pyrazol-1-yl]phenyl]amino]carbonyl]-2-fluoro- (CA INDEX NAME)



RN 112737-59-4 CAPLUS

CN Benzamide,


2-chloro-N-[[[3,5-dichloro-4-[4,5-dichloro-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]amino]carbonyl]-5-fluoro- (CA INDEX NAME)



RN 112737-60-7 CAPLUS


CN Benzamide,

2-chloro-N-[[[3,5-dichloro-4-[4,5-dichloro-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]amino]carbonyl]-6-fluoro- (CA INDEX NAME)




RN 112737-61-8 CAPLUS

CN Benzamide, 2,6-dichloro-N-[[[3,5-dichloro-4-[4,5-dichloro-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]amino]carbonyl]- (CA INDEX NAME)




RN 112737-62-9 CAPLUS

CN Benzamide, 2-chloro-N-[[[3,5-dichloro-4-(1H-pyrazol-1-yl)phenyl]amino]carbonyl]- (CA INDEX NAME)




RN 112737-63-0 CAPLUS

CN Benzamide, 2-chloro-N-[[[3,5-dichloro-4-(4-chloro-1H-pyrazol-1-yl)phenyl]amino]carbonyl]- (CA INDEX NAME)




RN 112737-64-1 CAPLUS

CN Benzamide, N-[[[4-[3,4-bis(trifluoromethyl)-1H-pyrazol-1-yl]-3,5-dichlorophenyl]amino]carbonyl]-2-chloro- (CA INDEX NAME)



RN 112737-65-2 CAPLUS


CN Benzamide, 2-chloro-N-[[[3,5-dichloro-4-(3-chloro-1H-pyrazol-1-yl)phenyl]amino]carbonyl]- (CA INDEX NAME)




RN 112737-66-3 CAPLUS

CN Benzamide, 2-chloro-N-[[[3,5-dichloro-4-[4-(4-chlorophenyl)-1H-pyrazol-1-yl]phenyl]amino]carbonyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 112737-67-4 CAPLUS


CN Benzamide,

2-chloro-N-[[[3,5-dichloro-4-[4-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]amino]carbonyl]- (CA INDEX NAME)



RN 112737-68-5 CAPLUS


CN Benzamide, 2-chloro-N-[[[3,5-dichloro-4-[5-chloro-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]amino]carbonyl]- (CA INDEX NAME)



RN 112737-69-6 CAPLUS

CN Benzamide,

2-chloro-N-[[[3,5-dichloro-4-[3-(1,1-dimethylethyl)-1H-pyrazol-1-yl]phenyl]amino]carbonyl]- (CA INDEX NAME)




RN 112737-70-9 CAPLUS

CN Benzamide, 2-chloro-N-[[[3,5-dichloro-4-[4-chloro-3-(4-chlorophenyl)-1H-


RN 112737-74-3 CAPLUS

CN Benzamide, 2-chloro-N-[[[3,5-dichloro-4-(3,4,5-tribromo-1H-pyrazol-1-yl)phenyl]amino]carbonyl]- (CA INDEX NAME)




RN 112737-75-4 CAPLUS

CN Benzamide, 2-chloro-N-[[[3,5-dichloro-4-[3-chloro-5-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]amino]carbonyl]- (CA INDEX NAME)




RN 112737-76-5 CAPLUS

CN Benzamide, 2-chloro-N-[[[3,5-dichloro-4-(3,4,5-trichloro-1H-pyrazol-1-yl)phenyl]amino]carbonyl]- (CA INDEX NAME)



RN 112737-77-6 CAPLUS


CN Benzamide, 2-chloro-N-[[[4-[4-chloro-3-(4-chlorophenyl)-1H-pyrazol-1-yl]-3,5-dimethylphenyl]amino]carbonyl]- (CA INDEX NAME)



RN 112737-78-7 CAPLUS

CN Benzamide,


N-[[[4-(4-bromo-1H-pyrazol-1-yl)-3-chlorophenyl]amino]carbonyl]-
2-chloro- (CA INDEX NAME)



RN 112737-79-8 CAPLUS


CN Benzamide, N-[[[4-(4-bromo-1H-pyrazol-1-yl)-3-

(trifluoromethyl)phenyl]amino]carbonyl]-2-chloro- (CA INDEX NAME)



RN 112737-80-1 CAPLUS


CN Benzamide, 2-chloro-N-[[[3,5-dichloro-4-[3-(2-chlorophenyl)-1H-pyrazol-1-yl]phenyl]amino]carbonyl]- (CA INDEX NAME)



RN 112737-81-2 CAPLUS

CN Benzamide,


2-chloro-N-[[[3,5-dichloro-4-[3-(2,4-dichlorophenyl)-1H-pyrazol-1-yl]phenyl]amino]carbonyl]- (CA INDEX NAME)



RN 112737-82-3 CAPLUS


CN Benzamide,

2-chloro-N-[[[3,5-dichloro-4-[3-(3,4-dichlorophenyl)-1H-pyrazol-1-yl]phenyl]amino]carbonyl]- (CA INDEX NAME)




RN 112737-83-4 CAPLUS

CN Benzamide, N-[[[4-[3-(4-bromophenyl)-1H-pyrazol-1-yl]-3,5-dichlorophenyl]amino]carbonyl]-2-chloro- (CA INDEX NAME)



RN 112737-84-5 CAPLUS


CN Benzamide, 2-chloro-N-[[[3-chloro-4-[4-chloro-3-(4-chlorophenyl)-1H-pyrazol-1-yl]-5-methylphenyl]amino]carbonyl]- (CA INDEX NAME)



RN 112737-85-6 CAPLUS

CN Benzamide, 2-chloro-N-[[[3,5-dichloro-4-[3-(4-fluorophenyl)-1H-pyrazol-1-


yl]phenyl]amino]carbonyl]- (CA INDEX NAME)



RN 112737-86-7 CAPLUS

CN Benzamide,


2-chloro-N-[[[3,5-dichloro-4-[3-[3-(trifluoromethyl)phenyl]-1H-pyrazol-1-yl]phenyl]amino]carbonyl]- (CA INDEX NAME)



RN 112737-87-8 CAPLUS


CN Benzamide,

2-chloro-N-[[[3,5-dichloro-4-[3-(5-chloro-2-thienyl)-1H-pyrazol-1-yl]phenyl]amino]carbonyl]- (CA INDEX NAME)



RN 112737-88-9 CAPLUS


CN Benzamide, 2-chloro-N-[[[3,5-dichloro-4-[3-(2-naphthalenyl)-1H-pyrazol-1-yl]phenyl]amino]carbonyl]- (CA INDEX NAME)



RN 112737-89-0 CAPLUS


CN Benzamide, 2-chloro-N-[[[3-chloro-4-[5-chloro-3-(trifluoromethyl)-1H-

pyrazol-1-yl]phenyl]amino]carbonyl]- (CA INDEX NAME)




RN 112737-90-3 CAPLUS

CN Benzamide, N-[[[4-[5-(4-bromophenyl)-1H-pyrazol-1-yl]-3,5-dichlorophenyl]amino]carbonyl]-2-chloro- (CA INDEX NAME)



RN 112737-91-4 CAPLUS


CN Benzamide, N-[[[4-[5-(4-bromophenyl)-1H-pyrazol-1-yl]-3,5-dichlorophenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)



RN 112737-92-5 CAPLUS

CN Benzamide, N-[[[4-[5-(4-bromophenyl)-4-chloro-1H-pyrazol-1-yl]-3,5-dichlorophenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A

Cl

RN 112737-93-6 CAPLUS


CN Benzamide, N-[[[3,5-dichloro-4-[3-(4-methylphenyl)-1H-pyrazol-1-

yl]phenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)




RN 112737-94-7 CAPLUS

CN Benzamide, 2-chloro-N-[[[3,5-dichloro-4-[3-(4-methylphenyl)-1H-pyrazol-1-yl]phenyl]amino]carbonyl]- (CA INDEX NAME)




RN 112737-96-9 CAPLUS

CN Benzamide, N-[[[3,5-dichloro-4-(3-chloro-1H-indazol-1-yl)phenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)




RN 112737-97-0 CAPLUS

CN Benzamide, N-[[[3,5-dichloro-4-(5,6-dichloro-1H-benzimidazol-1-yl)phenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)




RN 112737-98-1 CAPLUS

CN Benzamide, N-[[[3,5-dichloro-4-(5-chloro-1H-benzotriazol-1-yl)phenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)




RN 112737-99-2 CAPLUS

CN Benzamide, N-[[[3,5-dichloro-4-(6-chloro-1H-benzotriazol-1-yl)phenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)




RN 112738-00-8 CAPLUS

CN Benzamide, N-[[[3,5-dichloro-4-(5,6-dichloro-1H-benzotriazol-1-yl)phenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)




RN 112738-01-9 CAPLUS

CN Benzamide, 2-chloro-N-[[[3,5-dichloro-4-(5,6-dichloro-1H-benzimidazol-1-yl)phenyl]amino]carbonyl]- (CA INDEX NAME)




RN 112738-02-0 CAPLUS

CN Benzamide, 2-chloro-N-[[[3-chloro-4-(5,6-dichloro-1H-benzimidazol-1-yl)phenyl]amino]carbonyl]- (CA INDEX NAME)




RN 112738-03-1 CAPLUS

CN Benzamide, 2-chloro-N-[[[3,5-dichloro-4-(5-chloro-1H-benzotriazol-1-yl)phenyl]amino]carbonyl]- (CA INDEX NAME)




RN 112738-04-2 CAPLUS

CN Benzamide, 2-chloro-N-[[[3,5-dichloro-4-(5,6-dichloro-1H-benzotriazol-1-yl)phenyl]amino]carbonyl]- (CA INDEX NAME)



RN 112738-05-3 CAPLUS


CN Benzamide, N-[[[3-chloro-4-[5,6-dichloro-2-(trifluoromethyl)-1H-benzimidazol-1-yl]phenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)



RN 112738-06-4 CAPLUS


CN Benzamide,

N-[[[3,5-dichloro-4-(2H-indazol-2-yl)phenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)




RN 112738-07-5 CAPLUS

CN Benzamide, 2-chloro-N-[[[3,5-dichloro-4-(2H-indazol-2-yl)phenyl]amino]carbonyl]- (CA INDEX NAME)




RN 112762-62-6 CAPLUS

CN Benzamide, N-[[[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)




RN 112762-63-7 CAPLUS

CN Benzamide, 2-chloro-N-[[[3,5-dichloro-4-(3,4-dichloro-1H-pyrazol-1-yl)phenyl]amino]carbonyl]- (CA INDEX NAME)




RN 112762-64-8 CAPLUS

CN Benzamide, 2-chloro-N-[[[3-chloro-4-[4-chloro-3-(4-chlorophenyl)-1H-pyrazol-1-yl]phenyl]amino]carbonyl]- (CA INDEX NAME)




RN 112762-65-9 CAPLUS

CN Benzamide,
2-chloro-N-[[[4-[4-chloro-3-(4-chlorophenyl)-1H-pyrazol-1-yl]-3-(trifluoromethyl)phenyl]amino]carbonyl]- (CA INDEX NAME)




RN 112762-66-0 CAPLUS

CN Benzamide,
2-chloro-N-[[[4-[5-chloro-3-(trifluoromethyl)-1H-pyrazol-1-yl]-3-(trifluoromethyl)phenyl]amino]carbonyl]- (CA INDEX NAME)



RN 112762-67-1 CAPLUS
 CN Benzamide, N-[[[4-[5-(4-bromophenyl)-4-chloro-1H-pyrazol-1-yl]-3,5-dichlorophenyl]amino]carbonyl]-2-chloro- (CA INDEX NAME)


PAGE 1-A



PAGE 2-A

Cl

RN 112785-82-7 CAPLUS
 CN Benzamide, N-[[[3,5-dichloro-4-[3-(2-chlorophenyl)-1H-pyrazol-1-yl]phenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)



OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD
 (3 CITINGS)

L87 ANSWER 65 OF 84 CAPLUS COPYRIGHT 2011 ACS on STN
 ACCESSION NUMBER: 1987:617551 CAPLUS Full-text
 DOCUMENT NUMBER: 107:217551
 ORIGINAL REFERENCE NO.: 107:34903a,34906a

TITLE: Synthesis and antibacterial activity of some new selenadiazole- and thiadiazole-containing amino acid moieties

AUTHOR(S): Bayoumy, B. E.; Deeb, A.; El-Mobayed, M.; Abd-Alla, M. A.

CORPORATE SOURCE: Fac. Sci., Zagazig Univ., Egypt


SOURCE: Egyptian Journal of Pharmaceutical Sciences (1986), 27(1-4), 17-26

CODEN: EJPSBZ; ISSN: 0301-5068

DOCUMENT TYPE: Journal

LANGUAGE: English

GI



AB Title compds. I (X = Se, S; R = piperidino, piperazino, morpholino, NHR1; R1 = Et, 2-pyridyl, 2-thiazolyl, C6H4OMe-p, C6H4Cl-p), which were prepared, showed bactericidal and fungicidal activity. Heating 4-RCH2CONHC6H4CMe:NNHCONH2 (same R) with SeO2 yielded I (X = Se).


IT 111281-88-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(preparation and fungicidal activity of)

RN 111281-88-0 CAPLUS

CN Acetamide, 2-[(4-chlorophenyl)amino]-N-[4-(1,2,3-thiadiazol-4-yl)phenyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

L87 ANSWER 66 OF 84 CAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 1987:449424 CAPLUS Full-text

DOCUMENT NUMBER: 107:49424

ORIGINAL REFERENCE NO.: 107:8055a,8058a

TITLE: Silver halide color photographic couplers

INVENTOR(S): Yamada, Kozaburo; Ichijima, Yasushi; Obayashi, Keiji

PATENT ASSIGNEE(S): Fuji Photo Film Co., Ltd., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 33 pp.

DOCUMENT TYPE: CODEN: JKXXAF
 LANGUAGE: Patent
 FAMILY ACC. NUM. COUNT: 1 Japanese
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 61233741	A	19861018	JP 1985-72378	19850405 <--
JP 06080458	B	19941012		

PRIORITY APPLN. INFO.: JP 1985-72378 19850405 <--

GI For diagram(s), see printed CA Issue.


AB A Ag halide color photog. material contains ≥ 1 coupler selected from the compds. having the general formulas of I, II, III, IV, V, and VI [A = coupler group which splits off from O upon reaction with an oxidized developer; PUG = photog. useful group; R = H, substituent; R1 = acylamino, sulfonamido, ureido, sulfamoylamino, amino; Z = organic moiety fused to the benzene ring to form a 5-6-membered ring other than a benzene ring; l, m, n = 1, 2; n + m \leq 3 in I; n + m + l \leq 4 in II].

IT 109117-35-3P
 RL: PREP (Preparation)
 (preparation of, as photog. development inhibitor-releasing coupler)


RN 109117-35-3 CAPLUS

CN 1H-Benzotriazolecarboxylic acid, 1-[2-[2-[[2-chloro-5-[(dodecyloxy)carbonyl]phenyl]amino]-1-(4-methoxybenzoyl)-2-oxoethoxy]-5-hydroxy-4-[(phenylsulfonyl)amino]phenyl]-, phenyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD

(2 CITINGS)

L87 ANSWER 67 OF 84 CAPLUS COPYRIGHT 2011 ACS on STN
ACCESSION NUMBER: 1987:205102 CAPLUS Full-text
DOCUMENT NUMBER: 106:205102
ORIGINAL REFERENCE NO.: 106:33104h,33105a
TITLE: Color photographic coupler
INVENTOR(S): Ichijima, Yasushi; Obayashi, Keiji
PATENT ASSIGNEE(S): Fuji Photo Film Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 29 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
JP 61231553	A	19861015	JP 1985-72379	19850405 <--
JP 06090464	B	19941114		
PRIORITY APPLN. INFO.:			JP 1985-72379	19850405 <--
AB	A Ag halide color photog. material contains ≥ 1 compound which releases by coupling reaction with the oxidized form of the principal developer, a precursor of a compound capable of releasing a photog. useful group upon oxidation			
IT	108291-77-6 RL: USES (Uses) (photog. coupler from)			
RN	108291-77-6 CAPLUS			
CN	1H-Benzotriazolecarboxylic acid, 1-[5-(acetyloxy)-2-[1-[[[5-[[4-[2,4-bis(1,1-dimethylpropyl)phenoxy]-1-oxobutyl]amino]-2-chlorophenyl]amino]carbonyl]-3,3-dimethyl-2-oxobutoxy]-4-ethoxyphenyl]-, phenyl ester (9CI) (CA INDEX NAME)			





PAGE 1-B

—OAc

—OEt

L87 ANSWER 68 OF 84 CAPLUS COPYRIGHT 2011 ACS on STN
 ACCESSION NUMBER: 1987:186316 CAPLUS Full-text
 DOCUMENT NUMBER: 106:186316
 ORIGINAL REFERENCE NO.: 106:30057a,30060a
 TITLE: Silver halide color photographic material
 INVENTOR(S): Ichijima, Yasushi; Yamada, Kozaburo; Obayashi, Keiji
 PATENT ASSIGNEE(S): Fuji Photo Film Co., Ltd., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 29 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
JP 61238057	A	19861023	JP 1985-80021	19850415 <--
PRIORITY APPLN. INFO.: GI			JP 1985-80021	19850415 <--




AB A Ag halide color photog. material contains couplers of the formula I and/or II [A = coupler residue capable of splitting off the group beyond O on reaction with the oxidized form of the developer; R1, R2 = substituent; n = 1-3; PUG = photog. useful group] capable of releasing PUG groups during development.

IT 108089-14-1
 RL: USES (Uses)
 (photog. couplers, photog. useful group-releasing)


RN 108089-14-1 CAPLUS

CN 1H-Benzotriazolecarboxylic acid, 1-[2-[2-[[2-chloro-5-[(dodecyloxy)carbonyl]phenyl]amino]-1-(4-methoxybenzoyl)-2-oxoethoxy]-4-methoxy-5-[(phenylsulfonyl)amino]phenyl]-, 4-methoxyphenyl ester (9CI)
 (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



IT 108107-07-9P

RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation and use of, as photog. useful group-releasing couplers)


RN 108107-07-9 CAPLUS

CN Pentanamide, N-[5-[[4-[2,4-bis(1,1-dimethylpropyl)phenoxy]-1-


oxobutyl]amino]-2-chlorophenyl]-2-[4-(5,6-dimethyl-1H-benzotriazol-1-yl)-5-hydroxy-2-[[3-nitrophenyl]sulfonyl]amino]phenoxy]-4,4-dimethyl-3-oxo-

(CA INDEX NAME)

PAGE 1-A



PAGE 1-B



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
(1 CITINGS)

L87 ANSWER 69 OF 84 CAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 1987:186305 CAPLUS Full-text

DOCUMENT NUMBER: 106:186305

ORIGINAL REFERENCE NO.: 106:30057a,30060a

TITLE: Silver halide color photographic photosensitive materials

INVENTOR(S): Ninomiya, Hidetaka; Hirabayashi, Shigeto

PATENT ASSIGNEE(S): Konishiroku Photo Industry Co., Ltd., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 22 pp.

CODEN: JKXXAF


DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 61194443	A	19860828	JP 1985-34506	19850225 <--
JP 05049093	B	19930723		
PRIORITY APPLN. INFO.: GI			JP 1985-34506	19850225 <--



I

AB The claimed color photog. photosensitive materials contain ≥ 1 compound of the formula Y-A-PUG-B (Y = yellow coupler moiety; A = a group separated from

the Y during coupling reaction; B = a protective group for PUG which releases PUG during coupling reaction or by hydrolysis; PUG = photog. useful compound moiety; A can be released together with PUG to give a photog. useful compd of the formula A-PUG. The above PUG-releasing yellow couplers show good chemical stability and good PUG-releasing timing, and hence the color photog. materials show good storage stability, image quality, and sensitivity. Thus, a color photog. paper prepared by using the development inhibitor-releasing coupler I gave yellow dye images with high Dmax, low fog, and high modulation transfer function.

IT 107758-74-7 107758-76-9 107758-81-6


RL: USES (Uses)

(photog. development inhibitor-releasing yellow coupler)

RN 107758-74-7 CAPLUS

CN Pentanamide, N-[5-[[2-[2,4-bis(1,1-dimethylpropyl)phenoxy]-1-

oxobutyl]amino]-2-chlorophenyl]-2-[[4-[5-[[4-hydroxyphenoxy)methyl]thio]-1H-tetrazol-1-yl]phenyl]amino]-4,4-dimethyl-3-oxo- (CA INDEX NAME)




RN 107758-76-9 CAPLUS


CN Benzoic acid, 4-chloro-3-[[3-[(4-chlorophenyl)amino]-2-[4-[5-[[1,3-

dihydro-1,3-dioxo-2H-isindol-2-yl)methyl]thio]-1H-tetrazol-1-yl]phenoxy]-1,3-dioxopropyl]amino]-, 2-(dodecyloxy)-1-methyl-2-oxoethyl ester (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 107758-81-6 CAPLUS
 CN Pentanamide, N-[2-chloro-5-[[3-(dodecylsulfonyl)-2-methyl-1-oxopropyl]amino]phenyl]-2-[4-[5-[[[(1,1-dioxido-3-oxo-1,2-benzisothiazol-2(3H)-yl)methyl]thio]-1H-tetrazol-1-yl]phenoxy]-4,4-dimethyl-3-oxo- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



L87 ANSWER 70 OF 84 CAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 1987:1846 CAPLUS Full-text

DOCUMENT NUMBER: 106:1846

ORIGINAL REFERENCE NO.: 106:371a,374a

TITLE: Use of acylurea compounds for controlling
endoparasites and ectoparasites of warm-blooded
animals

INVENTOR(S): Potter, Michael Fred; Rotramel, George Lorton; Caruso,
Andrew James; Chou, David Teh Wei; Cain, Paul Alfred

PATENT ASSIGNEE(S): Union Carbide Corp., USA

SOURCE: PCT Int. Appl., 173 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 8603941	A1	19860717	WO 1985-US2545	19851227 <--
W: AU, BR, DK, FI, HU, JP, KR, LK, MW, NO, SD, SU				

RW: AT, BE, CF, CG, CH, CM, DE, FR, GA, GB, IT, LU, ML, MR, NL, SE,
SN, TD, TG

US 5135953	A	19920804	US 1985-804638	19851209 <--
AU 8653006	A	19860729	AU 1986-53006	19851227 <--
AU 599313	B2	19900719		
EP 211004	A1	19870225	EP 1986-900553	19851227 <--
R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
BR 8507149	A	19870331	BR 1985-7149	19851227 <--
JP 62501418	T	19870611	JP 1986-500537	19851227 <--
HU 43033	A2	19870928	HU 1986-555	19851227 <--
CN 85109721	A	19870715	CN 1985-109721	19851228 <--
ZA 8509897	A	19860827	ZA 1985-9897	19851230 <--
DK 8604082	A	19861017	DK 1986-4082	19860827 <--
FI 8603490	A	19860828	FI 1986-3490	19860828 <--
NO 8603463	A	19861027	NO 1986-3463	19860828 <--
US 5420163	A	19950530	US 1992-924089	19920803 <--
US 5776981	A	19980707	US 1995-426092	19950421 <--
US 5776982	A	19980707	US 1995-455097	19950531 <--
PRIORITY APPLN. INFO.:			US 1984-687249	A 19841228 <--
			US 1985-723588	A 19850415
<--				
			US 1985-804638	A 19851209
<--				
			WO 1985-US2545	A 19851227
<--				
			US 1992-924089	A3 19920803 <--


ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): CASREACT 106:1846; MARPAT 106:1846

AB The urea derivs. R1CONR2C(Y)NR3R4 [R1 = (un)substituted carbocyclic or heterocyclic ring, etc.; R2, R3 = H, (un)substituted alkyl -benzyl, PhSO2, PhS, etc., R4 = H, R1; Y = O, S] are prepared as endo- and ectoparasiticides. Thus, 3-chloro-4-(4-chloro-1-naphthoxy)-2,5-dimethylaniline (preparation given) was reacted with 2,6-difluorobenzoyl isocyanate in MePh at 50°, to give 1-[3-chloro-4-(4-chloro-1-naphthoxy)-2,5-dimethylphenyl]-3-(2,6-difluorobenzoyl)urea (I). Addition of 25 ppm I to the feed of chicken, totally controlled lice (*Menacanthus stramineus*).

IT 105621-79-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as endo- and ectoparasiticide)

RN 105621-79-2 CAPLUS

CN Benzamide, 2,6-difluoro-N-[[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]amino]carbonyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 13 THERE ARE 13 CAPLUS RECORDS THAT CITE THIS
RECORD (13 CITINGS)

REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L87 ANSWER 71 OF 84 CAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 1986:432893 CAPLUS Full-text

DOCUMENT NUMBER: 105:32893

ORIGINAL REFERENCE NO.: 105:5321a,5324a

TITLE: Silver halide photographic materials containing
development inhibitor-releasing photographic couplers

INVENTOR(S): Ono, Mitsunori; Sasaki, Noboru

PATENT ASSIGNEE(S): Fuji Photo Film Co., Ltd., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 27 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
JP 60230139	A	19851115	JP 1984-85835	19840427 <--
JP 05058177	B	19930825		

PRIORITY APPLN. INFO.: JP 1984-85835 19840427 <--

GI For diagram(s), see printed CA Issue.

AB The claimed Ag halide photog. photosensitive material contains a photog. useful compound-releaser of the formula I (R = coupler moiety; Z = heteroatom which forms an anion when R is released, Z1 = a group of atoms which transport charges toward R1 and forms an electrophilic center; R1 = electron attracting group, atom, or radical; R2 = a photog. useful group; R3 = Z3R4; R4 = nucleophilic group whose reaction with the electrophilic center results in release of R2; Z2, Z3 = bond or a divalent linkage).

IT 102827-64-5

RL: USES (Uses)


(photog. development inhibitor-releasing coupler)

RN 102827-64-5 CAPLUS

CN Pyridinium, 2-[4-[1-[[[2-chloro-5-
[[[(dodecyloxy)carbonyl]amino]phenyl]amino]carbonyl]-3,3-dimethyl-2-

oxobutoxy]-2-[(1-ethyl-1H-tetrazol-5-yl)thio]phenyl]-3-hydroxy-1-methyl-,
iodide (1:1) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



L87 ANSWER 72 OF 84 CAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 1986:196909 CAPLUS Full-text

DOCUMENT NUMBER: 104:196909

ORIGINAL REFERENCE NO.: 104:30989a,30992a

TITLE: Silver halide color photographic photosensitive materials

INVENTOR(S): Ichijima, Yasushi; Ono, Mitsunori; Sasaki, Noboru

PATENT ASSIGNEE(S): Fuji Photo Film Co., Ltd., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 27 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 60233649	A	19851120	JP 1984-90437	19840507 <--
PRIORITY APPLN. INFO.:			JP 1984-90437	19840507 <--
GI For diagram(s), see printed CA Issue.				
AB The claimed colorphotog. photosensitive materials contain a compound of the formula I (R = group released during reaction with an oxidized developing				


agent; Z = a linkage which releases a group containing Z1 after the releasing of the group R; Z1 = O, S; A = 4- to 7-membered ring; X = N, O, S; B = heterocyclic ring having photog. useful compound moiety). the compds. I releases photog. useful compound (such as development inhibitor) with excellent timing, and hence the colorphotog. material exhibit good image sharpness, granularity, and color tone reproducibility. The photog. materials also show excellent storage stability.

IT 102120-55-8P 102120-56-9P

RL: PREP (Preparation)
(preparation and reaction)


RN 102120-55-8 CAPLUS

CN Benzoic acid,
3-[[2-[3-[5-[[[4-(acetyloxy)phenyl]methyl]thio]-1H-tetrazol-1-yl]phenoxy]-4,4-dimethyl-1,3-dioxopentyl]amino]-4-chloro-, hexadecyl ester (CA INDEX NAME)



RN 102120-56-9 CAPLUS

CN Benzoic acid, 4-chloro-3-[[2-[3-(2,5-dihydro-5-thioxo-1H-tetrazol-1-yl)phenoxy]-4,4-dimethyl-1,3-dioxopentyl]amino]-, hexadecyl ester (CA INDEX NAME)



L87 ANSWER 73 OF 84 CAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 1986:159526 CAPLUS [Full-text](#)

DOCUMENT NUMBER: 104:159526

ORIGINAL REFERENCE NO.: 104:25069a, 25072a


TITLE: Silver halide color photographic photosensitive materials

INVENTOR(S): Ichiba, Yasushi; Usui, Hideo; Deguchi, Hisayasu

PATENT ASSIGNEE(S): Fuji Photo Film Co., Ltd., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 36 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 60185950	A	19850921	JP 1984-33059	19840223 <--
JP 05018092	B	19930311		
EP 157146	A2	19851009	EP 1985-101852	19850220 <--
EP 157146	A3	19861203		
EP 157146	B1	19890927		
R: CH, DE, FR, GB, IT, LI				
US 4618571	A	19861021	US 1985-705473	19850225 <--
PRIORITY APPLN. INFO.:			JP 1984-33059	A 19840223 <--
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT				
OTHER SOURCE(S): CASREACT 104:159526; MARPAT 104:159526				

GI



AB Ag halide color photog. photosensitive materials contain a coupler whose coupling reaction with the oxidized developing agent produces a compound which undergoes a redox reaction with a developing agent to release a photog. useful compound. The claimed couplers show improved storage stability over that of the couplers with timing groups, and release photog. useful compds. in a controlled manner. The couplers also improve image sharpness, granularity, and color tone reproducibility. Thus, a test photog. film was prepared by using a green-sensitive Ag(Br, I) emulsion containing a magenta coupler 1-(2,4,6-trichlorophenyl)-3-[3-[2-(2,4-di-tert-amylphenoxy)butyramido]benzamido-5-oxo-2-pyrazoline (I) and a new magenta coupler II (20 mol% of I). The film was sensitometrically exposed and developed to give Dmax, Dmin, image sharpness (MFT value at 10 cycles/mm), and granularity (RMS value at d. 0.5) of 2.83, 0.13, 114, and 0.0167, resp., vs. 2.95, 0.15, 103, and 0.0210, resp., for a II-free control.


IT 101124-57-6

RL: USES (Uses)

(photog. development inhibitor-releasing coupler)

RN 101124-57-6 CAPLUS

CN 1H-Benzotriazolecarboxylic acid, 1-[5-[1-[[[2-chloro-5-[(1-oxotetradecyl)amino]phenyl]amino]carbonyl]-3,3-dimethyl-2-oxobutoxy]-2-hydroxy-3-(1,1,3,3-tetramethylbutyl)phenyl]-, phenyl ester (9CI) (CA INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
(1 CITINGS)

L87 ANSWER 74 OF 84 CAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 1986:139248 CAPLUS Full-text

DOCUMENT NUMBER: 104:139248

ORIGINAL REFERENCE NO.: 104:21853a,21856a

TITLE: Colorless ligand-releasing monomers and polymers and
their use to provide dyes with metal ions

INVENTOR(S): Washburn, William N.; Hollister, Kenneth R.

PATENT ASSIGNEE(S): Eastman Kodak Co., USA

SOURCE: U.S., 10 pp.
CODEN: USXXAM


DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4557998	A	19851210	US 1985-688224	19850102 <--
CA 1252463	A1	19890411	CA 1985-482287	19850524 <--
US 4680356	A	19870714	US 1985-764152	19850809 <--
EP 186869	A2	19860709	EP 1985-116273	19851219 <--
EP 186869	A3	19880914		
EP 186869	B1	19900314		
R: DE, FR, GB, NL				
JP 61166545	A	19860728	JP 1985-293429	19851227 <--
PRIORITY APPLN. INFO.:			US 1985-688224	A 19850102 <--
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT				
OTHER SOURCE(S):		MARPAT 104:139248		
GI				



AB Colorless ligand-releasing polymers are described which can be used as masking dyes for color correction in photog. elements or to form reversal images in photog. elements. The polymer contains (1) recurring units derived from an ethylenically unsatd. polymerizable monomer $RCH_2:CCoup-Link-Lig$ ($R = H$, alkyl; Coup = photog. coupling moiety, Link = coupling group which can be cleaved by an oxidized developer, Lig = a ligand capable of complexing with metal ions. Thus, a 3:1 mol. mixture of a yellow dye-providing color coupler I and N-{{4-chloro-3-{4,4-dimethyl-2-[2,6-di(2-pyridyl)-4-pyridyloxy]-3-oxopentanamido}-phenyl}{-acrylamide-Na 2-acrylamido-2-methylpropane-1-sulfonate copolymer (II) was mixed with half their weight of di-Bu phthalate and 3 times their weight with of EtOAc, mixed with gelatin (until homogeneous). The coating levels on a suitable support was gelatin 3.8 g/m², I 1.8 g/m², the polymer II 764 mg/m². The element was imagewise exposed, developed and bleached. No masking dye scale was observed under these conditions but seasoned bleach or dilute ammonium ferrous sulfate solns. generated the magenta color correcting dye scale.

IT 101061-68-1 101061-70-5

RL: USES (Uses)

(colorless ligand-releasing photog. additive, for application as masking dye for color correction or formation of reversal images)

RN 101061-68-1 CAPLUS

CN 1-Propanesulfonic acid, 2-methyl-2-[(1-oxo-2-propenyl)amino]-, monosodium salt, polymer with N-[2-chloro-5-[(1-oxo-2-propenyl)amino]phenyl]-2-[3,5-di-2-pyridinyl-4-(4-pyridinyl)phenoxy]-4,4-dimethyl-3-oxopentamide


(9CI)

(CA INDEX NAME)

CM 1

CRN 101061-67-0


CMF C37 H32 Cl N5 O4



CM 2

CRN 5165-97-9

CMF C7 H13 N O4 S . Na



● Na


RN 101061-70-5 CAPLUS

CN 1-Propanesulfonic acid, 2-methyl-2-[(1-oxo-2-propenyl)amino]-, monosodium salt, polymer with N-[2-chloro-5-[(1-oxo-2-propenyl)amino]phenyl]-4,4-dimethyl-3-oxo-2-[4-[6-phenyl-3-(2-pyridinyl)-1,2,4-triazin-5-yl]phenoxy]pentanamide (9CI) (CA INDEX NAME)

CM 1


CRN 101061-69-2

CMF C36 H31 Cl N6 O4



CM 2

CRN 5165-97-9
 CMF C7 H13 N O4 S . Na



● Na

OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD
 (4 CITINGS)
 REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L87 ANSWER 75 OF 84 CAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 1986:43109 CAPLUS Full-text
 DOCUMENT NUMBER: 104:43109
 ORIGINAL REFERENCE NO.: 104:6879a,6882a
 TITLE: Photographic recording material
 INVENTOR(S): Becker, Manfred; Matejec, Reinhart; Endres, Lothar
 PATENT ASSIGNEE(S): Agfa-Gevaert A.-G., Fed. Rep. Ger.
 SOURCE: Ger. Offen., 43 pp.
 CODEN: GWXXBX
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
DE 3404854	A1	19850814	DE 1984-3404854	19840211 <--
EP 152822	A2	19850828	EP 1985-100911	19850130 <--
EP 152822	A3	19880127		
EP 152822	B1	19890531		
R: BE, DE, FR, GB				
US 4636461	A	19870113	US 1985-696901	19850131 <--
JP 60258536	A	19851220	JP 1985-22133	19850208 <--
JP 05008813	B	19930203		

PRIORITY APPLN. INFO.: DE 1984-3404854 A 19840211 <--
 ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
 OTHER SOURCE(S): MARPAT 104:43109

AB Photog. materials showing high edge effects in the presence of development inhibitor-releasing compds. contain ≥ 1 iodide-containing Ag halide emulsion in which the grains have zones of different halide compns. The grains are characterized such that from the grain surface to its center there are 3 zones of different halide concentration each following one another and the local iodide concentration is at a maximum at ≥ 1 point that is not on the surface or in the center; the difference between the iodide concentration of the zone with the highest iodide concentration and the iodide concentration of the

furthermost removed zone from the center is preferably ≥ 9 mol%; the portion (in mol% Ag halide) of the zone in which the iodide concentration reaches a maximum is preferably between 20 and 40%, and preferably 70% of the Ag halide grains are cubic or tetradecahedral or in a transition form therebetween. Thus, to a 3-zone gelatin Ag(Br,I) emulsion (AgBr0.995I0.005 30, AgBr0.92I0.08 60, and AgBr 10 mol%) were added a cyan coupler, a DIR compound, and other additives, and the emulsion coated on a support, dried, exposed, and the edge effects at a macrocolor d. of 1.0 for 0.75 g DIR and 1.0 g DIR/AgNO₃ determined to be 0.40 and 0.54, resp., vs. 0.27 and 0.25, resp., for a Ag(Br,Cl,I) emulsion.

IT 75956-70-6

RL: USES (Uses)

(photog. development inhibitor-releasing compound, color films with emulsions containing iodide-containing zoned silver halide grains and,

for


improved edge effects)

RN 75956-70-6 CAPLUS

CN Acetamide,

2-(4-chloro-2-tetradecylphenoxy)-N-[4-[4,5-dihydro-5-oxo-4-[(1-

phenyl-1H-tetrazol-5-yl)thio]-3-(1-pyrrolidinyl)-1H-pyrazol-1-yl]phenyl]-
(CA INDEX NAME)



OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD
(4 CITINGS)

L87 ANSWER 76 OF 84 CAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 1985:532313 CAPLUS Full-text

DOCUMENT NUMBER: 103:132313

ORIGINAL REFERENCE NO.: 103:21023a,21026a

TITLE: Color photographic recording material and development method

INVENTOR(S): Sauerteig, Wolfgang; Ranz, Erwin; Schuetz, Heinz

PATENT ASSIGNEE(S): Agfa-Gevaert A.-G., Fed. Rep. Ger.

SOURCE: Ger. Offen., 33 pp.

CODEN: GWXXBX

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----

DE 3346621	A1	19850704	DE 1983-3346621	19831223 <--
US 4571378	A	19860218	US 1984-680154	19841210 <--
EP 148441	A2	19850717	EP 1984-115219	19841212 <--
EP 148441	A3	19860625		
EP 148441	B1	19880217		
R: BE, DE, FR, GB				
JP 60227256	A	19851112	JP 1984-268710	19841221 <--
PRIORITY APPLN. INFO.:			DE 1983-3346621	A 19831223 <--
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT				
OTHER SOURCE(S):		MARPAT 103:132313		
GI				

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The sensitometric characteristics of color photog. materials, especially color grain in regions of low color d., can be improved, without adversely affecting the sensitivity, by using ≥ 1 emulsion layer of comparatively higher sensitivity and ≥ 1 emulsion layer of comparatively lower sensitivity, each having contained therein a coupler-DIR compound combination of different reactivities. The ratio of the effective reaction rate constant of the coupler and the DIR in the higher sensitivity emulsion layer is greater than in the lower sensitivity emulsion layer. Thus, a cellulose acetate support was coated with a red-sensitive gelatin-Ag(Br,I) emulsion layer of lower sensitivity containing I 600, II 30 mg, and a masking coupler, a red-sensitive gelatin-Ag(Br,I) emulsion layer of higher sensitivity containing I 200 and III 40 mg, an interlayer, a green-sensitive layer of lower sensitivity, a green-sensitive layer of higher sensitivity, an interlayer, a yellow filter layer, a blue-sensitive layer of lower sensitivity, a blue-sensitive layer of higher sensitivity, a UV absorber layer, and a top layer. The resultant photog. film was then exposed and developed to show a red sensitivity of 24.1 DIN and a granularity at 0.5 over fog, 1.0 over fog, and 1.5 over fog of 1.5, 1.5, and 1.4, resp., vs. 23.0 DIN, and 1.5, 1.5, and 1.4, resp., for a control containing II in place of III.

IT 75956-70-6

RL: USES (Uses)

(coupler-DIR compound combinations containing, for color photog. films with

improved color grains)


RN 75956-70-6 CAPLUS

CN Acetamide,

2-(4-chloro-2-tetradecylphenoxy)-N-[4-[4,5-dihydro-5-oxo-4-[(1-

phenyl-1H-tetrazol-5-yl)thio]-3-(1-pyrrolidinyl)-1H-pyrazol-1-yl]phenyl]-

(CA INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
(1 CITINGS)

L87 ANSWER 77 OF 84 CAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 1985:157924 CAPLUS Full-text

DOCUMENT NUMBER: 102:157924

ORIGINAL REFERENCE NO.: 102:24704h,24705a

TITLE: Silver halide color photographic photosensitive materials

PATENT ASSIGNEE(S): Fuji Photo Film Co., Ltd., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 27 pp.

CODEN: JKXXAF


DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 59206834	A	19841122	JP 1983-82018	19830511 <--
PRIORITY APPLN. INFO.: GI			JP 1983-82018	19830511 <--



I

AB Ag halide color photog. photosensitive materials contain compds. of formula RZZ1R1 (Z = nucleophilic group having N, O, or S as the nucleophilic center or its precursor, Z1 = photog. useful compound moiety; R = group separated from ZZ1R1 during the reaction with oxidized developing agent; R1 = electrophilic group which undergoes intramol. nucleophilic reactor with the

Z group to form 3- to 7-membered ring after the R-Z bond is broken. The photog. materials having good storage stability and good image quality. Thus, a multilayer color photog. material prepared by using a development inhibitor-releasing coupler I showed improved storage stability and development inhibiting characteristics over those of a control with a conventional development inhibitor-releasing coupler.

IT 95736-67-7


RL: USES (Uses)

(photo. development inhibitor-releasing coupler)

RN 95736-67-7 CAPLUS

CN Carbamothioic acid, diethyl-, S-[1-[2-[1-[[[5-[[2-[2,4-bis(1,1-

dimethylpropyl)phenoxy]-1-oxobutyl]amino]-2-chlorophenyl]amino]carbonyl]-3,3-dimethyl-2-oxobutoxy]-5-nitrophenyl]-1H-tetrazol-5-yl] ester (9CI)
(CA INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
(1 CITINGS)

L87 ANSWER 78 OF 84 CAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 1984:510569 CAPLUS Full-text

DOCUMENT NUMBER: 101:110569

ORIGINAL REFERENCE NO.: 101:16869a,16872a

TITLE: Benzoylurea derivatives

PATENT ASSIGNEE(S): Kumiai Chemical Industry Co., Ltd., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 5 pp.

CODEN: JKXXAF




DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
JP 59027864	A	19840214	JP 1982-138236	19820809 <--
PRIORITY APPLN. INFO.:			JP 1982-138236	19820809 <--
GI				




AB Eight benzoylureas (I, R = H, halo; R1 = halo, NO2; R2 = halo, CF3; X = halo; X1 = CH, N), which had insecticidal activity against *Prodenia litura*, etc., were prepared either by reaction of 2,6-RXC6H3CONCO (II) with phenylenediamines III or by reaction of 2,6-RXC6H3CONH2 with isocyanatoanilines IV. Thus, treatment of 3 g 50% II (R = X = F) in toluene with 2.4 % III (R1 = NO2, R2 = CF3, X1 = CH) in toluene at room temperature for 1 h gave 84.2% I (R = X = F, R1 = NO2, R2 = CF3, X1 = CH).

IT 91590-96-4P 91590-97-5P

RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation and insecticidal activity of)


RN 91590-96-4 CAPLUS

CN Benzamide, 2-chloro-N-[[[4-(3,5-dichloro-2-pyridinyl)phenyl]amino]carbonyl]- (CA INDEX NAME)



RN 91590-97-5 CAPLUS

CN Benzamide, N-[[[4-(3,5-dichloro-2-pyridinyl)phenyl]amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)



L87 ANSWER 79 OF 84 CAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 1981:165628 CAPLUS Full-text

DOCUMENT NUMBER: 94:165628

ORIGINAL REFERENCE NO.: 94:26927a, 26930a

TITLE: Color photographic recording material with a
DIR-coupler of high reactivity

INVENTOR(S): Ranz, Erwin; Lohmann, Joachim; Schuetz, Heinz Dieter

PATENT ASSIGNEE(S): Agfa-Gevaert A.-G., Fed. Rep. Ger.

SOURCE: Ger. Offen., 32 pp.

CODEN: GWXXBX

DOCUMENT TYPE: ~~Patent~~

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
DE 2853362	A1	19800612	DE 1978-2853362	19781211 <--
DE 2853362	C2	19811015		
JP 55084935	A	19800626	JP 1979-8295	19790129 <--
US 4315070	A	19820209	US 1980-158990	19800612 <--
PRIORITY APPLN. INFO.:			DE 1978-2853362	A 19781211 <--
			US 1979-16954	A1 19790302 <--

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB A color photog. recording material contains ≥ 3 different spectrally sensitized Ag halide emulsion layer units containing nondiffusing dye components and in ≥ 1 layer a development inhibitor-releasing (DIR) coupler with high reactivity (rate constant $> 20,000 \text{ L mol}^{-1} \text{ s}^{-1}$ at pH 10.2) in a concentration of 10^{-5} – 10^{-3} mol/mol Ag halide or in a concentration of 10^{-7} – 10^{-5} mol/g solid in a Ag halide-free intermediate binder layer adjacent to a Ag halide emulsion layer. Thus, the film tested had the following layers: (1) a red-sensitized Ag(Br,I) emulsion of low sensitivity containing 790 mg cyan coupler, 25 mg DIR coupler I, and 1.6 g gelatin; (2) an intermediate gelatin layer; (3) a green-sensitized Ag(Br,I) emulsion of low sensitivity containing 600 mg magenta coupler, 60 mg DIR coupler II, 80 mg of a masking coupler, and 2 g gelatin; (4) an intermediate gelatin layer; (5) a highly sensitive red-sensitized Ag(Br,I) emulsion containing 250 mg of cyan coupler and 1.0 g gelatin; (6) an intermediate layer containing gelatin, fine-grained AgCl, and DIR coupler III; (7) a highly sensitive green-sensitized Ag(Br,I) emulsion containing 170 mg of magenta coupler, 37

mg of a 2nd magenta coupler, and 2.1 g gelatin; (8) an intermediate gelatin layer; (9) a yellow filter layer; (10) a blue-sensitive layer containing both a sensitive and a relatively unsensitive Ag(Br,I) emulsion with 1.0 g yellow coupler and 2.0 g gelatin; (11) a cover layer of gelatin. The highly reactive DIR coupler IV ($k = 50,000 \text{ L mol}^{-1} \text{ s}^{-1}$) was added to layer 7 in increasing amts. from 6.07×10^{-5} to $3.03 \times 10^{-4} \text{ mol IV/mol Ag}$. Upon addition of $1.82 \times 10^{-4} \text{ mol IV/mol Ag}$ the magenta fog was decreased from 0.90 in the IV-free film to 0.83, without change in the sensitivity, gradation, or magenta- and cyan-interimage effects.

IT 75956-70-6

RL: USES (Uses)


(photog. development inhibitor-releasing coupler)

RN 75956-70-6 CAPLUS

CN Acetamide,

2-(4-chloro-2-tetradecylphenoxy)-N-[4-[4,5-dihydro-5-oxo-4-[(1-

phenyl-1H-tetrazol-5-yl)thio]-3-(1-pyrrolidinyl)-1H-pyrazol-1-yl]phenyl]-
(CA INDEX NAME)



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD
(2 CITINGS)

L87 ANSWER 80 OF 84 CAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 1981:123114 CAPLUS Full-text

DOCUMENT NUMBER: 94:123114

ORIGINAL REFERENCE NO.: 94:20143a, 20146a

TITLE: Disperse dyes and their use

INVENTOR(S): Neumann, Peter; Elser, Wolfgang; Bock, Gustav; Kermer, WolfDieter

PATENT ASSIGNEE(S): BASF A.-G., Fed. Rep. Ger.

SOURCE: Ger. Offen., 47 pp.

CODEN: GWXXBX

DOCUMENT TYPE: Patent


LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2912428	A1	19801009	DE 1979-2912428	19790329 <--
US 4373102	A	19830208	US 1980-128156	19800307 <--
EP 17132	A1	19801015	EP 1980-101558	19800325 <--
EP 17132	B1	19811014		

R: AT, BE, CH, DE, FR, GB, IT, LU, NL, SE
 JP 55131064 A 19801011 JP 1980-39143 19800328 <--
 JP 63060072 B 19881122
 PRIORITY APPLN. INFO.: DE 1979-2912428 A 19790329 <--
 ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
 OTHER SOURCE(S): MARPAT 94:123114
 GI



AB Substituted 1-(cyanomethylene)-3-(4-aminophenyl)-1H-isoindole derivs. are prepared and used to dye polyester fibers and polystyrene [9003-53-6] fast blue to violet shades. Thus, 3-(dicyanomethylene)-1-iminoisoindoline [43002-19-3] was heated with N,N-dimethylaniline [121-69-7] in Ac2O containing H2SO4 to give I [76751-73-0], reddish blue on polyester fibers.
 IT 76751-35-4
 RL: TEM (Technical or engineered material use); USES (Uses)
 (dye, for polyester fibers, preparation of)
 RN 76751-35-4 CAPLUS
 CN Acetamide, 2-(4-chloro-2-methylphenoxy)-N-[2-[1-(dicyanomethylene)-1H-isoindol-3-yl]-5-(diethylamino)phenyl]- (CA INDEX NAME)




OS.CITING REF COUNT: 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD
 (6 CITINGS)


L87 ANSWER 81 OF 84 CAPLUS COPYRIGHT 2011 ACS on STN
 ACCESSION NUMBER: 1980:613290 CAPLUS Full-text
 DOCUMENT NUMBER: 93:213290
 ORIGINAL REFERENCE NO.: 93:33906h,33907a
 TITLE: Cyan couplers for silver halide color photographic materials
 INVENTOR(S): Kojima, Tamotsu; Fujimatsu, Wataru; Udagawa, Yasushi;

PATENT ASSIGNEE(S): Sasaki, Osamu; Yamashita, Kiyoshi
 SOURCE: Konishiroku Photo Industry Co., Ltd., Japan
 Jpn. Kokai Tokkyo Koho, 17 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	---	-----	-----	-----
JP 55035377	A	19800312	JP 1978-108832	19780904 <--
JP 57004896	B	19820128		
PRIORITY APPLN. INFO.:			JP 1978-108832	19780904 <--
GI				



AB Ag halide color photog. materials contain cyan couplers of the formula I [R = H, C1-5 aliphatic hydrocarbon moiety with/without substituent; R1 = H, organic moiety; R2 = diffusion-resistant moiety conventionally used in color couplers; R1R2 in combination may complete N-containing heterocyclic ring; Z = O-containing organic moiety which is bonded via O to the active position of the coupler moiety; Z1 = simple bond, or n-valent organic moiety, or H (when n = 1); n = 1,2]. Thus, a cyan coupler
 6-[α-(2,4-di-tert-amylphenoxy)butyramido]-4-ethoxycarbonylmethoxy-2-fluoro-3-methylphenol was used to give a color photog. material, which gave photog. images with good stability, optical d., and high color-formation speed even in the absence of PhCH2OH in a color developer solution
 IT 75505-50-9P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 75505-50-9 CAPLUS
 CN Ethanedioic acid, 1-[5-[[2-[2-(2H-benzotriazol-2-yl)-4-(1,1-dimethylpropyl)phenoxy]acetyl]amino]-3-fluoro-4-hydroxy-2-methylphenyl]
 2-ethyl ester (CA INDEX NAME)



L87 ANSWER 82 OF 84 CAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 1979:195580 CAPLUS Full-text

DOCUMENT NUMBER: 90:195580

ORIGINAL REFERENCE NO.: 90:30969a,30972a

TITLE: Couplers for silver halide color photographic materials

INVENTOR(S): Ishikawa, Hitoshi; Fujiwara, Mitsuhiro; Kikuchi, Shoji; Wada, Hajime; Endo, Takanari

PATENT ASSIGNEE(S): Konishiroku Photo Industry Co., Ltd., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 28 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 53141622	A	19781209	JP 1977-56190	19770516 <--
JP 60039218	B	19850905		

PRIORITY APPLN. INFO.: JP 1977-56190 19770516 <--

GI For diagram(s), see printed CA Issue.

AB Ag halide color photog. materials contain ≥ 1 coupler selected from compds. of the general formulas I, II, and III (R, R1, R2, R3, R4, R5, R6, R7 = H, OH, NH2, NO2, halo, alkyl, alkenyl, aryl, alkoxy, alkenyloxy, aryloxy, acyloxy, alkylthio, alkenylthio, arylthio, monoalkylamino, dialkylamino, acylamino, sulfonamido, carbamoyl, sulfamoyl, sulfo, sulfinio, R9 Zm; R1R2, R1R2, or R2R3 combination may form a 5- or 6-membered ring; R8 = R9Zm, alkyl, alkenyl, cycloalkyl, aryl, acyl, alkylsulfonyl, arylsulfonyl, carbamoyl, sulfamoyl, oxalyl, oxamoyl, oxycarbonyl, oxalacetyl groups having substituents selected from alkyl, aryl and alkoxy group; R9 = cyan; magenta- or yellow-coupler moiety; Z = an organic moiety; m = 0,1; n ≥ 1 , Z1 = a divalent moiety obtained by removing a H atom from R8]. The dye images obtained from the above couplers exhibit excellent light fastness and moisture resistance. Thus, a multilayer color photog. paper was prepared by using the yellow coupler IV, the magenta coupler V, and the cyan coupler VI. The color photog. paper was imagewise exposed and developed to give a color image which showed good light and moisture resistances.


IT 69964-06-3

RL: TEM (Technical or engineered material use); USES (Uses)
(photog. cyan coupler)

RN 69964-06-3 CAPLUS

CN Acetamide, 2-[2-(2H-benzotriazol-2-yl)-4-(1,1-dimethylethyl)phenoxy]-N-

(3,5-dichloro-2-hydroxy-4-methylphenyl)- (CA INDEX NAME)




IT 69964-17-6

RL: TEM (Technical or engineered material use); USES (Uses)
(photog. magenta coupler)

RN 69964-17-6 CAPLUS

CN Acetamide,

N-[4-chloro-3-[[4,5-dihydro-5-oxo-1-(2,4,6-trichlorophenyl)-1H-pyrazol-3-yl]amino]phenyl]-2-[4-(1,1-dimethylethyl)-2-[5-[(methylsulfonyl)amino]-2H-benzotriazol-2-yl]phenoxy]- (CA INDEX NAME)




IT 69964-24-5

RL: TEM (Technical or engineered material use); USES (Uses)
(photog. yellow coupler)


RN 69964-24-5 CAPLUS

CN Pentanamide, N-[5-[2-[2-(2H-benzotriazol-2-yl)-4-(1,1-dimethylethyl)phenoxy]acetyl]amino]-2-chlorophenyl]-4,4-dimethyl-3-oxo- (CA INDEX NAME)



L87 ANSWER 83 OF 84 CAPLUS COPYRIGHT 2011 ACS on STN
 ACCESSION NUMBER: 1979:14636 CAPLUS Full-text
 DOCUMENT NUMBER: 90:14636
 ORIGINAL REFERENCE NO.: 90:2323a,2326a
 TITLE: Color complexes with moieties absorbing ultraviolet rays
 INVENTOR(S): Van Poucke, Raphael Karel; Vanden Eynde, Hector
 Alfons; Monbaliu, Marcel Jacob
 PATENT ASSIGNEE(S): Agfa-Gevaert N. V., Belg.
 SOURCE: Fr. Demande, 30 pp.
 CODEN: FRXXBL
 DOCUMENT TYPE: Patent
 LANGUAGE: French
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 2363133	A1	19780324	FR 1977-25623	19770822 <--
FR 2363133	B1	19800711		
PRIORITY APPLN. INFO.: GI			GB 1977-19578	A 19770510 <--



AB Color photog. emulsions giving color images with improved stability are obtained with the use of color formers, which are chemical bonded to a UV-absorbing moiety, i.e. in the form of I (Z = divalent organic groups; R1, R2 = substituted or unsubstituted alkyl and aryl; and R = color former radical). Thus, a red-sensitized photog. Ag(Br, I) emulsion (2.3 mol% I-) containing 0.006 mol II and 0.012 mol 2,2-dimethyl-6-hydroxy-7-isononylchroman per 0.032 mol Ag halide was coated on a suitable support, dried, imagewise exposed, developed in a N,N-diethyl-p-phenylenediamine type developer, and treated with a bleach-fix bath containing K3Fe(CN)6 and Na2S2O3 to give a cyan image which showed no change in color after 15-h exposure to radiation from a 1500-W Xe lamp.


IT 68658-25-3

RL: USES (Uses)


(photog. color coupler, for high-stability color image production)

RN 68658-25-3 CAPLUS
 CN Butanamide, 2-[4-[4,6-bis(2,4-dimethylphenyl)-1,3,5-triazin-2-yl]-3-hydroxyphenoxy]-N-[4-chloro-3-[[4,5-dihydro-5-oxo-1-(2,4,6-trichlorophenyl)-1H-pyrazol-3-yl]amino]phenyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



L87 ANSWER 84 OF 84 CAPLUS COPYRIGHT 2011 ACS on STN
 ACCESSION NUMBER: 1973:487360 CAPLUS Full-text
 DOCUMENT NUMBER: 79:87360
 ORIGINAL REFERENCE NO.: 79:14122h,14123a
 TITLE: Irreversible enzyme inhibitors. 198.
 Diaminodihydro-s-triazines and diaminopyrimidines bearing substituted (ureidomethyl)phenyl substituents as reversible inhibitors of dihydrofolate reductase
 AUTHOR(S): Ashton, Wallace T.; Kirk, Larry L.; Baker, B. R.
 CORPORATE SOURCE: Dep. Chem., Univ. California, Santa Barbara, CA, USA
 SOURCE: Journal of Medicinal Chemistry (1973), 16(5), 453-6
 CODEN: JMCMAR; ISSN: 0022-2623
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB Triazines bearing m-(aryluroidomethyl)phenyl substituents and pyrimidines bearing p-(aryluroidomethyl)phenyl substituents were inhibitors of dihydrofolate reductase [9002-03-3] from L1210 mouse leukemia cells, and of cultured L1210 cells. The most potent compound, 2,4-diamino-6-methyl-5-[p-[(3-nitrophenyl)ureidomethyl]phenyl]pyrimidine (I) [41935-22-2], inhibited L1210 cells at 61 pM in vitro and was thus 2000 times as active as 4,6-diamino-1,2-dihydro-2,2-dimethyl-1-[m-(m-fluorosulfonylphenylureidomethyl)phenyl]-s-triazine ethanesulfonate [19159-37-6], a compound with antileukemic activity in vivo. The enhanced activity of I and some other compds. on the cells was probably due to improved membrane transport, since all the compds. caused similar inhibition of the enzyme. Activity was correlated with the electron-withdrawing power of the

meta substituent on the terminal benzene ring. To synthesize I, 5-(p-aminophenyl)-2,4-diamino-6-methylpyrimidine [41935-24-4] was diazotized and reacted with CuCN to give the 5-(p-cyanophenyl) compound, which was reduced with H₂/Pt to the 5-(p-aminomethyl)phenyl compound and reacted with Ph N-(3-nitrophenyl)carbamate (prepared from Ph chloroformate [1885-14-9] and m-nitroaniline) to yield I.


IT 50699-45-1P

RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of, dihydrofolate reductase and leukemia inhibiting activities by)

RN 50699-45-1 CAPLUS

CN Urea, N-(3-chlorophenyl)-N'-[[4-(2,4-diamino-6-methyl-5-pyrimidinyl)phenyl]methyl]- (CA INDEX NAME)




OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)

FILE 'HOME' ENTERED AT 14:19:25 ON 14 SEP 2011

SEARCH HISTORY

=> d stat que l41; d his nofile

L10 STR



VAR G1=40/37

VAR G2=16-4 19-12/16-12 19-4/20-4 23-12/20-12 23-4/24-4 27-12/24-12 27-4/28-4 31-12/31-4 28-12

VPA 15-1/2/3/5/6 U

VPA 14-7/8/9/10/11 U

NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM

MLEVEL IS CLASS AT 15 28 36 38 39 40

GGCAT IS UNS AT 15

DEFAULT ECLEVEL IS LIMITED


GRAPH ATTRIBUTES:

RSPEC 12

NUMBER OF NODES IS 40

STEREO ATTRIBUTES: NONE

L11 STR



VAR G1=O/S/N

VAR G2=N/C

VAR G3=1/6/12/25/33/38/52

NODE ATTRIBUTES:


DEFAULT MLEVEL IS ATOM
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
 RING(S) ARE ISOLATED OR EMBEDDED
 NUMBER OF NODES IS 56


STEREO ATTRIBUTES: NONE

L13 5217 SEA FILE=REGISTRY SSS FUL L10 AND L11

L34 STR



Page 1-A



Page 2-A

VAR G1=23/29/32/38/42/44/48

VAR G2=BR/F/CL

NODE ATTRIBUTES:


DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
 RING(S) ARE ISOLATED OR EMBEDDED
 NUMBER OF NODES IS 62

STEREO ATTRIBUTES: NONE

L37 STR



NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 24

STEREO ATTRIBUTES: NONE

L40 9 SEA FILE=REGISTRY SUB=L13 CSS FUL (L34 OR L37)

L41 5208 SEA FILE=REGISTRY SPE=ON ABB=ON L13 NOT L40

(FILE 'HOME' ENTERED AT 11:53:42 ON 14 SEP 2011)

FILE 'CAPLUS' ENTERED AT 11:53:49 ON 14 SEP 2011

E US2007-569873/APPS

L1 1 SEA SPE=ON ABB=ON US2007-569873/AP
D SCA
SEL RN

FILE 'REGISTRY' ENTERED AT 11:54:12 ON 14 SEP 2011

L2 322 SEA SPE=ON ABB=ON (10269-01-9/BI OR 1041846-56-3/BI OR
1041847-07-7/BI OR 1041848-86-5/BI OR 106-41-2/BI OR 1066-54-2/
BI OR 109299-78-7/BI OR 125620-16-8/BI OR 138359-29-2/BI OR
14213-10-6/BI OR 14213-12-8/BI OR 1878-88-2/BI OR 198084-12-7/B
I OR 198084-13-8/BI OR 22948-02-3/BI OR 229643-02-1/BI OR
27246-81-7/BI OR 320-51-4/BI OR 327-78-6/BI OR 332176-73-5/BI
OR 332176-74-6/BI OR 337354-96-8/BI OR 337496-38-5/BI OR
337496-40-9/BI OR 351-33-7/BI OR 352347-24-1/BI OR 3544-24-9/BI
OR 4385-77-7/BI OR 460318-24-5/BI OR 462067-31-8/BI OR
483337-15-1/BI OR 483337-16-2/BI OR 483337-17-3/BI OR 483337-18
-4/BI OR 483337-19-5/BI OR 483337-20-8/BI OR 483337-21-9/BI OR
483337-22-0/BI OR 483337-23-1/BI OR 483337-24-2/BI OR 483337-25
-3/BI OR 483337-26-4/BI OR 483337-27-5/BI OR 483337-28-6/BI OR
483337-29-7/BI OR 483337-30-0/BI OR 483337-32-2/BI OR 483337-34
-4/BI OR 483337-36-6/BI OR 483337-37-7/BI OR 483337-38-8/BI OR
483337-39-9/BI OR 483337-40-2/BI OR 483337-41-3/BI OR 483337-42
-4/BI OR 483337-43-5/BI OR 483337-44-6/BI OR 483337-45-7/BI OR
483978-03-6/BI OR 490020-25-2/BI OR 494197-69-2/BI OR 494197-70
-5/BI OR 505052-18-6/BI OR 50528-73-9/BI OR 506433-09-6/BI OR

5445-17-0/BI OR 552825-29-3/BI OR 578748-03-5/BI OR 591-27-5/BI
 OR 6274-24-4/BI OR 628-36-4/BI OR 7409-18-9/BI OR 78-39-7/BI
 OR 79-04-9/BI OR 832739-85-2/BI OR 847606-67-1/BI OR 847606-68-
 2/BI OR 847606-69-3/BI OR 847606-70-6/BI OR 847606-71-7/BI OR
 847606-72-8/BI OR 847606-73-9/BI OR 847606-74-0/BI OR 847606-75
 -1/BI OR 847606-76-2/BI OR 847606-77-3/BI OR 847606-78-4/BI OR
 847606-79-5/BI OR 847606-81-9/BI OR 847606-82-0/BI OR 847606-83
 -1/BI OR 847606-84-2/BI OR 847606-85-3/BI OR 847606-86-4/BI OR
 847606-87-5/BI OR 847606-88-6/BI OR 847606-89-7/BI OR 847606-90
 -0/BI OR 847606-91-1/BI OR 847606-92-2/BI OR 847606-93-3/BI OR
 847606-94-4/BI OR 847606-95-5/BI OR 847607-05-0/BI OR 847607-13
 -0/BI OR 847607-14-1/BI OR 847607-15-2/BI OR 847607-16-3/BI OR
 847607-17-4/BI OR 847607-18-5/BI OR 847607-19-6/BI OR 847607-20
 -9/BI OR 847607-21-0/BI OR 847607-22-1/BI OR 847607

L3 STR
 L4 50 SEA SSS SAM L3

FILE 'ZCAPLUS' ENTERED AT 12:02:47 ON 14 SEP 2011
 L5 0 SEA SPE=ON ABB=ON L4

FILE 'REGISTRY' ENTERED AT 12:03:03 ON 14 SEP 2011
 L6 STR
 L7 STR
 L8 50 SEA SSS SAM L3 AND L7
 D STAT QUE L3
 D STAT QUE L4

FILE 'ZCAPLUS' ENTERED AT 12:18:08 ON 14 SEP 2011
 L9 1 SEA SPE=ON ABB=ON L8

FILE 'REGISTRY' ENTERED AT 12:18:22 ON 14 SEP 2011
 L10 STR L3
 L11 STR L7
 L12 50 SEA SSS SAM L10 AND L11
 L13 5217 SEA SSS FUL L10 AND L11
 SAVE TEMP L13 BIA873FULL/A
 L14 4232 SEA SPE=ON ABB=ON L13 NOT CAPLUS/LC
 L15 ANALYZE L14 1- LC : 1 TERM
 D
 L16 3173 SEA SPE=ON ABB=ON L14 AND CHEMCATS/LC
 L17 1059 SEA SPE=ON ABB=ON L14 NOT L16

FILE 'CAPLUS' ENTERED AT 12:31:01 ON 14 SEP 2011
 L18 165 SEA SPE=ON ABB=ON L13
 L19 145 SEA SPE=ON ABB=ON L18 AND PATENT/DT
 L20 0 SEA SPE=ON ABB=ON L18 AND REVIEW/DT
 L21 7 SEA SPE=ON ABB=ON (L18 NOT L19) AND PY<2004
 L22 77 SEA SPE=ON ABB=ON L19 AND (PD<20030829 OR AD<20030829 OR
 PRD<20030829)
 L23 84 SEA SPE=ON ABB=ON (L21 OR L22)
 L24 ANALYZE L23 1- RN HIT : 427 TERMS
 D

FILE 'REGISTRY' ENTERED AT 12:53:11 ON 14 SEP 2011
 L25 STR

```

L26          0 SEA CSS SAM L25
L27          STR L25
L28          STR L27
L29          0 SEA SUB=L13 CSS SAM (L27 OR L28)
L30          8 SEA SUB=L13 CSS FUL (L27 OR L28)
              SAVE TEMP L30 BIA873SUB1/A
              D SCA
              E 1/CL
L31          222 SEA SPE=ON  ABB=ON  L13 AND 1/CL AND 3/F
L32          63 SEA SPE=ON  ABB=ON  L31 AND 5/N
L33          25 SEA SPE=ON  ABB=ON  ?TETRAZOL?/CNS AND L32
              D SCA
              D QUE L30
L34          STR L27
              D SCA L30
L35          41 SEA SPE=ON  ABB=ON  L31 AND 4/N AND 3/NR
L36          18 SEA SPE=ON  ABB=ON  L35 AND 2/O
              D SCA
L37          STR L28
L38          1 SEA SUB=L13 SSS SAM (L34 OR L37)
L39          0 SEA SUB=L13 CSS SAM (L34 OR L37)
              D SCA L38
L40          9 SEA SUB=L13 CSS FUL (L34 OR L37)
              SAVE TEMP L40 BIA873SUB1/A
L41          5208 SEA SPE=ON  ABB=ON  L13 NOT L40

FILE 'CAPLUS' ENTERED AT 13:11:51 ON 14 SEP 2011
L42          165 SEA SPE=ON  ABB=ON  L41
L43          84 SEA SPE=ON  ABB=ON  L42 AND L23
L44          1 SEA SPE=ON  ABB=ON  L40
L45          84 SEA SPE=ON  ABB=ON  (L21 OR L22)
L46          0 SEA SPE=ON  ABB=ON  L45 AND L44
              SET NOTICE OFF DISPLAY
              SET NOTICE OFF SEARCH
              SET NOTICE LOGIN DISPLAY
              SET NOTICE LOGIN SEARCH
              E WANG CO E/AU
              D BIB L1
              SET NOTICE OFF DISPLAY
              SET NOTICE OFF SEARCH
L47          4779 SEA SPE=ON  ABB=ON  CHENG W?/AU,AUTH
L48          25 SEA SPE=ON  ABB=ON  CO E?/AU,AUTH
L49          28337 SEA SPE=ON  ABB=ON  KIM M?/AU,AUTH
L50          2799 SEA SPE=ON  ABB=ON  KLEIN R?/AU,AUTH
L51          282 SEA SPE=ON  ABB=ON  LEW A?/AU OR LEW TSUHAKO A?/AU OR TSUHAKO
              A?/AU,AUTH
L52          204 SEA SPE=ON  ABB=ON  NUSS J?/AU,AUTH
L53          16047 SEA SPE=ON  ABB=ON  XU W?/AU,AUTH
L54          5 SEA SPE=ON  ABB=ON  BAJJALIEH W?/AU,AUTH
L55          1 SEA SPE=ON  ABB=ON  L47 AND L48 AND L49 AND L50 AND L50 AND
              L51 AND L52 AND L53 AND L54
L56          11 SEA SPE=ON  ABB=ON  L47 AND (L48 OR L49 OR L50 OR L50 OR L51
              OR L52 OR L53 OR L54)
L57          8 SEA SPE=ON  ABB=ON  L48 AND (L49 OR L50 OR L50 OR L51 OR L52
              OR L53 OR L54)

```

L58 21 SEA SPE=ON ABB=ON L49 AND (L50 OR L50 OR L51 OR L52 OR L53
 OR L54)
 L59 2799 SEA SPE=ON ABB=ON L50 AND (L50 OR L51 OR L52 OR L53 OR L54)
 L60 5 SEA SPE=ON ABB=ON L50 AND (L51 OR L52 OR L53 OR L54)
 L61 10 SEA SPE=ON ABB=ON L51 AND (L52 OR L53 OR L54)
 L62 14 SEA SPE=ON ABB=ON L52 AND (L53 OR L54)
 L63 2 SEA SPE=ON ABB=ON L53 AND L54
 L64 2827 SEA SPE=ON ABB=ON L56 OR L57 OR L58 OR L59 OR L60 OR L61 OR
 L62 OR L63
 L65 4 SEA SPE=ON ABB=ON L56 AND (L57 OR L58 OR L59 OR L60 OR L61
 OR L62 OR L63)
 L66 7 SEA SPE=ON ABB=ON L57 AND (L58 OR L59 OR L60 OR L61 OR L62
 OR L63)
 L67 13 SEA SPE=ON ABB=ON L58 AND (L59 OR L60 OR L61 OR L62 OR L63)
 L68 5 SEA SPE=ON ABB=ON L59 AND (L60 OR L61 OR L62 OR L63)
 L69 5 SEA SPE=ON ABB=ON L60 AND (L61 OR L62 OR L63)
 L70 7 SEA SPE=ON ABB=ON L61 AND (L62 OR L63)
 L71 2 SEA SPE=ON ABB=ON L62 AND L63
 L72 15 SEA SPE=ON ABB=ON L65 OR L66 OR L67 OR L68 OR L69 OR L70 OR
 L71
 SET NOTICE LOGIN DISPLAY
 SET NOTICE LOGIN SEARCH
 L73 3 SEA SPE=ON ABB=ON L65 AND (L66 OR L67 OR L68 OR L69 OR L70
 OR L71)
 L74 7 SEA SPE=ON ABB=ON L66 AND (L67 OR L68 OR L69 OR L70 OR L71)
 L75 7 SEA SPE=ON ABB=ON L67 AND (L68 OR L69 OR L70 OR L71)
 L76 5 SEA SPE=ON ABB=ON L68 AND (L69 OR L70 OR L71)
 L77 5 SEA SPE=ON ABB=ON L69 AND (L70 OR L71)
 L78 1 SEA SPE=ON ABB=ON L70 AND L71
 L79 7 SEA SPE=ON ABB=ON (L73 OR L74 OR L75 OR L76 OR L77 OR L78)
 L80 1 SEA SPE=ON ABB=ON (L47 OR L48 OR L49 OR L50 OR L51 OR L52 OR
 L53 OR L54) AND L41
 L81 1 SEA SPE=ON ABB=ON (L47 OR L48 OR L49 OR L50 OR L51 OR L52 OR
 L53 OR L54) AND L18
 L82 7 SEA SPE=ON ABB=ON (L79 OR L81)

FILE 'CAPLUS' ENTERED AT 14:17:02 ON 14 SEP 2011
 D QUE NOS L82
 D IBIB ABS HITSTR L82 1-7

FILE 'REGISTRY' ENTERED AT 14:17:24 ON 14 SEP 2011
 D STAT QUE L41

FILE 'CAPLUS' ENTERED AT 14:17:33 ON 14 SEP 2011
 D QUE NOS L42
 L83 164 SEA SPE=ON ABB=ON L42 NOT L82
 L84 144 SEA SPE=ON ABB=ON L83 AND PATENT/DT
 L85 7 SEA SPE=ON ABB=ON (L83 NOT L84) AND PY<2004
 L86 77 SEA SPE=ON ABB=ON L84 AND (PD<20030829 OR AD<20030829 OR
 PRD<20030829)
 L87 84 SEA SPE=ON ABB=ON (L85 OR L86)
 D IBIB ABS HITSTR L87 1-84

FILE 'HOME' ENTERED AT 14:19:25 ON 14 SEP 2011
 D STAT QUE L41